{"meta":{"query_hash":"5b6606e725da","filters":{"venue":"Advances in Therapy"},"cohort_total":352,"direct_labels_cover":1,"predictions_cover":352,"exported":352,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/5b6606e725da","api":"https://metacan.xera.ac/api/v1/cohort?venue=Advances+in+Therapy"},"results":[{"id":"W1582892440","doi":"10.1007/s12325-015-0224-2","title":"Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study","year":2015,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Fingolimod; Medicine; Tolerability; Adverse effect; Internal medicine; Discontinuation; Multiple sclerosis; Expanded Disability Status Scale; Immunology","score_opus":0.03442763743359083,"score_gpt":0.28378565897330327,"score_spread":0.24935802153971243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1582892440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964832,0.0012692641,0.00012465497,0.00029307042,0.0000191445,0.00022858196,0.0005096376,0.000025704412,0.0010466438],"genre_scores_gemma":[0.9958935,0.0009656189,0.00038894886,0.00068878237,0.00009423911,0.0004223893,0.000893048,0.000008422413,0.0006449921],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99979776,0.00011230622,0.000014715236,0.000028857368,0.000023675228,0.000022679891],"domain_scores_gemma":[0.99934727,0.000095021205,0.00027289396,0.00005251229,0.00006615758,0.00016609157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011602775,0.0005602943,0.0008462628,0.00019019104,0.00032477843,0.0005242827,0.00029355273,0.00048337056,0.002374206],"category_scores_gemma":[0.00070491264,0.00021159442,0.00058375066,0.00023742557,0.00029524407,0.00034710267,0.00031747672,0.0006472597,0.000565412],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40444118,0.033420835,0.32569516,0.0016361608,0.004013282,0.001877105,0.0015615132,0.00076355966,0.046785995,0.00036104157,0.006127656,0.17331664],"study_design_scores_gemma":[0.2643411,0.14820859,0.5601382,0.00027667737,0.0022218393,0.0022756658,0.00067728607,0.0015477986,0.0039834874,0.00033018945,0.015902067,0.000097016615],"about_ca_topic_score_codex":0.00058481016,"about_ca_topic_score_gemma":0.00070796005,"teacher_disagreement_score":0.002374206,"about_ca_system_score_codex":0.00038800357,"about_ca_system_score_gemma":0.0006436154,"threshold_uncertainty_score":0.007942498},"labels":[],"label_agreement":null},{"id":"W1963508707","doi":"10.1007/bf02849799","title":"Evaluation of the comfort of Alphagan® P compared with Alphagan® in irritated eyes","year":2003,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Glaucoma and retinal disorders","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AGE-WELL; Allergan; American Glaucoma Society","keywords":"Brimonidine; Medicine; Tolerability; Eye drop; Crossover study; Anesthesia; Regimen; Ophthalmology; Adverse effect; Glaucoma; Internal medicine","score_opus":0.02132787291849239,"score_gpt":0.32099683399051654,"score_spread":0.2996689610720241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963508707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984804,0.00060566404,0.00020149589,0.000035137502,0.000028547576,0.000019916215,0.00006005018,0.0000057518155,0.00056315225],"genre_scores_gemma":[0.99872017,0.0002595626,0.000315196,0.000029831528,0.000024178107,0.00002068489,0.00007087451,0.0000037171087,0.0005557633],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9994997,0.00023161001,0.00005182962,0.000056158453,0.00009710171,0.000063624095],"domain_scores_gemma":[0.9991253,0.00047977746,0.00011952968,0.000048154085,0.00010655622,0.00012062029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006070304,0.00044118206,0.0005760424,0.00029035704,0.00026063583,0.00031790134,0.0002651446,0.00047341792,0.003215657],"category_scores_gemma":[0.0014815087,0.00014197381,0.0006056028,0.0002769188,0.00032864598,0.0005071882,0.00026411543,0.0006106767,0.00019793586],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38429433,0.0067446004,0.04277328,0.001981238,0.0006475397,0.0014692424,0.0018110758,0.0016091873,0.413379,0.0005215067,0.0008761261,0.14389284],"study_design_scores_gemma":[0.0037513748,0.4978237,0.2817496,0.00010176503,0.0010349222,0.0032089166,0.0020189977,0.0056398544,0.20098151,0.00028418133,0.0032436259,0.00016157582],"about_ca_topic_score_codex":0.0007691562,"about_ca_topic_score_gemma":0.0005630699,"teacher_disagreement_score":0.003215657,"about_ca_system_score_codex":0.00023984438,"about_ca_system_score_gemma":0.00020234098,"threshold_uncertainty_score":0.010757506},"labels":[],"label_agreement":null},{"id":"W1970194363","doi":"10.1007/s12325-015-0189-1","title":"Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users","year":2015,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Rivaroxaban; Medicine; Warfarin; Atrial fibrillation; Propensity score matching; Internal medicine; Pharmacy; Cohort; Anticoagulant; Emergency medicine; Family medicine","score_opus":0.05419746696597991,"score_gpt":0.36244004818528847,"score_spread":0.3082425812193086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970194363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995285,0.00012610844,0.000016266946,0.000013723678,0.0000023040213,0.0000036805095,0.00021999724,6.180819e-7,0.000088796005],"genre_scores_gemma":[0.99943274,0.00006107754,0.000023243696,0.000014109084,0.0000071624063,0.000004857205,0.000401554,7.5411987e-7,0.000054583143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988715,0.000398675,0.0001677824,0.00020637727,0.0002195796,0.00013601189],"domain_scores_gemma":[0.9967204,0.0007567513,0.0017648275,0.00020527303,0.00015212713,0.0004007458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001093295,0.00027797002,0.0006584752,0.0007858498,0.00034226017,0.0007590045,0.000416057,0.00037931674,0.0015767637],"category_scores_gemma":[0.003449623,0.00023272434,0.0014813294,0.000926474,0.00023825552,0.00048009903,0.0004040876,0.00045652039,0.00017589914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002010715,0.00013049069,0.9961104,0.000012494085,0.00048082045,0.000040290346,0.00003379969,0.000090785135,0.00012646649,0.000013861236,0.000051251987,0.00089856464],"study_design_scores_gemma":[0.00008248388,0.00043498195,0.9987779,0.000002621592,0.000111487825,0.00012453161,0.000046893987,0.00027910323,0.00006324072,0.000020493986,0.000052427295,0.0000039156193],"about_ca_topic_score_codex":0.0036472692,"about_ca_topic_score_gemma":0.003303917,"teacher_disagreement_score":0.0036472692,"about_ca_system_score_codex":0.00048797388,"about_ca_system_score_gemma":0.00031913907,"threshold_uncertainty_score":0.007252097},"labels":[],"label_agreement":null},{"id":"W1970541415","doi":"10.1007/s12325-013-0067-7","title":"Obesity and Bipolar Disorder: Synergistic Neurotoxic Effects?","year":2013,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"","keywords":"Medicine; Bipolar disorder; Obesity; Rheumatology; Neurology; Internal medicine; Psychiatry; Lithium (medication)","score_opus":0.0172866482341123,"score_gpt":0.3286273825403722,"score_spread":0.3113407343062599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970541415","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010035137,0.9988249,0.000037545262,0.00024235762,0.00015149511,0.000002058487,0.000010031151,0.0000028129316,0.0006285313],"genre_scores_gemma":[0.0009267127,0.9978625,0.000095544696,0.0003651082,0.00033182363,0.0000038295843,0.000015485017,7.8131967e-7,0.0003982605],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99984014,0.000036317633,0.00002962672,0.000023148668,0.000053300744,0.00001742677],"domain_scores_gemma":[0.999765,0.00010286245,0.00006129914,0.000006427658,0.000041404594,0.000023125815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004237987,0.00087934773,0.001492595,0.0014527951,0.0002594361,0.0009703957,0.00066530943,0.0012051533,0.0061935713],"category_scores_gemma":[0.0006340098,0.00027341078,0.00050066767,0.0015808714,0.0004308147,0.0011987472,0.00079775474,0.0015352191,0.0013345528],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025630946,0.00009397229,0.00029021438,0.014970902,0.00022600731,0.0002832864,0.00004771167,0.00011478118,0.0010521052,0.0017524688,0.028551038,0.9523612],"study_design_scores_gemma":[0.000187083,0.00028359194,0.0027839101,0.0102012325,0.0008112054,0.0030440288,0.00016771498,0.00012695226,0.0004092227,0.0033230316,0.978622,0.00004001262],"about_ca_topic_score_codex":0.000989642,"about_ca_topic_score_gemma":0.0037074802,"teacher_disagreement_score":0.0061935713,"about_ca_system_score_codex":0.00036149716,"about_ca_system_score_gemma":0.00083785166,"threshold_uncertainty_score":0.020719588},"labels":[],"label_agreement":null},{"id":"W1975674908","doi":"10.1007/s12325-010-0033-6","title":"Systematic review on evidence of the effectiveness of cholesterol-lowering drugs","year":2010,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regina Qu'Appelle Health Region","funders":"","keywords":"Medicine; Intensive care medicine; MEDLINE; Coronary heart disease; Diabetes mellitus; Disease; Population; Internal medicine; Environmental health; Endocrinology","score_opus":0.024738024962558287,"score_gpt":0.3738771809146772,"score_spread":0.3491391559521189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975674908","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00063475716,0.9985876,0.00007740764,0.00010987625,0.000096224176,0.000081731865,0.00019815845,0.0000045905103,0.00020959724],"genre_scores_gemma":[0.010061533,0.988882,0.00036137828,0.00032459083,0.00007302754,0.000078106146,0.00012636464,0.0000028057552,0.00009017001],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9957898,0.0014620872,0.001554141,0.00033638589,0.0007249365,0.00013264001],"domain_scores_gemma":[0.9868947,0.009352101,0.0025838297,0.00016945823,0.00082223216,0.00017763408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058166473,0.0017654333,0.010442932,0.0044978308,0.00039818787,0.0017927744,0.0019378002,0.0015449558,0.00498305],"category_scores_gemma":[0.02112679,0.0009181044,0.0069839326,0.0052092494,0.0008085481,0.0013077604,0.001216081,0.0014001542,0.00035800753],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012068312,0.00002488057,0.00067704,0.9097847,0.040607944,0.0001474421,0.000062233084,0.00017392734,0.00021366555,0.00019615843,0.0019912391,0.04491384],"study_design_scores_gemma":[0.0021659401,0.00057283207,0.007705844,0.44951054,0.50423926,0.0005167818,0.00016238572,0.0001570665,0.00041728173,0.0005869085,0.033899583,0.00006552178],"about_ca_topic_score_codex":0.008165033,"about_ca_topic_score_gemma":0.022470158,"teacher_disagreement_score":0.010442932,"about_ca_system_score_codex":0.0023162013,"about_ca_system_score_gemma":0.0048477715,"threshold_uncertainty_score":0.030761778},"labels":[],"label_agreement":null},{"id":"W1975715092","doi":"10.1007/s12325-013-0040-5","title":"Obesity and Mental Illness: Implications for Cognitive Functioning","year":2013,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Diet and metabolism studies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Obesity; Cognition; Rheumatology; Mental illness; Mental health; Psychiatry; Gerontology; Clinical psychology; Internal medicine","score_opus":0.054945110803057286,"score_gpt":0.40239120352450813,"score_spread":0.3474460927214508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975715092","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005039397,0.99944466,0.00002126883,0.0001548113,0.00006695871,0.0000018235505,0.000011679747,0.0000014435835,0.00024703835],"genre_scores_gemma":[0.00044492568,0.9991178,0.000070807786,0.00016545906,0.00008412587,0.0000034618442,0.000010755948,4.075571e-7,0.00010224755],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999747,0.000057129022,0.000052076426,0.00004763027,0.00007572344,0.000020534913],"domain_scores_gemma":[0.99932766,0.00041822268,0.00011284902,0.000012332158,0.000095359486,0.0000336926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007967444,0.0010251821,0.0021845389,0.0025199722,0.00028097152,0.0012010582,0.00074098917,0.0010789005,0.004108333],"category_scores_gemma":[0.0015647932,0.00028854454,0.0007852449,0.003580129,0.00063817244,0.0010858864,0.0009442038,0.001467231,0.00073884847],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016777856,0.00008739505,0.00043741093,0.04381691,0.0004742754,0.00011535848,0.00005446131,0.00016916948,0.00031879795,0.0013323611,0.017280845,0.93574524],"study_design_scores_gemma":[0.00022079336,0.00025242002,0.00854834,0.059590917,0.0027982804,0.0014392551,0.00038516356,0.00018279048,0.00035737478,0.0045581646,0.9215825,0.00008395329],"about_ca_topic_score_codex":0.0040832153,"about_ca_topic_score_gemma":0.011321495,"teacher_disagreement_score":0.004108333,"about_ca_system_score_codex":0.00086189917,"about_ca_system_score_gemma":0.0020888685,"threshold_uncertainty_score":0.013743758},"labels":[],"label_agreement":null},{"id":"W1976039492","doi":"10.1007/s12325-012-0064-2","title":"A Cross-sectional Survey of Hypertension Diagnosis and Treatment Practices Among Physicians in Yaroslavl Region, Russia","year":2012,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Healthcare Systems and Public Health","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Dyslipidemia; Blood pressure; Cross-sectional study; Internal medicine; Diabetes mellitus; Obesity; Abdominal obesity; Family history; Left ventricular hypertrophy; Pediatrics; Metabolic syndrome","score_opus":0.15393799147255197,"score_gpt":0.4277835206994374,"score_spread":0.27384552922688543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976039492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99937266,0.000083802566,0.000021032822,0.000032359585,0.0000018056957,0.000008630733,0.00028104967,0.0000013150152,0.0001972602],"genre_scores_gemma":[0.99950135,0.000085901636,0.000046721285,0.000024513876,0.000003404689,0.000010857115,0.00023965722,4.1090033e-7,0.00008711571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99955076,0.0001392219,0.000054877717,0.00007951833,0.00009879581,0.00007678422],"domain_scores_gemma":[0.9989517,0.0001972384,0.00052682956,0.000038897557,0.00011224253,0.0001730028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049355533,0.00011523361,0.00020995576,0.000557509,0.0003126042,0.0003659905,0.00022841519,0.00028573634,0.0010234739],"category_scores_gemma":[0.0010612822,0.00019753542,0.00013658068,0.0007950357,0.000207437,0.00023386764,0.00029962862,0.00021834613,0.00022297353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011064132,0.000028973696,0.9989176,0.000010507077,0.000008466774,0.00003829612,0.00030094726,0.000009789572,0.00019067517,0.0000038078613,0.00005773395,0.00042226858],"study_design_scores_gemma":[0.0000018208362,0.00003542627,0.9993999,0.000003891796,0.000002566684,0.000051209634,0.00038431957,0.000028010005,0.000014315788,0.0000011147631,0.00007674145,7.334224e-7],"about_ca_topic_score_codex":0.01764129,"about_ca_topic_score_gemma":0.02064748,"teacher_disagreement_score":0.01764129,"about_ca_system_score_codex":0.00046929938,"about_ca_system_score_gemma":0.0005661608,"threshold_uncertainty_score":0.035077214},"labels":[],"label_agreement":null},{"id":"W1976067058","doi":"10.1007/s12325-014-0146-4","title":"Lixisenatide Treatment for Older Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetics: Meta-Analysis of Five Randomized Controlled Trials","year":2014,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"","keywords":"Lixisenatide; Medicine; Hypoglycemia; Placebo; Glycated hemoglobin; Internal medicine; Type 2 Diabetes Mellitus; Type 2 diabetes; Postprandial; Diabetes mellitus; Clinical endpoint; Randomized controlled trial; Endocrinology; Exenatide","score_opus":0.05755748832539071,"score_gpt":0.37941524918592817,"score_spread":0.32185776086053747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976067058","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013429574,0.9849295,0.00051154284,0.00014461034,0.00020714059,0.0001855145,0.0002877503,0.000029504543,0.0002748643],"genre_scores_gemma":[0.29920635,0.69479215,0.0027718982,0.0011782072,0.00026442637,0.0003996395,0.00072973815,0.000035274777,0.0006223115],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9968984,0.0013518584,0.00093409314,0.0003809154,0.00028591766,0.00014878863],"domain_scores_gemma":[0.99559915,0.0029509892,0.0009267024,0.0001602511,0.0002445011,0.000118373355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00600002,0.002442241,0.014096307,0.002011794,0.00039272482,0.0019150149,0.0015256933,0.0015867776,0.003510856],"category_scores_gemma":[0.009598902,0.0012345373,0.023680642,0.002652705,0.00052302587,0.0014048731,0.0010664013,0.0020952257,0.00022355423],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019387366,0.000079062134,0.0033092848,0.17646566,0.7769416,0.0001180026,0.00007350422,0.0004728299,0.00048210513,0.000104854436,0.00070207246,0.02186368],"study_design_scores_gemma":[0.0056624995,0.00053843297,0.0032204604,0.0056634205,0.9830032,0.000074239746,0.00004529481,0.00014006642,0.00013477227,0.00015165287,0.0013402554,0.000025766223],"about_ca_topic_score_codex":0.0030092774,"about_ca_topic_score_gemma":0.009955025,"teacher_disagreement_score":0.014096307,"about_ca_system_score_codex":0.0014302132,"about_ca_system_score_gemma":0.0012493939,"threshold_uncertainty_score":0.031731546},"labels":[],"label_agreement":null},{"id":"W1986615261","doi":"10.1007/bf02850309","title":"A giant congenital nevus spilus in an 8-year-old girl","year":2006,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Genetic and rare skin diseases.","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Girl; Lesion; Dermatology; Lumbosacral joint; Anatomy; Surgery","score_opus":0.0048184559617286795,"score_gpt":0.2561688543908048,"score_spread":0.2513503984290761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986615261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777158,0.002288456,0.0017208549,0.0050683664,0.00050297804,0.00016107573,0.0004858857,0.00042340657,0.011633204],"genre_scores_gemma":[0.99318624,0.0010872547,0.001132738,0.00088402967,0.00031673268,0.000043679287,0.00012761178,0.00007573081,0.0031460475],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9995183,0.000045780173,0.000035757934,0.0001515471,0.00010918775,0.000139499],"domain_scores_gemma":[0.9984493,0.00057226885,0.00023500832,0.00008480729,0.000082179235,0.00057652564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034509442,0.0015732641,0.0014491742,0.0028276125,0.0027839164,0.00092150556,0.0011739681,0.004533262,0.0028961764],"category_scores_gemma":[0.0031464905,0.001018681,0.0010085376,0.00095527445,0.0019648755,0.0014359212,0.0014473315,0.002815163,0.0008545724],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025400266,0.000027478884,0.0016857878,0.000016889917,0.0000034536965,0.9963671,0.000093804105,0.000040628744,0.00096812553,0.00010514001,0.00012406457,0.0005420344],"study_design_scores_gemma":[0.000013219996,0.00012030063,0.005708961,0.000017243292,0.0000099799745,0.99308217,0.00011006346,0.00016039173,0.00030944694,0.00011476977,0.0003428682,0.000010423436],"about_ca_topic_score_codex":0.0030238316,"about_ca_topic_score_gemma":0.0028836944,"teacher_disagreement_score":0.004533262,"about_ca_system_score_codex":0.0010453187,"about_ca_system_score_gemma":0.00078216055,"threshold_uncertainty_score":0.009688735},"labels":[],"label_agreement":null},{"id":"W1986770646","doi":"10.1007/s12325-011-0015-3","title":"Surgical treatment of morbid obesity among patients with bipolar disorder: a research agenda","year":2011,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism","keywords":"Medicine; Morbid obesity; Bipolar disorder; Rheumatology; Obesity; Internal medicine; Psychiatry; Physical therapy; Family medicine; Intensive care medicine; Weight loss; Lithium (medication)","score_opus":0.0777282307428856,"score_gpt":0.3996709975142271,"score_spread":0.3219427667713415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986770646","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011231241,0.9990294,0.000044469096,0.0003887913,0.000111848196,0.0000020278387,0.0000046007917,0.0000016426765,0.00030496827],"genre_scores_gemma":[0.00067006674,0.99854916,0.00014036399,0.00027023477,0.0002444942,0.000003004423,0.000009271977,5.696075e-7,0.00011283587],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99978155,0.000046186036,0.00004316844,0.000035050536,0.00007446399,0.000019550616],"domain_scores_gemma":[0.99903786,0.00059080485,0.00016909701,0.000013926868,0.00014069756,0.00004766385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088244444,0.00061738037,0.001788523,0.0015882243,0.00026844727,0.00094385206,0.00074074446,0.0009961306,0.0030043458],"category_scores_gemma":[0.0012392446,0.00023800806,0.0007462668,0.0016830435,0.0005990812,0.0010863314,0.00045434514,0.0020472412,0.00066633354],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018020389,0.00015323606,0.00062230724,0.017304633,0.00019210835,0.00020887298,0.000039596605,0.00016438653,0.0007717533,0.0018644514,0.015901847,0.96259654],"study_design_scores_gemma":[0.00040074353,0.0009615969,0.011821113,0.04472172,0.0018869017,0.0054019364,0.0005225066,0.000563968,0.00085819606,0.006434549,0.9263402,0.00008648877],"about_ca_topic_score_codex":0.001257852,"about_ca_topic_score_gemma":0.0040666233,"teacher_disagreement_score":0.0030043458,"about_ca_system_score_codex":0.00046052272,"about_ca_system_score_gemma":0.0013340515,"threshold_uncertainty_score":0.010050535},"labels":[],"label_agreement":null},{"id":"W1986954788","doi":"10.1007/s12325-015-0182-8","title":"Ivabradine in Combination with Beta-Blockers in Patients with Chronic Stable Angina After Percutaneous Coronary Intervention","year":2015,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Heart rate and cardiovascular health","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Servier","keywords":"Medicine; Ivabradine; Percutaneous coronary intervention; Cardiology; Internal medicine; BETA (programming language); Angina; Stable angina; Rheumatology; Coronary heart disease; Heart rate; Myocardial infarction; Blood pressure","score_opus":0.00832923111248719,"score_gpt":0.26286330621842985,"score_spread":0.25453407510594267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986954788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99685234,0.0022219457,0.000058908357,0.000056339606,0.000012900723,0.000046513498,0.00031635814,0.0000047734407,0.00042984862],"genre_scores_gemma":[0.99818087,0.000578765,0.00022174095,0.000072109535,0.00006417654,0.000057434016,0.0006763778,0.0000015464739,0.0001469935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985794,0.0006559972,0.00016549202,0.00023880652,0.00025706177,0.000103317616],"domain_scores_gemma":[0.99805486,0.00060038106,0.00090006285,0.000097575976,0.0001143105,0.00023274994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019212379,0.00030452444,0.0011025134,0.00044148203,0.00026450175,0.0006079655,0.00029978322,0.000291362,0.0012436433],"category_scores_gemma":[0.0018503184,0.00018540281,0.00086668634,0.00071974075,0.00022401725,0.00030112953,0.00032578755,0.0004839937,0.00015155596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046024676,0.00077159144,0.92744136,0.00038149126,0.0014430636,0.00016964936,0.00008324231,0.00025465296,0.0021102687,0.000029565725,0.000356025,0.02093444],"study_design_scores_gemma":[0.0045938333,0.011582428,0.9802619,0.00006208916,0.0011816255,0.00030094717,0.00008329774,0.0004633103,0.00038957124,0.00004348645,0.0010233888,0.000014086148],"about_ca_topic_score_codex":0.00077087217,"about_ca_topic_score_gemma":0.002034243,"teacher_disagreement_score":0.0019212379,"about_ca_system_score_codex":0.00037668258,"about_ca_system_score_gemma":0.0005156182,"threshold_uncertainty_score":0.010160565},"labels":[],"label_agreement":null},{"id":"W1988415653","doi":"10.1007/s12325-010-0025-6","title":"Serum vitamin D concentration and short-term mortality among geriatric inpatients in acute care settings","year":2010,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Creatinine; Internal medicine; Vitamin D and neurology; Body mass index; Acute care; Odds ratio; Mortality rate; Confounding; Blood pressure; Proportional hazards model; Pediatrics; Health care","score_opus":0.009918325388342076,"score_gpt":0.33360327759883873,"score_spread":0.32368495221049665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988415653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99890804,0.00075050455,0.000012704267,0.00006567937,0.0000078395415,0.00000295259,0.00010504436,9.0165594e-7,0.0001463877],"genre_scores_gemma":[0.9992513,0.0004324932,0.000032594035,0.00004556969,0.000020139116,0.0000038060614,0.00014037457,4.6149873e-7,0.00007327387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994873,0.00018686416,0.00009278145,0.00005773047,0.000079689555,0.00009553594],"domain_scores_gemma":[0.99809927,0.0004834565,0.0006550955,0.00007996482,0.0002591058,0.00042311414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006674016,0.00038261968,0.00071172975,0.000814721,0.00052713964,0.0008115956,0.000309307,0.00067822216,0.0008452623],"category_scores_gemma":[0.0038694884,0.00027019126,0.00050385954,0.0010746287,0.0003283015,0.0005460555,0.00043138943,0.00076922844,0.00012075392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081155973,0.000113278125,0.9975163,0.000022377802,0.00011643985,0.00003903644,0.00008030271,0.000017615264,0.00011379807,0.000007971901,0.00006929356,0.001092011],"study_design_scores_gemma":[0.000030080844,0.00036544199,0.9988287,0.000011135719,0.00008485787,0.00011163595,0.00037116164,0.000056548888,0.000060770766,0.000020832815,0.000054397835,0.000004447473],"about_ca_topic_score_codex":0.0121758925,"about_ca_topic_score_gemma":0.012724625,"teacher_disagreement_score":0.0121758925,"about_ca_system_score_codex":0.00074845116,"about_ca_system_score_gemma":0.0005887235,"threshold_uncertainty_score":0.024210036},"labels":[],"label_agreement":null},{"id":"W1989894661","doi":"10.1007/s12325-011-0053-x","title":"Blood pressure control rates with an antihypertensive regimen including trandolapril in a canadian usual-care setting","year":2011,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Abbott (Canada); Hamilton Health Sciences","funders":"","keywords":"Medicine; Trandolapril; Blood pressure; Tolerability; Internal medicine; Regimen; Population; Physical therapy; Adverse effect; ACE inhibitor; Angiotensin-converting enzyme","score_opus":0.030645875290255628,"score_gpt":0.29488349914857104,"score_spread":0.2642376238583154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989894661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940528,0.0011051351,0.000035250814,0.0003821327,0.00002693839,0.00007452228,0.0013136739,0.000007628978,0.0030019896],"genre_scores_gemma":[0.9976943,0.00066956563,0.0001956875,0.00021058753,0.000013570353,0.000019358733,0.0006822269,0.0000044582866,0.0005102027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979253,0.00038879627,0.00018477169,0.00028386898,0.0006596964,0.0005576749],"domain_scores_gemma":[0.9954472,0.0005590908,0.00065786624,0.00014251139,0.0018124133,0.0013808793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015008042,0.00037961736,0.0009231753,0.00069642975,0.0022869208,0.00120801,0.0016281442,0.00083394005,0.0025009662],"category_scores_gemma":[0.007868379,0.0004909222,0.0012489686,0.0028617787,0.000695535,0.0006587514,0.00055143854,0.0015853053,0.00015616512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065938598,0.001685856,0.9691645,0.00037815422,0.0006791143,0.000269734,0.0017121522,0.0002960339,0.00033913885,0.0003398941,0.0035110717,0.015030386],"study_design_scores_gemma":[0.0006066332,0.0010410963,0.99471056,0.000056391516,0.00036269834,0.00010909722,0.0017197465,0.00032745104,0.00011603861,0.00003192648,0.000864928,0.000053420565],"about_ca_topic_score_codex":0.9818309,"about_ca_topic_score_gemma":0.985987,"teacher_disagreement_score":0.022660386,"about_ca_system_score_codex":0.022660386,"about_ca_system_score_gemma":0.025460722,"threshold_uncertainty_score":0.16441339},"labels":[],"label_agreement":null},{"id":"W1992925095","doi":"10.1007/bf02850083","title":"Penile dog bite in an adolescent","year":2005,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Rabies epidemiology and control","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Penis; Saline; Dog bite; Surgery; Syringe; External genitalia; Anesthesia; Anatomy; Pathology","score_opus":0.013125697588765457,"score_gpt":0.3090259655514643,"score_spread":0.2959002679626988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992925095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893066,0.0008487506,0.000349654,0.0018852985,0.000115572875,0.00005636941,0.00009782955,0.000036126963,0.0073037697],"genre_scores_gemma":[0.9977895,0.000648844,0.00018275497,0.00038498317,0.0001151438,0.000007867952,0.00005092599,0.000004956343,0.00081496744],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99972874,0.00004573443,0.000021619699,0.00003487005,0.000039444723,0.00012963248],"domain_scores_gemma":[0.9995789,0.000104424194,0.00008642881,0.000018052822,0.00003184843,0.00018048236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001970914,0.0007627699,0.0006282877,0.0011561123,0.0018453134,0.0007763037,0.0006326854,0.003210735,0.0037181247],"category_scores_gemma":[0.001475218,0.00045080285,0.00056911807,0.00044723126,0.0007230572,0.000962966,0.00061483396,0.002430848,0.0006350859],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008617818,0.00051731174,0.14319347,0.000029037285,0.000013787324,0.85159004,0.00036727986,0.00009113061,0.00056838506,0.0002731311,0.0006042965,0.0026659507],"study_design_scores_gemma":[0.000025014082,0.000663625,0.0918305,0.000051944593,0.000028368113,0.90370625,0.0016364658,0.0005405817,0.00037955737,0.00017523176,0.00094600563,0.000016349177],"about_ca_topic_score_codex":0.003515473,"about_ca_topic_score_gemma":0.0048224754,"teacher_disagreement_score":0.0037181247,"about_ca_system_score_codex":0.000792046,"about_ca_system_score_gemma":0.00067142275,"threshold_uncertainty_score":0.0124384165},"labels":[],"label_agreement":null},{"id":"W1995320490","doi":"10.1007/bf02877702","title":"A large hypopigmented skin lesion following extravasation of intravenous fluid","year":2007,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chemotherapy-related skin toxicity","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Extravasation; Lesion; Intravenous fluid; Complication; Anesthesia; Surgery; Radiology; Pathology","score_opus":0.01399578055989709,"score_gpt":0.31930434474719765,"score_spread":0.30530856418730057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995320490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9461219,0.003833893,0.011188955,0.0066197407,0.0010174197,0.0008335941,0.00069154915,0.0009696456,0.028723339],"genre_scores_gemma":[0.9924926,0.00058834895,0.001129958,0.0012331076,0.00021015112,0.000036060235,0.00009483606,0.000027808219,0.0041871495],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99977857,0.000034598106,0.000015348367,0.000037389287,0.000058065387,0.00007600474],"domain_scores_gemma":[0.9990766,0.00028635882,0.00020808209,0.0001458754,0.0000712124,0.00021183815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030755036,0.00087665976,0.0006688824,0.000855431,0.0005840231,0.0005081362,0.00076635083,0.0025169584,0.001917625],"category_scores_gemma":[0.0017599612,0.00042916063,0.0008241138,0.0004025635,0.00072998874,0.00097080995,0.00044749075,0.003090604,0.0006676379],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008556434,0.00022127878,0.0023527164,0.000104789186,0.000031418473,0.9728003,0.00008662807,0.00026906226,0.01465418,0.00031495286,0.00066633633,0.0076426594],"study_design_scores_gemma":[0.00019411455,0.0029470918,0.025938725,0.000030503474,0.00009004423,0.93125033,0.00011634667,0.0019682639,0.03262539,0.00050942064,0.0042913845,0.000038281974],"about_ca_topic_score_codex":0.0013307292,"about_ca_topic_score_gemma":0.0015428241,"teacher_disagreement_score":0.0025169584,"about_ca_system_score_codex":0.0010031826,"about_ca_system_score_gemma":0.000454052,"threshold_uncertainty_score":0.0072785616},"labels":[],"label_agreement":null},{"id":"W1996943621","doi":"10.1007/s12325-009-0039-0","title":"Long-acting risperidone: a review of its role in the treatment of bipolar disorder","year":2009,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Center for Research Resources","keywords":"Risperidone; Tolerability; Bipolar disorder; Medicine; Mania; Psychiatry; Treatment of bipolar disorder; Mood; Schizophrenia (object-oriented programming); Internal medicine; Adverse effect","score_opus":0.030544713264928573,"score_gpt":0.3798057100356378,"score_spread":0.3492609967707092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996943621","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000075468975,0.9994796,0.00004370914,0.00007865387,0.00006336021,0.0000028713841,0.000015884163,0.0000030347562,0.00023746543],"genre_scores_gemma":[0.00040617026,0.9991123,0.00015526125,0.000094827876,0.00008680983,0.000002673811,0.000016240583,6.66569e-7,0.00012505038],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999759,0.000038627742,0.000060060203,0.000042415497,0.000085545464,0.000014323963],"domain_scores_gemma":[0.99938774,0.00031659345,0.00012340507,0.0000104958635,0.00011783044,0.000043918335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006612555,0.00096285396,0.002147037,0.0025202085,0.00023936004,0.0008041399,0.0010565666,0.0008392588,0.0028178243],"category_scores_gemma":[0.0009464537,0.00033629106,0.0006489562,0.003215017,0.00037715025,0.0010730824,0.0005465442,0.0015081771,0.0009580919],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016488993,0.00008461145,0.00019663613,0.03184726,0.00020301992,0.00022829867,0.000049920513,0.00029581002,0.000988438,0.0007770134,0.020675236,0.94448894],"study_design_scores_gemma":[0.00011148906,0.00034259155,0.0034446977,0.016435834,0.0010954218,0.0032086398,0.00012474672,0.00032481187,0.00066172925,0.0015416554,0.9726375,0.0000709632],"about_ca_topic_score_codex":0.0025145127,"about_ca_topic_score_gemma":0.007042286,"teacher_disagreement_score":0.0028178243,"about_ca_system_score_codex":0.00046552537,"about_ca_system_score_gemma":0.001182718,"threshold_uncertainty_score":0.009426534},"labels":[],"label_agreement":null},{"id":"W1998390661","doi":"10.1007/s12325-013-0014-7","title":"Ocular Surface Tolerability of Prostaglandin Analogs and Prostamides in Patients with Glaucoma or Ocular Hypertension","year":2013,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Glaucoma and retinal disorders","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Allergan","keywords":"Bimatoprost; Latanoprost; Travoprost; Medicine; Tolerability; Ophthalmology; Glaucoma; Ocular hypertension; Prostaglandin analogue; Intraocular pressure; Internal medicine; Adverse effect","score_opus":0.006345377738646314,"score_gpt":0.23164891159234205,"score_spread":0.22530353385369573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998390661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951498,0.0038295994,0.00007594649,0.00010857834,0.000026205262,0.000052854313,0.0001196165,0.0000075101316,0.0006299633],"genre_scores_gemma":[0.9988262,0.00062844646,0.00011350003,0.0001333066,0.00005751172,0.000037673784,0.00007913324,0.0000014431114,0.00012275229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99952245,0.00021751998,0.000058367816,0.000062390034,0.00008352611,0.00005578054],"domain_scores_gemma":[0.99893767,0.00038138893,0.000431159,0.000034740202,0.00004491199,0.00017014779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008402878,0.00021642847,0.0006880131,0.00014652264,0.0001768043,0.00033520375,0.00014228973,0.00032993467,0.002086671],"category_scores_gemma":[0.0013283961,0.000120959965,0.0006220008,0.00024087242,0.0002186653,0.00026685797,0.00013079724,0.0004896503,0.00017235351],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31068423,0.0066598263,0.42337987,0.0014070804,0.0026071712,0.0007615195,0.000324345,0.0010583294,0.029212965,0.00014766348,0.0015416719,0.22221534],"study_design_scores_gemma":[0.036888555,0.31939703,0.63001233,0.00015524341,0.0017897879,0.001901287,0.00037168644,0.0011964792,0.0051080077,0.00018284889,0.0029582959,0.000038411443],"about_ca_topic_score_codex":0.00037366615,"about_ca_topic_score_gemma":0.0007514585,"teacher_disagreement_score":0.002086671,"about_ca_system_score_codex":0.00025370438,"about_ca_system_score_gemma":0.0003262768,"threshold_uncertainty_score":0.006980598},"labels":[],"label_agreement":null},{"id":"W2000423618","doi":"10.1007/bf02849889","title":"Eczema exacerbation and food atopy beyond infancy: How should we advise Chinese parents about dietary history, eczema severity, and skin prick testing?","year":2007,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Food Allergy and Anaphylaxis Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Atopy; Exacerbation; Atopic dermatitis; Food allergy; Allergy; Elimination diet; Food allergens; Egg white; Pediatrics; Dermatology; Immunology; Food science","score_opus":0.03479998323195881,"score_gpt":0.325063328086119,"score_spread":0.29026334485416017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000423618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75302655,0.028767642,0.0021831628,0.19758728,0.0019233613,0.00011523507,0.00022534127,0.00011885867,0.016052594],"genre_scores_gemma":[0.94907326,0.018043784,0.0033573231,0.02363277,0.002520753,0.00010859675,0.00015091695,0.000026867305,0.0030858812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996207,0.0001316618,0.000055297125,0.000046368757,0.00008047434,0.00006551896],"domain_scores_gemma":[0.99855214,0.0006361942,0.0002162695,0.000054566368,0.00020877666,0.0003319966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016964603,0.0005509988,0.0013457284,0.00042579428,0.0011265021,0.0008006052,0.0004431002,0.0034033046,0.002260159],"category_scores_gemma":[0.0051078666,0.0002970681,0.00062623597,0.00032854168,0.00079949066,0.002325458,0.00038953387,0.0028238774,0.00036977165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006739491,0.000833434,0.7827504,0.0005464491,0.00020535821,0.027801976,0.004090442,0.00029975997,0.0035522243,0.0017476183,0.02669321,0.15080513],"study_design_scores_gemma":[0.0003294761,0.0011495231,0.8856592,0.0023542242,0.00091749406,0.043079663,0.017453587,0.00296246,0.002643105,0.0070040156,0.036225203,0.00022201095],"about_ca_topic_score_codex":0.016368028,"about_ca_topic_score_gemma":0.014968536,"teacher_disagreement_score":0.016368028,"about_ca_system_score_codex":0.0009418614,"about_ca_system_score_gemma":0.0021129097,"threshold_uncertainty_score":0.032545507},"labels":[],"label_agreement":null},{"id":"W2001296167","doi":"10.1007/bf02849985","title":"Necrotizing fasciitis and gangrene associated with topical herbs in an infant","year":2007,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Streptococcal Infections and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Children's Hospital","funders":"","keywords":"Medicine; Fasciitis; Gangrene; Dermatology; Rheumatology; Fournier gangrene; Surgery; Internal medicine; Necrotising fasciitis","score_opus":0.016373178314668425,"score_gpt":0.3343752169303377,"score_spread":0.3180020386156693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001296167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99054295,0.0018442516,0.00069622736,0.00094155147,0.00011985488,0.00011888689,0.00008551171,0.00006899576,0.005581805],"genre_scores_gemma":[0.9958903,0.0014282321,0.0008836676,0.00029225706,0.00012073599,0.000021523752,0.000037106383,0.0000104885985,0.001315648],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9995915,0.00007037163,0.000047788788,0.000047587866,0.00009299399,0.0001497682],"domain_scores_gemma":[0.999388,0.0001808888,0.00015192786,0.000034384637,0.00005444501,0.0001903804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038925582,0.001076028,0.0011797043,0.0013289985,0.00151065,0.00049918424,0.0006638934,0.0021616893,0.0011663773],"category_scores_gemma":[0.002088644,0.0006276383,0.0009769403,0.00046033287,0.001122339,0.000617489,0.0005336539,0.0020651477,0.0002530649],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016800367,0.00013028867,0.007822122,0.000053438092,0.000008450233,0.98728687,0.00014604614,0.00004906056,0.0019694786,0.00017510416,0.00011613293,0.0020750521],"study_design_scores_gemma":[0.000045709527,0.0022078918,0.044448555,0.000060220857,0.00009322893,0.94563353,0.00050116156,0.00053896266,0.005169028,0.00014933261,0.001128188,0.000024152647],"about_ca_topic_score_codex":0.0033469542,"about_ca_topic_score_gemma":0.0049210372,"teacher_disagreement_score":0.0033469542,"about_ca_system_score_codex":0.0011922744,"about_ca_system_score_gemma":0.0007694843,"threshold_uncertainty_score":0.008650601},"labels":[],"label_agreement":null},{"id":"W2001359221","doi":"10.1007/s12325-008-0044-8","title":"Unusual loss of body hair in childhood: Trichotillomania or alopecia","year":2008,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Hair loss; Medicine; Scalp; Alopecia universalis; Dermatology; Psychosocial; Eyebrow; Alopecia areata; Body hair; Hair disease; Cabello; Pediatrics; Surgery; Psychiatry","score_opus":0.012844124039914353,"score_gpt":0.2946241467758194,"score_spread":0.281780022735905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001359221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9370778,0.0066777575,0.004889215,0.003516886,0.00062403333,0.0001326174,0.00091547624,0.0005577446,0.045608573],"genre_scores_gemma":[0.99546534,0.0013092351,0.000874594,0.0003580243,0.00018511721,0.000012476033,0.00010066789,0.000041695348,0.0016529793],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9994754,0.000041494295,0.000045067667,0.000116042924,0.00010087407,0.00022111103],"domain_scores_gemma":[0.9992737,0.00021181267,0.00020216107,0.00006721895,0.000070180395,0.00017488893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020726143,0.0010264907,0.00083067484,0.0010125668,0.0009954964,0.0006778984,0.00043114644,0.0019986092,0.0044672727],"category_scores_gemma":[0.002565369,0.00039591358,0.00044626748,0.00075854716,0.001277843,0.0008440321,0.00057131023,0.0013852213,0.0006733009],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021598993,0.000071575916,0.06722118,0.00022145578,0.00003225392,0.9012066,0.0005386368,0.00018387994,0.012366415,0.0010305257,0.0019810987,0.014930321],"study_design_scores_gemma":[0.000009897076,0.0000614525,0.034791335,0.00002445218,0.00002175357,0.96219194,0.00025399792,0.00009243923,0.001453682,0.0001825905,0.0009079808,0.00000836097],"about_ca_topic_score_codex":0.0030685558,"about_ca_topic_score_gemma":0.0040362887,"teacher_disagreement_score":0.0044672727,"about_ca_system_score_codex":0.0005549981,"about_ca_system_score_gemma":0.00069229194,"threshold_uncertainty_score":0.014944553},"labels":[],"label_agreement":null},{"id":"W2005097633","doi":"10.1007/s12325-012-0010-3","title":"Advances in Hemophilia Care: Report of Two Symposia at the Hemophilia 2010 World Congress","year":2012,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc; Queen's University","funders":"","keywords":"Medicine; Population; Health care; Factor VIIa; Family medicine; Gerontology; Pediatrics; Internal medicine","score_opus":0.022120555082914023,"score_gpt":0.36518792943755923,"score_spread":0.3430673743546452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005097633","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02946225,0.16898087,0.0015279865,0.4310824,0.34035426,0.00044101948,0.0011577135,0.00019609203,0.026797365],"genre_scores_gemma":[0.17792667,0.28089365,0.007993912,0.14171863,0.28997722,0.0008649201,0.003527476,0.00030796,0.09678964],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967237,0.00062146963,0.00019934936,0.00019837645,0.0013132895,0.00094372436],"domain_scores_gemma":[0.9877658,0.0012620498,0.0010058619,0.00021088978,0.0038273013,0.0059282053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011374898,0.0016040243,0.00077752525,0.001684415,0.0021882514,0.00377962,0.0011786029,0.0051563983,0.0056225313],"category_scores_gemma":[0.006477066,0.00042974539,0.0012008231,0.0017060287,0.0011068913,0.0020761865,0.0035691354,0.006663166,0.001465214],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005745956,0.00075222296,0.006794926,0.0014063638,0.0001302434,0.00088221824,0.00086159835,0.0003723527,0.0027000457,0.0014154981,0.92007935,0.06403073],"study_design_scores_gemma":[0.00010288116,0.00027808422,0.026010832,0.0007366282,0.000120132725,0.00040844013,0.002104276,0.00021602784,0.0014395444,0.00048388465,0.9680456,0.000053581563],"about_ca_topic_score_codex":0.0041429177,"about_ca_topic_score_gemma":0.013613989,"teacher_disagreement_score":0.011374898,"about_ca_system_score_codex":0.0021669338,"about_ca_system_score_gemma":0.008509118,"threshold_uncertainty_score":0.06015694},"labels":[],"label_agreement":null},{"id":"W2006060882","doi":"10.1007/s12325-009-0011-z","title":"Teratogenesis associated with antibipolar agents","year":2009,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Pharmacological Effects and Toxicity Studies","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University Health Network","funders":"","keywords":"Medicine; Rheumatology; Internal medicine; Intensive care medicine","score_opus":0.07467462525885635,"score_gpt":0.42572389444615055,"score_spread":0.3510492691872942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006060882","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039148366,0.9984086,0.00017746436,0.00008498794,0.000063737214,0.000005160733,0.000020394342,0.000005634139,0.0008426004],"genre_scores_gemma":[0.0016167624,0.9974607,0.00020892192,0.00007279491,0.000083093815,0.000005440642,0.000021022894,0.0000014849012,0.0005296513],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99979705,0.000035450554,0.000052247677,0.00003398129,0.000068556554,0.000012852228],"domain_scores_gemma":[0.99961424,0.00019715777,0.000099053235,0.000014287864,0.00006137483,0.000013931036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046236484,0.0007749829,0.0013290688,0.0021046735,0.00019690415,0.0005435007,0.0005337641,0.0005659692,0.002692754],"category_scores_gemma":[0.0007188966,0.00024095994,0.00039727445,0.0019207816,0.00037205286,0.0005817417,0.00044147318,0.0007035834,0.00079955655],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015415237,0.000071736744,0.00041335382,0.019224055,0.00011432352,0.00065966597,0.000044850458,0.0002774322,0.005785921,0.0010943003,0.006540052,0.96562016],"study_design_scores_gemma":[0.000075559474,0.00040156842,0.0031635077,0.005911837,0.0008988005,0.009672568,0.00012061088,0.00018080923,0.012003932,0.0017521398,0.96578306,0.000035542045],"about_ca_topic_score_codex":0.00069768593,"about_ca_topic_score_gemma":0.0015222338,"teacher_disagreement_score":0.002692754,"about_ca_system_score_codex":0.00034366956,"about_ca_system_score_gemma":0.0007239318,"threshold_uncertainty_score":0.009008169},"labels":[],"label_agreement":null},{"id":"W2012548303","doi":"10.1007/bf02850087","title":"The role of nebulized inhaled corticosteroid therapy in adult patients with asthma and chronic obstructive pulmonary disease","year":2005,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Inhalation and Respiratory Drug Delivery","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"New York Institute of Technology","funders":"AstraZeneca","keywords":"Medicine; Asthma; Corticosteroid; Pulmonary disease; Inhalation; Intensive care medicine; Anesthesia; Internal medicine","score_opus":0.008815677961129417,"score_gpt":0.28584112533893147,"score_spread":0.27702544737780205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012548303","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000094553034,0.9994272,0.00004946121,0.0001130492,0.000071735194,0.0000018576109,0.0000053504123,0.0000017978914,0.00023500505],"genre_scores_gemma":[0.00081698503,0.99843985,0.00016313518,0.00016434476,0.00016859785,0.0000037311222,0.000013216224,6.975664e-7,0.00022943217],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99969435,0.000055007487,0.00005747756,0.000045673794,0.000129035,0.000018492377],"domain_scores_gemma":[0.99938524,0.00035275175,0.000109959416,0.000011491957,0.00010977521,0.000030866402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090194854,0.0007451735,0.0024070446,0.0014013328,0.00020929617,0.00082168257,0.0008510663,0.0011051613,0.0019712886],"category_scores_gemma":[0.0010713929,0.00022148162,0.0007008026,0.001318877,0.00037032535,0.00089798943,0.0004278588,0.0014341064,0.0009624748],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013894912,0.00006076018,0.00042417162,0.010880686,0.00013746516,0.00021811767,0.00003568264,0.00016887455,0.0011301722,0.00062930887,0.008668455,0.9775073],"study_design_scores_gemma":[0.00020276221,0.00052673434,0.0074299867,0.009943852,0.00094632857,0.0050405106,0.00013400192,0.0003667899,0.0011192645,0.0012005991,0.9730449,0.000044319724],"about_ca_topic_score_codex":0.0013843285,"about_ca_topic_score_gemma":0.0033614521,"teacher_disagreement_score":0.0024070446,"about_ca_system_score_codex":0.00042151925,"about_ca_system_score_gemma":0.0010761434,"threshold_uncertainty_score":0.0065945983},"labels":[],"label_agreement":null},{"id":"W2012910796","doi":"10.1007/s12325-010-0095-5","title":"Safety and tolerability of high-dose intravenous esomeprazole for prevention of peptic ulcer rebleeding","year":2010,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Gastrointestinal Bleeding Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Esomeprazole; Tolerability; Internal medicine; Rheumatology; Peptic ulcer; Peptic; Gastroenterology; Adverse effect","score_opus":0.013608774039409877,"score_gpt":0.30872021979472913,"score_spread":0.2951114457553193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012910796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99627423,0.0025430052,0.00030873832,0.00008971756,0.00002620749,0.000041048363,0.00009484119,0.000019817422,0.0006023358],"genre_scores_gemma":[0.99913484,0.0003412445,0.00014737244,0.000065081054,0.00005040507,0.000011055674,0.000083528284,0.0000036346235,0.000162771],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999474,0.00032122366,0.000034065495,0.00004092111,0.000077199395,0.00005261726],"domain_scores_gemma":[0.9985833,0.0007386616,0.00030019996,0.00012852742,0.000079743695,0.00016950513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009949583,0.00029267694,0.001002203,0.0002392152,0.00017957643,0.00041578995,0.0003424537,0.00065142685,0.0010186246],"category_scores_gemma":[0.0024301705,0.00019273938,0.00064938713,0.00021702649,0.00032870928,0.00044167478,0.00011632704,0.0013030452,0.00018947409],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5720156,0.013084134,0.04530335,0.0007323089,0.001581699,0.00093870534,0.00022659797,0.002460532,0.06785493,0.00025452639,0.0009676698,0.29457992],"study_design_scores_gemma":[0.052848842,0.47508487,0.4240273,0.0001215447,0.002302486,0.002884752,0.00020790407,0.0077762282,0.03201139,0.00027377516,0.0023810081,0.00007981799],"about_ca_topic_score_codex":0.00038562,"about_ca_topic_score_gemma":0.00045062925,"teacher_disagreement_score":0.0010186246,"about_ca_system_score_codex":0.00031507653,"about_ca_system_score_gemma":0.00028091154,"threshold_uncertainty_score":0.0052619576},"labels":[],"label_agreement":null},{"id":"W2015342809","doi":"10.1007/bf02850032","title":"Group A β-hemolytic streptococcal pharyngitis in children","year":2004,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Streptococcal Infections and Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"University of Calgary; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Medicine; Pharyngitis; Throat culture; Penicillin; Cephalosporin; Antibiotics; Intensive care medicine; Acute Pharyngitis; Group A; Internal medicine; Streptococcus; Throat; Streptococcus pyogenes; Antibiotic therapy; Tonsillitis; Pediatrics; Surgery; Staphylococcus aureus; Microbiology","score_opus":0.025628955530901564,"score_gpt":0.37949815440554363,"score_spread":0.3538691988746421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015342809","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016564481,0.99924785,0.000045730263,0.000077823046,0.000077159486,0.0000030513672,0.000010263851,0.0000030051633,0.0003693414],"genre_scores_gemma":[0.00061819906,0.9989397,0.00008980888,0.00006361544,0.000086883854,0.0000036450201,0.000014819871,4.2447513e-7,0.00018283483],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99981815,0.000027173242,0.00004614088,0.000026406626,0.000064966516,0.000017180235],"domain_scores_gemma":[0.99969554,0.00013099531,0.00009564793,0.000006064427,0.00004568021,0.000026036416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035234506,0.00083425286,0.0017564872,0.0019055379,0.00019124906,0.0006161154,0.00051979366,0.00063077704,0.0018801624],"category_scores_gemma":[0.0006285321,0.0002512414,0.00047746525,0.0018549468,0.00029954268,0.0006696535,0.00039320186,0.0010048212,0.000681113],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001331539,0.00007901351,0.0009990259,0.027718842,0.00016860636,0.0007315183,0.000055858665,0.00019086008,0.0013458146,0.0006895136,0.018321117,0.9495667],"study_design_scores_gemma":[0.00016061535,0.00036873145,0.010033867,0.015982883,0.0009452497,0.013430223,0.00021483879,0.00012510024,0.0011141347,0.0007441909,0.9568428,0.000037376914],"about_ca_topic_score_codex":0.0020935286,"about_ca_topic_score_gemma":0.0035519842,"teacher_disagreement_score":0.0020935286,"about_ca_system_score_codex":0.0004210574,"about_ca_system_score_gemma":0.0011527654,"threshold_uncertainty_score":0.00628978},"labels":[],"label_agreement":null},{"id":"W2015769584","doi":"10.1007/bf02850204","title":"The dilution of benzalkonium chloride (BAK) in the tear Film","year":2006,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Ocular Infections and Treatments","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Allergan","keywords":"Gatifloxacin; Benzalkonium chloride; Medicine; Eye drop; Dilution; Chromatography; Ophthalmology; Antibiotics; Chemistry; Ciprofloxacin","score_opus":0.005948167077176857,"score_gpt":0.2835199093547235,"score_spread":0.2775717422775466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015769584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8339319,0.06217397,0.060426746,0.0067723794,0.0052625346,0.00047981998,0.00056805543,0.0009336631,0.029450903],"genre_scores_gemma":[0.94261533,0.010950661,0.028853722,0.0014836257,0.00055592053,0.00012031399,0.0003416038,0.00014872772,0.014930071],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99880564,0.0003418259,0.00008111717,0.0001429194,0.0005228129,0.00010565376],"domain_scores_gemma":[0.9989843,0.00045986805,0.00012534238,0.000082326755,0.0002550027,0.00009311431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012758686,0.00070298725,0.0004230663,0.0005296897,0.00045199948,0.0011038991,0.00050396303,0.00096155226,0.002304122],"category_scores_gemma":[0.0021272849,0.00032516013,0.00031266143,0.0002679908,0.0007679123,0.0011218924,0.0006304705,0.001410595,0.0013622651],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058677344,0.000042082276,0.0010455102,0.00018324179,0.0000129262135,0.00019636584,0.00009291983,0.00007167118,0.9840262,0.0008004261,0.0005562051,0.012385791],"study_design_scores_gemma":[0.000025220195,0.00062055973,0.00090101064,0.000025432233,0.000015938796,0.00053687097,0.00006927579,0.00049276784,0.9910458,0.00020559847,0.006047675,0.000013869832],"about_ca_topic_score_codex":0.0010412044,"about_ca_topic_score_gemma":0.0011493849,"teacher_disagreement_score":0.002304122,"about_ca_system_score_codex":0.00068986916,"about_ca_system_score_gemma":0.0007202218,"threshold_uncertainty_score":0.0077081323},"labels":[],"label_agreement":null},{"id":"W2015855111","doi":"10.1007/bf02877781","title":"Rabies: Epidemiology, pathogenesis, and prophylaxis","year":2007,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Rabies epidemiology and control","field":"Immunology and Microbiology","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"Merck Canada","keywords":"Rabies; Medicine; Vaccination; Rabies virus; Rabies vaccine; Post-exposure prophylaxis; Epidemiology; Herd immunity; Pre-exposure prophylaxis; Immunology; Virology; Pediatrics; Internal medicine; Syphilis","score_opus":0.07866749751149223,"score_gpt":0.40162682976966124,"score_spread":0.32295933225816903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015855111","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037322832,0.99883765,0.000091861846,0.0003167951,0.00030723112,0.0000036872514,0.000008426015,0.000006264293,0.00039079672],"genre_scores_gemma":[0.0002594074,0.9986047,0.00016674206,0.00019502117,0.0004511476,0.000005108402,0.000017132354,8.3704873e-7,0.00029993913],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995726,0.00008258619,0.000052508552,0.00005948217,0.00019227155,0.000040452094],"domain_scores_gemma":[0.9993254,0.00025661796,0.00009661704,0.00002652118,0.00021728699,0.000077539626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011972773,0.0016297245,0.0024668763,0.0021032707,0.00033746203,0.0014194801,0.0018429891,0.0018544825,0.0032017163],"category_scores_gemma":[0.0016049005,0.0003517998,0.000458792,0.0028255496,0.0009770353,0.0016761124,0.00081273133,0.002965157,0.0030349323],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009548072,0.000102901926,0.00023178075,0.0064354967,0.0000574669,0.00014282484,0.000032473876,0.00030870474,0.0008501424,0.0018442272,0.05538581,0.93451273],"study_design_scores_gemma":[0.00003377454,0.00008287562,0.00091917184,0.0030949519,0.000097877055,0.0014667425,0.00006222228,0.000105760715,0.00026596634,0.0020361538,0.99181765,0.000016943126],"about_ca_topic_score_codex":0.0017214367,"about_ca_topic_score_gemma":0.0030956974,"teacher_disagreement_score":0.0032017163,"about_ca_system_score_codex":0.0010469287,"about_ca_system_score_gemma":0.001930473,"threshold_uncertainty_score":0.010710835},"labels":[],"label_agreement":null},{"id":"W2025271862","doi":"10.1007/s12325-010-0065-y","title":"Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs","year":2010,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Circadian rhythm and melatonin","field":"Neuroscience","cited_by":130,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University; Centre for Addiction and Mental Health","funders":"","keywords":"Circadian rhythm; Medicine; Melatonin; Depression (economics); Internal medicine; Rhythm; Rheumatology; Sleep (system call); Lag; Endocrinology; Neuroscience; Psychology; Keynesian economics","score_opus":0.020232468540926883,"score_gpt":0.30113624049935034,"score_spread":0.2809037719584235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025271862","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000087104876,0.99931324,0.000061106584,0.00014719815,0.000115859126,0.0000019645472,0.000007643246,0.0000028178142,0.00026316114],"genre_scores_gemma":[0.0007518095,0.99825436,0.00014910444,0.00014227942,0.00037596675,0.000005658025,0.000015978938,8.5616523e-7,0.00030387583],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987304,0.000020514835,0.000023538461,0.000027487877,0.000045091874,0.000010456381],"domain_scores_gemma":[0.999726,0.00012639574,0.00005545606,0.00001005324,0.00005421623,0.000027901791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052616204,0.0009391601,0.0017509201,0.0014249126,0.00023785152,0.0009002918,0.0009321563,0.0012714415,0.002151972],"category_scores_gemma":[0.00068674056,0.00026976218,0.0004802096,0.0016535864,0.0005990166,0.0010810096,0.0005919314,0.0017603969,0.0011471928],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023863275,0.00013612339,0.0003986885,0.00825011,0.00012459188,0.00026376557,0.000037864713,0.00032280976,0.0022738662,0.0021464818,0.020763932,0.9650432],"study_design_scores_gemma":[0.00016123874,0.00036372806,0.0045283725,0.002594984,0.00033599813,0.003009053,0.00011538696,0.0003606051,0.0008550892,0.0042049126,0.9834245,0.000046201574],"about_ca_topic_score_codex":0.0016627761,"about_ca_topic_score_gemma":0.003361171,"teacher_disagreement_score":0.002151972,"about_ca_system_score_codex":0.0004909559,"about_ca_system_score_gemma":0.00081950997,"threshold_uncertainty_score":0.007199049},"labels":[],"label_agreement":null},{"id":"W2029482308","doi":"10.1007/bf02849951","title":"Hepatitis A: A preventable threat","year":2005,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Hepatitis Viruses Studies and Epidemiology","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"Centers for Disease Control and Prevention; Merck Canada","keywords":"Medicine; Hepatitis A; Subclinical infection; Fulminant hepatitis; Hepatitis; Transmission (telecommunications); Immunology; Population; Vaccination; Public health; Pediatrics; Hepatitis A vaccine; Disease; Internal medicine; Environmental health; Pathology","score_opus":0.0993260033890419,"score_gpt":0.4554084732739031,"score_spread":0.3560824698848612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029482308","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000036812457,0.99914277,0.000031181844,0.00031880185,0.00016597273,0.0000018705875,0.000006900082,0.0000025862776,0.00029313384],"genre_scores_gemma":[0.0003323601,0.9989679,0.00006431927,0.00025170128,0.00023273347,0.0000027019241,0.00000796943,4.14627e-7,0.00013990754],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99952924,0.00015048918,0.0001025394,0.000051638388,0.00013372026,0.000032347125],"domain_scores_gemma":[0.9983083,0.0009261082,0.0003856336,0.00003638573,0.00025073971,0.00009292289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013004972,0.0010225903,0.0023924515,0.003022646,0.00029619422,0.0012082303,0.00062835927,0.0014149919,0.0036226113],"category_scores_gemma":[0.002685947,0.00031107548,0.0005549026,0.003325657,0.00061839924,0.0016373744,0.0006971456,0.0015547466,0.0013642833],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107584485,0.000050836814,0.00044726822,0.030171497,0.00018631794,0.00020734151,0.000045357807,0.00014335949,0.00041844847,0.001303063,0.034693122,0.9322258],"study_design_scores_gemma":[0.000085382,0.00020391995,0.0031859588,0.030651754,0.00083173503,0.002161329,0.0001934981,0.000083523606,0.00034921407,0.002025667,0.96019924,0.000028727973],"about_ca_topic_score_codex":0.0022777824,"about_ca_topic_score_gemma":0.0038159783,"teacher_disagreement_score":0.0036226113,"about_ca_system_score_codex":0.0008794043,"about_ca_system_score_gemma":0.0027929621,"threshold_uncertainty_score":0.012118876},"labels":[],"label_agreement":null},{"id":"W2030454755","doi":"10.1007/s12325-014-0105-0","title":"A Vision for Drug Discovery and Development: Novel Targets and Multilateral Partnerships","year":2014,"lang":"en","type":"letter","venue":"Advances in Therapy","topic":"Treatment of Major Depression","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Psychiatry; Antidepressant; Anxiety; Psychotropic Agent; Tolerability; Psychotropic drug; Tetrabenazine; Mood; Drug; Pharmacology; Adverse effect","score_opus":0.03910138715306772,"score_gpt":0.3250471489770344,"score_spread":0.2859457618239667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030454755","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011701323,0.08455943,0.018760942,0.8395294,0.02185484,0.00008903107,0.00012400316,0.0003607452,0.03355146],"genre_scores_gemma":[0.16348065,0.16532779,0.063554324,0.4951176,0.04860912,0.0006983898,0.00057013956,0.00072736794,0.061914623],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.97659624,0.01045595,0.001007366,0.002218381,0.00642205,0.0033000645],"domain_scores_gemma":[0.9598019,0.009672305,0.0021694324,0.0035046753,0.007490557,0.017361129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.045589566,0.0014000855,0.0017786007,0.002225762,0.0043308586,0.019492175,0.0035492377,0.0144135095,0.021622576],"category_scores_gemma":[0.025048893,0.00079650944,0.001467472,0.0020678667,0.01386346,0.038217638,0.01776217,0.031110166,0.007827397],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019515688,0.0002602552,0.00028228597,0.00061595795,0.00008746063,0.00028682515,0.0007943974,0.0005979882,0.0010301867,0.5742919,0.29981232,0.121745266],"study_design_scores_gemma":[0.00006983256,0.00014697478,0.0001729672,0.0004658322,0.00001882704,0.00025132854,0.00069677795,0.00063258904,0.00030897258,0.3807137,0.61647725,0.000044924665],"about_ca_topic_score_codex":0.0010791256,"about_ca_topic_score_gemma":0.0013709364,"teacher_disagreement_score":0.045589566,"about_ca_system_score_codex":0.008738917,"about_ca_system_score_gemma":0.017103145,"threshold_uncertainty_score":0.24110353},"labels":[],"label_agreement":null},{"id":"W2031131661","doi":"10.1007/s12325-013-0060-1","title":"Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis","year":2013,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":520,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Sanofi; Genentech; AstraZeneca; Amgen; Pfizer; Allergan; Bristol-Myers Squibb; Genomic Health; GlaxoSmithKline","keywords":"Exemestane; Everolimus; Medicine; Hazard ratio; Internal medicine; Aromatase inhibitor; Breast cancer; Oncology; Clinical endpoint; Placebo; Population; Adverse effect; Progression-free survival; Confidence interval; Cancer; Clinical trial; Aromatase; Chemotherapy; Pathology","score_opus":0.004021741589793851,"score_gpt":0.25670740316139484,"score_spread":0.252685661571601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031131661","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16735528,0.8132425,0.001767264,0.0026364122,0.0003685164,0.0017180019,0.007271568,0.00013216499,0.0055083227],"genre_scores_gemma":[0.77074564,0.20601916,0.005952688,0.0024717436,0.00093079434,0.0015678093,0.008577686,0.0000791992,0.0036552653],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99664706,0.0020522536,0.00039386732,0.00031865243,0.0005016249,0.00008658597],"domain_scores_gemma":[0.9942009,0.003397727,0.0015612948,0.00020941315,0.0003596343,0.0002711225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010142779,0.0008271852,0.0042304,0.0013582386,0.00014164104,0.0015464864,0.0008153629,0.0007214081,0.0038643014],"category_scores_gemma":[0.0097401235,0.0004018172,0.007424362,0.00096483383,0.00028518113,0.00060834986,0.000587837,0.0013911573,0.0003548742],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34836662,0.0006139127,0.030491592,0.07844315,0.16513745,0.0003438335,0.00028047204,0.0051134904,0.004117961,0.0014840361,0.010513767,0.35509375],"study_design_scores_gemma":[0.23266841,0.07365602,0.23189825,0.019682791,0.34867597,0.0025385201,0.00026226768,0.009095668,0.0025014256,0.0045991237,0.07412112,0.00030048157],"about_ca_topic_score_codex":0.000929241,"about_ca_topic_score_gemma":0.0025740785,"teacher_disagreement_score":0.010142779,"about_ca_system_score_codex":0.0011449335,"about_ca_system_score_gemma":0.0016038731,"threshold_uncertainty_score":0.053640783},"labels":[],"label_agreement":null},{"id":"W2031765694","doi":"10.1007/bf02850014","title":"Twice-daily and once-daily nedocromil sodium 2% ophthalmic solution for the treatment of seasonal allergic conjunctivitis","year":2002,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Ocular Surface and Contact Lens","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Niagara","funders":"","keywords":"Medicine; Nedocromil Sodium; Regimen; Itching; Allergic conjunctivitis; Allergy; Erythema; Anesthesia; Nedocromil; Activities of daily living; Photophobia; Surgery; Dermatology; Internal medicine; Physical therapy; Placebo","score_opus":0.0250427320413113,"score_gpt":0.2884445988140779,"score_spread":0.2634018667727666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031765694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9633203,0.027028786,0.0011337491,0.0011129598,0.0008780951,0.000307958,0.00021581,0.0001554307,0.0058468566],"genre_scores_gemma":[0.98609793,0.0076719043,0.0013648265,0.00034019834,0.00021883106,0.00010634413,0.00022264289,0.000017639979,0.0039596437],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9998709,0.000031098745,0.000013723707,0.00001623513,0.000031276937,0.00003684726],"domain_scores_gemma":[0.9999299,0.000013020383,0.0000084041385,0.000006428148,0.0000076648585,0.00003458002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027801903,0.0003116469,0.0007873815,0.0003145816,0.0004134089,0.00014793224,0.000459385,0.00047619618,0.0018493949],"category_scores_gemma":[0.0003273854,0.00013606928,0.00054305565,0.00020923212,0.00021268529,0.00025030487,0.00012643261,0.0008196212,0.00027890498],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06836072,0.011818981,0.008025973,0.0017245268,0.0005102336,0.00443844,0.00038143952,0.00087644486,0.32810637,0.0007342062,0.008297008,0.5667258],"study_design_scores_gemma":[0.06940001,0.2779566,0.31923094,0.00045459022,0.0021814783,0.02460303,0.00093988416,0.0064144586,0.19595017,0.0009909344,0.10164649,0.00023134648],"about_ca_topic_score_codex":0.0018201016,"about_ca_topic_score_gemma":0.0059681595,"teacher_disagreement_score":0.0018493949,"about_ca_system_score_codex":0.00028643786,"about_ca_system_score_gemma":0.00047211605,"threshold_uncertainty_score":0.0061867833},"labels":[],"label_agreement":null},{"id":"W2034737107","doi":"10.1007/bf02850362","title":"Spermicidal activity of a new contraceptive sponge","year":2002,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hemostasis and retained surgical items","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Collège Shawinigan","funders":"","keywords":"Medicine; Sponge; Colposcopy; Cervix; Irritation; Gynecology; Internal medicine; Biology; Immunology","score_opus":0.04216022221333456,"score_gpt":0.32608020600497994,"score_spread":0.2839199837916454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034737107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.963777,0.021223241,0.003071803,0.00062505977,0.00043119027,0.00008878889,0.00018804998,0.000090504094,0.010504347],"genre_scores_gemma":[0.97608256,0.010159433,0.003956639,0.0002545793,0.00021276539,0.000032820688,0.00024198831,0.000023018229,0.009036055],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988914,0.00003919096,0.00000818959,0.000012671008,0.000027324468,0.000023510256],"domain_scores_gemma":[0.9998443,0.0000689944,0.0000212872,0.00001493944,0.000016011545,0.00003442751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024060272,0.00022435005,0.00022078144,0.00040529147,0.00019961737,0.00022291357,0.0002615454,0.00029064566,0.0019274967],"category_scores_gemma":[0.00037094508,0.00012414815,0.00031402273,0.0001491516,0.00034481194,0.00024716853,0.00017739617,0.0002834163,0.00036564074],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019223137,0.00030982954,0.001317516,0.00042554055,0.000055431523,0.0029251368,0.000115047755,0.00050674094,0.9566811,0.0007801756,0.00081329275,0.034147818],"study_design_scores_gemma":[0.00039913488,0.013767049,0.0061618364,0.00006323056,0.00019921415,0.008690004,0.00011988438,0.0027008879,0.92623585,0.00033901833,0.041263796,0.00006011436],"about_ca_topic_score_codex":0.00032096863,"about_ca_topic_score_gemma":0.00028282168,"teacher_disagreement_score":0.0019274967,"about_ca_system_score_codex":0.00009990973,"about_ca_system_score_gemma":0.00018001067,"threshold_uncertainty_score":0.00644809},"labels":[],"label_agreement":null},{"id":"W2037948983","doi":"10.1007/bf02849883","title":"Do angiotensin II antagonists provide benefits beyond blood pressure reduction?","year":2005,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Losartan; Irbesartan; Diabetes mellitus; Blood pressure; Internal medicine; Nephropathy; Angiotensin II; Diabetic nephropathy; Angiotensin II receptor type 1; Endocrinology; Pathophysiology of hypertension; Cardiology; Pharmacology","score_opus":0.04083159708548231,"score_gpt":0.3511079407050125,"score_spread":0.31027634361953016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037948983","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014569527,0.9986093,0.000039188417,0.0005303619,0.00016385491,0.0000049768582,0.00002238003,0.0000026786984,0.00048141935],"genre_scores_gemma":[0.0010884606,0.997554,0.00012721315,0.00068628375,0.00028487045,0.000008910241,0.000019333926,8.304224e-7,0.0002301089],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9995334,0.0001452732,0.00010921648,0.000057367335,0.00011920038,0.00003552266],"domain_scores_gemma":[0.9982496,0.0011843278,0.00033876757,0.00002916814,0.00014456535,0.000053504336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018797553,0.0009923928,0.004617948,0.0014267559,0.000208953,0.0011354694,0.00092540035,0.0014534828,0.0062457086],"category_scores_gemma":[0.0027571847,0.00031965948,0.0011326316,0.0017549578,0.0004864777,0.0013799412,0.0004154813,0.0017395158,0.0015226376],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015754546,0.00013249657,0.0003067346,0.05440886,0.0014270266,0.0002480892,0.00005356032,0.00010865827,0.0013043495,0.0016366083,0.023470227,0.91532797],"study_design_scores_gemma":[0.0031755574,0.0019343492,0.007884545,0.05455536,0.012322935,0.002045705,0.0003294426,0.0001818837,0.0013655798,0.003919441,0.91221005,0.00007502596],"about_ca_topic_score_codex":0.0009098393,"about_ca_topic_score_gemma":0.0039614327,"teacher_disagreement_score":0.0062457086,"about_ca_system_score_codex":0.00053961517,"about_ca_system_score_gemma":0.0011788746,"threshold_uncertainty_score":0.020893931},"labels":[],"label_agreement":null},{"id":"W2039599497","doi":"10.1007/bf02849796","title":"Attention deficit hyperactivity disorder: An update","year":2003,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"University of Calgary","keywords":"Attention deficit hyperactivity disorder; Stimulant; Medicine; Attention deficit disorder; Psychiatry; Attention deficit; Pediatrics","score_opus":0.05501411464251477,"score_gpt":0.4041931295709455,"score_spread":0.34917901492843073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039599497","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011301433,0.9975165,0.000116513416,0.0004186119,0.00079789775,0.0000099410745,0.000037513462,0.0000126066425,0.0009773689],"genre_scores_gemma":[0.00045912902,0.99703324,0.00032592277,0.000530092,0.0007313839,0.000013537107,0.000049738323,0.000002246229,0.00085471856],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99959093,0.00006512443,0.00009806393,0.000055455075,0.00015770721,0.0000327718],"domain_scores_gemma":[0.9989697,0.00043084382,0.00018940735,0.000027514949,0.0002885538,0.000093927585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010270894,0.0016480647,0.0032154433,0.00468316,0.00041454507,0.001749618,0.0013739838,0.0018580032,0.005717996],"category_scores_gemma":[0.0018945074,0.0004438279,0.00081386627,0.0051319343,0.00045496837,0.002669807,0.000849735,0.0020689326,0.0023673794],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011950648,0.00013362372,0.00038815895,0.012697801,0.00013424359,0.0004582821,0.000044013603,0.00026242042,0.00049929996,0.0005371956,0.083012074,0.9017135],"study_design_scores_gemma":[0.00012380238,0.00017535759,0.002079737,0.0089303125,0.0006703565,0.0038546019,0.000114039154,0.0001742093,0.00022130567,0.0007043846,0.98291886,0.00003310835],"about_ca_topic_score_codex":0.004195505,"about_ca_topic_score_gemma":0.012845184,"teacher_disagreement_score":0.005717996,"about_ca_system_score_codex":0.0011383248,"about_ca_system_score_gemma":0.0026075358,"threshold_uncertainty_score":0.01912862},"labels":[],"label_agreement":null},{"id":"W2041092876","doi":"10.1007/bf02849904","title":"Pertussis in Adolescents","year":2007,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Bacterial Infections and Vaccines","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"Sanofi Pasteur; Sanofi","keywords":"Medicine; Vaccination; Pediatrics; Diphtheria; Immunization; Immunology; Booster dose; Tetanus; Pertussis vaccine; Immunity; Pneumonia; Internal medicine; Immune system","score_opus":0.04383583736231224,"score_gpt":0.3751473641219168,"score_spread":0.33131152675960457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041092876","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003284282,0.9969152,0.00012141407,0.00064662995,0.0004159634,0.0000063968973,0.000018776102,0.00000686554,0.0015403099],"genre_scores_gemma":[0.0018183471,0.99597794,0.00016220025,0.00047557193,0.00050504826,0.000011650617,0.000034645098,0.0000013726808,0.0010133175],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987376,0.0000306122,0.000018442888,0.00002041506,0.000038799208,0.000017856855],"domain_scores_gemma":[0.99986017,0.000053482217,0.0000343096,0.000003440339,0.00002513838,0.000023452027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030816026,0.00064538314,0.0011225075,0.0011964644,0.00024406452,0.0005390777,0.00041651237,0.0008688172,0.0027024318],"category_scores_gemma":[0.00056892744,0.00020194372,0.0002734465,0.0008797647,0.0002486254,0.00057564175,0.0005476745,0.0013754251,0.0013511665],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010435089,0.00006214987,0.0009510441,0.008440791,0.00004330745,0.001108981,0.00008269806,0.00015679139,0.0008285492,0.0014474499,0.040729325,0.9460445],"study_design_scores_gemma":[0.000064036365,0.00016345493,0.0049318513,0.011026382,0.00020672771,0.013097537,0.00017703314,0.00011922429,0.00052673544,0.0010187111,0.9686529,0.00001551218],"about_ca_topic_score_codex":0.0020799856,"about_ca_topic_score_gemma":0.0035782668,"teacher_disagreement_score":0.0027024318,"about_ca_system_score_codex":0.0004160106,"about_ca_system_score_gemma":0.0011298008,"threshold_uncertainty_score":0.009040594},"labels":[],"label_agreement":null},{"id":"W2042419273","doi":"10.1007/bf02852391","title":"Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa","year":2001,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Sinusitis and nasal conditions","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Clarithromycin; Gastroenterology; Edema; Internal medicine; Sinusitis; Inflammation; Maxillary sinus; Sinus (botany); CD68; Pathology; Surgery; Immunohistochemistry","score_opus":0.008429592275651009,"score_gpt":0.28125749022338076,"score_spread":0.27282789794772977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042419273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98754287,0.0104946075,0.0000887647,0.00029860792,0.000060653147,0.000025983754,0.00011261228,0.000013337167,0.0013625444],"genre_scores_gemma":[0.9969438,0.002121545,0.00017169221,0.00014934699,0.00011217888,0.000014667606,0.00012247516,0.0000020019722,0.00036232997],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997228,0.00009902791,0.00005212058,0.00002827686,0.000055135468,0.00004259576],"domain_scores_gemma":[0.99928916,0.00025360382,0.00015059428,0.00002085733,0.00007683605,0.0002089489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003355815,0.00027080352,0.0009964962,0.00021223354,0.00028573387,0.00022986323,0.00011043381,0.00050335046,0.0013482223],"category_scores_gemma":[0.0016947082,0.00012282054,0.00026755553,0.000217024,0.00014797837,0.0003182783,0.0001300193,0.0005714562,0.00017206812],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053888556,0.0021432396,0.68843436,0.0010651676,0.00053349196,0.007526916,0.0010109388,0.0002652264,0.057307925,0.00012182457,0.0022776471,0.18542476],"study_design_scores_gemma":[0.0014609018,0.032575853,0.951002,0.000077730656,0.00053458184,0.0063717533,0.0005134773,0.00047204806,0.0038325756,0.000039665967,0.0030999475,0.000019564111],"about_ca_topic_score_codex":0.0012665096,"about_ca_topic_score_gemma":0.0030285215,"teacher_disagreement_score":0.0013482223,"about_ca_system_score_codex":0.00020167818,"about_ca_system_score_gemma":0.00028985314,"threshold_uncertainty_score":0.0045102835},"labels":[],"label_agreement":null},{"id":"W2042533101","doi":"10.1007/s12325-012-0040-x","title":"Impact of Daily Dosing Frequency on Adherence to Chronic Medications Among Nonvalvular Atrial Fibrillation Patients","year":2012,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Atrial fibrillation; Internal medicine; Dosing; Confounding; Odds ratio; Regimen; Logistic regression; Diabetes mellitus; Cardiology; Endocrinology","score_opus":0.03148974737146387,"score_gpt":0.37759576891472324,"score_spread":0.34610602154325937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042533101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998035,0.00044647267,0.000050690214,0.00024020145,0.000021478923,0.000006727339,0.00007957535,0.0000044368626,0.0011153591],"genre_scores_gemma":[0.9994079,0.00010203261,0.000093943694,0.000092978415,0.000034041255,0.000004352002,0.000068069756,0.0000021173344,0.00019452392],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804723,0.00080529257,0.00030636357,0.00015961756,0.0004390578,0.00024243144],"domain_scores_gemma":[0.9887106,0.0056255083,0.0032724452,0.0005600613,0.00065793784,0.0011734873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017317737,0.00022628739,0.00068956194,0.00048780133,0.0006255205,0.0010336052,0.00032426053,0.0008571207,0.0021591308],"category_scores_gemma":[0.015422974,0.00024125328,0.0013080768,0.0008059273,0.00021285203,0.0007116077,0.0004065981,0.0013012282,0.00016861416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012134298,0.000803228,0.98252696,0.000025544237,0.0003826872,0.00006880999,0.00017396074,0.00015603767,0.00023097321,0.000038133865,0.00012414262,0.014256151],"study_design_scores_gemma":[0.000039369577,0.0007133773,0.9982516,0.000008621117,0.00015236925,0.000086564076,0.00011181752,0.0004464646,0.00003788996,0.000044195232,0.00010095322,0.0000066569037],"about_ca_topic_score_codex":0.004386337,"about_ca_topic_score_gemma":0.006027254,"teacher_disagreement_score":0.004386337,"about_ca_system_score_codex":0.00049619627,"about_ca_system_score_gemma":0.0006436847,"threshold_uncertainty_score":0.009158552},"labels":[],"label_agreement":null},{"id":"W2042751221","doi":"10.1007/s12325-015-0195-3","title":"Efficacy and Safety of Linagliptin Co-Administered with Low-Dose Metformin Once Daily Versus High-Dose Metformin Twice Daily in Treatment-Naïve Patients with Type 2 Diabetes: a Double-Blind Randomized Trial","year":2015,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Metformin; Linagliptin; Medicine; Type 2 diabetes; Internal medicine; Nausea; Gastroenterology; Vildagliptin; Clinical endpoint; Diabetes mellitus; Vomiting; Dipeptidyl peptidase-4 inhibitor; Randomized controlled trial; Endocrinology; Insulin","score_opus":0.0350316925553353,"score_gpt":0.32522749050495703,"score_spread":0.29019579794962175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042751221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900433,0.004494423,0.000535395,0.00042665063,0.0005603523,0.0023112018,0.00054367067,0.00007476759,0.0010102335],"genre_scores_gemma":[0.9894155,0.0019348501,0.001567621,0.0008193964,0.00073860056,0.003449518,0.00062956626,0.000018130773,0.0014268651],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981323,0.0011597846,0.00017726963,0.0002850606,0.00012430368,0.00012130058],"domain_scores_gemma":[0.99746895,0.00091871456,0.00066219753,0.00020679802,0.00014597495,0.0005973562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033556852,0.0013103635,0.0038855153,0.00044506908,0.0005062946,0.0013336628,0.0011569859,0.0021776864,0.006961821],"category_scores_gemma":[0.0026816742,0.0008359808,0.0024988009,0.00043843326,0.0012185867,0.0010388785,0.00048492398,0.0026350904,0.0010576793],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99210817,0.0027065144,0.00038560174,0.00024215059,0.00055145763,0.000008337016,0.000012706601,0.00005975897,0.00061993324,0.000013562699,0.000089317014,0.0032024507],"study_design_scores_gemma":[0.96785474,0.030405099,0.0008442853,0.000016521099,0.00043470194,0.000009616327,0.0000055219284,0.00016622107,0.000135263,0.000027374048,0.000094225856,0.0000064103033],"about_ca_topic_score_codex":0.0005197124,"about_ca_topic_score_gemma":0.0010677415,"teacher_disagreement_score":0.006961821,"about_ca_system_score_codex":0.000795852,"about_ca_system_score_gemma":0.0011222258,"threshold_uncertainty_score":0.02328962},"labels":[],"label_agreement":null},{"id":"W2046049334","doi":"10.1007/s12325-013-0042-3","title":"The Effect of Personality Dimensions on Functional Outcomes in Mood Disorders","year":2013,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Personality Disorders and Psychopathology","field":"Psychology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Extraversion and introversion; Neuroticism; Agreeableness; Conscientiousness; Openness to experience; Big Five personality traits; Clinical psychology; Major depressive disorder; Personality; Psychology; Personality disorders; Mood; Medicine; Psychiatry","score_opus":0.012852323324248505,"score_gpt":0.33146203620695885,"score_spread":0.31860971288271034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046049334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981998,0.0006655394,0.00004288534,0.000115823,0.000027971168,0.000006923442,0.000039185757,0.0000019676113,0.0008998927],"genre_scores_gemma":[0.99947625,0.00023492091,0.000056294084,0.000025818774,0.000013734914,0.0000049761743,0.000037272755,0.0000011602255,0.00014961246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905497,0.00056419603,0.000063008265,0.000054798948,0.00014176563,0.00012135391],"domain_scores_gemma":[0.9955686,0.002444536,0.0006392291,0.00017499918,0.00016843122,0.0010043264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014872036,0.00027985053,0.00044427472,0.0003448361,0.00048649832,0.00060209614,0.00022448892,0.000307257,0.0015656122],"category_scores_gemma":[0.0057709725,0.000114188566,0.00073706533,0.00038806943,0.00050347496,0.0003342789,0.000605346,0.00082363526,0.00013222694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009329575,0.002172197,0.8963797,0.00011948598,0.0011538921,0.00020066071,0.00050170824,0.00061911915,0.0016535947,0.00023495348,0.000321397,0.08731361],"study_design_scores_gemma":[0.000062193205,0.0011486941,0.99811906,0.000011944295,0.00007791511,0.000040505296,0.00012968508,0.00013324527,0.00005979066,0.00012026747,0.000092175695,0.0000044639974],"about_ca_topic_score_codex":0.0016313609,"about_ca_topic_score_gemma":0.004515836,"teacher_disagreement_score":0.0016313609,"about_ca_system_score_codex":0.0004939679,"about_ca_system_score_gemma":0.00037431717,"threshold_uncertainty_score":0.0078651905},"labels":[],"label_agreement":null},{"id":"W2048070250","doi":"10.1007/bf02853165","title":"Nedocromil sodium in golfers with seasonal allergic conjunctivitis","year":2001,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Ocular Surface and Contact Lens","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Niagara College; Regional Municipality of Niagara","funders":"Allergan","keywords":"Medicine; Nedocromil Sodium; Ragweed; Erythema; Nedocromil; Allergy; Allergic conjunctivitis; Dermatology; Anesthesia; Photophobia; Eye drop; Itching; Internal medicine; Ophthalmology; Placebo","score_opus":0.00952622852601325,"score_gpt":0.2660237597901255,"score_spread":0.25649753126411223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048070250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98745465,0.007888182,0.0001157908,0.0009487295,0.00021504851,0.00008608066,0.00010505705,0.00003055201,0.0031559647],"genre_scores_gemma":[0.9967211,0.0017861174,0.0001516725,0.0003349946,0.00009818766,0.000020944392,0.00010132303,0.0000028666589,0.0007828845],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99971884,0.00009892898,0.000036742014,0.000021870404,0.000039994786,0.000083567706],"domain_scores_gemma":[0.9997509,0.00007759633,0.000031124946,0.000013811375,0.000023737217,0.000102887185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004278643,0.00037378707,0.00091852475,0.00032561427,0.0006264929,0.0002602961,0.00034582638,0.0008796347,0.0012277132],"category_scores_gemma":[0.0011752269,0.00012135253,0.00059294613,0.00025276278,0.00030282786,0.00036149958,0.00021843381,0.0007188367,0.00022931599],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18247955,0.010097108,0.3043825,0.0020398789,0.0010744128,0.11584873,0.001372546,0.0012103703,0.044535965,0.00058268174,0.0083978865,0.32797837],"study_design_scores_gemma":[0.01714254,0.1011586,0.7636475,0.00036333923,0.0015457858,0.08059946,0.0017351037,0.0031548827,0.0144689465,0.00044353717,0.01562924,0.00011113938],"about_ca_topic_score_codex":0.0048025385,"about_ca_topic_score_gemma":0.0103235375,"teacher_disagreement_score":0.0048025385,"about_ca_system_score_codex":0.00068041816,"about_ca_system_score_gemma":0.0006531772,"threshold_uncertainty_score":0.009549141},"labels":[],"label_agreement":null},{"id":"W2048501761","doi":"10.1007/bf02849928","title":"Genital infection with human papillomavirus in adolescents","year":2005,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Colposcopy; Genital warts; HPV infection; Sex organ; Dysplasia; Cervical cancer; Chlamydia; Cryotherapy; Gynecology; Subclinical infection; Cervical intraepithelial neoplasia; Dermatology; Internal medicine; Cancer; Immunology; Surgery","score_opus":0.07235310809388833,"score_gpt":0.46633267731604733,"score_spread":0.393979569222159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048501761","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011616395,0.9992982,0.00003009412,0.0001131074,0.00009474916,0.000003693979,0.00001388262,0.0000022524382,0.0003278413],"genre_scores_gemma":[0.00048520468,0.99914145,0.00005423106,0.00008460103,0.000068626694,0.0000034458194,0.000011692206,3.3642687e-7,0.00015042018],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997929,0.000042674623,0.00004907745,0.000029495024,0.00006987556,0.000015998558],"domain_scores_gemma":[0.99953914,0.00023375521,0.00012293167,0.000008102247,0.00006887331,0.000027228141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004803412,0.0006549303,0.0017635236,0.002505605,0.0001895769,0.0006873371,0.0004987474,0.00070322916,0.0026620491],"category_scores_gemma":[0.0011682014,0.00027952043,0.00048112936,0.0025970493,0.00026860624,0.00083392335,0.00050762057,0.0008265687,0.00065934187],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065602544,0.000049865965,0.0012396768,0.03584815,0.00013763538,0.00036712113,0.00008432713,0.00016130293,0.00058006594,0.0006392182,0.020500602,0.94032645],"study_design_scores_gemma":[0.00007287235,0.00023607672,0.008573232,0.043825407,0.0012092311,0.0067444076,0.00030810508,0.00011122777,0.0005594492,0.000719855,0.9376123,0.000027830341],"about_ca_topic_score_codex":0.002674537,"about_ca_topic_score_gemma":0.0050157,"teacher_disagreement_score":0.002674537,"about_ca_system_score_codex":0.00047000288,"about_ca_system_score_gemma":0.0015625055,"threshold_uncertainty_score":0.00890547},"labels":[],"label_agreement":null},{"id":"W2049211995","doi":"10.1007/bf02854842","title":"Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: a multicenter comparison in patients with seasonal allergic conjunctivitis","year":2000,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Ocular Surface and Contact Lens","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AGE-WELL","keywords":"Ketorolac Tromethamine; Medicine; Tolerability; Ketorolac; Anesthesia; Eye drop; Placebo; Pharmacology; Adverse effect","score_opus":0.0068114426366543785,"score_gpt":0.25747307312865775,"score_spread":0.25066163049200335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049211995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976788,0.0017852823,0.00005602883,0.0000732839,0.000034987894,0.00006538956,0.00009437259,0.0000069268135,0.00020486895],"genre_scores_gemma":[0.9988398,0.0005372747,0.00011487049,0.0000775174,0.00008590858,0.000062653075,0.00017323239,0.0000031353616,0.00010561424],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99844164,0.0008058117,0.00021046489,0.00022950523,0.00016506192,0.00014753966],"domain_scores_gemma":[0.99782145,0.0005647096,0.0006867582,0.00019534415,0.00020059185,0.0005310962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001968359,0.00088281324,0.002132976,0.00048403797,0.00041868392,0.00072118605,0.0007226332,0.001193974,0.0013041123],"category_scores_gemma":[0.0032061434,0.0005152031,0.001662686,0.00048232762,0.0009716595,0.0010627412,0.00034533336,0.0012783946,0.00034785218],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89449203,0.00788303,0.039460313,0.00037102005,0.0025255976,0.0001997516,0.00030903984,0.00052716094,0.016435836,0.00009108094,0.00038153576,0.037323672],"study_design_scores_gemma":[0.2430675,0.49933696,0.24344878,0.00009628807,0.0039124573,0.00081258296,0.00068979524,0.0021798795,0.0052223913,0.00013711644,0.000971853,0.00012446968],"about_ca_topic_score_codex":0.0015030317,"about_ca_topic_score_gemma":0.0013752464,"teacher_disagreement_score":0.002132976,"about_ca_system_score_codex":0.0010427475,"about_ca_system_score_gemma":0.00059492857,"threshold_uncertainty_score":0.010409772},"labels":[],"label_agreement":null},{"id":"W2052480782","doi":"10.1007/bf02850250","title":"Herbal medicine in pregnancy and childbirth","year":2001,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"","keywords":"Medicine; Miscarriage; Alternative medicine; Childbirth; Pregnancy; Traditional medicine; Medicinal herbs; Biomedicine; Intervention (counseling); Reproductive medicine; Family medicine; Nursing; Bioinformatics","score_opus":0.07442254208158312,"score_gpt":0.43475722358077035,"score_spread":0.36033468149918724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052480782","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009472268,0.99933344,0.000027730217,0.00008013703,0.000073654664,0.0000038816997,0.000008077984,0.0000015937212,0.00037665325],"genre_scores_gemma":[0.0005052011,0.9990447,0.00010320776,0.00007650945,0.00006815147,0.000004040755,0.000007518947,3.68027e-7,0.0001901559],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997358,0.00007056136,0.00006472852,0.00003837976,0.00007578233,0.000014808785],"domain_scores_gemma":[0.9993888,0.00040910777,0.00010096013,0.000015520629,0.00006490228,0.000020675303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007816021,0.00090800505,0.002182971,0.0038403138,0.00038186266,0.0010216497,0.0006557644,0.0010630484,0.004351756],"category_scores_gemma":[0.001373747,0.00037704024,0.0005615224,0.004662652,0.0005725237,0.0013189228,0.00070067606,0.0010246206,0.0007492993],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016099798,0.00009690906,0.00029179142,0.06455314,0.00019530836,0.00032986037,0.00010788091,0.00016732555,0.0009133945,0.0011885719,0.008106122,0.9238887],"study_design_scores_gemma":[0.00019071925,0.00038931597,0.0065927133,0.048178256,0.0017033879,0.0042716768,0.0005163775,0.00017202302,0.00073548045,0.002169746,0.9350306,0.000049730083],"about_ca_topic_score_codex":0.0028600716,"about_ca_topic_score_gemma":0.008693035,"teacher_disagreement_score":0.004351756,"about_ca_system_score_codex":0.000586274,"about_ca_system_score_gemma":0.0015265828,"threshold_uncertainty_score":0.014558077},"labels":[],"label_agreement":null},{"id":"W2058135699","doi":"10.1007/bf02849948","title":"Successful alpha-1 receptor blockade therapy in a toddler with infrequent and difficult voiding","year":2005,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Discontinuation; Blockade; Toddler; Glans penis; Penis; Urology; Internal medicine; Surgery; Anesthesia; Receptor","score_opus":0.016447433172502468,"score_gpt":0.31616925180182165,"score_spread":0.2997218186293192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058135699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97048384,0.0034768363,0.0031506016,0.013319022,0.0016137495,0.00019697036,0.0004067635,0.00036381045,0.0069883685],"genre_scores_gemma":[0.98581195,0.0024282879,0.003509127,0.0033418592,0.00040624445,0.000054124357,0.00021500466,0.00007710198,0.004156227],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9996799,0.00004000254,0.00004795418,0.000057246863,0.000041212967,0.00013369821],"domain_scores_gemma":[0.99939024,0.000105531864,0.00006765385,0.00004140506,0.00004407382,0.0003509998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024006994,0.0011100295,0.0014980779,0.000781024,0.0021515377,0.0005645824,0.001331043,0.003064333,0.00090634415],"category_scores_gemma":[0.0020670325,0.000380074,0.0015364191,0.00040666846,0.00074217323,0.0004522251,0.0010054978,0.0031404807,0.0005025829],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000809796,0.0012241575,0.032114405,0.000097075994,0.0001261236,0.9326205,0.0003253135,0.00037508493,0.004615071,0.00030306826,0.0025846057,0.02480485],"study_design_scores_gemma":[0.00025230556,0.006205231,0.08968737,0.0001241454,0.00013097157,0.8927936,0.0009066302,0.0017103862,0.0042451834,0.00049903797,0.003352327,0.00009276768],"about_ca_topic_score_codex":0.008849613,"about_ca_topic_score_gemma":0.014321467,"teacher_disagreement_score":0.008849613,"about_ca_system_score_codex":0.0012249739,"about_ca_system_score_gemma":0.0012688496,"threshold_uncertainty_score":0.017596245},"labels":[],"label_agreement":null},{"id":"W2058586677","doi":"10.1007/s12325-010-0072-z","title":"The rate of metabolic syndrome in euthymic Canadian individuals with bipolar I/II disorder","year":2010,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto","funders":"Core Research for Evolutional Science and Technology; University Health Network","keywords":"Medicine; Metabolic syndrome; Internal medicine; Blood pressure; Hypertriglyceridemia; Bipolar disorder; Abdominal obesity; Asymptomatic; National Cholesterol Education Program; Waist; Endocrinology; Diabetes mellitus; Obesity; Physical therapy; Cardiology; Triglyceride; Cholesterol; Lithium (medication)","score_opus":0.005858365976466883,"score_gpt":0.2597760844916533,"score_spread":0.2539177185151864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058586677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914458,0.0011686563,0.00006452247,0.00045531444,0.00003333943,0.000016662685,0.0015423741,0.000009284409,0.005264007],"genre_scores_gemma":[0.99767643,0.0006411448,0.000114204624,0.00010739556,0.000015008714,0.0000043930545,0.0005684276,0.0000043803907,0.00086853467],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995141,0.000058073227,0.000033478755,0.000050411512,0.00020682362,0.00013702706],"domain_scores_gemma":[0.99809057,0.00014486317,0.00049865316,0.000038858692,0.00084454723,0.00038248018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039491372,0.00019458552,0.00032547463,0.0012006006,0.0015113386,0.00097226875,0.00070663955,0.0004917439,0.002696978],"category_scores_gemma":[0.003657592,0.0001723144,0.0003362037,0.0018847381,0.00032638846,0.00033339192,0.00036363775,0.0009130469,0.00019189055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022363373,0.000028620037,0.9936985,0.000018125882,0.000037246667,0.00023642763,0.00034114884,0.000039568222,0.00022171486,0.00008904345,0.0005928163,0.0044732373],"study_design_scores_gemma":[0.000003792702,0.00001718591,0.9984578,0.00001028163,0.000020366113,0.00036883244,0.0006090456,0.000090637644,0.000033368415,0.000019641604,0.0003621347,0.00000705607],"about_ca_topic_score_codex":0.90918547,"about_ca_topic_score_gemma":0.93694234,"teacher_disagreement_score":0.09081453,"about_ca_system_score_codex":0.007942246,"about_ca_system_score_gemma":0.006196936,"threshold_uncertainty_score":0.18269867},"labels":[],"label_agreement":null},{"id":"W2060221163","doi":"10.1007/s12325-012-0037-5","title":"Treatment Patterns in the First Year After Initiating Tumor Necrosis Factor Blockers in Real-World Settings","year":2012,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thomson Reuters (Canada)","funders":"Pfizer; Amgen","keywords":"Etanercept; Medicine; Adalimumab; Infliximab; Golimumab; Psoriatic arthritis; Rheumatoid arthritis; Internal medicine; Abatacept; Ankylosing spondylitis; Psoriasis; Ustekinumab; Tumor necrosis factor alpha; Rituximab; Dermatology; Lymphoma","score_opus":0.020276430449864838,"score_gpt":0.3219488934943859,"score_spread":0.30167246304452106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060221163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980002,0.0004828957,0.00006818293,0.00006254933,0.0000074231325,0.000015179989,0.0009825443,0.0000043655373,0.00037662045],"genre_scores_gemma":[0.9988488,0.00012174926,0.00007091237,0.000041263298,0.00001167323,0.000017118819,0.00080930436,0.0000016082677,0.000077689285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980773,0.0004705576,0.00032532323,0.00045493952,0.0003132293,0.0003586682],"domain_scores_gemma":[0.9903302,0.0010238593,0.0072947815,0.0002140278,0.00036799716,0.0007691254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013719896,0.00021492402,0.00049983204,0.0012063322,0.0004537219,0.0011257613,0.0005374308,0.00059859006,0.0012839932],"category_scores_gemma":[0.00419742,0.00022025264,0.00069249945,0.0015905927,0.0002832035,0.0006096878,0.000621519,0.00080337055,0.00023654796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018423537,0.000031847878,0.9987821,0.000010398756,0.000043554555,0.000060783404,0.00004697287,0.000047632882,0.000054899094,0.000013033014,0.00009963541,0.00062481104],"study_design_scores_gemma":[0.000017935557,0.00013087736,0.99874866,0.000012734783,0.000028095843,0.0003247972,0.00018892802,0.00024261314,0.000045261804,0.000015408325,0.00023765957,0.0000069227185],"about_ca_topic_score_codex":0.007519461,"about_ca_topic_score_gemma":0.0110646915,"teacher_disagreement_score":0.007519461,"about_ca_system_score_codex":0.00088454393,"about_ca_system_score_gemma":0.0007341862,"threshold_uncertainty_score":0.014951348},"labels":[],"label_agreement":null},{"id":"W2060833967","doi":"10.1007/s12325-009-0042-5","title":"Aqueous prostaglandin E2 of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing","year":2009,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Emergent BioSolutions (Canada)","funders":"","keywords":"Ketorolac; Medicine; Dosing; Cataract surgery; Anesthesia; Latanoprost; Analgesic; Ophthalmology; Pharmacology; Intraocular pressure","score_opus":0.010197662211326224,"score_gpt":0.29404091042541247,"score_spread":0.28384324821408624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060833967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99830616,0.0002516178,0.00012160586,0.000042536536,0.000030228233,0.000015668553,0.00024424083,0.000015899914,0.0009721003],"genre_scores_gemma":[0.99907,0.000057171736,0.000088018896,0.000031442763,0.000010930309,0.0000059937497,0.00017843088,0.00000253285,0.000555428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997093,0.000032396863,0.000036580306,0.00003614407,0.00007339672,0.000112070644],"domain_scores_gemma":[0.9994137,0.00022613686,0.00007794062,0.000049477436,0.00010319922,0.00012955704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023488105,0.00021538927,0.00056896836,0.00042555158,0.00028694762,0.0003660968,0.00013065862,0.0003906629,0.002935302],"category_scores_gemma":[0.0013810615,0.000114351584,0.0003181645,0.0003591757,0.00024953688,0.0003876967,0.00016119836,0.00067448645,0.0003047568],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3246224,0.004831458,0.35863903,0.0002786356,0.00043523946,0.009037011,0.0012167111,0.0011009442,0.16649948,0.0003901056,0.0030550116,0.129894],"study_design_scores_gemma":[0.0017763708,0.032289878,0.90317535,0.000025718406,0.00039089218,0.0055674063,0.0013138234,0.0025896549,0.049393486,0.0004117202,0.002990697,0.00007506245],"about_ca_topic_score_codex":0.0043674945,"about_ca_topic_score_gemma":0.003010306,"teacher_disagreement_score":0.0043674945,"about_ca_system_score_codex":0.000407343,"about_ca_system_score_gemma":0.0004292817,"threshold_uncertainty_score":0.009819508},"labels":[],"label_agreement":null},{"id":"W2061217629","doi":"10.1007/s12325-009-0084-8","title":"New pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010","year":2009,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thrombosis and Atherosclerosis Research Institute; McMaster University","funders":"","keywords":"Medicine; Antithrombotic; Atrial fibrillation; Stroke (engine); Internal medicine; Intensive care medicine; Heart failure; Diabetes mellitus; Cardiology; Pharmacotherapy","score_opus":0.10478713936967743,"score_gpt":0.4629706243164416,"score_spread":0.35818348494676416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061217629","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017885756,0.99701726,0.00018877417,0.0007373038,0.00060885726,0.000020304678,0.000100357065,0.000020361727,0.0011278881],"genre_scores_gemma":[0.0007644342,0.9965906,0.00046449012,0.0009056151,0.0005505228,0.00001761556,0.00012674546,0.0000033028437,0.0005767083],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995384,0.00006983533,0.00013156876,0.000049085364,0.00017813683,0.000033030752],"domain_scores_gemma":[0.9982468,0.0008091178,0.00041624243,0.000029972825,0.0003999633,0.00009796186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010689416,0.0011106054,0.0028418638,0.0034476928,0.0001950689,0.0011109472,0.0008553719,0.0012824996,0.004091459],"category_scores_gemma":[0.0027605677,0.00040346,0.001127603,0.0029877112,0.00030437266,0.0013192465,0.0006893629,0.0020670984,0.0016013187],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001963612,0.00011927333,0.0002550795,0.02169766,0.00045495442,0.0001341479,0.000025481606,0.00017684553,0.0005695329,0.00046756308,0.07757204,0.89833105],"study_design_scores_gemma":[0.00063050503,0.00043059408,0.0041619386,0.01947952,0.003473572,0.0017447736,0.00006727138,0.00038220113,0.0005351965,0.0007969016,0.9682444,0.000053131047],"about_ca_topic_score_codex":0.0034591309,"about_ca_topic_score_gemma":0.00941628,"teacher_disagreement_score":0.004091459,"about_ca_system_score_codex":0.00091204874,"about_ca_system_score_gemma":0.0025671304,"threshold_uncertainty_score":0.013687313},"labels":[],"label_agreement":null},{"id":"W2063592677","doi":"10.1007/bf02850036","title":"Surgical outcome following treatment of isolated subaortic obstruction","year":2004,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Cardiovascular Syncope and Autonomic Disorders","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Asymptomatic; Ventricular outflow tract; Surgery; Stenosis; Regurgitation (circulation); Internal medicine; Aortic valve replacement; Cardiology","score_opus":0.01501869987417275,"score_gpt":0.31362138837833886,"score_spread":0.2986026885041661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063592677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99650455,0.0008215025,0.00023391035,0.00018697149,0.00007459068,0.000018758632,0.00019073336,0.000016836342,0.0019521682],"genre_scores_gemma":[0.998806,0.00028806608,0.00006708684,0.00007231645,0.00011737089,0.000009149901,0.0003482903,0.0000049218675,0.00028666784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995592,0.00006378859,0.00005128583,0.000045772664,0.000064025,0.0002159583],"domain_scores_gemma":[0.9981528,0.0005191191,0.00033796966,0.00011630821,0.00010981197,0.0007640168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000357796,0.00050063286,0.0011615637,0.0010705114,0.0012444829,0.0010789869,0.0005497977,0.00086084526,0.0023508552],"category_scores_gemma":[0.0018096872,0.00015882224,0.00096811703,0.00060814724,0.0010045962,0.00057117274,0.0009650123,0.00096072815,0.00042932734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026502166,0.0052007074,0.71859866,0.0006974753,0.0016446665,0.11272326,0.0016209482,0.002794368,0.016091738,0.0013147284,0.0021250122,0.11068635],"study_design_scores_gemma":[0.00047041537,0.012164181,0.9145024,0.0000949962,0.0003844573,0.06511252,0.0011958708,0.0013861057,0.0026496784,0.00082230585,0.0011153893,0.00010164775],"about_ca_topic_score_codex":0.000783066,"about_ca_topic_score_gemma":0.0016693304,"teacher_disagreement_score":0.0023508552,"about_ca_system_score_codex":0.0007125095,"about_ca_system_score_gemma":0.0005762192,"threshold_uncertainty_score":0.007864416},"labels":[],"label_agreement":null},{"id":"W2073818920","doi":"10.1007/s12325-009-0021-x","title":"Psychotropic drugs and renal failure: Translating the evidence for clinical practice","year":2009,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Nephrotoxicity and Medicinal Plants","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Ottawa; University Health Network","funders":"","keywords":"Medicine; Pharmacokinetics; Dosing; Intensive care medicine; Renal function; Psychotropic drug; Pharmacology; Drug; Adverse effect; Psychotropic Agent; Internal medicine; Psychiatry","score_opus":0.20780326168326121,"score_gpt":0.5466009045532716,"score_spread":0.33879764287001035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073818920","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000052093077,0.9991524,0.000035475136,0.00040198825,0.00010783452,0.000002243216,0.0000058792357,0.000002003595,0.00023996091],"genre_scores_gemma":[0.00049692136,0.9988709,0.00012296178,0.00025562948,0.00016961282,0.000002392031,0.0000070751985,5.022512e-7,0.00007395857],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99932396,0.0001546601,0.00014384389,0.000097307,0.0002485414,0.000031758456],"domain_scores_gemma":[0.996179,0.0025540595,0.00048304966,0.00007247098,0.00060617505,0.00010528279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022655528,0.0009331466,0.003524329,0.0028282849,0.00029997074,0.0019326664,0.0013964096,0.0019008026,0.003906996],"category_scores_gemma":[0.0037804958,0.0003719678,0.0009251138,0.0035457686,0.0009271645,0.0019655835,0.00087454345,0.0021309776,0.0010413234],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019812776,0.00008883633,0.0005231371,0.044197913,0.0004050233,0.00030837418,0.000062210864,0.00024909538,0.00069535227,0.002104149,0.019229349,0.9319385],"study_design_scores_gemma":[0.00026684767,0.0003360296,0.0062496914,0.06062952,0.0017755643,0.0026404068,0.0004092004,0.000483254,0.0006392699,0.0075253565,0.91896594,0.00007900311],"about_ca_topic_score_codex":0.0028320139,"about_ca_topic_score_gemma":0.0062085907,"teacher_disagreement_score":0.003906996,"about_ca_system_score_codex":0.001091071,"about_ca_system_score_gemma":0.0031684677,"threshold_uncertainty_score":0.013070226},"labels":[],"label_agreement":null},{"id":"W2075706156","doi":"10.1007/s12325-010-0074-x","title":"Food effects on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules","year":2010,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celerion (Canada)","funders":"","keywords":"Naltrexone; Bioavailability; Morphine; Pharmacokinetics; Pharmacology; Naloxone Hydrochloride; Medicine; Area under the curve; Opioid; (+)-Naloxone; Anesthesia; Internal medicine","score_opus":0.009219676054082446,"score_gpt":0.2752405418032308,"score_spread":0.26602086574914835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075706156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986652,0.00054386834,0.00013308697,0.00003939134,0.000022284588,0.000010602116,0.00012873768,0.000014635818,0.0004422691],"genre_scores_gemma":[0.9979881,0.00037329464,0.00031880714,0.00004063934,0.00003051969,0.000013093149,0.00018020697,0.00002009571,0.0010352429],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99978787,0.00008130053,0.000012541994,0.000029105582,0.000049082588,0.00004008465],"domain_scores_gemma":[0.99869835,0.0007011688,0.00026353804,0.000095585434,0.00006207933,0.00017920679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029635153,0.0003060551,0.0004317786,0.00020158419,0.00017635275,0.0004036058,0.00019784739,0.00043386902,0.002891251],"category_scores_gemma":[0.0022646969,0.00043405933,0.00042438915,0.00015929376,0.0005175351,0.0008330759,0.00019677858,0.00085539964,0.0003502921],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4524294,0.0027458465,0.01700777,0.00035578126,0.00052043836,0.001118065,0.00060209073,0.0020901803,0.44144362,0.0007497122,0.0009887051,0.07994834],"study_design_scores_gemma":[0.011915017,0.15337087,0.49879032,0.00009352799,0.0008594913,0.0038689156,0.0007639566,0.02066478,0.3012406,0.00089543377,0.0072783846,0.00025862837],"about_ca_topic_score_codex":0.0013274249,"about_ca_topic_score_gemma":0.001638672,"teacher_disagreement_score":0.002891251,"about_ca_system_score_codex":0.0004261894,"about_ca_system_score_gemma":0.00042894876,"threshold_uncertainty_score":0.009672165},"labels":[],"label_agreement":null},{"id":"W2076727357","doi":"10.1007/s12325-010-0011-z","title":"Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: Points of pathophysiological commonality with mood disorders?","year":2010,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Diabetes Management and Education","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Neurocognitive; Mood disorders; Medicine; Major depressive disorder; Neuroimaging; Brain size; Mood; Neuroscience; Depression (economics); Brain morphometry; Psychiatry; Psychology; Magnetic resonance imaging; Cognition; Anxiety","score_opus":0.019410776111079563,"score_gpt":0.31175643743194625,"score_spread":0.2923456613208667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076727357","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013524605,0.99926513,0.000048517588,0.0002150986,0.00006826168,0.0000016132186,0.000009131151,0.0000025192337,0.00025436433],"genre_scores_gemma":[0.0010712226,0.99810624,0.00015085762,0.0001867701,0.00026610907,0.0000040156788,0.000024687239,5.9819143e-7,0.00018939984],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99979943,0.000031489795,0.000043447253,0.000038124428,0.00007023747,0.000017304981],"domain_scores_gemma":[0.9996026,0.00018734897,0.00009309867,0.000008735678,0.00007892099,0.000029375115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060258294,0.0009907018,0.0026872724,0.0015634699,0.00020516725,0.001097456,0.0013407251,0.001391973,0.0017501719],"category_scores_gemma":[0.0009837511,0.00027435605,0.0005096746,0.0019739848,0.00065546675,0.0012677478,0.0006773288,0.0015726389,0.0010525445],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002204288,0.000093343435,0.0013533275,0.008853561,0.00025536655,0.0007990364,0.000055083292,0.00016139378,0.000995014,0.0016398525,0.017995782,0.96757776],"study_design_scores_gemma":[0.00031894716,0.0004069538,0.0259033,0.012228221,0.0013321004,0.019005576,0.0005713136,0.0005021338,0.0010352338,0.009566965,0.92899966,0.00012957897],"about_ca_topic_score_codex":0.0019212316,"about_ca_topic_score_gemma":0.0037030391,"teacher_disagreement_score":0.0026872724,"about_ca_system_score_codex":0.0004280507,"about_ca_system_score_gemma":0.0010055619,"threshold_uncertainty_score":0.0058549047},"labels":[],"label_agreement":null},{"id":"W2080506224","doi":"10.1007/s12325-013-0027-2","title":"Efficacy and Safety of Lisdexamfetamine Dimesylate in Children with Attention-Deficit/Hyperactivity Disorder and Recent Methylphenidate Use","year":2013,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Interior Health","funders":"","keywords":"Methylphenidate; Attention deficit hyperactivity disorder; Medicine; Stimulant; Tolerability; Rating scale; Post-hoc analysis; Placebo; Population; Atomoxetine; Randomized controlled trial; Psychiatry; Adverse effect; Physical therapy; Pediatrics; Psychology; Internal medicine","score_opus":0.01579585432148466,"score_gpt":0.2965676978646019,"score_spread":0.28077184354311724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080506224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99557084,0.0036537347,0.000034245793,0.00008365367,0.000010079167,0.000046214256,0.00023492891,0.000005734508,0.00036053345],"genre_scores_gemma":[0.9978397,0.0015518939,0.0001635055,0.000045049772,0.000018979952,0.000053289154,0.00023058301,0.0000013942379,0.00009557586],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99928135,0.00022543989,0.0001302528,0.00009550405,0.00022090034,0.000046630576],"domain_scores_gemma":[0.997866,0.00062823726,0.0010358528,0.00006312672,0.00018441355,0.00022242506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015580553,0.00025844786,0.0007039332,0.0004689331,0.00027188123,0.0002500096,0.00029156014,0.00047926774,0.0009362146],"category_scores_gemma":[0.0032304158,0.00019864431,0.0008688875,0.00041152097,0.0002290105,0.00030517197,0.00022029695,0.0004820928,0.00012989921],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06271255,0.0032774757,0.7709603,0.0014510828,0.0020297696,0.00059383793,0.00073605636,0.00038729157,0.005980088,0.000062727166,0.0007122906,0.15109664],"study_design_scores_gemma":[0.005196195,0.0284928,0.95983756,0.00018232779,0.0010259592,0.0010462083,0.00016298573,0.00029957425,0.0024189511,0.00003073142,0.0012903244,0.000016356613],"about_ca_topic_score_codex":0.002189766,"about_ca_topic_score_gemma":0.0050964225,"teacher_disagreement_score":0.002189766,"about_ca_system_score_codex":0.0006177082,"about_ca_system_score_gemma":0.00055770035,"threshold_uncertainty_score":0.008239865},"labels":[],"label_agreement":null},{"id":"W2085150507","doi":"10.1007/bf02877706","title":"Urinary bladder calculi in a sliding vesical-inguinal-scrotal hernia diagnosed preoperatively by plain abdominal radiography","year":2007,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Urological Disorders and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Groin; Inguinal hernia; Hernia; Abdomen; Surgery; Urinary bladder; Radiography; Radiology; Urology; General surgery","score_opus":0.010834104121687015,"score_gpt":0.3038250883144985,"score_spread":0.2929909841928115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085150507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98589337,0.0030907264,0.0012272542,0.0016056428,0.0002264152,0.000105284205,0.00023341131,0.000120813274,0.007497219],"genre_scores_gemma":[0.9974578,0.0005347924,0.000637612,0.00024565984,0.00040633345,0.0000072420603,0.00007370392,0.000010889779,0.0006260139],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99942493,0.000043111166,0.00009131318,0.00009258368,0.00009945377,0.00024864494],"domain_scores_gemma":[0.9977743,0.00085555325,0.0003511984,0.00015787117,0.00014553277,0.0007154744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031953212,0.0014122179,0.0013814416,0.0038394458,0.0015311504,0.0009599197,0.001321259,0.003562257,0.006219925],"category_scores_gemma":[0.0062168776,0.0013713895,0.0011686321,0.0019078074,0.0019897372,0.002458144,0.0011859987,0.0024615221,0.0008943114],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026042302,0.00008787806,0.050349936,0.00005597057,0.000016735823,0.94575155,0.00010715785,0.00009021806,0.0011367399,0.000099519275,0.00016945532,0.0018744379],"study_design_scores_gemma":[0.00006275959,0.00036430822,0.074459575,0.000038587776,0.00010608892,0.92061245,0.0003174235,0.0007574458,0.002591563,0.00017944393,0.00047344496,0.000036776848],"about_ca_topic_score_codex":0.0037589872,"about_ca_topic_score_gemma":0.0036367017,"teacher_disagreement_score":0.006219925,"about_ca_system_score_codex":0.0008209293,"about_ca_system_score_gemma":0.0009319955,"threshold_uncertainty_score":0.020807743},"labels":[],"label_agreement":null},{"id":"W2087672673","doi":"10.1007/bf02849989","title":"Assessing itch in children with atopic dermatitis treated with tacrolimus: Objective versus subjective assessment","year":2007,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Atopic dermatitis; SCORAD; Tacrolimus; Interquartile range; Internal medicine; Sleep disorder; Scratching; Anesthesia; Dermatology; Dermatology Life Quality Index; Insomnia; Pharmacology; Transplantation","score_opus":0.01014758653676302,"score_gpt":0.33327214353218987,"score_spread":0.32312455699542686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087672673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99840385,0.00043724518,0.00016971517,0.00003807393,0.000007929097,0.00001754727,0.00007674221,0.0000058011287,0.0008430569],"genre_scores_gemma":[0.9992888,0.00024752898,0.00025271915,0.0000218752,0.0000072290118,0.000009300471,0.00006126919,0.0000016519236,0.00010959339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994568,0.0001631292,0.00008308179,0.000062801584,0.00014754229,0.0000866694],"domain_scores_gemma":[0.9986694,0.00050497183,0.00041511256,0.000034217144,0.00016348048,0.00021290885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007803749,0.00028931943,0.00054627494,0.0005258259,0.00021971465,0.0003887207,0.00018379421,0.0003477323,0.0010209301],"category_scores_gemma":[0.0031770742,0.00013870078,0.0003464068,0.00041923387,0.00035253775,0.00048885704,0.0003074932,0.00051213807,0.00015505421],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004501537,0.00008831039,0.99032277,0.00005892494,0.000033706947,0.00080865127,0.00021215636,0.000076476004,0.0010163751,0.000014312412,0.00010668126,0.006811427],"study_design_scores_gemma":[0.000030633728,0.0008002756,0.9929932,0.000019716454,0.00006247267,0.004331358,0.00056403107,0.00033487173,0.0006616851,0.000017441427,0.00017627284,0.000008124689],"about_ca_topic_score_codex":0.0027551556,"about_ca_topic_score_gemma":0.004685012,"teacher_disagreement_score":0.0027551556,"about_ca_system_score_codex":0.00035687606,"about_ca_system_score_gemma":0.00025879577,"threshold_uncertainty_score":0.005478263},"labels":[],"label_agreement":null},{"id":"W2095488032","doi":"10.1007/bf02850199","title":"Managing childhood atopic dermatitis","year":2003,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Novartis Pharmaceuticals Canada; University of Calgary","keywords":"Medicine; Pimecrolimus; Atopic dermatitis; Tacrolimus; Adverse effect; Dermatology; Calcineurin; Quality of life (healthcare); Allergy; Safety profile; Rheumatology; Intensive care medicine; Immunology; Internal medicine","score_opus":0.019004405860379953,"score_gpt":0.3447816084987121,"score_spread":0.32577720263833215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095488032","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028163687,0.9978904,0.00014774285,0.00012790797,0.00025718886,0.000008796802,0.00001066125,0.000008136984,0.0012675262],"genre_scores_gemma":[0.0020924248,0.995545,0.00040556586,0.00037290447,0.00034903063,0.000012279739,0.000035979097,0.000001815045,0.0011850038],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997826,0.000040580508,0.00003883217,0.000032478558,0.00008251663,0.000022962626],"domain_scores_gemma":[0.99981195,0.000070151196,0.00004976443,0.0000074436966,0.00003834547,0.000022226504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003667932,0.0008658643,0.0014192564,0.0017377249,0.00023402313,0.0006532871,0.00067882193,0.0007146414,0.0031477786],"category_scores_gemma":[0.0005835918,0.00019841941,0.00049621024,0.0012329645,0.0002484496,0.0007992808,0.0005001604,0.0014882986,0.0012945986],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008358064,0.00008816096,0.00026474774,0.009131707,0.00008695223,0.0005223977,0.000032007163,0.00016254578,0.0011952028,0.0003514245,0.016710943,0.9713703],"study_design_scores_gemma":[0.00017019045,0.0003546331,0.004651361,0.009092566,0.0006579833,0.011391403,0.0001179185,0.00019276075,0.0011489943,0.0008041831,0.97139233,0.000025669171],"about_ca_topic_score_codex":0.0010167995,"about_ca_topic_score_gemma":0.002882513,"teacher_disagreement_score":0.0031477786,"about_ca_system_score_codex":0.00032256072,"about_ca_system_score_gemma":0.00054884504,"threshold_uncertainty_score":0.010530353},"labels":[],"label_agreement":null},{"id":"W2118917324","doi":"10.1007/s12325-009-0041-6","title":"Ramelteon: a review of its therapeutic potential in sleep disorders","year":2009,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Sleep and Wakefulness Research","field":"Neuroscience","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Sleep Institute","funders":"","keywords":"Medicine; Rheumatology; Sleep (system call); Internal medicine","score_opus":0.06156079004945493,"score_gpt":0.41364070236413764,"score_spread":0.3520799123146827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118917324","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015227021,0.9985403,0.00010178054,0.0001560771,0.00015369311,0.0000069199277,0.000020614412,0.00000558535,0.0008628723],"genre_scores_gemma":[0.0010588912,0.9973767,0.0003519523,0.0002724795,0.0002256583,0.000012503576,0.000028501992,0.0000022966153,0.00067110057],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99986947,0.000022768098,0.00002898281,0.000026633228,0.000039000257,0.000013116956],"domain_scores_gemma":[0.9997049,0.00016560999,0.000048708243,0.0000069435423,0.000047061665,0.000026759952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006134009,0.0010253589,0.0017224385,0.0023273614,0.0002836761,0.0007240674,0.0010418033,0.0010574003,0.00369485],"category_scores_gemma":[0.00080445607,0.00029961034,0.00056701136,0.0017294554,0.00043387257,0.0011376088,0.00054106885,0.001899775,0.0015560647],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027004487,0.0001366033,0.00012313605,0.013280881,0.000112127986,0.00037697403,0.000048148577,0.0003400273,0.0020648348,0.0017155973,0.02322446,0.95830727],"study_design_scores_gemma":[0.00015069694,0.00041452513,0.0013149512,0.004734166,0.00034326265,0.0030433738,0.00007717634,0.00020311549,0.0012460737,0.0014667851,0.9869556,0.00005042288],"about_ca_topic_score_codex":0.001353296,"about_ca_topic_score_gemma":0.0043386393,"teacher_disagreement_score":0.00369485,"about_ca_system_score_codex":0.00047468027,"about_ca_system_score_gemma":0.00080149755,"threshold_uncertainty_score":0.012360573},"labels":[],"label_agreement":null},{"id":"W2124283923","doi":"10.1007/s12325-010-0081-y","title":"Lasofoxifene in osteoporosis and its place in therapy","year":2010,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Women's College Hospital","funders":"","keywords":"Medicine; Raloxifene; Osteoporosis; Selective estrogen receptor modulator; Endometrial cancer; Antiestrogen; Internal medicine; Breast cancer; Endometrial hyperplasia; Oncology; Tamoxifen; Gynecology; Cancer; Hyperplasia","score_opus":0.05658703699730556,"score_gpt":0.4284445847616713,"score_spread":0.37185754776436575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124283923","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000068764006,0.99899274,0.000049533013,0.00021828015,0.00017078374,0.000003084032,0.00001406831,0.000004374995,0.00047832206],"genre_scores_gemma":[0.00065248634,0.9981509,0.000120643854,0.00022213174,0.00026313323,0.0000048368765,0.000017534494,9.911171e-7,0.00056729605],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996581,0.0000588982,0.00007392359,0.000041422638,0.00013949416,0.0000280857],"domain_scores_gemma":[0.9995363,0.00021215706,0.00009999384,0.000011465176,0.00010040905,0.00003972431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084970216,0.0010112089,0.0026513012,0.0033832174,0.00028087912,0.0012807504,0.0008003501,0.0014424551,0.005606311],"category_scores_gemma":[0.0012664553,0.00039183273,0.00061026704,0.0036952398,0.000604722,0.0015414241,0.0007317195,0.0018722079,0.002050924],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023525293,0.00009328562,0.00017831457,0.019921193,0.00019753801,0.00024289366,0.000050794115,0.000287232,0.001301021,0.0020191437,0.03626838,0.939205],"study_design_scores_gemma":[0.00013678624,0.000214643,0.0010395858,0.0049097263,0.00047509634,0.0013473425,0.00007470762,0.00016194303,0.00029593796,0.0012667297,0.9900552,0.000022265353],"about_ca_topic_score_codex":0.0021538485,"about_ca_topic_score_gemma":0.006548345,"teacher_disagreement_score":0.005606311,"about_ca_system_score_codex":0.00075949036,"about_ca_system_score_gemma":0.0017134405,"threshold_uncertainty_score":0.018755019},"labels":[],"label_agreement":null},{"id":"W2162865421","doi":"10.1007/s12325-015-0239-8","title":"Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease","year":2015,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Tiotropium bromide; COPD; Inhaler; Bronchodilator; Placebo; Anesthesia; Indacaterol; Lama; Crossover study; Fixed-dose combination; Internal medicine; Lung; Lung function; Asthma","score_opus":0.04984266687401399,"score_gpt":0.35668945740424357,"score_spread":0.30684679053022956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162865421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880144,0.0016683382,0.00071418786,0.00053802173,0.00087634154,0.0062074866,0.0007058707,0.00013493405,0.0011404583],"genre_scores_gemma":[0.9835524,0.0010753821,0.0024009498,0.000987877,0.0009131115,0.007748287,0.000721711,0.000024457207,0.0025757765],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981989,0.00091770675,0.00014619857,0.00036983407,0.00014039587,0.00022691385],"domain_scores_gemma":[0.9972487,0.0010022073,0.00047194798,0.00030964302,0.00022051955,0.00074693345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003202185,0.0022024163,0.005814419,0.00076198997,0.0008265305,0.0014608477,0.0014537978,0.0031917305,0.0067508323],"category_scores_gemma":[0.0036158639,0.0015462068,0.002313522,0.00059299957,0.0024425443,0.0014573622,0.00067365327,0.0032380356,0.0015208458],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9854944,0.008168211,0.00026237924,0.00018241783,0.00021754015,0.00001779312,0.000025453,0.00009135599,0.0023496812,0.000025906174,0.00014295203,0.0030218435],"study_design_scores_gemma":[0.9113772,0.08743381,0.0005907641,0.0000065628465,0.00011944733,0.000009313934,0.0000067274814,0.000103468425,0.00019518397,0.00002640966,0.00012348995,0.000007647674],"about_ca_topic_score_codex":0.00085462397,"about_ca_topic_score_gemma":0.0013288035,"teacher_disagreement_score":0.0067508323,"about_ca_system_score_codex":0.0009576297,"about_ca_system_score_gemma":0.0018502182,"threshold_uncertainty_score":0.022583723},"labels":[],"label_agreement":null},{"id":"W2170947953","doi":"10.1007/s12325-010-0059-9","title":"Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease","year":2010,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Dialysis and Renal Disease Management","field":"Medicine","cited_by":232,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; The Scarborough Hospital","funders":"","keywords":"Medicine; Kidney disease; Creatinine; Uric acid; Internal medicine; Renal function; Blood urea nitrogen; Probiotic; Adverse effect; Placebo; Gastroenterology; Statistical significance; Physiology; Biology; Pathology","score_opus":0.012994408743484414,"score_gpt":0.29893293728402465,"score_spread":0.28593852854054025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170947953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987639,0.00019529813,0.00010435906,0.000082808954,0.000037772417,0.0004877295,0.000078386984,0.0000089429395,0.00024084291],"genre_scores_gemma":[0.99730754,0.00026452047,0.0007449074,0.00022915186,0.000107388616,0.00064066116,0.000161704,0.000004590681,0.0005395265],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999395,0.0002742645,0.00005852407,0.000109132656,0.00004496513,0.00011816878],"domain_scores_gemma":[0.9986137,0.00038262314,0.00008835404,0.00012442627,0.00014274879,0.00064812775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014792349,0.0008807695,0.0022195026,0.00046473194,0.0017037968,0.0006595631,0.00061937096,0.0013571817,0.004419811],"category_scores_gemma":[0.0019444255,0.0004985727,0.0011795043,0.00048966083,0.0008641829,0.0007384683,0.0007406252,0.001871302,0.0004767717],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7311554,0.19111982,0.015815087,0.00047409078,0.00059640076,0.0005172047,0.00076996203,0.0002928724,0.028797995,0.00008384191,0.00033977532,0.030037515],"study_design_scores_gemma":[0.066669896,0.9065012,0.023658698,0.00002411877,0.00044050824,0.00007013252,0.00020807837,0.00019670278,0.0017808303,0.000036926027,0.00039426886,0.000018616971],"about_ca_topic_score_codex":0.0021238108,"about_ca_topic_score_gemma":0.0025493659,"teacher_disagreement_score":0.004419811,"about_ca_system_score_codex":0.00048966805,"about_ca_system_score_gemma":0.0015504357,"threshold_uncertainty_score":0.014785707},"labels":[],"label_agreement":null},{"id":"W2171321375","doi":"10.1007/s12325-013-0054-z","title":"OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Activity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology","year":2013,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Anticholinergic; Concomitant; Urinary incontinence; Urinary system; Etiology; Placebo; Adverse effect; Urology; Spinal cord injury; Internal medicine; Overactive bladder; Anticholinergic agents; Anesthesia; Spinal cord","score_opus":0.015837238646286878,"score_gpt":0.3063505204633182,"score_spread":0.2905132818170313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171321375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97342426,0.02467522,0.00022434481,0.0001993595,0.000052996522,0.00019232814,0.0002124368,0.000019508867,0.0009995892],"genre_scores_gemma":[0.99039006,0.0081266435,0.00048427444,0.0002592646,0.000091585425,0.00012268113,0.0002928602,0.000003330919,0.00022926588],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99965656,0.00015489804,0.00005053442,0.0000422166,0.00006150041,0.000034286197],"domain_scores_gemma":[0.9992132,0.00022280417,0.0004230577,0.000026181877,0.000032057756,0.00008259864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094004645,0.00031852175,0.0012146797,0.00027392842,0.0002104237,0.0003486704,0.00025522363,0.00039178415,0.0015928403],"category_scores_gemma":[0.0011228743,0.00017746606,0.0008100681,0.0003074167,0.00023648908,0.00022566688,0.00017133777,0.0004560652,0.00010773782],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34134942,0.0074474616,0.05430953,0.008438423,0.011151967,0.0007108518,0.0003093864,0.00076818216,0.09709182,0.00017281361,0.0017854732,0.47646466],"study_design_scores_gemma":[0.19115937,0.3448334,0.4181622,0.001728601,0.00894311,0.0032685108,0.00031211498,0.0010776775,0.01849165,0.00031517263,0.0116411215,0.00006702379],"about_ca_topic_score_codex":0.00030220143,"about_ca_topic_score_gemma":0.0013003158,"teacher_disagreement_score":0.0015928403,"about_ca_system_score_codex":0.000290457,"about_ca_system_score_gemma":0.00032346055,"threshold_uncertainty_score":0.0053285956},"labels":[],"label_agreement":null},{"id":"W2178569306","doi":"10.1007/s12325-015-0261-x","title":"Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease","year":2015,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Medicine; Metformin; Liraglutide; Kidney disease; Intensive care medicine; Glycemic; Diabetes mellitus; Guideline; Alogliptin; Type 2 Diabetes Mellitus; Type 2 diabetes; Saxagliptin; Internal medicine; Pharmacology; Sitagliptin; Endocrinology; Pathology","score_opus":0.1538682301300158,"score_gpt":0.41104867924444327,"score_spread":0.2571804491144275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2178569306","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000085202395,0.99904066,0.00007814794,0.00019892749,0.000097085525,0.0000072971384,0.00006602146,0.00000448022,0.00042217804],"genre_scores_gemma":[0.0004422251,0.99886346,0.00022326848,0.00019689793,0.00010621391,0.0000063451266,0.000056849716,8.7671077e-7,0.00010389318],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99934095,0.00010671886,0.00021691996,0.00008079706,0.0002156286,0.000038953895],"domain_scores_gemma":[0.99816954,0.0010390762,0.00042625572,0.00002975455,0.00027398905,0.00006135788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014171819,0.0009381844,0.0024365077,0.003391675,0.00025106804,0.0012780622,0.0012380383,0.0011059495,0.0046711466],"category_scores_gemma":[0.002749091,0.00037284417,0.0016238288,0.003836731,0.00033372137,0.0012881106,0.00076707016,0.0015416427,0.0009775492],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028145267,0.00008503355,0.00045305467,0.114568986,0.00066020456,0.00020009422,0.00006896755,0.00028433345,0.0010087343,0.0019887732,0.022523839,0.8578766],"study_design_scores_gemma":[0.00012293522,0.00029371565,0.0036046954,0.04855258,0.0025318325,0.0013515978,0.00010798478,0.00018003961,0.0005072868,0.0021852055,0.94050395,0.0000581924],"about_ca_topic_score_codex":0.0021115737,"about_ca_topic_score_gemma":0.0038936925,"teacher_disagreement_score":0.0046711466,"about_ca_system_score_codex":0.00060908403,"about_ca_system_score_gemma":0.0023391063,"threshold_uncertainty_score":0.01562655},"labels":[],"label_agreement":null},{"id":"W2185217562","doi":"10.1007/bf02850040","title":"Travelers’ diarrhea","year":2006,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Travel-related health issues","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"Sanofi Pasteur","keywords":"Medicine; Diarrhea; Rheumatology; Internal medicine; Traveler's diarrhea; Intensive care medicine","score_opus":0.06446604584214048,"score_gpt":0.4379302285489221,"score_spread":0.3734641827067816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2185217562","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001458098,0.99837685,0.000053203556,0.00025024783,0.00022858607,0.000007758029,0.000030174207,0.000006361656,0.00090102584],"genre_scores_gemma":[0.0006685349,0.9980708,0.00015035187,0.0002780945,0.00016732956,0.000006834984,0.000042584466,7.798516e-7,0.00061472284],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999798,0.000050313185,0.000045227116,0.000023906478,0.000059530208,0.0000231554],"domain_scores_gemma":[0.9997018,0.000099336925,0.00009539592,0.00000909649,0.0000688878,0.000025521787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055106345,0.0008747035,0.0019476264,0.0021578202,0.00023436072,0.00079711236,0.0005011263,0.0007772382,0.0050631706],"category_scores_gemma":[0.0007609965,0.00025491646,0.0006211655,0.0023182451,0.00026066217,0.00094105146,0.0006369772,0.0010548432,0.0012934715],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000111348694,0.00006998365,0.00030368162,0.02479165,0.00015783666,0.000141179,0.000044412336,0.00011501725,0.0005131014,0.0003998338,0.03829321,0.93505883],"study_design_scores_gemma":[0.00012420319,0.0003275475,0.004060754,0.016758127,0.00077208376,0.0018622912,0.00015526333,0.000082881605,0.0003562014,0.00044109722,0.9750403,0.00001925162],"about_ca_topic_score_codex":0.0019960657,"about_ca_topic_score_gemma":0.0055163144,"teacher_disagreement_score":0.0050631706,"about_ca_system_score_codex":0.00041144958,"about_ca_system_score_gemma":0.0012161174,"threshold_uncertainty_score":0.01693803},"labels":[],"label_agreement":null},{"id":"W2292982366","doi":"10.1007/s12325-016-0310-0","title":"Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology; Allergan; Novartis Pharma; National Institute for Health and Care Research","keywords":"Medicine; Diabetic macular edema; Visual impairment; Rheumatology; Ophthalmology; Diabetic retinopathy; Internal medicine; Clinical trial; Optometry; Diabetes mellitus","score_opus":0.08482711340155047,"score_gpt":0.4125311927779988,"score_spread":0.32770407937644835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2292982366","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68635184,0.033754464,0.236407,0.004309633,0.0019725652,0.008020592,0.018322509,0.0010729319,0.009788391],"genre_scores_gemma":[0.9743343,0.000981132,0.017319554,0.00084330357,0.00015417064,0.0027728337,0.0026930247,0.00005800718,0.0008436587],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.7741062,0.20276006,0.0060537024,0.010819994,0.0046253884,0.0016346734],"domain_scores_gemma":[0.73244506,0.21659034,0.026300907,0.02070646,0.0028643429,0.0010929256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.18863481,0.0023282818,0.0041074553,0.0015938592,0.00047049846,0.0038089084,0.0025122664,0.0026781822,0.006211989],"category_scores_gemma":[0.18237798,0.00105048,0.014584312,0.0016512107,0.0013228788,0.0024057971,0.0022979414,0.0032178115,0.00048420363],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058356397,0.0013468611,0.37094346,0.007440433,0.3010196,0.0008615153,0.00046775976,0.17221047,0.001859436,0.008795986,0.0061204936,0.07057766],"study_design_scores_gemma":[0.021963025,0.05089681,0.28448164,0.0026632487,0.16278826,0.0015655624,0.00049577066,0.3808171,0.0058745453,0.051856022,0.036012687,0.000585354],"about_ca_topic_score_codex":0.0011285702,"about_ca_topic_score_gemma":0.00083174295,"teacher_disagreement_score":0.18863481,"about_ca_system_score_codex":0.0012510539,"about_ca_system_score_gemma":0.001443839,"threshold_uncertainty_score":0.9976082},"labels":[],"label_agreement":null},{"id":"W2307057396","doi":"10.1007/s12325-016-0285-x","title":"Differential Protein Expression Profiles in Glaucomatous Trabecular Meshwork: An Evaluation Study on a Small Primary Open Angle Glaucoma Population","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Glaucoma and retinal disorders","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"Fondazione Roma; Ministero della Salute","keywords":"Trabecular meshwork; Medicine; Population; Glaucoma; Vascular endothelial growth factor; Myocilin; Ophthalmology; Pathology; Internal medicine","score_opus":0.03003669115185202,"score_gpt":0.3344425589051861,"score_spread":0.30440586775333406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2307057396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999539,0.000114862574,0.00008858414,0.000005161282,0.0000012245822,0.0000065981826,0.00010512906,0.0000017303635,0.00013775073],"genre_scores_gemma":[0.99935097,0.00007997826,0.000094614916,0.000011040225,0.000005790761,0.000013173697,0.00019370425,0.0000017609105,0.00024893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998832,0.000014552284,0.000010003021,0.000044249446,0.000029441451,0.000018600995],"domain_scores_gemma":[0.99984586,0.000025568539,0.0000499975,0.000010758737,0.00003381642,0.000034030494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016104273,0.00018267936,0.0002648803,0.0006963999,0.00031749668,0.00026458522,0.000090349546,0.00021165941,0.0012580431],"category_scores_gemma":[0.00031644202,0.00009507496,0.00016865645,0.00048350284,0.00021853359,0.00017358734,0.00019133149,0.00011489842,0.00027154913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040529604,0.00008414351,0.98292357,0.000027327822,0.00003613443,0.00035927774,0.00028493928,0.000019077002,0.011985232,0.00001292252,0.000078715195,0.0037832963],"study_design_scores_gemma":[0.000004870497,0.00023219903,0.9985368,0.0000016581608,0.000019324683,0.00050660956,0.00015772098,0.000048102596,0.00031824043,0.000008264004,0.0001644667,0.0000016611062],"about_ca_topic_score_codex":0.0012832431,"about_ca_topic_score_gemma":0.0015274814,"teacher_disagreement_score":0.0012832431,"about_ca_system_score_codex":0.00012650943,"about_ca_system_score_gemma":0.00010060487,"threshold_uncertainty_score":0.0042085648},"labels":[],"label_agreement":null},{"id":"W2339565695","doi":"10.1007/s12325-016-0327-4","title":"nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec; Hôpital du Sacré-Cœur de Montréal; Royal Victoria Regional Health Centre; BC Cancer Agency; Centre Hospitalier de l’Université de Montréal","funders":"Celgene","keywords":"Medicine; Gemcitabine; Hazard ratio; Clinical endpoint; Internal medicine; Subgroup analysis; Population; Deoxycytidine; Gastroenterology; Pancreatic cancer; Oncology; Cancer; Randomized controlled trial; Confidence interval","score_opus":0.02993689696633579,"score_gpt":0.3525140922893385,"score_spread":0.3225771953230027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339565695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657123,0.022965068,0.0003142196,0.0011473256,0.00019606024,0.0010828549,0.00557929,0.000041888798,0.0029608775],"genre_scores_gemma":[0.988533,0.0048588226,0.00049119984,0.00065970124,0.00012890204,0.000434653,0.0040208246,0.000015412195,0.0008574123],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99903995,0.00035279602,0.000076701086,0.00013529671,0.00019978841,0.0001953672],"domain_scores_gemma":[0.99892235,0.0002117489,0.00030494167,0.00009164527,0.00017562974,0.0002936298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020637293,0.001073903,0.0019767927,0.00046349276,0.0007289797,0.0009484406,0.0009125225,0.00078109954,0.0022514337],"category_scores_gemma":[0.0026233292,0.00029082166,0.0043187155,0.0013700416,0.00049772795,0.00028094233,0.00042999885,0.0013464951,0.00014735082],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7726845,0.0010052512,0.11235163,0.0021674922,0.033979595,0.00027650842,0.0002156514,0.0026416972,0.00274018,0.00046839178,0.0099335015,0.06153554],"study_design_scores_gemma":[0.36601785,0.025644585,0.4995724,0.0008187697,0.078576736,0.00077026547,0.00052521634,0.006347005,0.0016030213,0.0017830356,0.018074831,0.0002662662],"about_ca_topic_score_codex":0.3111344,"about_ca_topic_score_gemma":0.5919269,"teacher_disagreement_score":0.6888656,"about_ca_system_score_codex":0.0067592524,"about_ca_system_score_gemma":0.014117463,"threshold_uncertainty_score":0.6186468},"labels":[],"label_agreement":null},{"id":"W2343491610","doi":"10.1007/s12325-016-0333-6","title":"Quality of Life in Glaucoma: A Review of the Literature","year":2016,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Glaucoma and retinal disorders","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"Fondazione Roma; Ministero della Salute","keywords":"Medicine; Blinding; Quality of life (healthcare); Glaucoma; Intensive care medicine; Anxiety; Disease; Affect (linguistics); Disease management; Physical therapy; Open angle glaucoma; Internal medicine; Ophthalmology; Psychiatry; Randomized controlled trial; Nursing","score_opus":0.026842871584040952,"score_gpt":0.38615842102961173,"score_spread":0.35931554944557076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343491610","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011017149,0.9996125,0.000016218928,0.00009714981,0.000044215616,0.0000025925174,0.000022634378,9.205163e-7,0.00009356501],"genre_scores_gemma":[0.0008761044,0.9988129,0.000079689264,0.000092562375,0.00008286018,0.0000040385153,0.000018843533,3.5448235e-7,0.00003263453],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9991731,0.00016120965,0.0002815375,0.000111360394,0.00023179327,0.000040880946],"domain_scores_gemma":[0.99774545,0.0014085715,0.0005314839,0.000021230664,0.00022987995,0.00006342611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015416346,0.0012165844,0.0030422937,0.006874933,0.0003770677,0.0017105809,0.0009916589,0.0010497901,0.0031192538],"category_scores_gemma":[0.0030906997,0.00040969963,0.0016944008,0.008090806,0.0006192293,0.002148718,0.0010955142,0.0013472474,0.0003571645],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023616814,0.000112393325,0.0021663092,0.19320928,0.0011134763,0.00030966217,0.00025268152,0.00033051046,0.0004163091,0.0011489074,0.016398419,0.7843059],"study_design_scores_gemma":[0.0001970581,0.00061399693,0.03266486,0.32096666,0.0089465715,0.007308001,0.0015647988,0.00061674055,0.0005396993,0.004411687,0.62191755,0.00025240736],"about_ca_topic_score_codex":0.002229692,"about_ca_topic_score_gemma":0.0050017694,"teacher_disagreement_score":0.006874933,"about_ca_system_score_codex":0.0009699581,"about_ca_system_score_gemma":0.0017111127,"threshold_uncertainty_score":0.010434985},"labels":[],"label_agreement":null},{"id":"W2346712961","doi":"10.1007/s12325-016-0331-8","title":"Cost-Effectiveness of Different Forms of Intra-Articular Injections for the Treatment of Osteoarthritis of the Knee","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Ferring Pharmaceuticals","keywords":"Medicine; Osteoarthritis; Viscosupplementation; Cost effectiveness; Physical therapy; Quality-adjusted life year; Quality of life (healthcare); Randomized controlled trial; Surgery; Intra articular; Alternative medicine","score_opus":0.022036727815490015,"score_gpt":0.30876176629746077,"score_spread":0.28672503848197073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346712961","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88653064,0.10149509,0.0020457173,0.0013849437,0.00019200827,0.00096659985,0.00217602,0.000030474022,0.005178558],"genre_scores_gemma":[0.98977005,0.007862929,0.0010613087,0.00012697121,0.000042996202,0.00025384713,0.0005723289,0.0000041186286,0.0003055211],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9967212,0.0020040611,0.00029917163,0.00017311142,0.00063259236,0.00016981366],"domain_scores_gemma":[0.99617624,0.0024374253,0.0008275505,0.0000726106,0.00027276372,0.0002133487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003847806,0.0007902285,0.0013124396,0.0017634798,0.000178169,0.0011777905,0.00061154953,0.0008203631,0.00338646],"category_scores_gemma":[0.01023514,0.0002273434,0.0041897115,0.0013935792,0.0003595102,0.000891404,0.00061939517,0.0006887682,0.00013877725],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1981188,0.0053948117,0.082852446,0.020263093,0.0351531,0.000700058,0.0002761398,0.09649139,0.0039432584,0.0043671746,0.0035892683,0.54885054],"study_design_scores_gemma":[0.049037576,0.132453,0.4990707,0.011351594,0.10323587,0.0058447956,0.001397786,0.15607202,0.012508195,0.010374083,0.018165506,0.0004889015],"about_ca_topic_score_codex":0.0023647265,"about_ca_topic_score_gemma":0.0018272271,"teacher_disagreement_score":0.003847806,"about_ca_system_score_codex":0.0027080765,"about_ca_system_score_gemma":0.0012451392,"threshold_uncertainty_score":0.020349383},"labels":[],"label_agreement":null},{"id":"W2360207919","doi":"10.1007/s12325-016-0342-5","title":"Erratum to: Quality of Life in Glaucoma: A Review of the Literature","year":2016,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Glaucoma and retinal disorders","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Glaucoma; Rheumatology; Quality of life (healthcare); Ophthalmology; Optometry; Internal medicine; Nursing","score_opus":0.026939274480881646,"score_gpt":0.386671971147752,"score_spread":0.35973269666687036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2360207919","genre_codex":"review","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015221216,0.97933996,0.00007557762,0.004759446,0.015069129,0.000012936442,0.00012445157,0.000007874519,0.00045831533],"genre_scores_gemma":[0.001098698,0.9866153,0.0003002134,0.0037388469,0.007343857,0.000014432881,0.000132249,0.0000054528346,0.0007507837],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988714,0.00018861619,0.0004351874,0.00010492087,0.00034762567,0.00005223944],"domain_scores_gemma":[0.9945781,0.0027019617,0.0009912887,0.000070940856,0.0014796869,0.00017804824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017021446,0.0011393293,0.0025804904,0.006339759,0.0005651432,0.0017865715,0.0011652181,0.0020733085,0.0081886845],"category_scores_gemma":[0.008767531,0.00039954396,0.001288296,0.006812676,0.0008213863,0.0026857583,0.0012605481,0.0026272058,0.002375678],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029040047,0.00006487953,0.0011483864,0.10791947,0.00046585145,0.00083010964,0.00025862103,0.00015431395,0.0005570733,0.0014357392,0.42593193,0.46094322],"study_design_scores_gemma":[0.0001243417,0.0001685891,0.0052347113,0.0766104,0.001497704,0.0053347456,0.0005678493,0.00014627118,0.0003302516,0.0019211011,0.9079562,0.000107860695],"about_ca_topic_score_codex":0.0015502351,"about_ca_topic_score_gemma":0.0037693204,"teacher_disagreement_score":0.0081886845,"about_ca_system_score_codex":0.00077834143,"about_ca_system_score_gemma":0.0025773076,"threshold_uncertainty_score":0.027393937},"labels":[],"label_agreement":null},{"id":"W2423086444","doi":"10.1007/s12325-016-0363-0","title":"Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel®","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals; University of Washington","keywords":"Medicine; Medical prescription; Internal medicine; Mallinckrodt; Confidence interval; Retrospective cohort study; Multiple sclerosis; Prescription costs; Logistic regression; Prescription drug; Immunology","score_opus":0.050959097623084565,"score_gpt":0.31567756864026963,"score_spread":0.26471847101718504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2423086444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995592,0.00017434548,0.000010865907,0.000043961663,0.0000018459704,0.0000027310386,0.00011510385,0.0000010962366,0.00009088824],"genre_scores_gemma":[0.9997067,0.00007632978,0.000020819813,0.000018543165,0.0000052278865,0.0000045236293,0.00013350659,5.112544e-7,0.00003386364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99946505,0.00019603239,0.00007034434,0.00006810638,0.00008185527,0.00011867298],"domain_scores_gemma":[0.9988267,0.00020472065,0.00070523325,0.000023527578,0.000055233708,0.000184611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040297164,0.00021421532,0.0003796923,0.000682089,0.00035762225,0.0005976047,0.00030539697,0.00036218463,0.001306615],"category_scores_gemma":[0.0017995961,0.00019534418,0.000840275,0.0010575444,0.00018228576,0.00034729548,0.00042007817,0.00049325364,0.0001274308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023083492,0.00008020541,0.9979824,0.000011139216,0.0000983346,0.000106560154,0.00004180476,0.00012861652,0.00006635497,0.000011607345,0.000093196206,0.0011490156],"study_design_scores_gemma":[0.000014249734,0.0001745487,0.9987393,0.000009472474,0.000038229595,0.00022174187,0.00019035954,0.0005056589,0.000028322364,0.000014277143,0.00005963334,0.0000040931272],"about_ca_topic_score_codex":0.009548092,"about_ca_topic_score_gemma":0.0075380886,"teacher_disagreement_score":0.009548092,"about_ca_system_score_codex":0.00078979484,"about_ca_system_score_gemma":0.00039364892,"threshold_uncertainty_score":0.018985033},"labels":[],"label_agreement":null},{"id":"W2467376457","doi":"10.1007/s12325-016-0364-z","title":"Promoting Patient and Family Partnerships in Ambulatory Care Improvement: A Narrative Review and Focus Group Findings","year":2016,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Mental Health and Patient Involvement","field":"Health Professions","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre","funders":"Gordon and Betty Moore Foundation","keywords":"General partnership; Medicine; Focus group; Ambulatory care; Nursing; Quality management; Family medicine; Ambulatory; Empowerment; Patient satisfaction; Health care; Management; Internal medicine","score_opus":0.16735982206120661,"score_gpt":0.459091784820796,"score_spread":0.29173196275958935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2467376457","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00062619045,0.9976472,0.00009795495,0.0008566697,0.00008913203,0.0000372098,0.000027446677,0.0000018920352,0.0006163162],"genre_scores_gemma":[0.009896671,0.9887012,0.00037872672,0.000687692,0.00007900433,0.00010250602,0.000030106437,0.0000014438759,0.00012256682],"study_design_codex":"systematic_review","study_design_gemma":"qualitative","domain_scores_codex":[0.9951703,0.002627694,0.000995678,0.000273704,0.0007871314,0.00014551234],"domain_scores_gemma":[0.9773276,0.018287407,0.0023671035,0.00021149605,0.0015631884,0.0002433135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076104053,0.0006638467,0.001141656,0.004857982,0.00078126445,0.0020857053,0.0010405941,0.001550816,0.0020061373],"category_scores_gemma":[0.023334095,0.00040642387,0.0012924309,0.0061614593,0.0009618904,0.0024158063,0.0012599876,0.0013344041,0.00027815055],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018599027,0.00009386068,0.0020821046,0.5185735,0.0010255273,0.00073438336,0.008020536,0.00021498186,0.0003968568,0.0059683938,0.01933932,0.44336444],"study_design_scores_gemma":[0.000051947536,0.00020166676,0.0054220497,0.73558533,0.0027460859,0.0022320272,0.0060709864,0.000098181954,0.0003452694,0.001362228,0.24584185,0.000042275682],"about_ca_topic_score_codex":0.0040516257,"about_ca_topic_score_gemma":0.010963036,"teacher_disagreement_score":0.0076104053,"about_ca_system_score_codex":0.0023807904,"about_ca_system_score_gemma":0.008123088,"threshold_uncertainty_score":0.040248156},"labels":[],"label_agreement":null},{"id":"W2470584189","doi":"10.1007/s12325-016-0368-8","title":"Comparative Analysis of Length of Stay and Inpatient Costs for Orthopedic Surgery Patients Treated with IV Acetaminophen and IV Opioids vs. IV Opioids Alone for Post-Operative Pain","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Acetaminophen; Orthopedic surgery; Rheumatology; Anesthesia; Pain management; Opioid; Surgery; Internal medicine","score_opus":0.013558695467122945,"score_gpt":0.2987284612931916,"score_spread":0.2851697658260686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2470584189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999286,0.00018481165,0.000027346949,0.000019791265,0.0000028785232,0.0000046511072,0.00037182381,0.0000010112415,0.0001017914],"genre_scores_gemma":[0.99877304,0.000113285496,0.00007831754,0.000014354997,0.000010728964,0.000009444362,0.000938399,9.274158e-7,0.00006159767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990747,0.00029678375,0.00014870615,0.00014595709,0.00017093381,0.00016283993],"domain_scores_gemma":[0.99677086,0.00086160784,0.0017629991,0.00006953924,0.00018851094,0.00034662528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008476356,0.00021806026,0.00042919844,0.0015864228,0.00019250208,0.00050662435,0.00046614057,0.00027463763,0.0013577525],"category_scores_gemma":[0.0031194955,0.00019057989,0.00094673375,0.0013449084,0.00020969106,0.00040126505,0.0004378746,0.00040304425,0.000089319095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091700465,0.00006710443,0.99640083,0.000028058199,0.0003307781,0.000052442218,0.000026079693,0.00018013532,0.000110945664,0.000032640524,0.00012838673,0.0017254853],"study_design_scores_gemma":[0.00004668715,0.0006053379,0.9979913,0.000009798784,0.0001354525,0.00016163579,0.00015512745,0.00067810336,0.00007608334,0.000017090573,0.00011823971,0.0000051527004],"about_ca_topic_score_codex":0.0055600344,"about_ca_topic_score_gemma":0.007072145,"teacher_disagreement_score":0.0055600344,"about_ca_system_score_codex":0.0009498101,"about_ca_system_score_gemma":0.00058780285,"threshold_uncertainty_score":0.01105535},"labels":[],"label_agreement":null},{"id":"W2472041818","doi":"10.1007/s12325-016-0361-2","title":"Healthcare Costs and Resource Utilization in Patients with Infantile Spasms Treated with H.P. Acthar Gel®","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals; University of Washington","keywords":"Medicine; Medical prescription; Mallinckrodt; Medicaid; Health care; Emergency medicine; Family medicine; Emergency department; Pharmacy; Pediatrics; Psychiatry; Nursing","score_opus":0.011470060869914842,"score_gpt":0.26962164256589277,"score_spread":0.2581515816959779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2472041818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989698,0.00030807132,0.00003061744,0.00010535114,0.0000030362241,0.000004269892,0.000378981,0.000001190993,0.00019871317],"genre_scores_gemma":[0.99931276,0.00013461616,0.000059395803,0.000045224057,0.000009607175,0.000006105294,0.00038848547,5.828243e-7,0.000043072712],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99937624,0.00020182254,0.00009559031,0.000080062775,0.0001275973,0.00011881519],"domain_scores_gemma":[0.99788374,0.00041633754,0.0013517184,0.00003185573,0.00010122648,0.00021507118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004471381,0.00016408294,0.00024474703,0.00056527456,0.00023718143,0.00055092893,0.0002837113,0.0002645812,0.001301504],"category_scores_gemma":[0.0026408539,0.00014826565,0.00062670227,0.0008676143,0.00016221308,0.00032359996,0.00031417757,0.000493157,0.00009372418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007806234,0.00004550419,0.997775,0.000014803115,0.00007502008,0.00008881268,0.000023590044,0.00014159252,0.00005572111,0.000020171901,0.00012594387,0.0015558574],"study_design_scores_gemma":[0.000006331177,0.000062639694,0.9990513,0.000013127214,0.000019899742,0.00020310943,0.000092262395,0.0004203812,0.00003082553,0.00001518372,0.000082435035,0.0000025472787],"about_ca_topic_score_codex":0.010635308,"about_ca_topic_score_gemma":0.012755074,"teacher_disagreement_score":0.010635308,"about_ca_system_score_codex":0.0008856269,"about_ca_system_score_gemma":0.0005138117,"threshold_uncertainty_score":0.021146834},"labels":[],"label_agreement":null},{"id":"W2505145747","doi":"10.1007/s12325-016-0377-7","title":"Effectiveness and Tolerability of Ivabradine with or Without Concomitant Beta-Blocker Therapy in Patients with Chronic Stable Angina in Routine Clinical Practice","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Heart rate and cardiovascular health","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Servier Deutschland","keywords":"Ivabradine; Medicine; Tolerability; Internal medicine; Angina; Concomitant; Cardiology; Canadian Cardiovascular Society; Myocardial infarction; Beta blocker; Aspirin; Heart rate; Heart failure; Adverse effect; Blood pressure","score_opus":0.016993157748444145,"score_gpt":0.34925465251682297,"score_spread":0.33226149476837885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2505145747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963831,0.0031088456,0.000053372827,0.000049001115,0.000008478134,0.0000222098,0.00006662937,0.000005201688,0.00030319084],"genre_scores_gemma":[0.998917,0.0006064295,0.000153114,0.000089113564,0.000034837754,0.000017845095,0.00012320702,9.198898e-7,0.00005756507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879175,0.00056766294,0.00015790349,0.00019840074,0.00021780771,0.00006657372],"domain_scores_gemma":[0.99732864,0.00082991587,0.0012646121,0.000088004694,0.00014137202,0.00034748408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001867685,0.00024051854,0.0007187165,0.00031134044,0.00019884517,0.0005354801,0.00023984986,0.0004373882,0.0006156939],"category_scores_gemma":[0.0035169104,0.00013167408,0.0004556233,0.00034220162,0.0002625771,0.00032176034,0.00020796062,0.000363178,0.00012853304],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0479088,0.003171252,0.8371069,0.0006742593,0.0010461954,0.00025873625,0.00035873393,0.00037498938,0.0056850202,0.00003063947,0.0003940177,0.10299049],"study_design_scores_gemma":[0.0045914883,0.05090464,0.9408352,0.00009123122,0.00056243327,0.0007756147,0.00018227243,0.0007154738,0.00056623743,0.00003615479,0.0007188549,0.000020397538],"about_ca_topic_score_codex":0.00044572886,"about_ca_topic_score_gemma":0.0008168809,"teacher_disagreement_score":0.001867685,"about_ca_system_score_codex":0.00029255418,"about_ca_system_score_gemma":0.0002454874,"threshold_uncertainty_score":0.009877384},"labels":[],"label_agreement":null},{"id":"W2539484952","doi":"10.1007/s12325-016-0426-2","title":"Self-Administration of Medicines and Dietary Supplements Among Female Amateur Runners: A Cross-Sectional Analysis","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Muscle metabolism and nutrition","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"World Anti-Doping Agency","keywords":"Medicine; Context (archaeology); Self-administration; Dietary supplement; Amateur; Athletes; Interquartile range; Family medicine; Confounding; Self-medication; Physical therapy; Environmental health; Internal medicine; Food science","score_opus":0.01027175277952836,"score_gpt":0.31093646866712515,"score_spread":0.3006647158875968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2539484952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999509,0.000096168944,0.00003511779,0.000012075933,0.0000015818138,0.000014438768,0.0001337747,0.0000010576657,0.00019679459],"genre_scores_gemma":[0.9993647,0.00012691595,0.000093588125,0.00002788878,0.000006531451,0.000033335935,0.0002059755,9.763268e-7,0.00014004803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994642,0.00014520455,0.00007124247,0.00010520083,0.00013183994,0.00008219814],"domain_scores_gemma":[0.998931,0.00025178536,0.00045134773,0.00006420848,0.0001629874,0.00013863729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008095592,0.00023827644,0.00037449365,0.0009749384,0.00043822202,0.00047029156,0.00029642758,0.0004537654,0.001690701],"category_scores_gemma":[0.0013484611,0.00029344304,0.00038358988,0.001003641,0.0002532469,0.0003731535,0.00045678896,0.0002696956,0.0003743469],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032026106,0.000054637712,0.9988456,0.000015262582,0.000023694041,0.0000325297,0.00019652428,0.0000049130294,0.000113407885,0.000004034428,0.000029666882,0.00064779306],"study_design_scores_gemma":[0.0000020779105,0.00012449293,0.99912673,0.00000654411,0.00001723522,0.00013044794,0.00043011934,0.000046919977,0.000023094086,0.000002442824,0.00008808201,0.000001845228],"about_ca_topic_score_codex":0.005178865,"about_ca_topic_score_gemma":0.0062770075,"teacher_disagreement_score":0.005178865,"about_ca_system_score_codex":0.00023903737,"about_ca_system_score_gemma":0.00028324884,"threshold_uncertainty_score":0.010297477},"labels":[],"label_agreement":null},{"id":"W2544647701","doi":"10.1007/s12325-016-0430-6","title":"Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; COPD; Clinical endpoint; Internal medicine; Hazard ratio; Confidence interval; Population; Exacerbation; Post-hoc analysis; Tiotropium bromide; Randomized controlled trial; Lung function; Lung","score_opus":0.033483033267643056,"score_gpt":0.35798235088669333,"score_spread":0.32449931761905026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2544647701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.54707754,0.44020137,0.004695783,0.00065015303,0.0008779498,0.0021994081,0.0023889972,0.00023065924,0.0016781227],"genre_scores_gemma":[0.96959126,0.024971709,0.002078749,0.0004698477,0.0002927367,0.0009503638,0.0012258814,0.000031972864,0.00038745863],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9900816,0.006309115,0.0017713825,0.0008691193,0.0007252694,0.00024355407],"domain_scores_gemma":[0.9931973,0.0033673223,0.0021357674,0.00055705424,0.0005118529,0.00023073239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015721379,0.0022935793,0.011107779,0.0015503753,0.00026362285,0.0020197758,0.0008326208,0.0017825806,0.0012882744],"category_scores_gemma":[0.011872605,0.0009485214,0.020934714,0.001576495,0.00050393783,0.0010233062,0.00088725996,0.001395135,0.00018126178],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33671662,0.0002715484,0.0109992735,0.015370271,0.610765,0.00009564029,0.00006907763,0.0011049618,0.0020503267,0.00006265858,0.0004357771,0.022058858],"study_design_scores_gemma":[0.115151316,0.020136805,0.036100764,0.00096025364,0.82260406,0.00016791283,0.0000833511,0.0017101557,0.00119217,0.00027385607,0.0015381329,0.00008123312],"about_ca_topic_score_codex":0.0010303741,"about_ca_topic_score_gemma":0.0023191904,"teacher_disagreement_score":0.015721379,"about_ca_system_score_codex":0.0007371433,"about_ca_system_score_gemma":0.0008477204,"threshold_uncertainty_score":0.08314359},"labels":[],"label_agreement":null},{"id":"W2549779468","doi":"10.1007/s12325-016-0438-y","title":"Estimating the Effect of Intravenous Acetaminophen for Postoperative Pain Management on Length of Stay and Inpatient Hospital Costs","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Acetaminophen; Perioperative; Emergency medicine; Opioid; Complication; Orthopedic surgery; Adverse effect; Health care; Anesthesia; Surgery; Internal medicine","score_opus":0.004345064428919162,"score_gpt":0.27259209289911807,"score_spread":0.2682470284701989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549779468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844993,0.00046215364,0.009306426,0.0005852031,0.000024400895,0.00015927324,0.0031221411,0.00005781073,0.0017832952],"genre_scores_gemma":[0.992566,0.00025647637,0.0051766885,0.000070487025,0.00001150011,0.00010350049,0.0012705241,0.000009393673,0.00053547946],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99868506,0.0007130152,0.00007228239,0.00020024554,0.00012708234,0.00020242887],"domain_scores_gemma":[0.99083835,0.0071021332,0.0011831403,0.00014839189,0.00042404892,0.00030386192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025135092,0.0009815014,0.0005973695,0.0011396332,0.0002639659,0.00098999,0.0012659319,0.00088202924,0.0030137943],"category_scores_gemma":[0.01010088,0.00065932743,0.0020972975,0.0008457369,0.00034603564,0.00083556067,0.00065732934,0.0011197969,0.00022984768],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004378903,0.0003385442,0.1215112,0.000110932444,0.00048270475,0.000063094485,0.000040162897,0.867911,0.00020364915,0.0010393156,0.0005408569,0.0073207538],"study_design_scores_gemma":[0.00012377465,0.00080550427,0.053409968,0.000068233516,0.0003205586,0.00005794848,0.00015139626,0.9423549,0.00037948333,0.0016416138,0.0006598549,0.000026843918],"about_ca_topic_score_codex":0.060023274,"about_ca_topic_score_gemma":0.034535393,"teacher_disagreement_score":0.060023274,"about_ca_system_score_codex":0.0041555553,"about_ca_system_score_gemma":0.004309277,"threshold_uncertainty_score":0.11934781},"labels":[],"label_agreement":null},{"id":"W2557456288","doi":"10.1007/s12325-016-0455-x","title":"Sirukumab: A Potential Treatment for Mood Disorders?","year":2016,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Tryptophan and brain disorders","field":"Neuroscience","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; University Health Network","funders":"Pfizer; H. Lundbeck A/S; Purdue University; AstraZeneca; Allergan; Eli Lilly and Company","keywords":"Medicine; Mood; Anxiety; Mood disorders; Cognition; Anhedonia; Disease; Major depressive disorder; Research Domain Criteria; Bioinformatics; Psychiatry; Clinical psychology; Immunology; Internal medicine","score_opus":0.04639387100269654,"score_gpt":0.3714001226772261,"score_spread":0.32500625167452957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557456288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012110661,0.9910789,0.0001633218,0.003871636,0.0004176443,0.00002456224,0.00011735749,0.000010631632,0.003104822],"genre_scores_gemma":[0.022821385,0.96537423,0.00093666225,0.006072191,0.00095827214,0.00007483618,0.00020702933,0.0000056595295,0.0035497535],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99973994,0.000101451435,0.00006101113,0.000031929598,0.000047620262,0.000018024555],"domain_scores_gemma":[0.9996424,0.00016435793,0.00010759826,0.000007610002,0.000051096667,0.00002690852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059720926,0.00031963724,0.0012038413,0.0011036047,0.00024356911,0.0010482061,0.0003980848,0.001273805,0.0089939805],"category_scores_gemma":[0.0010675945,0.00016611766,0.0010042724,0.00085160095,0.00035410267,0.0009752751,0.0003939902,0.0011765015,0.0018914993],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011215871,0.0000946,0.0007939327,0.06434633,0.00065351796,0.00072601746,0.00016655229,0.00016461582,0.0027773585,0.0048984317,0.02829283,0.8959642],"study_design_scores_gemma":[0.001454028,0.0012484374,0.006258186,0.056434114,0.0024007221,0.005077687,0.00040887148,0.00040207824,0.0012940423,0.009407667,0.91553104,0.00008322166],"about_ca_topic_score_codex":0.00063154555,"about_ca_topic_score_gemma":0.003345534,"teacher_disagreement_score":0.0089939805,"about_ca_system_score_codex":0.00046722204,"about_ca_system_score_gemma":0.00071698223,"threshold_uncertainty_score":0.030087888},"labels":[],"label_agreement":null},{"id":"W2560603998","doi":"10.1007/s12325-016-0449-8","title":"Hospitalization Costs for Patients Undergoing Orthopedic Surgery Treated With Intravenous Acetaminophen (IV-APAP) Plus Other IV Analgesics or IV Opioid Monotherapy for Postoperative Pain","year":2016,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Anesthesia and Pain Management","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Acetaminophen; Orthopedic surgery; Anesthesia; Opioid; Postoperative pain; Rheumatology; Pain management; Surgery; Internal medicine","score_opus":0.014268676420290291,"score_gpt":0.26463255496456717,"score_spread":0.2503638785442769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560603998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99496955,0.00088908995,0.00014685326,0.00020919206,0.000019361618,0.00003418681,0.003016186,0.0000054066018,0.00071020337],"genre_scores_gemma":[0.9962741,0.00048795476,0.0002011009,0.00008592456,0.000019726027,0.000040562238,0.002716758,0.0000015626738,0.00017237724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99917847,0.00021527139,0.00017585982,0.00011103807,0.00019615568,0.00012321273],"domain_scores_gemma":[0.9980532,0.00023357694,0.0014010849,0.00003810371,0.00007422072,0.00019986594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048091542,0.00019640592,0.00032685214,0.0007450471,0.00024470946,0.00050446694,0.0002883141,0.00020313488,0.0018035707],"category_scores_gemma":[0.0026521133,0.00014127509,0.00091769325,0.0010414837,0.00016991436,0.00028152525,0.0004208447,0.00038498343,0.00010137305],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008957344,0.00014043863,0.98577046,0.00016204656,0.00068316277,0.00009576653,0.00003892197,0.00083602977,0.0002122553,0.00016063852,0.0011795509,0.009824982],"study_design_scores_gemma":[0.000062270556,0.00032650537,0.99722314,0.000052743253,0.00017126503,0.00024406755,0.00012244101,0.0010254526,0.00010107875,0.00008507237,0.000576934,0.000009046881],"about_ca_topic_score_codex":0.007370527,"about_ca_topic_score_gemma":0.010931841,"teacher_disagreement_score":0.007370527,"about_ca_system_score_codex":0.0014756473,"about_ca_system_score_gemma":0.0009223124,"threshold_uncertainty_score":0.014655232},"labels":[],"label_agreement":null},{"id":"W2562907299","doi":"10.1007/s12325-016-0468-5","title":"Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study","year":2017,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Obsessive-Compulsive Spectrum Disorders","field":"Psychology","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Placebo; Medicine; Internal medicine; Randomized controlled trial; Adverse effect; Interim analysis","score_opus":0.012365340215467053,"score_gpt":0.3564717850763892,"score_spread":0.3441064448609222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562907299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870508,0.0042843577,0.0010092804,0.00048462953,0.00048574648,0.0044184425,0.000777495,0.00019747573,0.001291824],"genre_scores_gemma":[0.9826058,0.0043569026,0.002930124,0.0010535292,0.00053675036,0.004888885,0.0009131262,0.000052629708,0.0026622482],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994122,0.00023899041,0.00004185683,0.000110764064,0.000051288167,0.00014504032],"domain_scores_gemma":[0.99931073,0.00020962165,0.00013869502,0.000077834244,0.00005165591,0.0002114306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017483393,0.0023186544,0.0043114014,0.0006975539,0.0005413319,0.0014293636,0.0012598394,0.0026121307,0.0063252943],"category_scores_gemma":[0.0014337649,0.0010893133,0.0022247212,0.00046731732,0.0016566528,0.0021012442,0.00039917522,0.0036239177,0.0010842413],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94203407,0.019525979,0.00039390044,0.0010365521,0.0010816866,0.00008921413,0.00010859073,0.00029483612,0.010506612,0.0001809736,0.0006425587,0.024105117],"study_design_scores_gemma":[0.8915865,0.10565226,0.0009650575,0.000029117225,0.00034401688,0.000045073735,0.000030864012,0.00022723679,0.0005870927,0.000100482546,0.00041047108,0.000021883252],"about_ca_topic_score_codex":0.0009461399,"about_ca_topic_score_gemma":0.0025066123,"teacher_disagreement_score":0.0063252943,"about_ca_system_score_codex":0.0006882223,"about_ca_system_score_gemma":0.0011283337,"threshold_uncertainty_score":0.021160245},"labels":[],"label_agreement":null},{"id":"W2569887051","doi":"10.1007/s12325-016-0467-6","title":"Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age","year":2017,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Cilag; Takeda Oncology; Pfizer; Takeda Pharmaceuticals International; Biogen; Bristol-Myers Squibb","keywords":"Vedolizumab; Medicine; Ulcerative colitis; Internal medicine; Placebo; Adverse effect; Incidence (geometry); Clinical trial; Gastroenterology; Disease; Pathology","score_opus":0.006579731256089791,"score_gpt":0.2727616399943329,"score_spread":0.2661819087382431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569887051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969112,0.0024148256,0.00005198927,0.000056190915,0.0000108551185,0.000025347359,0.00018154069,0.0000019205575,0.00034615165],"genre_scores_gemma":[0.9992249,0.00030074743,0.00007204989,0.000049872095,0.000020889272,0.000016180833,0.00025356963,5.590744e-7,0.000061270934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992532,0.0003196518,0.00009554828,0.00011666463,0.00010460424,0.00011027819],"domain_scores_gemma":[0.99857426,0.0003481592,0.00071524514,0.00006385725,0.000078370904,0.00022014696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013500841,0.00028162994,0.0007816066,0.0003788166,0.00026974804,0.0004489879,0.00012922702,0.00037497788,0.0011653788],"category_scores_gemma":[0.001973932,0.000130522,0.001061667,0.00038109208,0.00018252022,0.00029990645,0.0003036958,0.00043128355,0.00014486308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.064754955,0.000466365,0.9038261,0.00020517975,0.001562317,0.00012274858,0.00010706076,0.00035074394,0.002481564,0.000052917356,0.00038458768,0.025685422],"study_design_scores_gemma":[0.0017314703,0.009741727,0.9854188,0.00005255836,0.0009200467,0.00029030925,0.0000724397,0.00042476304,0.0005046142,0.00008550932,0.0007475798,0.000010205591],"about_ca_topic_score_codex":0.00040824292,"about_ca_topic_score_gemma":0.000879965,"teacher_disagreement_score":0.0013500841,"about_ca_system_score_codex":0.00021040386,"about_ca_system_score_gemma":0.0002594742,"threshold_uncertainty_score":0.0071400404},"labels":[],"label_agreement":null},{"id":"W2587678696","doi":"10.1007/s12325-017-0480-4","title":"When People with Opioid-Induced Constipation Speak: A Patient Survey","year":2017,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AstraZeneca; Pfizer","keywords":"Medicine; Constipation; Opioid; Rheumatology; Opioid epidemic; Internal medicine; Physical therapy; Family medicine; Intensive care medicine; Receptor","score_opus":0.028674183054209615,"score_gpt":0.30907903382730484,"score_spread":0.28040485077309524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587678696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99549806,0.00024005838,0.00015039543,0.0016170504,0.00001935964,0.00014048789,0.001126024,0.000013668222,0.0011949068],"genre_scores_gemma":[0.99612206,0.00057473,0.0003771651,0.0014991335,0.000024387446,0.00033852673,0.000686796,0.000008977691,0.00036827032],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99677795,0.0015513053,0.00048123606,0.0002924841,0.00048638938,0.00041065004],"domain_scores_gemma":[0.99287826,0.002540516,0.0022284635,0.00018621667,0.0012251845,0.0009413551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033073323,0.00018453297,0.0004543235,0.001185273,0.0011654405,0.0015736792,0.00037494037,0.0012068471,0.002412686],"category_scores_gemma":[0.013581735,0.0003975351,0.0004436156,0.0013308376,0.00066452264,0.0024241358,0.0016872623,0.0011512942,0.00060444116],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014960277,0.00026525324,0.8951535,0.0004921419,0.000072745475,0.00058645965,0.081284545,0.00007864986,0.0007690693,0.000103031714,0.0048839585,0.01616103],"study_design_scores_gemma":[0.000035941277,0.0007848781,0.77865773,0.00029326303,0.000047829722,0.0011892841,0.20884362,0.0003887372,0.0002949531,0.00011908785,0.00926925,0.0000754031],"about_ca_topic_score_codex":0.0058297515,"about_ca_topic_score_gemma":0.007168023,"teacher_disagreement_score":0.0058297515,"about_ca_system_score_codex":0.0009096369,"about_ca_system_score_gemma":0.0007536669,"threshold_uncertainty_score":0.017491043},"labels":[],"label_agreement":null},{"id":"W2606607892","doi":"10.1007/s12325-017-0529-4","title":"Is There a Role for Ivabradine in the Contemporary Management of Patients with Chronic Heart Failure in Academic and Community Heart Failure Clinics in Canada?","year":2017,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Heart rate and cardiovascular health","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Health Sciences Centre; The Scarborough Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Health Canada; Servier","keywords":"Ivabradine; Medicine; Ejection fraction; Heart failure; Internal medicine; Sinus rhythm; Guideline; Cardiology; Adverse effect; Heart rate; Atrial fibrillation; Blood pressure","score_opus":0.027726990296504602,"score_gpt":0.33454451083910275,"score_spread":0.30681752054259814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606607892","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2057581,0.13113415,0.00064559106,0.6219497,0.0033467393,0.00011640509,0.0010445178,0.00009671595,0.035908114],"genre_scores_gemma":[0.84373873,0.07046807,0.0042773644,0.07323493,0.0031351098,0.0000703726,0.00054663495,0.000067603185,0.004461181],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982303,0.00034475265,0.00016497758,0.00017099484,0.0004609861,0.0006280469],"domain_scores_gemma":[0.9869582,0.0019335856,0.0019086308,0.00019880122,0.003492444,0.005508378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020659596,0.00016923092,0.0007687617,0.0005091769,0.0021511363,0.003727429,0.0015367753,0.0015051594,0.00843413],"category_scores_gemma":[0.013013372,0.00021442478,0.0005168811,0.0012877837,0.001839214,0.0014778178,0.0009177305,0.0033432723,0.00040827622],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026708504,0.0010489462,0.3745666,0.0019695438,0.0002620548,0.0008771456,0.0029996345,0.0007975466,0.0013841206,0.011233641,0.07028444,0.5319055],"study_design_scores_gemma":[0.002638821,0.001384857,0.72281575,0.01113619,0.0008672315,0.0010916996,0.015968282,0.0024088512,0.0004948037,0.0040263236,0.23690563,0.00026160965],"about_ca_topic_score_codex":0.8704715,"about_ca_topic_score_gemma":0.9494063,"teacher_disagreement_score":0.12952852,"about_ca_system_score_codex":0.022499403,"about_ca_system_score_gemma":0.07417454,"threshold_uncertainty_score":0.26058263},"labels":[],"label_agreement":null},{"id":"W2607307651","doi":"10.1007/s12325-017-0523-x","title":"Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A Randomized Crossover Simulated-Use Study","year":2017,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Merck Canada Inc. (Canada); Université de Montréal","funders":"Merck","keywords":"Medicine; Rheumatoid arthritis; Crossover study; Randomized controlled trial; Crossover; Preference; Rheumatology; Health professionals; Health care; Internal medicine; Physical therapy; Alternative medicine; Statistics","score_opus":0.03973123510095347,"score_gpt":0.3763175813045308,"score_spread":0.3365863462035773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607307651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957872,0.00009995681,0.00019687254,0.00008635194,0.000063726475,0.003210266,0.00013705084,0.000013368258,0.00040518682],"genre_scores_gemma":[0.9877365,0.00025783124,0.0015533168,0.00031224606,0.00018015422,0.008812313,0.00018933264,0.000005409425,0.0009529068],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961052,0.0024066085,0.00026842716,0.00047665165,0.00038967023,0.00035342513],"domain_scores_gemma":[0.9916666,0.0041415044,0.0015983034,0.00056953914,0.0004409603,0.0015831459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049957694,0.001152392,0.0022364233,0.0005857498,0.0010694044,0.001149392,0.0009871908,0.0022200954,0.011944947],"category_scores_gemma":[0.008361937,0.0009692785,0.0016673283,0.00049193355,0.0015050531,0.001457562,0.0006611629,0.002227141,0.0013119902],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70766944,0.26636845,0.0070418604,0.0005492128,0.0004960494,0.00006724352,0.00085593614,0.00039086895,0.0016626068,0.00011280668,0.00052126945,0.014264294],"study_design_scores_gemma":[0.29486063,0.6934022,0.009393942,0.000044005217,0.00024141828,0.000025161062,0.0003176623,0.0007531644,0.00034664894,0.00009912653,0.00047520787,0.000040914387],"about_ca_topic_score_codex":0.0014833093,"about_ca_topic_score_gemma":0.0020059862,"teacher_disagreement_score":0.011944947,"about_ca_system_score_codex":0.0014902934,"about_ca_system_score_gemma":0.0023151152,"threshold_uncertainty_score":0.039959848},"labels":[],"label_agreement":null},{"id":"W2730094282","doi":"10.1007/s12325-017-0569-9","title":"Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications","year":2017,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Rheumatoid arthritis; Dermatomyositis; Internal medicine; Intensive care medicine; Immunology","score_opus":0.15013388212145573,"score_gpt":0.5094959900189787,"score_spread":0.359362107897523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2730094282","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007294271,0.99735165,0.000065414206,0.00070745574,0.00006518653,0.000049511666,0.0003885163,0.0000026235643,0.0006402714],"genre_scores_gemma":[0.009647982,0.9887504,0.00027727673,0.0007202952,0.00014644001,0.00012059092,0.00026794607,0.0000033986814,0.000065702225],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953342,0.0015622362,0.0016568899,0.00034077952,0.0009297954,0.00017612331],"domain_scores_gemma":[0.97204113,0.020633683,0.00489735,0.00017661517,0.0019819115,0.00026919658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005634129,0.00089368277,0.0036440908,0.0084185405,0.00040039196,0.0030182896,0.0012497522,0.0013520535,0.0069290968],"category_scores_gemma":[0.029763348,0.00049389846,0.0032523598,0.011863374,0.000799959,0.0017791933,0.00094909186,0.0013935302,0.00041864222],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012146758,0.00014277018,0.0035565398,0.5292972,0.0055670976,0.0002583203,0.00024602056,0.00073882827,0.00016592488,0.0041005854,0.017150192,0.43756184],"study_design_scores_gemma":[0.0004312509,0.0006808173,0.014688176,0.82305217,0.024530401,0.001395052,0.00069480296,0.00045808457,0.00027425832,0.0024423245,0.1312484,0.00010421592],"about_ca_topic_score_codex":0.0046685734,"about_ca_topic_score_gemma":0.008134495,"teacher_disagreement_score":0.0084185405,"about_ca_system_score_codex":0.0039921757,"about_ca_system_score_gemma":0.0070745256,"threshold_uncertainty_score":0.029796481},"labels":[],"label_agreement":null},{"id":"W2752535758","doi":"10.1007/s12325-017-0604-x","title":"Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial","year":2017,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University; AstraZeneca","keywords":"Medicine; Fluticasone propionate; Formoterol; Budesonide; Formoterol Fumarate; Inhaler; COPD; Budesonide/formoterol; Dry-powder inhaler; Physical therapy; Internal medicine; Asthma","score_opus":0.05241790545422739,"score_gpt":0.3686619351293873,"score_spread":0.31624402967515985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752535758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811086,0.011402415,0.00013867207,0.0007042211,0.00009162185,0.00037236526,0.0038500114,0.000022357497,0.0023098239],"genre_scores_gemma":[0.9881455,0.002988413,0.00026203343,0.00041917127,0.00027036722,0.0005246258,0.0064472817,0.0000075122202,0.00093517447],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9985349,0.00092331885,0.00012613468,0.00010922294,0.00019689738,0.00010948325],"domain_scores_gemma":[0.9975551,0.00065113045,0.0011336526,0.00015823466,0.00012827659,0.00037365576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026720706,0.0008584122,0.0023611328,0.00044253242,0.0003091664,0.0012984533,0.000524986,0.0010565153,0.003865405],"category_scores_gemma":[0.0027372648,0.00029113432,0.0029397206,0.00057561323,0.00047323026,0.00078882906,0.0006371527,0.0010500277,0.00042926514],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9413211,0.002066887,0.022209635,0.0019990166,0.0057739415,0.000121947785,0.00009450105,0.0016333932,0.0011198367,0.00036197776,0.0027810764,0.020516733],"study_design_scores_gemma":[0.6619588,0.1156077,0.19494869,0.0010524292,0.0114914235,0.00060419267,0.0003089349,0.0033371446,0.0012596457,0.0009303,0.008298231,0.00020256668],"about_ca_topic_score_codex":0.0009064228,"about_ca_topic_score_gemma":0.0021432645,"teacher_disagreement_score":0.003865405,"about_ca_system_score_codex":0.000728175,"about_ca_system_score_gemma":0.00064972485,"threshold_uncertainty_score":0.014131486},"labels":[],"label_agreement":null},{"id":"W2766244499","doi":"10.1007/s12325-017-0627-3","title":"Prevalence of Co-existing Autoimmune Disease in Rheumatoid Arthritis: A Cross-Sectional Study","year":2017,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University","funders":"Genentech; Bristol-Myers Squibb","keywords":"Medicine; Rheumatoid arthritis; Psoriatic arthritis; Ankylosing spondylitis; Rheumatology; Internal medicine; Autoimmune disease; Psoriasis; Odds ratio; Cross-sectional study; Arthritis; Population; Immunology; Disease; Pathology","score_opus":0.03297485079590612,"score_gpt":0.38565105918668574,"score_spread":0.3526762083907796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766244499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99882096,0.00037234556,0.00012453995,0.000026062258,0.000005537604,0.000019575953,0.00039501113,0.000003169155,0.00023277315],"genre_scores_gemma":[0.9993297,0.00013287421,0.00013839522,0.000033942935,0.000011076416,0.0000149319785,0.00029994798,9.2056564e-7,0.00003825639],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809843,0.000687268,0.00033918014,0.00036413604,0.00036565313,0.00014534353],"domain_scores_gemma":[0.9948407,0.0010403328,0.0026692678,0.00033082382,0.0005010472,0.0006177903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002484683,0.00030270952,0.0004602425,0.0011755286,0.00044139387,0.0007815939,0.0005402471,0.0006927925,0.0012315025],"category_scores_gemma":[0.004038939,0.0005495423,0.00055205566,0.0015551317,0.0004471507,0.0008476191,0.0006048045,0.0006316391,0.00032439255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019710917,0.000019477078,0.99969995,0.000005761357,0.000041971627,0.000014898969,0.000025264848,0.000005993401,0.000042948355,0.0000021347885,0.000010017874,0.00011185935],"study_design_scores_gemma":[0.0000053717563,0.00013060779,0.9992679,0.000006126857,0.000033230885,0.00028212008,0.0001209001,0.00006057299,0.000026265892,0.0000053772715,0.000058650992,0.0000028816655],"about_ca_topic_score_codex":0.0037027048,"about_ca_topic_score_gemma":0.0038139415,"teacher_disagreement_score":0.0037027048,"about_ca_system_score_codex":0.0002663143,"about_ca_system_score_gemma":0.000321265,"threshold_uncertainty_score":0.01314038},"labels":[],"label_agreement":null},{"id":"W2789321069","doi":"10.1007/s12325-018-0689-x","title":"Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Breast cancer; Internal medicine; Metastatic breast cancer; Oncology; Rheumatology; Cancer; Gynecology","score_opus":0.009575853979504405,"score_gpt":0.3136427364288696,"score_spread":0.3040668824493652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789321069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98280555,0.0047122114,0.00004932627,0.0038665915,0.00006490608,0.000017208982,0.0035844445,0.0000037276357,0.0048959474],"genre_scores_gemma":[0.9928671,0.0045787184,0.00005682789,0.00031644435,0.00008324371,0.000009386116,0.0011660035,0.0000015034093,0.0009207702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998419,0.000046937537,0.000017305438,0.000010146434,0.000029474031,0.0000542249],"domain_scores_gemma":[0.999708,0.000029990519,0.00015116169,0.000005042929,0.00002478619,0.000081092796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016258907,0.00011581592,0.00014259791,0.00042291667,0.00025103235,0.0004758176,0.00015646679,0.00031483182,0.002712843],"category_scores_gemma":[0.0010106305,0.000103626495,0.0003631896,0.00085175916,0.00011990666,0.00026642834,0.00043496315,0.00036999065,0.00018143955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055986096,0.00010816469,0.97118044,0.00010300507,0.00019027464,0.0008235782,0.00015623217,0.00030547028,0.00021719336,0.00058079546,0.004755955,0.021019032],"study_design_scores_gemma":[0.000017932845,0.0000848796,0.99506783,0.00007898087,0.000065853674,0.0005239489,0.0007846678,0.00041293327,0.000025009545,0.00016235631,0.0027703142,0.0000052747214],"about_ca_topic_score_codex":0.025146272,"about_ca_topic_score_gemma":0.03893504,"teacher_disagreement_score":0.025146272,"about_ca_system_score_codex":0.0007836904,"about_ca_system_score_gemma":0.0006190449,"threshold_uncertainty_score":0.049999833},"labels":[],"label_agreement":null},{"id":"W2789545915","doi":"10.1007/s12325-018-0688-y","title":"A Comparison Between Rheological Properties of Intra-articular Hyaluronic Acid Preparations and Reported Human Synovial Fluid","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Proteoglycans and glycosaminoglycans research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Ferring Pharmaceuticals","keywords":"Synovial fluid; Rheology; Hyaluronic acid; Medicine; Crossover study; Shear rate; Viscosity; Osteoarthritis; Materials science; Pathology; Composite material; Anatomy","score_opus":0.049905807584411814,"score_gpt":0.3757283335257441,"score_spread":0.32582252594133226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789545915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891123,0.0060008965,0.0035205444,0.000024326006,0.000029647594,0.0000471242,0.00020218297,0.000024746369,0.001038313],"genre_scores_gemma":[0.9930479,0.0017967175,0.004045704,0.000039878993,0.000020774796,0.000054158307,0.00048159133,0.000012964431,0.00050040666],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991335,0.00027222114,0.00013083254,0.00013724047,0.00027662778,0.000049587637],"domain_scores_gemma":[0.9991277,0.00026643346,0.00031843208,0.00006023197,0.00018215872,0.00004509962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010553785,0.00035889156,0.0002071194,0.00072153425,0.00015849742,0.00045467922,0.00015230145,0.00027730747,0.0015307836],"category_scores_gemma":[0.0010745842,0.000102695114,0.00026628104,0.0005184648,0.00023153581,0.00037344143,0.00024328643,0.0002474397,0.0003208224],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001961401,0.00030963926,0.034663707,0.00075924053,0.00013250542,0.00021700432,0.00046106777,0.00020943092,0.92455024,0.00009518374,0.000118303295,0.036522318],"study_design_scores_gemma":[0.000061705665,0.009897923,0.14990483,0.0001787876,0.00033517036,0.0033699085,0.000856085,0.0012416262,0.82517403,0.00012231084,0.00880793,0.000049678594],"about_ca_topic_score_codex":0.0001757305,"about_ca_topic_score_gemma":0.00013396205,"teacher_disagreement_score":0.0015307836,"about_ca_system_score_codex":0.00011972307,"about_ca_system_score_gemma":0.00018806387,"threshold_uncertainty_score":0.0055814385},"labels":[],"label_agreement":null},{"id":"W2790461977","doi":"10.1007/s12325-018-0681-5","title":"Efficacy of Ivabradine in Combination with Beta-Blockers Versus Uptitration of Beta-Blockers in Patients with Stable Angina (CONTROL-2 Study)","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Heart rate and cardiovascular health","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Servier","keywords":"Ivabradine; Medicine; BETA (programming language); Bisoprolol; Internal medicine; Cardiology; Angina; Carvedilol; Beta blocker; Stable angina; Adrenergic beta-Antagonists; Heart failure; Heart rate; Coronary artery disease; Blood pressure; Myocardial infarction","score_opus":0.01224413159374573,"score_gpt":0.2892618491991901,"score_spread":0.2770177176054444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790461977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99597317,0.0021026928,0.000157348,0.00014600244,0.00015429506,0.0005650387,0.0003186144,0.000025095402,0.0005576791],"genre_scores_gemma":[0.99454933,0.0012171202,0.00066999515,0.00034855586,0.0006162233,0.00083023665,0.0006756977,0.000010990607,0.0010819074],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99871564,0.00072495546,0.00008520018,0.00023298511,0.00009183048,0.00014941025],"domain_scores_gemma":[0.9983785,0.00040147908,0.00042304426,0.00014505691,0.000094836796,0.00055702013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028085995,0.0018635278,0.0036404738,0.0005521331,0.00034307587,0.0012788988,0.0011400958,0.0015194396,0.0035981468],"category_scores_gemma":[0.0017340266,0.0009392712,0.0024858816,0.0004839934,0.0010653721,0.0009399081,0.00049788837,0.002602383,0.00059374125],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9770925,0.010020675,0.0021765605,0.00019843085,0.0007508099,0.000029088344,0.00003214362,0.00013135104,0.002834139,0.000022528118,0.00019161323,0.006520186],"study_design_scores_gemma":[0.76222175,0.2295882,0.0064386097,0.00001871342,0.00066457456,0.000036005724,0.000019618848,0.00026719357,0.00045232917,0.000036791305,0.00024111707,0.000015085778],"about_ca_topic_score_codex":0.0010406288,"about_ca_topic_score_gemma":0.0022176935,"teacher_disagreement_score":0.0036404738,"about_ca_system_score_codex":0.00072828983,"about_ca_system_score_gemma":0.0008612301,"threshold_uncertainty_score":0.0148534775},"labels":[],"label_agreement":null},{"id":"W2790923252","doi":"10.1007/s12325-018-0676-2","title":"Current Treatment Patterns Among Postmenopausal Women with HR+/HER2− Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Regimen; Fulvestrant; Internal medicine; Metastatic breast cancer; Discontinuation; Oncology; Aromatase inhibitor; Breast cancer; Cancer; Tamoxifen","score_opus":0.138153164960228,"score_gpt":0.4640211901505986,"score_spread":0.3258680251903706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790923252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99778265,0.0004396844,0.00004906887,0.000106030406,0.000006217577,0.000014797991,0.0011663996,0.0000027852639,0.00043239596],"genre_scores_gemma":[0.9984176,0.00024837846,0.00005663083,0.000115970644,0.000008877453,0.00002096706,0.00096743036,0.00000302075,0.00016107348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991278,0.0001563108,0.00016406667,0.0002373445,0.00013530732,0.00017923942],"domain_scores_gemma":[0.99763465,0.00039735495,0.0011692926,0.00013320803,0.00023658334,0.00042894832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049035094,0.0002779716,0.00053888094,0.0011469235,0.00086411735,0.001070333,0.0007261889,0.0009674002,0.0019482761],"category_scores_gemma":[0.003247275,0.0005548029,0.0007838585,0.003435019,0.00041822877,0.0010665902,0.00083223486,0.0010401747,0.0002965248],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004874402,0.000058338956,0.9990977,0.000011734946,0.000048953054,0.000028464176,0.00015780175,0.0000087675035,0.00004169106,0.000006874897,0.00010404844,0.00038685944],"study_design_scores_gemma":[0.0000093738145,0.00005846238,0.99825877,0.000017480272,0.000042782718,0.0001275383,0.001174348,0.00007598147,0.000016881333,0.000013955958,0.00019884726,0.0000056060467],"about_ca_topic_score_codex":0.06711625,"about_ca_topic_score_gemma":0.089691415,"teacher_disagreement_score":0.06711625,"about_ca_system_score_codex":0.0010001094,"about_ca_system_score_gemma":0.0011263973,"threshold_uncertainty_score":0.13345122},"labels":[],"label_agreement":null},{"id":"W2790983276","doi":"10.1007/s12325-018-0678-0","title":"Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn’s Disease: A Pooled Analysis of 11 Clinical Studies","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"AbbVie","keywords":"Adalimumab; Medicine; Placebo; Internal medicine; Arthritis; Crohn's disease; Rheumatology; Gastroenterology; Surgery; Disease; Pathology","score_opus":0.017511156106649904,"score_gpt":0.3510851749995052,"score_spread":0.3335740188928553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790983276","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24962798,0.7447641,0.0013070959,0.00031649493,0.00021724992,0.00041094268,0.0022195973,0.00007251149,0.0010638965],"genre_scores_gemma":[0.9048401,0.09027032,0.001682272,0.00030268726,0.00034647444,0.00039051453,0.0019341203,0.00002742317,0.00020612816],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9820696,0.010637647,0.0034864983,0.00182417,0.0016685806,0.00031340084],"domain_scores_gemma":[0.9758724,0.015199795,0.0059753885,0.0012639755,0.0012764963,0.00041201545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020396542,0.0018114402,0.009580067,0.0044569066,0.00041208393,0.0024559258,0.0007790999,0.0012183958,0.0014521934],"category_scores_gemma":[0.0221654,0.001219018,0.017202947,0.004076231,0.00045594524,0.0008267593,0.0012290499,0.00072305545,0.00014941182],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035774566,0.00012609549,0.12276572,0.023386855,0.77385575,0.00018670483,0.00009250239,0.0011880065,0.00090086693,0.000058065772,0.0006830362,0.040981837],"study_design_scores_gemma":[0.008679396,0.0041832454,0.24042588,0.00237968,0.73893833,0.00050987315,0.00011332724,0.0010650791,0.00046297986,0.00019098869,0.0029779978,0.000073241055],"about_ca_topic_score_codex":0.0011519985,"about_ca_topic_score_gemma":0.0026081114,"teacher_disagreement_score":0.020396542,"about_ca_system_score_codex":0.0007256849,"about_ca_system_score_gemma":0.00090949825,"threshold_uncertainty_score":0.10786855},"labels":[],"label_agreement":null},{"id":"W2792899705","doi":"10.1007/s12325-018-0666-4","title":"Prospective Evaluation of Two iStent® Trabecular Stents, One iStent Supra® Suprachoroidal Stent, and Postoperative Prostaglandin in Refractory Glaucoma: 4-year Outcomes","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Glaucoma and retinal disorders","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Glaucoma; Ophthalmology; Intraocular pressure; Glaucoma surgery; Cataract surgery; Prospective cohort study; Glaucoma medication; Visual acuity; Surgery","score_opus":0.0229214098921999,"score_gpt":0.33895937717182156,"score_spread":0.31603796727962163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792899705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993886,0.00031570398,0.000027820539,0.000010029186,0.0000041094586,0.000035208155,0.000103391874,0.0000017544846,0.00011353037],"genre_scores_gemma":[0.9991109,0.00019155457,0.00010551927,0.00003382313,0.00002236357,0.00006411914,0.0003454911,0.0000011481798,0.00012504843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888235,0.0002919511,0.0001544955,0.00019636852,0.00032056664,0.0001543609],"domain_scores_gemma":[0.99585044,0.0006197239,0.002125878,0.00025291872,0.00052377774,0.00062734063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021280472,0.0005339811,0.00069215865,0.00066258945,0.00038512587,0.0006342977,0.00037134686,0.0006687495,0.0012615438],"category_scores_gemma":[0.0022667602,0.0002856631,0.0017805336,0.00067980564,0.00046762705,0.0008841563,0.0005153413,0.00070090516,0.00028697608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06803816,0.0044162124,0.9027549,0.00026925383,0.0016506478,0.00015713945,0.00022837397,0.00027218202,0.0016426248,0.00003492139,0.00018204469,0.020353498],"study_design_scores_gemma":[0.0036354864,0.07892196,0.91309404,0.00005735692,0.0015542348,0.00036884923,0.00026933727,0.0004019401,0.0011846152,0.000029380522,0.00044677345,0.000036049816],"about_ca_topic_score_codex":0.0010661758,"about_ca_topic_score_gemma":0.0016646548,"teacher_disagreement_score":0.0021280472,"about_ca_system_score_codex":0.00076263794,"about_ca_system_score_gemma":0.0007780849,"threshold_uncertainty_score":0.011254311},"labels":[],"label_agreement":null},{"id":"W2806677947","doi":"10.1007/s12325-018-0701-5","title":"Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2− Metastatic Breast Cancer","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Palbociclib; Medicine; Dosing; Metastatic breast cancer; Oncology; Breast cancer; Internal medicine; Cancer; Medical prescription; Pharmacology","score_opus":0.012626847874048403,"score_gpt":0.326261645675861,"score_spread":0.31363479780181264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806677947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950487,0.0014399603,0.00013257531,0.00042162387,0.000010643052,0.000008778103,0.001151827,0.0000035137116,0.0017823504],"genre_scores_gemma":[0.9981516,0.000592166,0.00006833612,0.00007309822,0.000014707619,0.000004342844,0.0006839229,0.000005679709,0.00040613106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99960524,0.00010276404,0.00006015075,0.00006248655,0.00007460311,0.00009472323],"domain_scores_gemma":[0.99843746,0.00028343778,0.00095104653,0.00005854617,0.000100985206,0.00016858232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045422977,0.00012852151,0.00026172577,0.0006765875,0.0001800153,0.0008119738,0.00024827555,0.00025045406,0.0030129794],"category_scores_gemma":[0.003449915,0.0001746001,0.00068096956,0.0016761969,0.00015805115,0.0006376432,0.00043874996,0.00057890284,0.00023384913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016989384,0.000057706446,0.9789611,0.00003436643,0.00025167307,0.00023443907,0.000057684763,0.0012321767,0.00048848905,0.00032572303,0.0007052035,0.015952593],"study_design_scores_gemma":[0.000024340672,0.00013344783,0.99606603,0.000027620104,0.000076868906,0.00045638785,0.00018379657,0.0013424562,0.00009450124,0.000300455,0.0012846716,0.000009522413],"about_ca_topic_score_codex":0.006390331,"about_ca_topic_score_gemma":0.008725227,"teacher_disagreement_score":0.006390331,"about_ca_system_score_codex":0.00094999425,"about_ca_system_score_gemma":0.00047433563,"threshold_uncertainty_score":0.01270628},"labels":[],"label_agreement":null},{"id":"W2810702595","doi":"10.1007/s12325-018-0740-y","title":"Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2− Metastatic Breast Cancer","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Breast cancer; Rheumatology; Metastatic breast cancer; Oncology; Cancer; Cardiac function curve; Hematology; Heart failure","score_opus":0.010532308368372332,"score_gpt":0.3003753413487511,"score_spread":0.2898430329803788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810702595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931636,0.0037102145,0.00016862727,0.00023005728,0.000021814865,0.000032881057,0.00028167886,0.000014970091,0.0023763324],"genre_scores_gemma":[0.9981331,0.00091155374,0.00018505848,0.00014211121,0.0000317649,0.000018113704,0.00016796117,0.0000022467073,0.00040811455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998876,0.000036127836,0.000013731896,0.000020537998,0.000022282647,0.00001970097],"domain_scores_gemma":[0.9997571,0.000060603867,0.000074920616,0.000010573035,0.00003927441,0.000057436453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002581666,0.00026296338,0.00041602703,0.0003495582,0.00023708149,0.0003513875,0.00015199736,0.0002732948,0.00061824505],"category_scores_gemma":[0.00081121095,0.00010950232,0.0001556083,0.00036782617,0.00011846129,0.00020091276,0.00014490631,0.000357567,0.00014463533],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023505779,0.00016299803,0.9693588,0.000071520066,0.00006649038,0.0010618605,0.00016881248,0.00017007906,0.00405466,0.000024568148,0.00043934153,0.022070276],"study_design_scores_gemma":[0.000048709742,0.001593017,0.9931986,0.000032485863,0.000093748225,0.0018047589,0.00035223342,0.0004656186,0.0013360395,0.000071332535,0.0009963646,0.0000072457137],"about_ca_topic_score_codex":0.0019628904,"about_ca_topic_score_gemma":0.0030743538,"teacher_disagreement_score":0.0019628904,"about_ca_system_score_codex":0.00021294542,"about_ca_system_score_gemma":0.00020147926,"threshold_uncertainty_score":0.0039029717},"labels":[],"label_agreement":null},{"id":"W2887418167","doi":"10.1007/s12325-018-0764-3","title":"Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2− Advanced Breast Cancer","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Chemotherapy; Breast cancer; Cancer; Oncology","score_opus":0.010342238505599505,"score_gpt":0.30675490596671456,"score_spread":0.29641266746111505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887418167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970168,0.00081079296,0.00007059349,0.00019317665,0.000008301007,0.000010272834,0.0004128977,0.000005477784,0.0014717045],"genre_scores_gemma":[0.9989091,0.00032240408,0.00006435739,0.00009354627,0.000008951451,0.0000064925744,0.00025645873,0.000002519636,0.00033620786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998406,0.00003649528,0.000022299417,0.00003114051,0.000028101489,0.000041357405],"domain_scores_gemma":[0.9995617,0.00011151361,0.00019113542,0.000018146291,0.000043516615,0.000073941075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015147419,0.00008845336,0.00019870757,0.00046296086,0.00032489022,0.0003094433,0.0001287375,0.0002718359,0.0012146096],"category_scores_gemma":[0.0013863655,0.000109796754,0.00022099224,0.00071560737,0.00011851948,0.00024375938,0.00018378178,0.00032312612,0.00012174963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021815885,0.00005433781,0.99387276,0.0000100516845,0.000017973389,0.00009987706,0.00009483743,0.000036074372,0.000360185,0.000016240005,0.00013506666,0.005084574],"study_design_scores_gemma":[0.000004994976,0.000096735486,0.99854493,0.000008900662,0.00002390203,0.00031888313,0.00031820723,0.00012708378,0.00008763033,0.000025268988,0.00044052774,0.000002978708],"about_ca_topic_score_codex":0.007219231,"about_ca_topic_score_gemma":0.011752069,"teacher_disagreement_score":0.007219231,"about_ca_system_score_codex":0.00026826662,"about_ca_system_score_gemma":0.00027529488,"threshold_uncertainty_score":0.014354408},"labels":[],"label_agreement":null},{"id":"W2888099086","doi":"10.1007/s12325-018-0757-2","title":"Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review","year":2018,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Institute for Health and Care Research; Pfizer","keywords":"Medicine; Adalimumab; Etanercept; Certolizumab pegol; Tofacitinib; Abatacept; Tocilizumab; Internal medicine; Rheumatoid arthritis; Combination therapy; Randomized controlled trial; Rheumatism; Rheumatology; Golimumab; Physical therapy; Rituximab","score_opus":0.033422360059289696,"score_gpt":0.3604072040944361,"score_spread":0.3269848440351464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888099086","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012419437,0.99782914,0.00008590772,0.00012258078,0.00007246805,0.00019090313,0.00026947443,0.0000063592156,0.00018120599],"genre_scores_gemma":[0.019298676,0.9789833,0.0004327966,0.0004614175,0.00008777155,0.00038307763,0.00024448088,0.0000052971495,0.000103268576],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9940988,0.0018341319,0.0024791074,0.00048642058,0.00093345204,0.00016804275],"domain_scores_gemma":[0.9819235,0.011874771,0.0040595043,0.00024107547,0.0016397025,0.00026144047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005911318,0.0014433806,0.010560554,0.008369523,0.0005724099,0.002134964,0.0018234791,0.0016612855,0.00435992],"category_scores_gemma":[0.021500893,0.0010032711,0.009728287,0.008875629,0.00080803817,0.0020256042,0.001213774,0.0009841673,0.00031115883],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039135432,0.000013937828,0.0005713811,0.96317613,0.018877931,0.00006867869,0.00007835218,0.00006581457,0.00012888694,0.000082320556,0.00070966175,0.01583567],"study_design_scores_gemma":[0.0009979565,0.0004496534,0.004584875,0.7048288,0.277242,0.0004351284,0.00021410306,0.00013805758,0.00023907778,0.0002538166,0.010562796,0.000053772626],"about_ca_topic_score_codex":0.0071866936,"about_ca_topic_score_gemma":0.020606458,"teacher_disagreement_score":0.010560554,"about_ca_system_score_codex":0.0028739364,"about_ca_system_score_gemma":0.007918828,"threshold_uncertainty_score":0.031262398},"labels":[],"label_agreement":null},{"id":"W2888908066","doi":"10.1007/s12325-018-0772-3","title":"Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Nilotinib; Dasatinib; Medicine; Myeloid leukemia; Internal medicine; Cohort; Retrospective cohort study; Oncology; Imatinib","score_opus":0.023342761391455184,"score_gpt":0.34780418259492707,"score_spread":0.3244614212034719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888908066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923205,0.00078815816,0.00013068132,0.00017668541,0.000011131805,0.000009772996,0.0061228173,0.000007762601,0.0004325174],"genre_scores_gemma":[0.996639,0.0002835569,0.0000770228,0.000079235666,0.000012467023,0.00000920603,0.0028211426,0.000002293779,0.00007602215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881065,0.000254524,0.00026149212,0.0003076371,0.00019380549,0.000171904],"domain_scores_gemma":[0.9971565,0.00035817214,0.0018543426,0.00017175735,0.00021749632,0.00024166616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069335924,0.0003056967,0.0005061479,0.001157036,0.00040139418,0.0011183236,0.0005277668,0.00070721086,0.001150461],"category_scores_gemma":[0.0022405388,0.00047421036,0.0010165379,0.002711459,0.00035092887,0.0008506476,0.0008439613,0.000808718,0.00016492778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069987225,0.000021238922,0.998882,0.000012548591,0.00013578833,0.000036246063,0.00002749564,0.00006549927,0.00005532682,0.000029880926,0.00022764721,0.00043625472],"study_design_scores_gemma":[0.000008385535,0.000035958263,0.99850464,0.000013620638,0.00006324374,0.00023666323,0.00025857647,0.00052001403,0.000049444312,0.00003408059,0.0002674586,0.000008053377],"about_ca_topic_score_codex":0.022731582,"about_ca_topic_score_gemma":0.026329244,"teacher_disagreement_score":0.022731582,"about_ca_system_score_codex":0.00086361193,"about_ca_system_score_gemma":0.0007662628,"threshold_uncertainty_score":0.0451985},"labels":[],"label_agreement":null},{"id":"W2894087307","doi":"10.1007/s12325-018-0796-8","title":"The Association Between Overactive Bladder and Falls and Fractures: A Systematic Review","year":2018,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Broadcom (Canada); Vancouver Coastal Health","funders":"Astellas Pharma Global Development; Astellas Pharma","keywords":"Medicine; Overactive bladder; Rheumatology; Systematic review; Internal medicine; MEDLINE; Urology; Physical therapy; Alternative medicine; Pathology","score_opus":0.034209186532766216,"score_gpt":0.43118571396180544,"score_spread":0.3969765274290392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894087307","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016969779,0.9973718,0.000072781266,0.00017152056,0.000059241782,0.00010699051,0.0003753883,0.00000483453,0.00014046211],"genre_scores_gemma":[0.021645578,0.9770473,0.00037893464,0.00029939838,0.00008305379,0.00025794425,0.00022785936,0.0000028235554,0.00005698652],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99435955,0.001671835,0.0022582486,0.0004846308,0.0010760651,0.00014970785],"domain_scores_gemma":[0.9733714,0.019124392,0.0053206137,0.00028797792,0.0016453939,0.00025023535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054691522,0.0010866092,0.0066880696,0.009804343,0.0005408543,0.0020442284,0.0015208002,0.0016073649,0.0028343485],"category_scores_gemma":[0.02857763,0.00094192283,0.005880915,0.012130902,0.0007709607,0.0015722151,0.0010941045,0.0008335968,0.0002008963],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015858699,0.000013753457,0.0036367802,0.9551347,0.012634997,0.00013187091,0.0001515755,0.00009091942,0.00007748351,0.000107552645,0.0011753874,0.026686277],"study_design_scores_gemma":[0.0002106686,0.000224376,0.019153396,0.86347824,0.104686946,0.0007138156,0.00029618893,0.00012508631,0.00013526398,0.00030279745,0.010628308,0.000044989138],"about_ca_topic_score_codex":0.010875268,"about_ca_topic_score_gemma":0.025711343,"teacher_disagreement_score":0.010875268,"about_ca_system_score_codex":0.002423535,"about_ca_system_score_gemma":0.008402511,"threshold_uncertainty_score":0.028924048},"labels":[],"label_agreement":null},{"id":"W2898518424","doi":"10.1007/s12325-018-0805-y","title":"Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician","year":2018,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Chronic Disease Management Strategies","field":"Medicine","cited_by":720,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Family Medicine; Western University","funders":"National Institute for Health and Care Research; Novo Nordisk; Intarcia Therapeutics; Sanofi; Janssen Pharmaceuticals; NIHR Leicester Biomedical Research Centre; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Interpretation (philosophy); Rheumatology; Medical physics; Internal medicine; Physical therapy; Intensive care medicine; Computer science","score_opus":0.28715436918372156,"score_gpt":0.6055987002079172,"score_spread":0.3184443310241956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898518424","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025164692,0.8567611,0.019896025,0.08547065,0.010499151,0.0015308625,0.005373128,0.00020305724,0.017749513],"genre_scores_gemma":[0.0774587,0.7952439,0.06785556,0.03637243,0.012185037,0.0037692622,0.004468761,0.00031482152,0.0023315519],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.7720795,0.14309134,0.034337424,0.0057425937,0.043724597,0.0010245388],"domain_scores_gemma":[0.28681433,0.6044467,0.03260977,0.028257312,0.046313297,0.0015586377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.18826674,0.0017142775,0.0072655804,0.008966731,0.0008540672,0.013740544,0.0039409646,0.0041635092,0.010364909],"category_scores_gemma":[0.49596998,0.0013053014,0.002827809,0.007988338,0.004169102,0.0097380355,0.0045605926,0.0069661145,0.0028278076],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004530207,0.00011078662,0.0055036275,0.13854629,0.0033826414,0.00048699975,0.0013965763,0.0010667519,0.0005109601,0.016976755,0.06424364,0.767322],"study_design_scores_gemma":[0.00033119874,0.00026088188,0.008947928,0.40282536,0.00433043,0.0012988031,0.0026447263,0.0013654486,0.0010494193,0.054004233,0.522698,0.00024362886],"about_ca_topic_score_codex":0.0028600486,"about_ca_topic_score_gemma":0.0033393453,"teacher_disagreement_score":0.18826674,"about_ca_system_score_codex":0.0031245158,"about_ca_system_score_gemma":0.020828186,"threshold_uncertainty_score":0.99566156},"labels":[],"label_agreement":null},{"id":"W2902165389","doi":"10.1007/s12325-018-0847-1","title":"The Impact of Excluding Patients with End-Stage Knee Disease in Intra-Articular Hyaluronic Acid Trials: A Systematic Review and Meta-Analysis","year":2018,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Ferring Pharmaceuticals","keywords":"Medicine; Osteoarthritis; Subgroup analysis; Adverse effect; Internal medicine; Meta-analysis; Randomized controlled trial; Hyaluronic acid; Relative risk; Stage (stratigraphy); Rheumatology; Knee pain; Saline; Surgery; Confidence interval; Pathology","score_opus":0.08384372937227681,"score_gpt":0.4099463210476332,"score_spread":0.3261025916753564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902165389","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003199737,0.99476385,0.00059861166,0.00021000084,0.00019390107,0.00051702023,0.00028332233,0.000020899335,0.00021265505],"genre_scores_gemma":[0.21753424,0.7711917,0.0042722635,0.001724344,0.00043783782,0.0035581628,0.000815816,0.00005043937,0.00041518302],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.96758914,0.01825891,0.008757827,0.0022350578,0.0025897494,0.0005692408],"domain_scores_gemma":[0.93733907,0.05039826,0.007467838,0.0013950361,0.0028881158,0.0005115874],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.035111114,0.0030676094,0.027666766,0.006063258,0.00081563916,0.0046227444,0.0027296385,0.0034207788,0.0036336277],"category_scores_gemma":[0.06973446,0.0018380415,0.046196606,0.006623652,0.0011895389,0.002960172,0.0017710001,0.0022507291,0.00029158962],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022845324,0.000024237614,0.0021703916,0.43922105,0.54511243,0.000101043144,0.00007281383,0.00039892472,0.00015106687,0.00016445339,0.00040280537,0.009896088],"study_design_scores_gemma":[0.0011745074,0.00026023286,0.0020766528,0.03460521,0.9600342,0.00006993874,0.000044357264,0.00019578735,0.00009684129,0.00023739574,0.0011825078,0.000022272327],"about_ca_topic_score_codex":0.005603444,"about_ca_topic_score_gemma":0.012799041,"teacher_disagreement_score":0.97233325,"about_ca_system_score_codex":0.003562159,"about_ca_system_score_gemma":0.0052141836,"threshold_uncertainty_score":0.18568754},"labels":[],"label_agreement":null},{"id":"W2903222903","doi":"10.1007/s12325-018-0845-3","title":"Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study","year":2018,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Spirometry; Interstitial lung disease; Vital capacity; Physical therapy; Clinical endpoint; Disease; Radiological weapon; Internal medicine; Lung; Surgery; Diffusing capacity; Clinical trial; Lung function; Asthma","score_opus":0.008695563804266344,"score_gpt":0.2921466742122927,"score_spread":0.28345111040802634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903222903","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76697403,0.0025384314,0.0051827277,0.00096212875,0.00067205087,0.20991385,0.0071999626,0.00010246991,0.006454396],"genre_scores_gemma":[0.60933757,0.0007739099,0.013363844,0.0028636584,0.00063828216,0.36367306,0.0058667776,0.000036682606,0.0034462453],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9850612,0.010331438,0.0010069556,0.0016929131,0.0010028069,0.0009046409],"domain_scores_gemma":[0.99163616,0.0015932937,0.0022643823,0.0010330157,0.0017653318,0.0017077978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02287999,0.001998071,0.0024530431,0.0009845949,0.0014064414,0.0015565271,0.0013838046,0.0025895417,0.0049206656],"category_scores_gemma":[0.011825133,0.001157735,0.0027293842,0.0012285975,0.0011667997,0.001956419,0.0016394813,0.0018044147,0.0027541376],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31590462,0.046793774,0.5801895,0.004095861,0.003955895,0.0009831286,0.0029439116,0.0011721406,0.0034457552,0.0014084505,0.0068037948,0.032303188],"study_design_scores_gemma":[0.11311758,0.37865397,0.47861922,0.00071192643,0.0022156318,0.0005785189,0.0019720348,0.0015181218,0.0009040669,0.001458729,0.020012325,0.0002379186],"about_ca_topic_score_codex":0.0018658281,"about_ca_topic_score_gemma":0.0032165912,"teacher_disagreement_score":0.02287999,"about_ca_system_score_codex":0.0014987269,"about_ca_system_score_gemma":0.0043696202,"threshold_uncertainty_score":0.121002376},"labels":[],"label_agreement":null},{"id":"W2913175198","doi":"10.1007/s12325-019-0880-8","title":"Characterizing the Health-Related Quality of Life Burden of Overactive Bladder Using Disease-Specific Patient-Reported Outcome Measures: A Systematic Literature Review","year":2019,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Broadcom (Canada); Vancouver Coastal Health","funders":"U.S. Food and Drug Administration; Astellas Pharma Global Development; Astellas Pharma","keywords":"Medicine; Overactive bladder; Quality of life (healthcare); Patient-reported outcome; Rheumatology; Health related quality of life; Intensive care medicine; Disease; Systematic review; Internal medicine; Urology; MEDLINE; Physical therapy; Alternative medicine; Pathology; Nursing","score_opus":0.23859904890892009,"score_gpt":0.4527896577481489,"score_spread":0.2141906088392288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913175198","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015539578,0.9969181,0.00019552126,0.00022905998,0.00006981173,0.0002515458,0.0006076059,0.0000057683396,0.00016859166],"genre_scores_gemma":[0.030418623,0.96627575,0.0010383449,0.0005955047,0.00013008079,0.0009565052,0.00051901554,0.000006346143,0.000059811173],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98460937,0.00532059,0.005971148,0.0012115561,0.0025921275,0.0002952221],"domain_scores_gemma":[0.92810744,0.053548656,0.013191864,0.00079336896,0.0040077795,0.0003509056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015789969,0.0016977207,0.009514137,0.0134854885,0.0005535389,0.002939613,0.0018259526,0.0019274582,0.0028928088],"category_scores_gemma":[0.06804658,0.000979075,0.009814454,0.013875159,0.00102942,0.0024239088,0.001626989,0.0013190943,0.00021237321],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014167576,0.000020432708,0.002328087,0.9489619,0.014332024,0.00005414601,0.00014816898,0.00012582279,0.000087799606,0.00016056647,0.00079001824,0.032849357],"study_design_scores_gemma":[0.00022671088,0.00030205396,0.013941488,0.8827758,0.09160477,0.0003825874,0.00035656596,0.00015720555,0.0001650145,0.0003422044,0.009685635,0.000059856127],"about_ca_topic_score_codex":0.0058170194,"about_ca_topic_score_gemma":0.01390259,"teacher_disagreement_score":0.015789969,"about_ca_system_score_codex":0.0039460007,"about_ca_system_score_gemma":0.009830487,"threshold_uncertainty_score":0.083506346},"labels":[],"label_agreement":null},{"id":"W2920055646","doi":"10.1007/s12325-019-00911-y","title":"Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Université Laval; University of Toronto; Women's College Hospital; Institut Universitaire de Cardiologie et de Pneumologie de Québec","funders":"Grifols; GlaxoSmithKline; Boehringer Ingelheim; AstraZeneca; Pfizer","keywords":"Medicine; Tiotropium bromide; COPD; Fixed-dose combination; Bronchodilator; Anesthesia; Clinical endpoint; Internal medicine; Randomized controlled trial; Asthma; Lung; Lung function","score_opus":0.010788667445627217,"score_gpt":0.331679366715968,"score_spread":0.32089069927034075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920055646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93817264,0.006582016,0.003715388,0.0024125464,0.003211712,0.038608063,0.0021338314,0.0005964877,0.0045673936],"genre_scores_gemma":[0.9236565,0.0032037608,0.010328176,0.0035445679,0.0015716292,0.049175028,0.0015750142,0.00011818117,0.0068271942],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978225,0.0012204995,0.00013793999,0.00038111254,0.0001759442,0.00026193119],"domain_scores_gemma":[0.99820745,0.0005604975,0.00040400645,0.00017255718,0.0001532592,0.00050218025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037760737,0.0032426068,0.0055647455,0.0011327874,0.00075327925,0.0020916816,0.0017851042,0.0043436545,0.008072828],"category_scores_gemma":[0.003922907,0.0013532045,0.0029800038,0.00069897634,0.0021263356,0.002124116,0.0007146012,0.0051610162,0.0017023667],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.978456,0.0111330245,0.00013559818,0.00041722192,0.00038660865,0.000026407462,0.000033700886,0.00022087114,0.0024328995,0.0001031914,0.00044714,0.006207175],"study_design_scores_gemma":[0.95617265,0.04278569,0.00019799339,0.000014716881,0.000105224826,0.000009932854,0.0000063759876,0.00021409907,0.00016872563,0.000071434886,0.00024362012,0.000009623011],"about_ca_topic_score_codex":0.00069239945,"about_ca_topic_score_gemma":0.0013808386,"teacher_disagreement_score":0.008072828,"about_ca_system_score_codex":0.0011933242,"about_ca_system_score_gemma":0.001787712,"threshold_uncertainty_score":0.027006269},"labels":[],"label_agreement":null},{"id":"W2931180315","doi":"10.1007/s12325-019-00904-x","title":"Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph's Hospital; Western University","funders":"Feinberg School of Medicine; Northwestern University","keywords":"Tacrolimus; Medicine; Transplantation; Kidney transplantation; Intensive care medicine; Health care; Rheumatology; Immediate release; Internal medicine; Pharmacology","score_opus":0.04955026989090665,"score_gpt":0.40331114580104915,"score_spread":0.3537608759101425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2931180315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992329,0.00031118124,0.00006565319,0.000023981698,0.0000035585595,0.000012483888,0.0002520727,0.0000012250842,0.00009697206],"genre_scores_gemma":[0.9993759,0.00008719661,0.00009093225,0.00002863524,0.00001039495,0.000017494076,0.00037274897,8.804458e-7,0.000015859992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99696416,0.0015403136,0.00040522666,0.00043109668,0.00047967906,0.00017949475],"domain_scores_gemma":[0.9918407,0.0016721069,0.0050703906,0.00029734947,0.00047062038,0.00064894714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003137762,0.00021592945,0.0005314666,0.0006020654,0.00030228065,0.0010218755,0.00042073702,0.000297867,0.00079318206],"category_scores_gemma":[0.004581895,0.00017486834,0.00066342193,0.0015120432,0.00036882513,0.0006791345,0.00057370466,0.0004529147,0.00011204536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071038853,0.00011750203,0.99747235,0.00003568753,0.00022659457,0.000036543246,0.000059317408,0.0000817513,0.000101002144,0.000013586341,0.000062367915,0.0010829028],"study_design_scores_gemma":[0.00009164279,0.0011278183,0.99680376,0.000020942374,0.0001830097,0.00028456555,0.00030304008,0.0006598439,0.00019352789,0.000025073921,0.00029704502,0.000009707322],"about_ca_topic_score_codex":0.0016048852,"about_ca_topic_score_gemma":0.001793324,"teacher_disagreement_score":0.003137762,"about_ca_system_score_codex":0.0006365454,"about_ca_system_score_gemma":0.0005844134,"threshold_uncertainty_score":0.01659429},"labels":[],"label_agreement":null},{"id":"W2933517521","doi":"10.1007/s12325-019-00925-6","title":"Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different","year":2019,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Diabetes Management and Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"HLS Therapeutics; Novo Nordisk; Intarcia Therapeutics; Sanofi; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Insulin; Insulin glargine; Insulin degludec; Insulin detemir; Basal (medicine); Glycemic; Hypoglycemia; Internal medicine; Diabetes mellitus; Endocrinology; Basal insulin; Type 2 diabetes; Intensive care medicine","score_opus":0.17621454717089274,"score_gpt":0.39889117346332426,"score_spread":0.2226766262924315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2933517521","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02332626,0.6920264,0.024911467,0.20465492,0.017243758,0.00025860005,0.00049943203,0.00036694837,0.03671218],"genre_scores_gemma":[0.25026068,0.563093,0.05721953,0.09284064,0.014128593,0.0006853971,0.0007962978,0.0005420464,0.020433726],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.993054,0.0024888539,0.00068396924,0.0012137786,0.0021210862,0.00043836064],"domain_scores_gemma":[0.9910567,0.0038193676,0.0014338079,0.0005893181,0.0022442339,0.00085657707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012247273,0.0008848032,0.0012044349,0.0014174775,0.0006795423,0.0075415005,0.0012415845,0.0033569757,0.0038479045],"category_scores_gemma":[0.021755416,0.0004627597,0.0010996289,0.0011248147,0.005224592,0.006512245,0.0015143061,0.005707185,0.0027845202],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018725414,0.00035192736,0.010301729,0.003340185,0.0002010409,0.00066344376,0.0015953272,0.0005075372,0.005647186,0.05861673,0.048280507,0.8686219],"study_design_scores_gemma":[0.0005658771,0.0018705341,0.027964463,0.010239121,0.00064784026,0.00675302,0.0036247214,0.0022567145,0.011687713,0.14964348,0.784419,0.00032755264],"about_ca_topic_score_codex":0.002719997,"about_ca_topic_score_gemma":0.0014837777,"teacher_disagreement_score":0.012247273,"about_ca_system_score_codex":0.0027190582,"about_ca_system_score_gemma":0.0026917425,"threshold_uncertainty_score":0.06477058},"labels":[],"label_agreement":null},{"id":"W2939873404","doi":"10.1007/s12325-019-00944-3","title":"Efficacy of Triamcinolone Acetonide Extended-Release in Participants with Unilateral Knee Osteoarthritis: A Post Hoc Analysis","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Leeds Biomedical Research Centre; National Institute for Health and Care Research; U.S. Department of Defense","keywords":"Medicine; Triamcinolone acetonide; Post-hoc analysis; Osteoarthritis; Rheumatology; Post hoc; Physical therapy; Internal medicine; Surgery; Alternative medicine; Pathology","score_opus":0.01081824141690586,"score_gpt":0.2841077123767207,"score_spread":0.2732894709598149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2939873404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98564017,0.0023181944,0.0018638427,0.00020100937,0.0005510453,0.0050197938,0.0024813984,0.000114269744,0.0018101934],"genre_scores_gemma":[0.9842429,0.00039970095,0.0022124215,0.00029739333,0.00018066067,0.009466964,0.0012284733,0.000038233666,0.001933268],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99178207,0.0043977206,0.0007366689,0.0012401531,0.0009882012,0.0008551933],"domain_scores_gemma":[0.9857142,0.008656314,0.0022890829,0.0012468635,0.0013835111,0.00071000855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0103852805,0.0019481444,0.005047009,0.0006737258,0.00047475446,0.0010263671,0.0012202465,0.0014267124,0.00876029],"category_scores_gemma":[0.014863502,0.00044833866,0.008249461,0.0005200794,0.00075133966,0.001152901,0.00093080057,0.0018560198,0.0006621706],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9512348,0.0033013078,0.010862214,0.0017403457,0.014809093,0.00015389873,0.00020317809,0.00067730073,0.0036639804,0.00013054827,0.0011617655,0.012061577],"study_design_scores_gemma":[0.20584951,0.54922295,0.18739241,0.00031102423,0.03776455,0.00024194838,0.00052975304,0.008069924,0.0050085033,0.0006644954,0.004746754,0.00019824579],"about_ca_topic_score_codex":0.0008817166,"about_ca_topic_score_gemma":0.0012701004,"teacher_disagreement_score":0.0103852805,"about_ca_system_score_codex":0.0008143651,"about_ca_system_score_gemma":0.0014432919,"threshold_uncertainty_score":0.054923236},"labels":[],"label_agreement":null},{"id":"W2944942906","doi":"10.1007/s12325-019-00964-z","title":"Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort Study","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Merck Sharp and Dohme; Celgene; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; AbbVie","keywords":"Medicine; Psoriatic arthritis; Hazard ratio; Ankylosing spondylitis; Internal medicine; Cohort; Retrospective cohort study; Psoriasis; Cohort study; Rheumatoid arthritis; Confidence interval; Immunology","score_opus":0.007925741234522941,"score_gpt":0.2905770794905939,"score_spread":0.28265133825607097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944942906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985165,0.00021889762,0.00020971628,0.000023127706,0.000009925497,0.00005232632,0.00072778616,0.00000388724,0.00023786438],"genre_scores_gemma":[0.99901545,0.0001166866,0.00016094676,0.000031460004,0.000010524353,0.00003383364,0.0005556138,0.0000017046362,0.00007379094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987224,0.00025566676,0.00014516128,0.000481678,0.00022546209,0.00016959828],"domain_scores_gemma":[0.99824786,0.00024206104,0.00076567,0.00033707797,0.00017707165,0.00023030517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015967969,0.00038548012,0.00047787413,0.0010365394,0.00065804453,0.0007009546,0.0005601488,0.0005980643,0.0016393398],"category_scores_gemma":[0.0031403587,0.0007248869,0.00090542756,0.0015472546,0.00027994768,0.0005973675,0.00060941215,0.0006873941,0.00027913426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022558018,0.00006506921,0.99865866,0.000009778246,0.00016138933,0.0001188885,0.000047682264,0.000030755375,0.00010340981,0.000022042597,0.000092028284,0.0004646264],"study_design_scores_gemma":[0.00007529622,0.00035482636,0.99757975,0.000014797747,0.0001870335,0.0006925198,0.00018796226,0.00047210013,0.00006920624,0.000038324866,0.00031786994,0.000010221742],"about_ca_topic_score_codex":0.008925263,"about_ca_topic_score_gemma":0.0069686114,"teacher_disagreement_score":0.008925263,"about_ca_system_score_codex":0.000399059,"about_ca_system_score_gemma":0.00057704805,"threshold_uncertainty_score":0.017746627},"labels":[],"label_agreement":null},{"id":"W2947268672","doi":"10.1007/s12325-019-00986-7","title":"Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto; Pfizer","keywords":"Medicine; Biosimilar; Rheumatoid arthritis; Methotrexate; Rheumatology; Internal medicine; Antirheumatic Agents; Arthritis; Intensive care medicine; Oncology; Pharmacology","score_opus":0.01538381736389248,"score_gpt":0.2861293139357488,"score_spread":0.2707454965718563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947268672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775179,0.0082039535,0.008779581,0.0013743133,0.00006122717,0.000290694,0.0011242423,0.00006126362,0.0025868637],"genre_scores_gemma":[0.9978707,0.00054672663,0.0010528186,0.000093215815,0.000010158776,0.00005647703,0.00023250534,0.0000025186446,0.00013492757],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9982362,0.0012443701,0.00007544658,0.00013915646,0.00012911481,0.00017571845],"domain_scores_gemma":[0.9941585,0.0044772103,0.0007800757,0.000111368274,0.00013176525,0.0003410501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027868622,0.00069178606,0.0009846161,0.000445166,0.00019045618,0.0010186775,0.0006809887,0.0008859235,0.0032841614],"category_scores_gemma":[0.009301893,0.0003195894,0.002697478,0.00028721476,0.00036370519,0.0007860928,0.0007162559,0.0010505159,0.00011383611],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05672671,0.0037240968,0.10792277,0.0022349546,0.007348881,0.0005217885,0.00017816851,0.6768245,0.0019037548,0.004823836,0.0019299899,0.13586052],"study_design_scores_gemma":[0.01799653,0.030569412,0.09892435,0.0012393644,0.011112807,0.0013495103,0.0002907676,0.82219815,0.002667192,0.010933693,0.0025436124,0.00017455769],"about_ca_topic_score_codex":0.006206469,"about_ca_topic_score_gemma":0.004154782,"teacher_disagreement_score":0.006206469,"about_ca_system_score_codex":0.002367742,"about_ca_system_score_gemma":0.002427443,"threshold_uncertainty_score":0.017179191},"labels":[],"label_agreement":null},{"id":"W2949352054","doi":"10.1007/s12325-019-00994-7","title":"Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"Astellas Pharma Global Development; Astellas Pharma","keywords":"Mirabegron; Medicine; Overactive bladder; Quality of life (healthcare); Internal medicine; Adverse effect; Prospective cohort study; Discontinuation; Intensive care medicine; Urology; Alternative medicine","score_opus":0.041444666041875966,"score_gpt":0.36510910909168837,"score_spread":0.3236644430498124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949352054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980566,0.00036245555,0.00012885519,0.00007885538,0.000006603519,0.000029656767,0.00092950603,0.0000047071817,0.00040268592],"genre_scores_gemma":[0.99866855,0.0001562516,0.00013083017,0.000050982282,0.000016144842,0.000039306735,0.000874988,0.0000019488136,0.000060976854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997638,0.0010980753,0.00042885513,0.00033117397,0.00033522156,0.00016867915],"domain_scores_gemma":[0.98957026,0.0017852285,0.007150073,0.00051182735,0.000531913,0.00045073638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028848217,0.00017599107,0.0004827241,0.00055588695,0.00026499017,0.00078847405,0.00027132116,0.000392585,0.0010086856],"category_scores_gemma":[0.0072683217,0.00015774867,0.00092532183,0.001412023,0.00019852121,0.00063846295,0.0004454746,0.00063065265,0.00016544267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046204563,0.00009316251,0.99703467,0.000037415473,0.00017012695,0.000036229165,0.0000597974,0.00005947793,0.000103674975,0.000012832165,0.0001244476,0.0018061548],"study_design_scores_gemma":[0.00004608014,0.0006065991,0.9985153,0.000012136721,0.00013330743,0.00016184285,0.000106983935,0.00014223535,0.000073158204,0.0000105087665,0.00018555003,0.000006149335],"about_ca_topic_score_codex":0.0008875309,"about_ca_topic_score_gemma":0.0011869458,"teacher_disagreement_score":0.0028848217,"about_ca_system_score_codex":0.00022496308,"about_ca_system_score_gemma":0.0004889309,"threshold_uncertainty_score":0.015256584},"labels":[],"label_agreement":null},{"id":"W2955635155","doi":"10.1007/s12325-019-01015-3","title":"A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"AstraZeneca","keywords":"Dry-powder inhaler; Medicine; Glycopyrrolate; Inhaler; Formoterol Fumarate; Metered-dose inhaler; COPD; Anesthesia; Crossover study; Double blind; Formoterol; Internal medicine; Asthma; Atropine","score_opus":0.039033257202496,"score_gpt":0.35943753139944573,"score_spread":0.3204042741969497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955635155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831445,0.0026364434,0.0013063028,0.0007773615,0.0020992444,0.005871575,0.0012706057,0.00029296288,0.0026010394],"genre_scores_gemma":[0.97660476,0.0027183755,0.0038806584,0.0015281256,0.0017902625,0.006515698,0.0010118495,0.000090660484,0.005859569],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988476,0.0005154668,0.00011254725,0.00022919099,0.000081308164,0.00021386861],"domain_scores_gemma":[0.9982552,0.000663729,0.00020120277,0.0001938365,0.000108668566,0.00057733007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022020924,0.0021356337,0.0073640654,0.0009472236,0.0008147447,0.001336401,0.0019332037,0.0030050527,0.010250624],"category_scores_gemma":[0.002758627,0.0016146709,0.0020877835,0.00065580726,0.002632086,0.002145,0.0006501975,0.0038561476,0.0018359867],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9901308,0.004799058,0.000054787994,0.00019021088,0.00015247652,0.000010202225,0.00001744111,0.00006488365,0.0018270235,0.000060805716,0.00014179842,0.0025505018],"study_design_scores_gemma":[0.9597399,0.039105136,0.00033766186,0.000008056313,0.00013381155,0.0000064733117,0.00000887001,0.00017004876,0.00027637588,0.000054979402,0.00014880768,0.00000973374],"about_ca_topic_score_codex":0.001402841,"about_ca_topic_score_gemma":0.0021888681,"teacher_disagreement_score":0.010250624,"about_ca_system_score_codex":0.0007415999,"about_ca_system_score_gemma":0.0019082396,"threshold_uncertainty_score":0.034291744},"labels":[],"label_agreement":null},{"id":"W2966608893","doi":"10.1007/s12325-019-01035-z","title":"An Evaluation of Longitudinal Measures of Anticholinergic Exposure for Application in Retrospective Administrative Data Analyses","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Pesticide Exposure and Toxicity","field":"Agricultural and Biological Sciences","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Vancouver Coastal Health","funders":"Astellas Pharma Global Development; Astellas Pharma","keywords":"Anticholinergic; Medicine; Interquartile range; Adverse effect; Retrospective cohort study; Gold standard (test); Internal medicine; Potency","score_opus":0.20861809529254643,"score_gpt":0.4335322824545844,"score_spread":0.22491418716203798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966608893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71310574,0.005837239,0.21980473,0.0018843359,0.0006945862,0.007055939,0.04069493,0.000754284,0.0101682255],"genre_scores_gemma":[0.89942694,0.0008269874,0.08038907,0.00044210537,0.00023685487,0.008742683,0.009109599,0.000079327365,0.00074633793],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9110614,0.06188362,0.01179128,0.005102903,0.009246827,0.0009140415],"domain_scores_gemma":[0.7494308,0.11911221,0.07313101,0.034424726,0.022149084,0.0017521852],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.13066329,0.0008731035,0.0011915915,0.0038374148,0.0009400854,0.0024707385,0.0017132033,0.0010567079,0.0031391645],"category_scores_gemma":[0.21885425,0.0006190989,0.0035523993,0.0057174102,0.00079662894,0.0025587925,0.001788936,0.0015337864,0.00048108443],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012759014,0.00028994415,0.95369023,0.0010719677,0.005723412,0.000111597445,0.00059130945,0.002214812,0.000533757,0.0029972366,0.0034744984,0.028025325],"study_design_scores_gemma":[0.00037417002,0.0039277114,0.9419737,0.0010050434,0.002523748,0.000686296,0.0010538265,0.022426631,0.0015175059,0.003643812,0.020729894,0.00013764473],"about_ca_topic_score_codex":0.0025659488,"about_ca_topic_score_gemma":0.0033523554,"teacher_disagreement_score":0.8693367,"about_ca_system_score_codex":0.0011218745,"about_ca_system_score_gemma":0.0031436845,"threshold_uncertainty_score":0.6910218},"labels":[],"label_agreement":null},{"id":"W2972252679","doi":"10.1007/s12325-019-01071-9","title":"Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Merck KGaA","keywords":"Medicine; Health professionals; Health care; Patient care; Medical emergency; Nursing","score_opus":0.0456769955406498,"score_gpt":0.38274375470398936,"score_spread":0.33706675916333956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972252679","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058262914,0.011658042,0.450924,0.23963417,0.012883172,0.017644286,0.0018080883,0.009047612,0.19813778],"genre_scores_gemma":[0.22658859,0.0068197954,0.7128434,0.016391722,0.0017402332,0.01494438,0.0018351013,0.0010896506,0.017747162],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.7902473,0.14956042,0.018660216,0.004588863,0.032837093,0.004106175],"domain_scores_gemma":[0.70945215,0.12269905,0.023720235,0.020982435,0.09416209,0.028983954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.1653694,0.0015158029,0.001403558,0.0058125095,0.0041037956,0.0117713455,0.004206191,0.003524088,0.013812437],"category_scores_gemma":[0.2872212,0.00088440115,0.0018378051,0.003618815,0.0037157093,0.0066820565,0.015965428,0.0065381215,0.006550681],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023318244,0.0008860616,0.0067466986,0.0036605855,0.0001420861,0.000500248,0.029022496,0.0011604091,0.0014271588,0.0139389075,0.15391324,0.788369],"study_design_scores_gemma":[0.00047085457,0.0011424805,0.0135475295,0.013242104,0.00019969682,0.001251372,0.028519813,0.004475284,0.005572285,0.039605547,0.89157885,0.0003940859],"about_ca_topic_score_codex":0.0030326953,"about_ca_topic_score_gemma":0.0028536425,"teacher_disagreement_score":0.1653694,"about_ca_system_score_codex":0.008159185,"about_ca_system_score_gemma":0.05114407,"threshold_uncertainty_score":0.87456745},"labels":[],"label_agreement":null},{"id":"W2972614719","doi":"10.1007/s12325-019-01074-6","title":"Examination of a New Delivery Approach for Oral Cannabidiol in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Pharmacokinetics Study","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Okanagan University College; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"","keywords":"Medicine; Placebo; Pharmacokinetics; Cannabidiol; Bioavailability; Dosing; Area under the curve; Dose; Pharmacology; Anesthesia; Internal medicine; Pathology","score_opus":0.037461864111367565,"score_gpt":0.37129879425205675,"score_spread":0.33383693014068916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972614719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96914107,0.0033714795,0.0071935835,0.0014872473,0.0015669493,0.014080317,0.00093453913,0.0002546792,0.0019701668],"genre_scores_gemma":[0.9688821,0.0022958282,0.014108023,0.002143263,0.0012516687,0.0075210035,0.00046721,0.000088198685,0.0032427493],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99345726,0.0041515157,0.0005091212,0.00091109256,0.00060229935,0.00036866835],"domain_scores_gemma":[0.99407506,0.0026242076,0.0010992707,0.0008231807,0.0006631186,0.0007151795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011805263,0.0016715045,0.0035623196,0.0006811334,0.0008451613,0.0016030448,0.0013702681,0.004191674,0.005483548],"category_scores_gemma":[0.010312577,0.0012753711,0.0017686337,0.000568784,0.0026263716,0.002112381,0.00074086984,0.003136599,0.0009420903],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9521048,0.014936876,0.0005224796,0.00047611157,0.00066186924,0.00002699673,0.00011955627,0.00014093259,0.012558214,0.00018578724,0.00034246474,0.017923934],"study_design_scores_gemma":[0.65669864,0.33381328,0.0027119992,0.00004155253,0.0015441271,0.00003726663,0.00005110302,0.0005415857,0.0026164358,0.00023448905,0.0016612223,0.00004821115],"about_ca_topic_score_codex":0.0011901276,"about_ca_topic_score_gemma":0.0018350466,"teacher_disagreement_score":0.011805263,"about_ca_system_score_codex":0.0010288694,"about_ca_system_score_gemma":0.002850853,"threshold_uncertainty_score":0.062432945},"labels":[],"label_agreement":null},{"id":"W2972756983","doi":"10.1007/s12325-019-01086-2","title":"The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Genentech; Gilead Sciences","keywords":"Medicine; Pirfenidone; Rheumatoid arthritis; Interstitial lung disease; Rheumatology; Internal medicine; Randomized controlled trial; Clinical trial; Physical therapy; Lung; Intensive care medicine; Idiopathic pulmonary fibrosis","score_opus":0.03812078492113691,"score_gpt":0.36960967182665533,"score_spread":0.3314888869055184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972756983","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22351229,0.015320613,0.02011395,0.0074871103,0.0086629605,0.704369,0.0065415967,0.0008875558,0.013104991],"genre_scores_gemma":[0.2508252,0.004432971,0.03680216,0.007887778,0.0029055031,0.6871528,0.0020212224,0.00017012253,0.0078022704],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9890267,0.0073652365,0.00077773153,0.0012441409,0.0007330312,0.00085329247],"domain_scores_gemma":[0.99689615,0.001075589,0.0005914835,0.0003989672,0.00033645335,0.0007013494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015878858,0.004913692,0.0062127104,0.0010179232,0.0021673918,0.0027194344,0.001961219,0.005802298,0.011495583],"category_scores_gemma":[0.012901804,0.0026933353,0.0032483293,0.0010273986,0.0051029185,0.0024941438,0.0011036989,0.0072481013,0.0031012767],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9639367,0.0062298058,0.00071057415,0.0027291523,0.0009829025,0.00011488457,0.00014809064,0.0010696604,0.002374952,0.0027649011,0.0036655182,0.015272885],"study_design_scores_gemma":[0.9731141,0.020575227,0.00036396523,0.000116305426,0.00036923809,0.00003310004,0.000018848415,0.00044694878,0.00024066889,0.00081149576,0.0038762693,0.000033867633],"about_ca_topic_score_codex":0.00072807126,"about_ca_topic_score_gemma":0.0014034937,"teacher_disagreement_score":0.015878858,"about_ca_system_score_codex":0.0012358952,"about_ca_system_score_gemma":0.004548268,"threshold_uncertainty_score":0.08397645},"labels":[],"label_agreement":null},{"id":"W2981743123","doi":"10.1007/s12325-019-01126-x","title":"Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine","year":2019,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Sanofi","keywords":"Lixisenatide; Medicine; Insulin glargine; Type 2 diabetes; Population; Insulin; Diabetes mellitus; Basal insulin; Glucagon-like peptide 1 receptor; Intensive care medicine; Internal medicine; Endocrinology; Receptor","score_opus":0.016104954431143098,"score_gpt":0.2998611474260131,"score_spread":0.28375619299487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981743123","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029189812,0.99880123,0.00005793819,0.00038388703,0.000100386605,0.000005543851,0.000008547692,0.0000023787795,0.00034817692],"genre_scores_gemma":[0.0015634045,0.99716777,0.00025179653,0.00059059355,0.00020051282,0.000013532931,0.000019712206,0.0000015528304,0.00019119261],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996289,0.00011353319,0.000115744835,0.000043380143,0.000078257,0.00002019703],"domain_scores_gemma":[0.9991936,0.0005520684,0.00013706023,0.000008744488,0.00008452076,0.000023934808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001287268,0.00034826229,0.0010718568,0.0008713789,0.000107376494,0.00066971773,0.000465974,0.000697337,0.001536452],"category_scores_gemma":[0.0015451346,0.00015791437,0.0009909642,0.0007977928,0.0002514338,0.0009965716,0.00038872127,0.0012583426,0.00039832378],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006156828,0.000074816664,0.00038731215,0.05389003,0.00049077737,0.00033277957,0.00012541807,0.00019632695,0.0010803189,0.0015972856,0.011282735,0.9299266],"study_design_scores_gemma":[0.0005150572,0.0018566699,0.005377984,0.069904976,0.0024715743,0.0035724605,0.00024685415,0.00027061097,0.0010699678,0.0021215824,0.9125309,0.00006147371],"about_ca_topic_score_codex":0.00071086513,"about_ca_topic_score_gemma":0.0015735038,"teacher_disagreement_score":0.001536452,"about_ca_system_score_codex":0.0003791996,"about_ca_system_score_gemma":0.000687999,"threshold_uncertainty_score":0.006807804},"labels":[],"label_agreement":null},{"id":"W2982028489","doi":"10.1007/s12325-019-01123-0","title":"Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Liver Centre","funders":"AbbVie","keywords":"Medicine; Internal medicine; Regimen; Gastroenterology; Cirrhosis; Adverse effect; Hepatitis C virus; Hepatitis C; Viral load; Immunology; Virus","score_opus":0.03369446746467003,"score_gpt":0.36134465885659334,"score_spread":0.3276501913919233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982028489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988728,0.00035809845,0.0001015314,0.000047320846,0.000014515897,0.00021397478,0.00019407948,0.000013933958,0.00018364002],"genre_scores_gemma":[0.99832743,0.00020376792,0.00030625003,0.000117630014,0.000053920827,0.00028813077,0.00045753023,0.0000049049345,0.00024040315],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9987895,0.0006930671,0.000078432364,0.00021038688,0.00012837801,0.00010030427],"domain_scores_gemma":[0.9979432,0.00028419588,0.00070870144,0.00025346476,0.00013187807,0.000678552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00296324,0.0013202525,0.001514529,0.0002870538,0.00033123852,0.00085227715,0.00063087477,0.0010305787,0.0018255207],"category_scores_gemma":[0.0020671329,0.0006037436,0.0013699138,0.00034628698,0.000651411,0.00097308744,0.00034723227,0.0016055705,0.000510043],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8688099,0.037866466,0.038801864,0.00038392548,0.0024875016,0.000112258764,0.0003012542,0.0008608889,0.010818174,0.00006666613,0.0007041162,0.0387869],"study_design_scores_gemma":[0.4402015,0.4419008,0.11141695,0.00004368236,0.0011094506,0.00027355296,0.00010593815,0.0022256917,0.0018718428,0.00010825303,0.00067121966,0.00007115281],"about_ca_topic_score_codex":0.0005462502,"about_ca_topic_score_gemma":0.00091519376,"teacher_disagreement_score":0.00296324,"about_ca_system_score_codex":0.0006095948,"about_ca_system_score_gemma":0.00089860824,"threshold_uncertainty_score":0.015671313},"labels":[],"label_agreement":null},{"id":"W2983410614","doi":"10.1007/s12325-019-01128-9","title":"Dyspnea in COPD: New Mechanistic Insights and Management Implications","year":2019,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; University of British Columbia; Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; COPD; Deconditioning; Intensive care medicine; Psychological intervention; Physical therapy; Physical medicine and rehabilitation; Internal medicine; Psychiatry","score_opus":0.05063204960442954,"score_gpt":0.3964695328104613,"score_spread":0.3458374832060318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983410614","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009177408,0.8627021,0.0050759083,0.102422625,0.0037900591,0.00009150796,0.00022419634,0.000071203154,0.01644498],"genre_scores_gemma":[0.11008796,0.84940577,0.005105762,0.01898207,0.011866679,0.00024576279,0.0002316319,0.000026372445,0.004047971],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994598,0.00018244708,0.000043472694,0.00008901288,0.00011931522,0.00010595177],"domain_scores_gemma":[0.99885285,0.0005101504,0.00012217314,0.000071881834,0.00024168675,0.00020122438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019394757,0.0009987678,0.0017525401,0.0010029987,0.0008704454,0.0036259536,0.0018228403,0.003490743,0.005185953],"category_scores_gemma":[0.0021497693,0.00033017478,0.0013380585,0.000562053,0.0030864843,0.0043497398,0.0020918478,0.0065751355,0.0010218517],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013422936,0.0022476306,0.007193155,0.012715509,0.00039830193,0.0045676194,0.002873353,0.0032768785,0.008958841,0.27411917,0.06291345,0.61939377],"study_design_scores_gemma":[0.00030532817,0.0025858146,0.018920131,0.012515911,0.00045600854,0.006346833,0.006685186,0.0064883563,0.002075472,0.4458314,0.49756834,0.00022123837],"about_ca_topic_score_codex":0.001339524,"about_ca_topic_score_gemma":0.0020066623,"teacher_disagreement_score":0.005185953,"about_ca_system_score_codex":0.0016457504,"about_ca_system_score_gemma":0.0025001385,"threshold_uncertainty_score":0.017348766},"labels":[],"label_agreement":null},{"id":"W2990283038","doi":"10.1007/s12325-019-01145-8","title":"Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis","year":2019,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"AbbVie; Celgene; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Adalimumab; Clinical trial; Rheumatology; Internal medicine; Term (time); Intensive care medicine; Safety profile; Adverse effect; Medical physics; Rheumatoid arthritis","score_opus":0.04198891975818134,"score_gpt":0.44708754123904815,"score_spread":0.40509862148086684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990283038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55884224,0.41308022,0.0030646196,0.0008129791,0.00012618226,0.00092267495,0.018767238,0.00012369861,0.004260161],"genre_scores_gemma":[0.93115544,0.049964625,0.002212366,0.0009633533,0.0002791414,0.0010438977,0.013837188,0.0000662505,0.00047779217],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98215795,0.006522475,0.00516478,0.0022643625,0.003445092,0.00044530636],"domain_scores_gemma":[0.9645136,0.016443282,0.013427158,0.0021706996,0.0027637647,0.00068161555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.027403135,0.0009038838,0.003863523,0.0024260287,0.00032479144,0.0022084655,0.0007610951,0.00086046883,0.001835528],"category_scores_gemma":[0.022366278,0.00055685185,0.005722802,0.004658644,0.0005028481,0.0014769778,0.0010080265,0.0009992342,0.00034304676],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031488657,0.00022753957,0.5990624,0.025438024,0.116536394,0.0007748672,0.0005711908,0.002658868,0.0035269486,0.0002737538,0.006563009,0.21287835],"study_design_scores_gemma":[0.007583716,0.0054800706,0.8615445,0.003279343,0.09385922,0.0023489292,0.00020024781,0.00097196567,0.0015093682,0.00040662315,0.022712242,0.00010382589],"about_ca_topic_score_codex":0.0005691411,"about_ca_topic_score_gemma":0.001154506,"teacher_disagreement_score":0.027403135,"about_ca_system_score_codex":0.00074420695,"about_ca_system_score_gemma":0.0010504023,"threshold_uncertainty_score":0.14492333},"labels":[],"label_agreement":null},{"id":"W2995427723","doi":"10.1007/s12325-019-01169-0","title":"Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia","year":2019,"lang":"en","type":"letter","venue":"Advances in Therapy","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVRAZ (Canada); TransCanada (Canada)","funders":"Pfizer","keywords":"Blinatumomab; Medicine; Refractory (planetary science); Lymphoblastic Leukemia; Internal medicine; Oncology; Salvage therapy; Pediatrics; Leukemia; Chemotherapy","score_opus":0.03605871875456865,"score_gpt":0.36249777461210675,"score_spread":0.3264390558575381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995427723","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006885424,0.0010679757,0.00008398056,0.94441897,0.05151158,0.000033459553,0.0002566423,0.000056719382,0.0018821493],"genre_scores_gemma":[0.005374856,0.00094627694,0.0002350842,0.92623395,0.06164882,0.000078176694,0.00010610586,0.00004063586,0.00533618],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977198,0.000874919,0.00037777348,0.000271731,0.00048565792,0.00027017592],"domain_scores_gemma":[0.99183357,0.0041558864,0.00078422367,0.00022035193,0.0020251267,0.0009807509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030946808,0.00066092407,0.0018029355,0.00077291374,0.0020124442,0.0023840975,0.0016940323,0.024494074,0.008324848],"category_scores_gemma":[0.024797682,0.0005113785,0.0011316335,0.0008820296,0.0009453943,0.0016172657,0.0006766572,0.017874787,0.006927394],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019203531,0.000038676855,0.00043366512,0.00006718143,0.000018173296,0.0011107248,0.000030540636,0.000043982123,0.00008489532,0.00039284804,0.9934788,0.00410843],"study_design_scores_gemma":[0.0008399415,0.00034761807,0.003290477,0.000636012,0.00015918833,0.0043603317,0.0004025712,0.00090514787,0.000744352,0.0047191186,0.9834781,0.000117123505],"about_ca_topic_score_codex":0.0031433303,"about_ca_topic_score_gemma":0.0046075117,"teacher_disagreement_score":0.024494074,"about_ca_system_score_codex":0.0037481347,"about_ca_system_score_gemma":0.0034302315,"threshold_uncertainty_score":0.027849436},"labels":[],"label_agreement":null},{"id":"W2996864695","doi":"10.1007/s12325-019-01185-0","title":"Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine","year":2019,"lang":"en","type":"erratum","venue":"Advances in Therapy","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Lixisenatide; Medicine; Basal insulin; Insulin glargine; Internal medicine; Glucagon-like peptide 1 receptor; Endocrinology; Type 2 diabetes; Insulin; Diabetes mellitus; Basal (medicine); Receptor; Agonist","score_opus":0.004104802182319163,"score_gpt":0.2401947953812758,"score_spread":0.23608999319895665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996864695","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007005177,0.0015207292,0.0005298214,0.060138665,0.9330423,0.00002290536,0.00066625734,0.00024123916,0.0037680983],"genre_scores_gemma":[0.006030557,0.011235536,0.0063741077,0.18584953,0.4768008,0.00023997015,0.0023877271,0.0020113583,0.3090704],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964948,0.00074487773,0.0007350032,0.00039809258,0.0013682274,0.00025904452],"domain_scores_gemma":[0.97638047,0.0067765694,0.0014295281,0.0008569838,0.013264799,0.001291596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039033212,0.0018779775,0.0014226022,0.002345615,0.0020334676,0.0032990088,0.0023428516,0.005056929,0.050123636],"category_scores_gemma":[0.043246366,0.0007737867,0.0016236054,0.0013539579,0.0019707154,0.0017546796,0.0012819897,0.011143746,0.040372893],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026448233,0.000003730583,0.000021481397,0.00006539555,0.0000037455054,0.00009736589,0.000008756348,0.000015946911,0.000022248105,0.00030578414,0.994709,0.004720068],"study_design_scores_gemma":[0.000037905374,0.000017205224,0.0002484633,0.00030028328,0.00001680859,0.0004608203,0.00003328072,0.00008926187,0.00017978917,0.0006994338,0.9978998,0.00001698016],"about_ca_topic_score_codex":0.013729014,"about_ca_topic_score_gemma":0.020547735,"teacher_disagreement_score":0.050123636,"about_ca_system_score_codex":0.0031389303,"about_ca_system_score_gemma":0.004694249,"threshold_uncertainty_score":0.16768026},"labels":[],"label_agreement":null},{"id":"W2997991791","doi":"10.1007/s12325-019-01205-z","title":"New Technologies and Applications in Sacral Neuromodulation: An Update","year":2019,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Institute for Health and Care Research; Medtronic","keywords":"Medicine; Neuromodulation; Sacral nerve stimulation; Groundwater recharge; Magnetic resonance imaging; Perspective (graphical); Health professionals; Medical physics; Health care; Radiology; Surgery; Internal medicine; Computer science; Engineering; Artificial intelligence","score_opus":0.0701502830510855,"score_gpt":0.43091270964932504,"score_spread":0.36076242659823954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997991791","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000048458543,0.9987012,0.000042483465,0.00034422686,0.00030267678,0.0000021841777,0.000013808313,0.0000028977158,0.00054204534],"genre_scores_gemma":[0.00028916346,0.99866784,0.00010308857,0.00032002042,0.0003199234,0.000002779834,0.0000189158,0.0000010121389,0.00027729842],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99962974,0.000069709684,0.00008147029,0.000048355985,0.0001407538,0.00002992038],"domain_scores_gemma":[0.9987709,0.0008011343,0.00013817225,0.00001969256,0.00022590716,0.000044236738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086120545,0.00079262065,0.0013172256,0.0037004189,0.00035013538,0.0014679402,0.00074788503,0.0013655521,0.006143167],"category_scores_gemma":[0.0016923446,0.00027701387,0.00092453347,0.0034146819,0.000555786,0.0020140968,0.0007535036,0.0021437122,0.0015932415],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006572545,0.00005635591,0.00022942603,0.049025256,0.0001246836,0.0003489531,0.00014099093,0.00025594348,0.0009274456,0.0056190407,0.058974154,0.8842321],"study_design_scores_gemma":[0.000010040161,0.000049239927,0.0005314191,0.009351818,0.00015195474,0.0013258209,0.00009483157,0.000056239933,0.00011849481,0.0015918806,0.9867011,0.000017145783],"about_ca_topic_score_codex":0.0015333871,"about_ca_topic_score_gemma":0.0036029438,"teacher_disagreement_score":0.006143167,"about_ca_system_score_codex":0.0007732032,"about_ca_system_score_gemma":0.0016583999,"threshold_uncertainty_score":0.020550907},"labels":[],"label_agreement":null},{"id":"W3009978386","doi":"10.1007/s12325-020-01262-9","title":"Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ortho Dermatologics; LEO Pharma; Dermira; Valeant Pharmaceuticals International; Regeneron Pharmaceuticals; Celgene; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Apremilast; Psoriatic arthritis; Propensity score matching; Internal medicine; Wilcoxon signed-rank test; Rheumatology; Physical therapy; Arthritis; Mann–Whitney U test","score_opus":0.015003431222160853,"score_gpt":0.28428561481140935,"score_spread":0.2692821835892485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009978386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994517,0.00019443396,0.000031703592,0.000036083926,0.0000038800276,0.0000054698476,0.000148643,9.241202e-7,0.00012711732],"genre_scores_gemma":[0.99946195,0.000084020205,0.00004120115,0.00003059582,0.000008377149,0.000007499367,0.00030766687,8.3329945e-7,0.000057851852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871063,0.00035806865,0.00021887776,0.00024765087,0.00023526249,0.00022962883],"domain_scores_gemma":[0.99809176,0.00040021478,0.0010835633,0.00009129979,0.00010004692,0.00023304083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009353176,0.00017761842,0.00046527694,0.00096632424,0.0004074521,0.00077111315,0.00029190417,0.0005692743,0.0015059945],"category_scores_gemma":[0.003769439,0.00022597067,0.0010066873,0.001412655,0.00017688033,0.00068340177,0.00048556965,0.0008080828,0.0001352297],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005032154,0.00010011442,0.9966822,0.000014231332,0.000161942,0.000041027317,0.00005040165,0.00010633642,0.000071210365,0.000028150804,0.00008386791,0.0021571992],"study_design_scores_gemma":[0.00004434733,0.00022370604,0.9983158,0.000010811287,0.000058122932,0.00013386409,0.00016097384,0.0008298806,0.000036011377,0.00005952602,0.00012078168,0.000006115138],"about_ca_topic_score_codex":0.0054849624,"about_ca_topic_score_gemma":0.0073482087,"teacher_disagreement_score":0.0054849624,"about_ca_system_score_codex":0.00073916744,"about_ca_system_score_gemma":0.0004048912,"threshold_uncertainty_score":0.0109061},"labels":[],"label_agreement":null},{"id":"W3015761876","doi":"10.1007/s12325-020-01324-y","title":"A Map of Racial and Ethnic Disparities in Influenza Vaccine Uptake in the Medicare Fee-for-Service Program","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Sanofi Pasteur; Sanofi","keywords":"Medicine; Vaccination; Ethnic group; Zip code; Public health; Influenza vaccine; Environmental health; Health equity; Fee-for-service; Demography; Gerontology; Health care; Immunology; Geography; Nursing; Economic growth","score_opus":0.12331492227544757,"score_gpt":0.4532602491306299,"score_spread":0.3299453268551823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015761876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87377167,0.0011015157,0.0034381333,0.0017221184,0.00007198466,0.00023706944,0.06593785,0.0006102425,0.05310941],"genre_scores_gemma":[0.97743386,0.0005699143,0.0077330843,0.00004828018,0.00001791415,0.00012498657,0.011644644,0.000026748039,0.0024004956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997906,0.00004696553,0.000012419836,0.000036510508,0.00006401991,0.000049571485],"domain_scores_gemma":[0.99944705,0.00014848774,0.00010912574,0.000028996217,0.00021621595,0.00005013347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024321058,0.00027552096,0.0001970495,0.003981829,0.0004333276,0.0008538524,0.00026494925,0.00021029494,0.008705145],"category_scores_gemma":[0.0017232242,0.00009903707,0.000344903,0.004926361,0.0001914669,0.00043948923,0.00089292944,0.00022829088,0.00065987965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042267612,0.00024192448,0.75865257,0.00067275635,0.00018539921,0.00034171753,0.00448082,0.005335018,0.0022356985,0.009568039,0.030746326,0.18711707],"study_design_scores_gemma":[0.000027626671,0.0001010934,0.95930904,0.00018372669,0.000055463912,0.00017557843,0.0045022015,0.005257449,0.0004244873,0.0013515109,0.028590117,0.00002182854],"about_ca_topic_score_codex":0.077957384,"about_ca_topic_score_gemma":0.05747676,"teacher_disagreement_score":0.077957384,"about_ca_system_score_codex":0.0008202501,"about_ca_system_score_gemma":0.0015750898,"threshold_uncertainty_score":0.15500724},"labels":[],"label_agreement":null},{"id":"W3016333849","doi":"10.1007/s12325-020-01303-3","title":"Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Gilead Sciences; AbbVie; Sanofi; Amgen; Pfizer; Eli Lilly and Company","keywords":"Medicine; Tofacitinib; Rheumatoid arthritis; Internal medicine; Rheumatology; Janus kinase inhibitor; Randomized controlled trial; Gastroenterology","score_opus":0.07489998418923918,"score_gpt":0.3565567765297657,"score_spread":0.28165679234052654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016333849","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16296923,0.8056902,0.016716737,0.0015181293,0.0008192697,0.0014639247,0.008361202,0.0003240166,0.00213721],"genre_scores_gemma":[0.93534523,0.051589087,0.0070874,0.0007207766,0.00027727953,0.0016163324,0.0027795637,0.000081285114,0.00050307804],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9633995,0.02762428,0.00331844,0.003443503,0.001630665,0.00058349955],"domain_scores_gemma":[0.9419535,0.05033863,0.0041485196,0.0018454145,0.0011721228,0.0005418618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03279858,0.0028819593,0.012655406,0.005447678,0.00051422796,0.0026437014,0.0024501884,0.0020605244,0.0040849647],"category_scores_gemma":[0.0441885,0.0014612137,0.049690034,0.0051307073,0.0006699948,0.0016738974,0.0015963475,0.0021507628,0.00027287874],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008101327,0.0000338423,0.01404634,0.018749388,0.951775,0.00009120035,0.00003576659,0.0032124869,0.00019756398,0.0001578764,0.00044163,0.0031576278],"study_design_scores_gemma":[0.0018492982,0.00036532883,0.0067205606,0.0011745717,0.9856645,0.00007189046,0.000025779029,0.0029842122,0.00011555662,0.00037985473,0.00062206015,0.000026357715],"about_ca_topic_score_codex":0.0049543497,"about_ca_topic_score_gemma":0.0058266735,"teacher_disagreement_score":0.03279858,"about_ca_system_score_codex":0.0015023492,"about_ca_system_score_gemma":0.0014849338,"threshold_uncertainty_score":0.1734575},"labels":[],"label_agreement":null},{"id":"W3016888407","doi":"10.1007/s12325-020-01318-w","title":"Management of Patients with Overactive Bladder in Brazil: A Retrospective Observational Study Using Data From the Brazilian Public Health System","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"Astellas Pharma Global Development; Astellas Pharma","keywords":"Medicine; Overactive bladder; Public health; Cohort; Health care; Retrospective cohort study; Diagnosis code; Family medicine; Medical record; Population; Observational study; Cohort study; Emergency medicine; Internal medicine; Environmental health; Alternative medicine; Nursing","score_opus":0.18177862390595162,"score_gpt":0.41671995338618817,"score_spread":0.23494132948023655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016888407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99414825,0.0017288559,0.00019429199,0.00034846747,0.000010362095,0.00011327441,0.002418327,0.0000056212048,0.0010325493],"genre_scores_gemma":[0.99726605,0.0009968574,0.00018322282,0.00014626962,0.000009472602,0.000071882925,0.0012788982,0.0000031026527,0.000044222525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855155,0.00038644962,0.00031112807,0.00024906485,0.00033133183,0.00017047599],"domain_scores_gemma":[0.9956934,0.0005389493,0.0026832246,0.00027120888,0.00049626525,0.00031698457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016507895,0.00029917902,0.0006795712,0.0018161744,0.00058672146,0.00099106,0.0005164113,0.00040277332,0.00093074166],"category_scores_gemma":[0.0067949444,0.0005188623,0.00077909173,0.0031940402,0.0005239984,0.00074465247,0.001038874,0.00053291506,0.000119635995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015447084,0.000024854302,0.9982338,0.00006281548,0.000050792645,0.00005573913,0.00036814326,0.000012476533,0.000059687114,0.000030507097,0.00013436738,0.0009513727],"study_design_scores_gemma":[0.000011184761,0.00006418536,0.9969176,0.00017590723,0.00007489951,0.0003558531,0.0014565028,0.00014275797,0.000029373678,0.00003160813,0.0007322293,0.000007894027],"about_ca_topic_score_codex":0.058194064,"about_ca_topic_score_gemma":0.05717637,"teacher_disagreement_score":0.058194064,"about_ca_system_score_codex":0.001297172,"about_ca_system_score_gemma":0.0020892345,"threshold_uncertainty_score":0.115710676},"labels":[],"label_agreement":null},{"id":"W3017316429","doi":"10.1007/s12325-020-01327-9","title":"Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hepatitis Viruses Studies and Epidemiology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Altasciences (Canada)","funders":"Grifols","keywords":"Medicine; Cmax; Adverse effect; Tolerability; Pharmacokinetics; Internal medicine; Titer; Antibody; Antibody titer; Hepatitis A; Gastroenterology; Hepatitis; Immunology","score_opus":0.10374191705892144,"score_gpt":0.45089586179378316,"score_spread":0.3471539447348617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017316429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998725,0.000303294,0.00027146938,0.000029297309,0.00001603995,0.00038765816,0.000088233115,0.000018818979,0.00016010401],"genre_scores_gemma":[0.9973368,0.0003244779,0.000758907,0.00019683245,0.00007635542,0.0005193104,0.00023173826,0.000007438693,0.0005482506],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99915075,0.00044761616,0.000052407166,0.00015676553,0.000097320946,0.00009518372],"domain_scores_gemma":[0.99845874,0.00042755256,0.0003208129,0.00017780886,0.00010752939,0.0005076237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027953933,0.0015125948,0.0015016148,0.00042225342,0.00048180125,0.00076405937,0.00057247345,0.0012640577,0.0013435577],"category_scores_gemma":[0.0014471317,0.00069177087,0.00073959475,0.00034356012,0.0016152697,0.0010213738,0.0003754332,0.001716256,0.00046264482],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7155429,0.1284462,0.0493179,0.0005025686,0.0009759863,0.00031026496,0.00053449837,0.0010736929,0.056488883,0.000114634495,0.0004883218,0.046204083],"study_design_scores_gemma":[0.07564181,0.8880922,0.03258448,0.0000124750695,0.00021926306,0.000117621435,0.00006029763,0.0006889789,0.002133067,0.000054675165,0.00037382118,0.000021450547],"about_ca_topic_score_codex":0.00047377395,"about_ca_topic_score_gemma":0.00057250564,"teacher_disagreement_score":0.0027953933,"about_ca_system_score_codex":0.00032361413,"about_ca_system_score_gemma":0.00076084316,"threshold_uncertainty_score":0.01478368},"labels":[],"label_agreement":null},{"id":"W3018014849","doi":"10.1007/s12325-020-01348-4","title":"Developing Classifications of Laryngeal Dysplasia: The Historical Basis","year":2020,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Oral Health Pathology and Treatment","field":"Dentistry","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Dysplasia; Grading (engineering); Larynx; Cervical intraepithelial neoplasia; Dermatology; Intraepithelial neoplasia; Pathology; Terminology; Cancer; Radiology; Internal medicine; Surgery; Cervical cancer; Prostate cancer","score_opus":0.13085465112690103,"score_gpt":0.42986762151626207,"score_spread":0.29901297038936103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3018014849","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019805728,0.8008522,0.07571041,0.052827004,0.013810364,0.00041823788,0.00058363966,0.00029963235,0.03569285],"genre_scores_gemma":[0.12197575,0.7161328,0.122335985,0.012804758,0.016669475,0.00087282935,0.0019548351,0.00036909274,0.006884433],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9907353,0.0028500005,0.0022745742,0.0018675927,0.0018860534,0.0003865605],"domain_scores_gemma":[0.9760774,0.006825245,0.0018468124,0.0012580518,0.012939879,0.0010526278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.024626484,0.0017139316,0.0015316352,0.014204955,0.0029825806,0.004858296,0.004202324,0.0028514601,0.0017249361],"category_scores_gemma":[0.033491492,0.0011779531,0.0010613322,0.00752001,0.01365322,0.011903435,0.004881446,0.009671641,0.0016144863],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002180931,0.00015655847,0.014481657,0.003289308,0.00007476829,0.0005894669,0.0046177045,0.0020972777,0.00121788,0.23636313,0.040182818,0.6967113],"study_design_scores_gemma":[0.00002117746,0.00024106287,0.013089829,0.0076377387,0.000086874876,0.0039993534,0.004805444,0.0020351564,0.0013648951,0.0914565,0.87504005,0.00022199894],"about_ca_topic_score_codex":0.009424797,"about_ca_topic_score_gemma":0.0069793435,"teacher_disagreement_score":0.024626484,"about_ca_system_score_codex":0.010746309,"about_ca_system_score_gemma":0.006182598,"threshold_uncertainty_score":0.13023883},"labels":[],"label_agreement":null},{"id":"W3020183939","doi":"10.1007/s12325-020-01314-0","title":"The Myeloproliferative Neoplasm Landscape: A Patient’s Eye View","year":2020,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Foundation for Healthcare Improvement","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Polycythaemia; Quality of life (healthcare); Myelofibrosis; Myeloproliferative neoplasm; Psychosocial; Anxiety; Palliative care; Depression (economics); Physical therapy; Disease; Intensive care medicine; Internal medicine; Psychiatry; Nursing","score_opus":0.026338501614843735,"score_gpt":0.3577173501751318,"score_spread":0.33137884856028804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020183939","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0108937835,0.074638486,0.0013485043,0.8420457,0.024096383,0.00003511648,0.00030923862,0.00043520686,0.046197418],"genre_scores_gemma":[0.15137224,0.079150505,0.0028634188,0.6880519,0.036242858,0.000076158634,0.0002773597,0.0003912503,0.04157433],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99790585,0.0009727448,0.0000965863,0.00017714391,0.00047567388,0.00037197178],"domain_scores_gemma":[0.99469095,0.0013023983,0.00023587557,0.00012318711,0.0010891726,0.0025584185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002282901,0.0007727705,0.0011044409,0.0010180571,0.005954994,0.0068857986,0.0013007809,0.0092852805,0.024840485],"category_scores_gemma":[0.0075822663,0.0004013754,0.001115206,0.0005939388,0.0031611954,0.011709642,0.006586336,0.013567216,0.006109778],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007096119,0.00008628201,0.0041014547,0.0004466889,0.00004709558,0.0060760994,0.0075572245,0.00011416716,0.00044162004,0.005451023,0.90299386,0.07261347],"study_design_scores_gemma":[0.000029194716,0.00015117628,0.0017386572,0.0014298443,0.00004220513,0.019608296,0.027040694,0.000113891714,0.00013866418,0.007751025,0.9418673,0.00008914919],"about_ca_topic_score_codex":0.0050324877,"about_ca_topic_score_gemma":0.014402127,"teacher_disagreement_score":0.024840485,"about_ca_system_score_codex":0.002244401,"about_ca_system_score_gemma":0.0030734362,"threshold_uncertainty_score":0.08309966},"labels":[],"label_agreement":null},{"id":"W3022780576","doi":"10.1007/s12325-020-01275-4","title":"Qualitative Interviews to Better Understand the Patient Experience and Evaluate Patient-Reported Outcomes (PRO) in RLBP1 Retinitis Pigmentosa (RLBP1 RP)","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Retinal Development and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Retinitis pigmentosa; Qualitative research; Rheumatology; Family medicine; Physical therapy; Internal medicine; Ophthalmology","score_opus":0.054409213103887,"score_gpt":0.3765654363577753,"score_spread":0.32215622325388826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022780576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95012575,0.0018289095,0.019744663,0.010682376,0.00034173965,0.0021513083,0.0012170564,0.000065533255,0.013842617],"genre_scores_gemma":[0.98075014,0.0013606078,0.009152163,0.0022414785,0.00006009079,0.0029098166,0.00028672005,0.00003679882,0.00320216],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9747624,0.021235118,0.00067373377,0.0006622882,0.001039835,0.0016266035],"domain_scores_gemma":[0.9488095,0.041263226,0.0029806935,0.00085852237,0.004308903,0.001779171],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.028987171,0.0007513876,0.00065395766,0.0016860868,0.0046681412,0.0033188376,0.001457111,0.0018338215,0.0041053104],"category_scores_gemma":[0.033288315,0.0004600105,0.0005677165,0.0017475836,0.006444135,0.0036777013,0.0050787213,0.0029527997,0.0005701182],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006290351,0.000034415825,0.0018845805,0.00037840536,0.000004556276,0.0005497575,0.9889255,0.000081163904,0.0006655994,0.0017432396,0.00081132515,0.0048585874],"study_design_scores_gemma":[0.000016144584,0.00007109467,0.0011368,0.00036194,0.000005346592,0.00029757185,0.9834269,0.00015514041,0.0004884164,0.0011893752,0.012831802,0.000019482057],"about_ca_topic_score_codex":0.003941376,"about_ca_topic_score_gemma":0.0053137247,"teacher_disagreement_score":0.028987171,"about_ca_system_score_codex":0.006627885,"about_ca_system_score_gemma":0.005695504,"threshold_uncertainty_score":0.15330064},"labels":[],"label_agreement":null},{"id":"W3024587646","doi":"10.1007/s12325-020-01364-4","title":"Identification of Patient Needs and Preferences in Pigmented Villonodular Synovitis (PVNS) Using a Qualitative Online Bulletin Board Study","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis","keywords":"Pigmented villonodular synovitis; Medicine; Tendon sheath; Rheumatology; Referral; Internal medicine; Family medicine; Physical therapy; Surgery; Synovitis; Tendon; Rheumatoid arthritis","score_opus":0.029991610497227365,"score_gpt":0.34877265339725144,"score_spread":0.31878104290002407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024587646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952937,0.0002838999,0.00084106374,0.0013349521,0.000041825464,0.0005498803,0.00013594607,0.000010300314,0.0015083606],"genre_scores_gemma":[0.9958651,0.00036185098,0.0009678058,0.0008189918,0.000017816008,0.0010124953,0.00007127919,0.000012654845,0.000871959],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9831223,0.013524352,0.00049268856,0.0006598051,0.0007225073,0.0014782773],"domain_scores_gemma":[0.96877253,0.023727616,0.002196325,0.00057599606,0.0019773142,0.0027501557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020822285,0.0006841655,0.0009557314,0.0018369193,0.0060178176,0.0044430993,0.0019152134,0.0017991397,0.0036950642],"category_scores_gemma":[0.027614128,0.0007508651,0.00055944023,0.001375625,0.007079538,0.0046860683,0.0060331104,0.0030775315,0.000425897],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006591904,0.00013368501,0.004207179,0.00026784124,0.0000059443123,0.00033579828,0.99073225,0.000029831659,0.00037495428,0.00043431376,0.00031650736,0.0030958327],"study_design_scores_gemma":[0.000017944769,0.0001596722,0.0019559641,0.00014610193,0.0000050323674,0.00012839043,0.99463886,0.00009564261,0.0001278389,0.00022472705,0.002482628,0.000017215052],"about_ca_topic_score_codex":0.003920067,"about_ca_topic_score_gemma":0.006134405,"teacher_disagreement_score":0.020822285,"about_ca_system_score_codex":0.0051439116,"about_ca_system_score_gemma":0.0047708396,"threshold_uncertainty_score":0.11012012},"labels":[],"label_agreement":null},{"id":"W3024736928","doi":"10.1007/s12325-020-01371-5","title":"Preoperative Versus Extended Postoperative Antimicrobial Prophylaxis of Surgical Site Infection During Spinal Surgery: A Comprehensive Systematic Review and Meta-Analysis","year":2020,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Surgical site infection prevention","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Spinal surgery; Meta-analysis; Antimicrobial; Surgical site infection; Surgery; Antibiotic prophylaxis; Orthopedic surgery; Rheumatology; Surgical Infections; Internal medicine; Antibiotics","score_opus":0.07163690651770108,"score_gpt":0.39063357979123453,"score_spread":0.3189966732735334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024736928","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0046612346,0.9939161,0.00036233035,0.00015544056,0.00007651078,0.00020039012,0.00045333992,0.000016506081,0.00015818124],"genre_scores_gemma":[0.16322275,0.8313631,0.0023930117,0.00067830156,0.00021692475,0.0011043624,0.0008058004,0.000023220808,0.00019267872],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9891529,0.0050007687,0.0031975845,0.0010890309,0.0012118965,0.00034785966],"domain_scores_gemma":[0.97635955,0.017435076,0.0036758287,0.0006564654,0.0015752277,0.0002977479],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.014300749,0.0023072723,0.018956179,0.0077667437,0.0006615521,0.0032056936,0.0022287779,0.0021695832,0.0026002305],"category_scores_gemma":[0.03256751,0.0014933768,0.037201356,0.008983794,0.0007002165,0.0017759028,0.0014834737,0.0017048677,0.00020364783],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013897447,0.000029184672,0.006252411,0.39937007,0.5803734,0.00012069262,0.000089281755,0.00063145603,0.00017443481,0.000117300704,0.00052418886,0.01092791],"study_design_scores_gemma":[0.00035771428,0.0001736758,0.0048580174,0.027499063,0.96546406,0.00008547762,0.000040613428,0.00018550089,0.000084299405,0.00012686427,0.0011021433,0.00002252784],"about_ca_topic_score_codex":0.007986068,"about_ca_topic_score_gemma":0.016910275,"teacher_disagreement_score":0.9810438,"about_ca_system_score_codex":0.0027238296,"about_ca_system_score_gemma":0.0044464944,"threshold_uncertainty_score":0.075630486},"labels":[],"label_agreement":null},{"id":"W3025066905","doi":"10.1007/s12325-020-01359-1","title":"Pattern of Laboratory Parameters and Management of Secondary Hyperparathyroidism in Countries of Europe, Asia, the Middle East, and North America","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Parathyroid Disorders and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AbbVie","keywords":"Medicine; Middle East; Rheumatology; East Asia; Internal medicine; China; Geography; Archaeology","score_opus":0.026024623134855776,"score_gpt":0.25363635452912137,"score_spread":0.2276117313942656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025066905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981828,0.0005674062,0.00007921421,0.000053121126,0.0000018382826,0.0000048979796,0.0003506648,0.0000040117916,0.00075611053],"genre_scores_gemma":[0.99959964,0.00013154093,0.00007849545,0.000017588403,0.0000023245616,0.0000022287013,0.00013161871,8.803053e-7,0.00003568198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995869,0.000112813184,0.000072682094,0.00008765655,0.000083624596,0.00005631809],"domain_scores_gemma":[0.99846977,0.00020514558,0.0009427639,0.00005364639,0.0001969452,0.00013157394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057283015,0.00011300872,0.00021861402,0.0007547451,0.00018192963,0.000445895,0.00019183218,0.00015286187,0.00090126944],"category_scores_gemma":[0.0014867061,0.00007791062,0.00030934508,0.0013339199,0.00021843691,0.0001760807,0.0002704477,0.00015882374,0.000089843765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011159639,0.0000038317053,0.99904484,0.0000067569895,0.000018774033,0.000031401218,0.000029130973,0.000019103794,0.00006473945,0.0000070721194,0.000030155663,0.0007330287],"study_design_scores_gemma":[0.0000018515242,0.000017988776,0.9990589,0.000011121813,0.000012711337,0.00048024932,0.00014831177,0.00004903852,0.00004919099,0.000008918552,0.00016055944,0.0000012447782],"about_ca_topic_score_codex":0.011526725,"about_ca_topic_score_gemma":0.011299559,"teacher_disagreement_score":0.011526725,"about_ca_system_score_codex":0.00034917367,"about_ca_system_score_gemma":0.0006062924,"threshold_uncertainty_score":0.022919297},"labels":[],"label_agreement":null},{"id":"W3045848823","doi":"10.1007/s12325-020-01445-4","title":"The Burden of Pain Associated with Osteoarthritis in the Hip or Knee from the Patient’s Perspective: A Multinational Cross-Sectional Study","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Regeneron Pharmaceuticals; Teva Pharmaceutical Industries","keywords":"Medicine; Cross-sectional study; Osteoarthritis; Rheumatology; Physical therapy; Perspective (graphical); Multinational corporation; Knee pain; Internal medicine; Alternative medicine; Pathology","score_opus":0.020184110138256273,"score_gpt":0.30509680475788925,"score_spread":0.284912694619633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045848823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99867475,0.0002027098,0.00006862991,0.00004879076,0.000006129285,0.000016315154,0.00067528733,0.0000016892981,0.00030572616],"genre_scores_gemma":[0.99876606,0.00017361983,0.00011081719,0.00008166863,0.000014718807,0.000028068318,0.0007289862,0.0000013592103,0.00009479709],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99909556,0.00041208183,0.00012367785,0.000119367556,0.00016471276,0.000084691914],"domain_scores_gemma":[0.9979576,0.00031216984,0.001151649,0.00014389264,0.00018893616,0.00024570184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020242233,0.00029613494,0.00033911667,0.00081292883,0.00038202322,0.00080850837,0.0004429249,0.0004007455,0.0010283868],"category_scores_gemma":[0.0027386332,0.0003250932,0.00050162117,0.001459196,0.00033616557,0.0006757965,0.0006852611,0.0004970602,0.00024185599],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002321232,0.000020927011,0.9995401,0.000005347792,0.00004705216,0.000013394755,0.000044059747,0.0000084521325,0.00002609794,0.0000030183548,0.00003959945,0.00022878473],"study_design_scores_gemma":[0.000005249917,0.000069582515,0.9994555,0.000007040968,0.000026363561,0.000098528515,0.00018286068,0.000056088,0.00001353053,0.0000053869303,0.000077109085,0.0000027103986],"about_ca_topic_score_codex":0.005533257,"about_ca_topic_score_gemma":0.007473868,"teacher_disagreement_score":0.005533257,"about_ca_system_score_codex":0.00032328666,"about_ca_system_score_gemma":0.00030105028,"threshold_uncertainty_score":0.011002064},"labels":[],"label_agreement":null},{"id":"W3082719138","doi":"10.1007/s12325-020-01466-z","title":"Terlipressin May Decrease In-Hospital Mortality of Cirrhotic Patients with Acute Gastrointestinal Bleeding and Renal Dysfunction: A Retrospective Multicenter Observational Study","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Liver Disease and Transplantation","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Terlipressin; Observational study; Gastrointestinal bleeding; Internal medicine; Retrospective cohort study; Multicenter study; Acute kidney injury; Hepatology; Intensive care medicine; Cirrhosis; Randomized controlled trial; Hepatorenal syndrome","score_opus":0.023841223111348835,"score_gpt":0.2943993613864541,"score_spread":0.2705581382751053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082719138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99883693,0.0006073761,0.00008570507,0.00003104047,0.000007359606,0.000016241682,0.0002614651,0.0000019136858,0.00015195215],"genre_scores_gemma":[0.9993599,0.00017032283,0.00007102204,0.0000343319,0.000016867252,0.000019429626,0.0002938329,0.000001064768,0.000033150947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99927694,0.00023522039,0.00010989612,0.00016839309,0.00010212642,0.00010742392],"domain_scores_gemma":[0.9976453,0.0002913802,0.0013614108,0.00018583584,0.00019197569,0.00032411364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010223258,0.0003837942,0.000733583,0.00061565486,0.00048185844,0.00068154547,0.0003195827,0.00048906606,0.0010235937],"category_scores_gemma":[0.0022286696,0.00035481484,0.0010774707,0.0011971376,0.00024108909,0.00041413034,0.0003551497,0.0005792933,0.00014367205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005962487,0.000051703606,0.9984303,0.00003172192,0.00025773255,0.000061526276,0.000028541519,0.000018391867,0.00009415985,0.000009050874,0.000046288154,0.00037422194],"study_design_scores_gemma":[0.00008037407,0.00037968502,0.9982114,0.000015241403,0.00033387184,0.00032725654,0.00012801563,0.00026706868,0.000055669934,0.000020772044,0.00017282712,0.000007843074],"about_ca_topic_score_codex":0.0020213807,"about_ca_topic_score_gemma":0.0022430548,"teacher_disagreement_score":0.0020213807,"about_ca_system_score_codex":0.00037097602,"about_ca_system_score_gemma":0.0005073577,"threshold_uncertainty_score":0.005406618},"labels":[],"label_agreement":null},{"id":"W3083451975","doi":"10.1007/s12325-020-01483-y","title":"Relation of High Lipoprotein (a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Fundação de Amparo à Pesquisa do Estado de São Paulo","keywords":"Medicine; Internal medicine; Coronary artery disease; Lipoprotein(a); Population; Platelet; P2Y12; Gastroenterology; Univariate analysis; Endocrinology; Lipoprotein; Cardiology; Cholesterol; Multivariate analysis; Platelet aggregation","score_opus":0.014335108524475558,"score_gpt":0.2750602372448577,"score_spread":0.2607251287203821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083451975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99898344,0.000372735,0.000072034665,0.000027502972,0.0000076746455,0.000005280359,0.0001277719,0.000002677901,0.00040079662],"genre_scores_gemma":[0.99962807,0.00006928408,0.000059678834,0.000017993721,0.0000115476105,0.0000061093288,0.00011253275,0.0000010536266,0.00009371944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994759,0.00015032596,0.00007001768,0.0001427421,0.000103206236,0.00005785548],"domain_scores_gemma":[0.99819714,0.0006112272,0.0007048042,0.000108276814,0.00017204697,0.00020649597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006791309,0.0002349095,0.0002805339,0.0007689825,0.00031311484,0.0006139852,0.00029638657,0.000683646,0.0016582862],"category_scores_gemma":[0.002775522,0.00021918317,0.0002536739,0.0006305468,0.00025050231,0.00024624716,0.0002740418,0.0006786456,0.00027169028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039271804,0.000042730877,0.9979527,0.000009175311,0.00007472872,0.00007707873,0.000034673987,0.000021738027,0.0003467151,0.000016507356,0.000051249426,0.000979943],"study_design_scores_gemma":[0.000011380515,0.00019979134,0.9990183,0.0000036520473,0.000037343325,0.00035934738,0.000063184256,0.0001228478,0.00007688734,0.0000385291,0.00006523688,0.0000033214585],"about_ca_topic_score_codex":0.0008118408,"about_ca_topic_score_gemma":0.0006322083,"teacher_disagreement_score":0.0016582862,"about_ca_system_score_codex":0.0001402594,"about_ca_system_score_gemma":0.00011075239,"threshold_uncertainty_score":0.0055475235},"labels":[],"label_agreement":null},{"id":"W3085906625","doi":"10.1007/s12325-020-01472-1","title":"The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence","year":2020,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care; Robarts Clinical Trials; Western University","funders":"AbbVie","keywords":"Biosimilar; Medicine; Narrative review; Interchangeability; Clinical Practice; Randomized controlled trial; Intensive care medicine; Risk analysis (engineering); Family medicine; Surgery; Internal medicine","score_opus":0.1170445249525093,"score_gpt":0.437350677947818,"score_spread":0.32030615299530873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3085906625","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016283635,0.997638,0.00015577035,0.0013513966,0.00015402239,0.00002390411,0.000038796054,0.0000033630065,0.00047194312],"genre_scores_gemma":[0.0022041036,0.995678,0.00041340248,0.00130049,0.00021356395,0.000040661052,0.000044498433,0.0000029676444,0.00010217022],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99413526,0.0020351082,0.0018962077,0.0005302653,0.0012167064,0.00018645368],"domain_scores_gemma":[0.9664648,0.027513256,0.003630774,0.00026301664,0.001873815,0.0002543858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007346578,0.0010287439,0.0022611206,0.0039987112,0.0005985838,0.0043969224,0.0014661344,0.0029378373,0.0045465105],"category_scores_gemma":[0.031736027,0.0005891892,0.0029790818,0.003809507,0.00116834,0.0033463642,0.0015204215,0.0025820974,0.0006917403],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026805085,0.00007178205,0.0009288309,0.45426193,0.0014107495,0.00056024705,0.0011313643,0.00057198625,0.00035922497,0.010938961,0.02127732,0.5082195],"study_design_scores_gemma":[0.000055625515,0.00018429365,0.0014658454,0.5332656,0.004031944,0.0019984217,0.0011880343,0.00024149515,0.00024152186,0.005435271,0.4518275,0.00006438068],"about_ca_topic_score_codex":0.002836167,"about_ca_topic_score_gemma":0.0059173177,"teacher_disagreement_score":0.007346578,"about_ca_system_score_codex":0.00209965,"about_ca_system_score_gemma":0.008911097,"threshold_uncertainty_score":0.03885293},"labels":[],"label_agreement":null},{"id":"W3088534458","doi":"10.1007/s12325-020-01497-6","title":"PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Manchester Biomedical Research Centre; LEO Pharma; Regeneron Pharmaceuticals; Sun Pharma; Dermira; National Institute for Health and Care Research; Celgene; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Calcipotriol; Betamethasone dipropionate; Psoriasis; Discontinuation; Adverse effect; Randomized controlled trial; Maintenance therapy; Clinical trial; Internal medicine; Dermatology; Surgery; Chemotherapy","score_opus":0.07843577025216758,"score_gpt":0.32965928514946174,"score_spread":0.25122351489729416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088534458","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96141714,0.0016266835,0.0016344041,0.0007710283,0.00080518454,0.029178761,0.0009722119,0.00019154297,0.0034031596],"genre_scores_gemma":[0.92540395,0.0013208205,0.0070638615,0.0016601335,0.0009147329,0.05474709,0.0012438835,0.000052480544,0.0075930734],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9985796,0.00065433094,0.00009263718,0.00029961942,0.000093892435,0.00027987722],"domain_scores_gemma":[0.9988036,0.00020198523,0.00022994539,0.00014464116,0.000108872286,0.00051104533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034856596,0.0020662153,0.0026954557,0.00056794734,0.00066567824,0.0015515434,0.0011829907,0.0026127794,0.00882789],"category_scores_gemma":[0.001910366,0.0008687033,0.0014370285,0.0003726599,0.0016626194,0.0018474226,0.00087472604,0.0030975388,0.0018976956],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93541145,0.04491218,0.0003916434,0.00032383524,0.00030832135,0.00004421175,0.0000848128,0.00031253998,0.005541233,0.00016791605,0.0005619377,0.011939951],"study_design_scores_gemma":[0.71686023,0.2803114,0.00091368105,0.000018433011,0.00017059955,0.000026291149,0.000022163662,0.00032185967,0.0003933466,0.00015944222,0.0007864328,0.000016194743],"about_ca_topic_score_codex":0.00060797133,"about_ca_topic_score_gemma":0.0013170375,"teacher_disagreement_score":0.00882789,"about_ca_system_score_codex":0.00088863896,"about_ca_system_score_gemma":0.0020377357,"threshold_uncertainty_score":0.029532254},"labels":[],"label_agreement":null},{"id":"W3091817477","doi":"10.1007/s12325-020-01520-w","title":"Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c+ Expression in Tumor","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Vetenskapsrådet; Cancerfonden","keywords":"Mesothelin; Ovarian cancer; Medicine; Oncology; Serous fluid; Immunohistochemistry; Cancer research; Internal medicine; Cancer; Pathology","score_opus":0.016252761461244766,"score_gpt":0.30337798459558013,"score_spread":0.28712522313433536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091817477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999203,0.0002821343,0.000068489375,0.000028572162,0.0000042666024,0.0000031723814,0.000079712794,0.0000027494998,0.0003279702],"genre_scores_gemma":[0.9997992,0.00003903875,0.000026792099,0.0000064225283,0.0000038296907,0.000001694791,0.00006395967,4.628063e-7,0.000058614947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998716,0.00003144285,0.000017077224,0.00003122611,0.00002577694,0.00002293099],"domain_scores_gemma":[0.9991122,0.00024712298,0.0003419641,0.000058064987,0.00007243333,0.00016828763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029515938,0.00014123779,0.00017882272,0.00035116012,0.00024255663,0.0003389263,0.00011937185,0.0002639367,0.001763568],"category_scores_gemma":[0.0014116176,0.000114785296,0.00014062486,0.00039356586,0.00026154667,0.0002163055,0.00019390303,0.0002708402,0.00021123663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009293981,0.0000059986737,0.9984738,0.0000059521903,0.000008271415,0.00006593883,0.000012389198,0.00001884754,0.00064581126,0.0000040664645,0.000032218784,0.00063373457],"study_design_scores_gemma":[0.000005129491,0.00008720163,0.9986827,0.0000032801483,0.000017507533,0.000628664,0.00004337431,0.00012975719,0.00022817726,0.000013502376,0.00015963116,0.0000011090722],"about_ca_topic_score_codex":0.0005711284,"about_ca_topic_score_gemma":0.0010082816,"teacher_disagreement_score":0.001763568,"about_ca_system_score_codex":0.00013452568,"about_ca_system_score_gemma":0.00016382203,"threshold_uncertainty_score":0.005899787},"labels":[],"label_agreement":null},{"id":"W3097915981","doi":"10.1007/s12325-020-01525-5","title":"Dorzolamide/Timolol Fixed Combination: Learning from the Past and Looking Toward the Future","year":2020,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Glaucoma and retinal disorders","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Dorzolamide; Tolerability; Medicine; Pharmacology; Intraocular pressure; Timolol; Ophthalmology","score_opus":0.018950805254272715,"score_gpt":0.311059292853311,"score_spread":0.2921084875990383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097915981","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00075087557,0.9926018,0.00021872825,0.0049895654,0.00045900256,0.000006186998,0.000015598749,0.000013651742,0.0009445438],"genre_scores_gemma":[0.007821154,0.98343,0.0012257689,0.004370508,0.0022742054,0.00001892853,0.00004833975,0.000007540287,0.0008035447],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99950683,0.0001436199,0.000088752844,0.00007649011,0.00013134671,0.00005302845],"domain_scores_gemma":[0.9986821,0.0005787059,0.00032650502,0.000040225907,0.00022603232,0.00014631773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018757042,0.00060498697,0.0012236445,0.00092150376,0.00028378487,0.0014982881,0.00093195424,0.0014587278,0.0028283051],"category_scores_gemma":[0.0023582166,0.00020751219,0.0007017095,0.0007862411,0.000840639,0.0031675776,0.00056260533,0.0029576805,0.0008953456],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052029337,0.00011392504,0.0007091548,0.008446871,0.00011395134,0.0005502316,0.000110017776,0.00027217667,0.0013714432,0.004151911,0.02547617,0.9581639],"study_design_scores_gemma":[0.0002316814,0.002029572,0.0044253455,0.010932485,0.000533233,0.006969658,0.00056703197,0.0009082509,0.0012170477,0.008274848,0.9638165,0.00009434274],"about_ca_topic_score_codex":0.00086539495,"about_ca_topic_score_gemma":0.0030910126,"teacher_disagreement_score":0.0028283051,"about_ca_system_score_codex":0.0010004053,"about_ca_system_score_gemma":0.0012038936,"threshold_uncertainty_score":0.009919763},"labels":[],"label_agreement":null},{"id":"W3109214388","doi":"10.1007/s12325-020-01577-7","title":"A Patient Charter for Chronic Obstructive Pulmonary Disease","year":2020,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; COPD; Quality of life (healthcare); Guideline; Intensive care medicine; Disease; Health care; Socioeconomic status; Population; Internal medicine; Nursing; Environmental health; Pathology","score_opus":0.018755212966720843,"score_gpt":0.3109301882022402,"score_spread":0.2921749752355194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109214388","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.048777442,0.0096898945,0.07329995,0.25482672,0.02811916,0.018371064,0.142722,0.03138044,0.39281335],"genre_scores_gemma":[0.3026022,0.011436503,0.2761884,0.102928534,0.012883756,0.021371884,0.109747395,0.0046924693,0.15814897],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99470407,0.0021744478,0.000768468,0.00042184035,0.0015545844,0.00037663017],"domain_scores_gemma":[0.95810676,0.011765597,0.0051202094,0.0027519125,0.014714229,0.0075413724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055668517,0.00049554725,0.0006321649,0.0013395649,0.001538347,0.0016636145,0.0009746468,0.0014852576,0.05885397],"category_scores_gemma":[0.036895532,0.00022673207,0.00053359923,0.0014938619,0.00038480808,0.0021046815,0.0020859018,0.0032924397,0.011921237],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016321133,0.00013979003,0.0041294396,0.000163585,0.000010543843,0.0002120908,0.00043162954,0.00015677825,0.00022216648,0.0026408813,0.8904871,0.101242885],"study_design_scores_gemma":[0.00016438308,0.00020600058,0.009631151,0.0004066668,0.000012817957,0.0005020365,0.00036908465,0.00056501216,0.00026118985,0.001549193,0.9862521,0.00008039994],"about_ca_topic_score_codex":0.005513696,"about_ca_topic_score_gemma":0.010158302,"teacher_disagreement_score":0.05885397,"about_ca_system_score_codex":0.002004058,"about_ca_system_score_gemma":0.006250994,"threshold_uncertainty_score":0.19688612},"labels":[],"label_agreement":null},{"id":"W3111560043","doi":"10.1007/s12325-020-01591-9","title":"Naltrexone’s Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures","year":2020,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Mount Sinai Hospital; Western University","funders":"","keywords":"Medicine; Naltrexone; Cancer; Oncology; Clinical trial; Internal medicine; Animal studies; Bioinformatics; Opioid","score_opus":0.08723121654515832,"score_gpt":0.48236513564791916,"score_spread":0.39513391910276086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111560043","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027409103,0.9993488,0.000041899464,0.000058369253,0.000030366129,0.000022491982,0.0001456564,0.0000021120668,0.00007612046],"genre_scores_gemma":[0.002015565,0.99754506,0.00015325422,0.00013416946,0.000020348893,0.000023216926,0.000066886656,0.0000011296087,0.00004036712],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99871576,0.00030708994,0.0005193049,0.00016423613,0.00025027333,0.000043327833],"domain_scores_gemma":[0.9951633,0.003551163,0.00080929924,0.000075597345,0.00034405218,0.000056599114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002808717,0.0008809705,0.004724354,0.0030291465,0.00025544735,0.0014056165,0.0011214152,0.0009993664,0.0034051344],"category_scores_gemma":[0.007658435,0.0004218388,0.004880403,0.0038448572,0.00043800886,0.0008652321,0.000823259,0.0008577008,0.00027281605],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006655948,0.00004287486,0.0008649392,0.77265346,0.010236434,0.00008209163,0.00008681808,0.00019865466,0.0005862065,0.0002946389,0.0029690422,0.21131922],"study_design_scores_gemma":[0.0008870258,0.001108574,0.015419991,0.63208973,0.18596773,0.0009390749,0.00038819865,0.00022501478,0.0008838011,0.0009846274,0.16097175,0.00013451221],"about_ca_topic_score_codex":0.0049539693,"about_ca_topic_score_gemma":0.017353738,"teacher_disagreement_score":0.0049539693,"about_ca_system_score_codex":0.0009892441,"about_ca_system_score_gemma":0.003189365,"threshold_uncertainty_score":0.014854133},"labels":[],"label_agreement":null},{"id":"W3112399669","doi":"10.1007/s12325-020-01557-x","title":"Effects of Tiotropium/Olodaterol on Activity-Related Breathlessness, Exercise Endurance and Physical Activity in Patients with COPD: Narrative Review with Meta-/Pooled Analyses","year":2020,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; COPD; Placebo; Lama; Bronchodilator; Physical therapy; Quality of life (healthcare); Pulmonary rehabilitation; Anesthesia; Internal medicine; Asthma","score_opus":0.02741308040920549,"score_gpt":0.3744169351233517,"score_spread":0.34700385471414624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112399669","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018494568,0.99706906,0.00017246843,0.00010310254,0.00009352153,0.00016026106,0.00035106298,0.000012335068,0.0001888515],"genre_scores_gemma":[0.04920811,0.94758135,0.0008958527,0.00061128504,0.00020948457,0.0005716654,0.00063934346,0.000016457387,0.00026648407],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9971123,0.0010196512,0.0009988705,0.0003289289,0.00041743583,0.000122889],"domain_scores_gemma":[0.9928322,0.0049040285,0.0015190445,0.00015328452,0.0004891329,0.000102241545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058427686,0.0024747164,0.014190899,0.0037720236,0.00039108619,0.002881843,0.0015922218,0.0017305327,0.003647148],"category_scores_gemma":[0.014159341,0.0010072571,0.030559616,0.004476114,0.0005012177,0.001281485,0.0012457133,0.00172144,0.00027603918],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002530678,0.000043543365,0.0012158016,0.6457148,0.32384327,0.00011358787,0.00007336785,0.0004691427,0.00039379558,0.0001364852,0.0009717812,0.024493657],"study_design_scores_gemma":[0.00063126103,0.00027807956,0.002799902,0.03957186,0.95202583,0.00010928527,0.000044587876,0.00014021296,0.00017739764,0.00017622994,0.004019173,0.000026235992],"about_ca_topic_score_codex":0.0047746263,"about_ca_topic_score_gemma":0.010730079,"teacher_disagreement_score":0.014190899,"about_ca_system_score_codex":0.0017723308,"about_ca_system_score_gemma":0.002396707,"threshold_uncertainty_score":0.030899942},"labels":[],"label_agreement":null},{"id":"W3122551350","doi":"10.1007/s12325-020-01598-2","title":"The Myth of Mild: Severe Exacerbations in Mild Asthma: An Underappreciated, but Preventable Problem","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"AstraZeneca","keywords":"Medicine; Asthma; Exacerbation; Formoterol; Intensive care medicine; Asthma exacerbations; Salmeterol; Allergy; Budesonide; Pediatrics; Internal medicine; Immunology","score_opus":0.017427622104883734,"score_gpt":0.3125373688970818,"score_spread":0.29510974679219804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122551350","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027947687,0.051338833,0.0003743135,0.80930614,0.1372613,0.000008782508,0.000066651664,0.000042276013,0.0013221956],"genre_scores_gemma":[0.0048043462,0.050415207,0.00045010453,0.7185175,0.22276987,0.000024932333,0.00005770069,0.00007003865,0.0028903412],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99355704,0.0026511643,0.0008055447,0.00086053147,0.001676154,0.0004495792],"domain_scores_gemma":[0.97647595,0.014894704,0.0013951194,0.00057419733,0.0049081887,0.001751867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054878485,0.00094602956,0.0016904515,0.0010126367,0.0025521964,0.0041738497,0.0031296113,0.017435074,0.004664988],"category_scores_gemma":[0.03287417,0.00051800837,0.001682193,0.0006659472,0.0071761245,0.0091659315,0.0024609119,0.03138303,0.0032856225],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005988579,0.000010613796,0.00017520892,0.00085974456,0.00003091424,0.0005866265,0.0006695292,0.000036930545,0.00015293948,0.0040018214,0.97117347,0.02224244],"study_design_scores_gemma":[0.000039034177,0.000062118204,0.0004437547,0.002851182,0.00004690471,0.0029807698,0.0008601773,0.00009107712,0.000115566356,0.007921461,0.98452514,0.00006278741],"about_ca_topic_score_codex":0.006151756,"about_ca_topic_score_gemma":0.011152261,"teacher_disagreement_score":0.017435074,"about_ca_system_score_codex":0.0030767752,"about_ca_system_score_gemma":0.0056632156,"threshold_uncertainty_score":0.029022813},"labels":[],"label_agreement":null},{"id":"W3128620818","doi":"10.1007/s12325-020-01583-9","title":"Efficacy of Agomelatine 25–50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies","year":2021,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","field":"Psychology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Servier","keywords":"Agomelatine; Placebo; Medicine; Internal medicine; Anxiety; Randomized controlled trial; Generalized anxiety disorder; Meta-analysis; Placebo-controlled study; Psychiatry; Antidepressant; Double blind","score_opus":0.13215638460390228,"score_gpt":0.439351069680078,"score_spread":0.3071946850761757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128620818","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034252148,0.9626364,0.0009211347,0.0002681904,0.00027932666,0.0005702099,0.0005163981,0.00006928334,0.00048688913],"genre_scores_gemma":[0.523972,0.46750885,0.0036970545,0.0012348567,0.00042687127,0.0014737048,0.0011448119,0.00007015766,0.00047178453],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9941649,0.0030473617,0.001360627,0.00070812687,0.00055894285,0.00016008208],"domain_scores_gemma":[0.9925209,0.0047047427,0.0017729412,0.0003451729,0.00047871444,0.00017748452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012355491,0.0026034713,0.016246589,0.0039651804,0.0005970562,0.0030328066,0.0016249911,0.0019026163,0.0027715638],"category_scores_gemma":[0.014528818,0.001412491,0.03799074,0.0034531332,0.0007704139,0.0011114675,0.0008891413,0.0015217208,0.00020529602],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030538678,0.00015590401,0.0026670864,0.11338277,0.8329335,0.00009954248,0.00007283545,0.0006710351,0.0010989296,0.00008314619,0.00033147694,0.017965086],"study_design_scores_gemma":[0.007563339,0.0013656232,0.004413415,0.004618478,0.980459,0.000080457896,0.000028754843,0.0002023238,0.00023789945,0.00013614062,0.00086967525,0.00002495571],"about_ca_topic_score_codex":0.0025584386,"about_ca_topic_score_gemma":0.005404767,"teacher_disagreement_score":0.016246589,"about_ca_system_score_codex":0.001753282,"about_ca_system_score_gemma":0.0015007899,"threshold_uncertainty_score":0.06534284},"labels":[],"label_agreement":null},{"id":"W3128831572","doi":"10.1007/s12325-021-01627-8","title":"Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Natural Science Foundation of Hunan Province","keywords":"Cetuximab; Medicine; Internal medicine; Oncology; Colorectal cancer; Irinotecan; Cancer","score_opus":0.04293897035453263,"score_gpt":0.3990481494591079,"score_spread":0.35610917910457524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128831572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95191455,0.035539366,0.0007353951,0.0026546305,0.000232063,0.00034520225,0.0050221765,0.000034779307,0.0035217109],"genre_scores_gemma":[0.9926602,0.0044619585,0.00037355747,0.00058629084,0.000073253235,0.000106513326,0.001331536,0.0000057976686,0.00040095922],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99698895,0.0019744812,0.00021184374,0.00017175895,0.00031784349,0.00033521265],"domain_scores_gemma":[0.99719125,0.001599225,0.000571363,0.000057931855,0.00020362007,0.00037670834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026926936,0.0006885126,0.0017652072,0.0014783568,0.00017442321,0.0012679574,0.00059382303,0.0008227155,0.0019125274],"category_scores_gemma":[0.0071626594,0.00042888068,0.0058532753,0.002118886,0.00034281806,0.00085553294,0.00059993484,0.0013446471,0.000084086445],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31624308,0.0038030918,0.22248882,0.009963009,0.089287266,0.0010616672,0.0002019457,0.16296731,0.0027368423,0.005268649,0.014488178,0.17149018],"study_design_scores_gemma":[0.05880345,0.042646483,0.60183156,0.0026832784,0.12218609,0.0014985313,0.0012199861,0.14876585,0.0023265674,0.0032921145,0.014417573,0.00032852255],"about_ca_topic_score_codex":0.036857735,"about_ca_topic_score_gemma":0.049112357,"teacher_disagreement_score":0.036857735,"about_ca_system_score_codex":0.006741601,"about_ca_system_score_gemma":0.0030293653,"threshold_uncertainty_score":0.073286355},"labels":[],"label_agreement":null},{"id":"W3130559363","doi":"10.1007/s12325-021-01621-0","title":"Global Quality Statements on Reliever Use in Asthma in Adults and Children Older than 5 Years of Age","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; College of Family Physicians of Canada; McMaster University; University of Toronto","funders":"Grifols; Novo Nordisk; University of New South Wales; Imperial College London; Imperial College Healthcare NHS Trust; Covis Pharma; Sanofi; Universidade do Minho; University of Toronto; GlaxoSmithKline; Purdue University; AstraZeneca; McMaster University; Pfizer","keywords":"Medicine; Asthma; Exacerbation; Health care; Quality (philosophy); Family medicine; Pandemic; Quality of life (healthcare); Quality management; Intensive care medicine; Disease; Nursing; Coronavirus disease 2019 (COVID-19); Internal medicine; Operations management; Infectious disease (medical specialty)","score_opus":0.01564464155227903,"score_gpt":0.35845565454646217,"score_spread":0.34281101299418315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130559363","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036452297,0.16347058,0.06940928,0.4293312,0.024102878,0.028308699,0.12337478,0.002015225,0.1235351],"genre_scores_gemma":[0.37742767,0.10859135,0.2109889,0.12794149,0.0047898083,0.036356732,0.12383979,0.00058023294,0.009483983],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.8492697,0.05198117,0.049167037,0.0030710027,0.042521935,0.0039891982],"domain_scores_gemma":[0.6244774,0.09707475,0.10398914,0.010390108,0.14930566,0.014762887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.16624445,0.0011197265,0.0021668216,0.006133617,0.0013519645,0.003720118,0.0033765594,0.0031713243,0.0032344963],"category_scores_gemma":[0.24689,0.0006459561,0.004909949,0.006588533,0.002505108,0.0022087083,0.0058058673,0.004106291,0.0010419417],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011736096,0.0003163682,0.064295195,0.053315744,0.0018925706,0.00023588893,0.0033196774,0.0037585478,0.0012853344,0.03421695,0.5577305,0.27845964],"study_design_scores_gemma":[0.00095668406,0.00077914796,0.14685865,0.09534132,0.001538842,0.00041394882,0.002229388,0.0030929933,0.0018311236,0.02294524,0.7236395,0.0003730789],"about_ca_topic_score_codex":0.02485468,"about_ca_topic_score_gemma":0.014947239,"teacher_disagreement_score":0.16624445,"about_ca_system_score_codex":0.008966448,"about_ca_system_score_gemma":0.032495435,"threshold_uncertainty_score":0.87919515},"labels":[],"label_agreement":null},{"id":"W313488173","doi":"10.1007/s12325-015-0207-3","title":"Real-World Determinants of Adjunctive Antipsychotic Prescribing for Patients with Major Depressive Disorder and Inadequate Response to Antidepressants: A Case Review Study","year":2015,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Treatment of Major Depression","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Irritability; Psychiatry; Adjunctive treatment; Antipsychotic; Major depressive disorder; Quetiapine; Mood; Psychomotor agitation; Bipolar disorder; Anxiety; Schizophrenia (object-oriented programming); Internal medicine","score_opus":0.04618772225519249,"score_gpt":0.4056765103500457,"score_spread":0.3594887880948532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W313488173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.944347,0.05080272,0.000493966,0.0010409992,0.000055564386,0.00024372905,0.00050230115,0.000012946642,0.0025007776],"genre_scores_gemma":[0.97504663,0.023255672,0.0006123297,0.0003335864,0.000105262196,0.00008331254,0.0002999107,0.000007611632,0.00025569383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975006,0.0006833601,0.000850144,0.00033885607,0.00042647962,0.00020056254],"domain_scores_gemma":[0.9891172,0.0039181886,0.005273035,0.00035002758,0.0009747015,0.00036696065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020503153,0.00028444687,0.00069565035,0.0033147405,0.0007871719,0.0012625668,0.000814721,0.0012645941,0.0011206506],"category_scores_gemma":[0.0094946595,0.00044670948,0.0008864031,0.0041516814,0.00055600854,0.0009195261,0.0006704962,0.00046786136,0.00029398518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020622849,0.00021908173,0.7763387,0.004615279,0.00048214808,0.17926502,0.0054860506,0.00011580556,0.00073213223,0.0004135896,0.003331897,0.028794114],"study_design_scores_gemma":[0.000057919482,0.000445782,0.54656637,0.0036798667,0.0009884665,0.42499834,0.0117794145,0.00044773595,0.0004483807,0.00016560481,0.010317457,0.00010467719],"about_ca_topic_score_codex":0.005083381,"about_ca_topic_score_gemma":0.009320829,"teacher_disagreement_score":0.005083381,"about_ca_system_score_codex":0.0014213184,"about_ca_system_score_gemma":0.0015844573,"threshold_uncertainty_score":0.010843217},"labels":[],"label_agreement":null},{"id":"W3137313628","doi":"10.1007/s12325-021-01648-3","title":"Non-Inferiority of a Single Injection of Sodium Hyaluronate Plus Sorbitol to Hylan G-F20: A 6-Month Randomized Controlled Trial","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; WOMAC; Osteoarthritis; Randomized controlled trial; Viscosupplementation; Clinical endpoint; Clinical trial; Internal medicine; Physical therapy; Anesthesia; Surgery; Intra articular","score_opus":0.011345467674052341,"score_gpt":0.2894799067866917,"score_spread":0.27813443911263935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137313628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9600691,0.015690738,0.002048994,0.0016680673,0.003124967,0.013720336,0.0010083447,0.0002518877,0.002417565],"genre_scores_gemma":[0.9642454,0.006050856,0.0031940034,0.001703665,0.0023650678,0.018008962,0.0006858761,0.000048404254,0.003697724],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99601007,0.0023942294,0.00039202516,0.00058644154,0.00030252576,0.00031472105],"domain_scores_gemma":[0.99445915,0.002483046,0.0014801852,0.00043913335,0.00032765596,0.00081077183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069708657,0.0021249107,0.0073910197,0.00090750464,0.00078940357,0.0022073132,0.0016242224,0.0047168443,0.011714536],"category_scores_gemma":[0.005992213,0.0010601287,0.00397313,0.0008964412,0.0021889699,0.0021598232,0.0006655469,0.003403866,0.0013976443],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9932487,0.0021646626,0.00009448674,0.0005309826,0.00046988868,0.00001556643,0.000019709325,0.00004678075,0.00048237274,0.00003753136,0.0001001051,0.0027891698],"study_design_scores_gemma":[0.9609412,0.03796196,0.00027216208,0.000042678723,0.0003172922,0.000009752385,0.000009974588,0.00012111192,0.00010520188,0.00007073955,0.00014018833,0.0000077594195],"about_ca_topic_score_codex":0.0004359058,"about_ca_topic_score_gemma":0.00068639935,"teacher_disagreement_score":0.011714536,"about_ca_system_score_codex":0.0009310884,"about_ca_system_score_gemma":0.0016031585,"threshold_uncertainty_score":0.03918904},"labels":[],"label_agreement":null},{"id":"W3137461700","doi":"10.1007/s12325-021-01642-9","title":"Authors’ Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis","year":2021,"lang":"en","type":"letter","venue":"Advances in Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Rheumatoid arthritis; Meta-analysis; Rheumatology; Internal medicine; Physical therapy","score_opus":0.05917231811826728,"score_gpt":0.3501777814734969,"score_spread":0.2910054633552296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137461700","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023005139,0.0017974875,0.00011875608,0.9326476,0.0639627,0.000022373355,0.0004300591,0.000035412773,0.0007554549],"genre_scores_gemma":[0.0022073037,0.0010325735,0.00021517108,0.92918915,0.06522203,0.00007921116,0.00008109942,0.00004128,0.0019321418],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9863062,0.006318423,0.0027189534,0.0013006115,0.0026302682,0.0007254934],"domain_scores_gemma":[0.91821516,0.059717678,0.0060056224,0.001747535,0.010997908,0.0033161975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018165795,0.0010725034,0.004180985,0.0016869025,0.0025196185,0.0041280654,0.002581642,0.031161863,0.0092286905],"category_scores_gemma":[0.1206501,0.0011940161,0.003029946,0.0018652057,0.0017384571,0.0023176915,0.0013428106,0.025287377,0.0063874037],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026637633,0.000018755261,0.0004818181,0.00024540018,0.00014847837,0.0003702209,0.0000523571,0.000068713896,0.000052043375,0.0004378166,0.9936487,0.004209221],"study_design_scores_gemma":[0.0022080154,0.00026949716,0.003535838,0.0027870755,0.0013607087,0.0019833022,0.00047955042,0.0013158785,0.0005680466,0.009254512,0.97597516,0.000262357],"about_ca_topic_score_codex":0.006286869,"about_ca_topic_score_gemma":0.0096286405,"teacher_disagreement_score":0.031161863,"about_ca_system_score_codex":0.00439198,"about_ca_system_score_gemma":0.006706236,"threshold_uncertainty_score":0.096071064},"labels":[],"label_agreement":null},{"id":"W3143513781","doi":"10.1007/s12325-021-01661-6","title":"Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy Volunteers","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Tolerability; Pharmacokinetics; Cmax; Confidence interval; Randomized controlled trial; Randomization; Adverse effect; Internal medicine; Pharmacology","score_opus":0.025623361726226656,"score_gpt":0.35381250518862584,"score_spread":0.3281891434623992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143513781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848986,0.0014518901,0.0021272146,0.00026888918,0.00044703516,0.00888744,0.0007102694,0.00009530681,0.001113241],"genre_scores_gemma":[0.98424107,0.00068319985,0.003464505,0.000649342,0.00038038255,0.008734582,0.0006538746,0.000028392808,0.0011645848],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951218,0.0031518703,0.00039609126,0.0006446208,0.0003550275,0.00033059364],"domain_scores_gemma":[0.9961701,0.0011873201,0.00090851425,0.0007368751,0.0003472534,0.000649999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0077790823,0.0012265735,0.0025908377,0.00038068244,0.0004709202,0.001123756,0.0008329485,0.0022652014,0.0036281315],"category_scores_gemma":[0.0077097774,0.00097045355,0.001819867,0.00043642177,0.0015087518,0.0015750366,0.00047947202,0.002255849,0.0006402413],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97757566,0.008626099,0.0006787686,0.0001740418,0.0005769186,0.000028609102,0.00006804417,0.00015969723,0.004748476,0.00008012395,0.00020255311,0.0070809256],"study_design_scores_gemma":[0.6723744,0.32120764,0.0031388055,0.000020323056,0.00056235364,0.000036900637,0.000028169792,0.0004915519,0.0012910732,0.0002023426,0.00062030787,0.000026027965],"about_ca_topic_score_codex":0.00036219624,"about_ca_topic_score_gemma":0.0006143405,"teacher_disagreement_score":0.0077790823,"about_ca_system_score_codex":0.0005291778,"about_ca_system_score_gemma":0.0015476488,"threshold_uncertainty_score":0.0411402},"labels":[],"label_agreement":null},{"id":"W3145132769","doi":"10.1007/s12325-021-01707-9","title":"Capsule and Sprinkle Formulations of Lubiprostone Are Not Biologically Similar in Patients with Functional Constipation","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Lubiprostone; Medicine; Placebo; Bioequivalence; Bioavailability; Internal medicine; Crossover study; Gastroenterology; Pharmacokinetics; Constipation; Pharmacology; Chronic constipation","score_opus":0.014422123039740801,"score_gpt":0.2503218450046884,"score_spread":0.2358997219649476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3145132769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99364376,0.0050664973,0.00025101608,0.00019381632,0.000051681618,0.00012848686,0.00016172108,0.000016895458,0.00048628723],"genre_scores_gemma":[0.99732924,0.001252622,0.00061482197,0.00015193332,0.00004532689,0.00010291142,0.00017411003,0.0000034419977,0.0003255839],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99943405,0.000272863,0.00006177955,0.0000861528,0.00009891032,0.000046193454],"domain_scores_gemma":[0.99917954,0.00029778652,0.00031514408,0.000047190057,0.00005147957,0.00010885365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00128858,0.00026162722,0.00091250194,0.00017314663,0.00019212965,0.00057350815,0.00019619873,0.0005118177,0.0033734944],"category_scores_gemma":[0.0021427404,0.00016469818,0.0006501355,0.00020207143,0.00030270315,0.0004676248,0.00021946507,0.00068328716,0.0003371808],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58966124,0.007025309,0.045848027,0.003286284,0.0022106178,0.0006978389,0.0006372696,0.00089672004,0.09818729,0.0003820481,0.0018230904,0.2493443],"study_design_scores_gemma":[0.08029957,0.5579027,0.32673633,0.00032293372,0.0020889072,0.0022685947,0.0006946697,0.0020021393,0.016789202,0.00029560536,0.010526968,0.000072326555],"about_ca_topic_score_codex":0.00041139216,"about_ca_topic_score_gemma":0.00057872216,"teacher_disagreement_score":0.0033734944,"about_ca_system_score_codex":0.00027362147,"about_ca_system_score_gemma":0.0003414659,"threshold_uncertainty_score":0.011285484},"labels":[],"label_agreement":null},{"id":"W3149655449","doi":"10.1007/s12325-021-01718-6","title":"Sensitivity, Specificity and Accuracy of a Novel EEG-Based Objective Test, the Cognalyzer®, in Detecting Cannabis Psychoactive Effects","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Louisiana-Pacific (Canada)","funders":"Ontario Centre of Innovation","keywords":"McNemar's test; Medicine; Cannabis; Inhalation; Electroencephalography; Anesthesia; Internal medicine; Psychiatry","score_opus":0.01565861447248026,"score_gpt":0.3360289790813329,"score_spread":0.32037036460885265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3149655449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99305964,0.0012518611,0.0034952473,0.000048490296,0.000042959324,0.000044881534,0.00029452663,0.000063541316,0.0016988548],"genre_scores_gemma":[0.99630356,0.00029697895,0.0026775815,0.00003203209,0.000021278373,0.000019371997,0.00026282814,0.0000108745435,0.00037557233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99729913,0.0008701355,0.00041490784,0.0005476468,0.0007061351,0.00016202679],"domain_scores_gemma":[0.99313205,0.004024312,0.0010937435,0.00050799834,0.0009763115,0.0002656324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037353828,0.00051262643,0.0004701062,0.0012394286,0.0001493705,0.00090129854,0.0003876082,0.0008455378,0.00094852055],"category_scores_gemma":[0.010373202,0.0002882888,0.0004725732,0.0003303835,0.00035692385,0.0006515147,0.00065290363,0.00032737793,0.00044703836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003948022,0.00023161841,0.92737937,0.00014961396,0.00048324314,0.00016757536,0.00017020229,0.0009780679,0.013703659,0.00010241869,0.00032364452,0.052362587],"study_design_scores_gemma":[0.00012236381,0.0014551226,0.9765534,0.00005400584,0.00035262576,0.0018390972,0.00017259337,0.010313371,0.008258029,0.0001567825,0.00068214495,0.000040408257],"about_ca_topic_score_codex":0.0010048336,"about_ca_topic_score_gemma":0.002381725,"teacher_disagreement_score":0.0037353828,"about_ca_system_score_codex":0.00017232426,"about_ca_system_score_gemma":0.00018080091,"threshold_uncertainty_score":0.019754827},"labels":[],"label_agreement":null},{"id":"W3154210799","doi":"10.1007/s12325-021-01731-9","title":"Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Glaucoma and retinal disorders","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Université de Montréal","funders":"","keywords":"Medicine; Tolerability; Latanoprost; Ocular hypertension; Glaucoma; Post-hoc analysis; Ophthalmology; Internal medicine; Pooled analysis; Odds ratio; Randomized controlled trial; Intraocular pressure; Adverse effect; Confidence interval","score_opus":0.024013876953742578,"score_gpt":0.29905243355993355,"score_spread":0.275038556606191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154210799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6996127,0.26173827,0.013533377,0.0005335369,0.0025536434,0.006810313,0.011044509,0.00055280083,0.0036208627],"genre_scores_gemma":[0.9683745,0.015398254,0.0046132426,0.00062969915,0.000556614,0.006021053,0.0025638745,0.000114325456,0.0017285239],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.9759503,0.015344709,0.0032456368,0.0025637285,0.00203634,0.0008592896],"domain_scores_gemma":[0.97921413,0.014209397,0.0035311088,0.0014179588,0.001285291,0.00034206227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025612904,0.002853443,0.017627593,0.002672246,0.00034221087,0.0026354187,0.0015951373,0.0022514863,0.005066025],"category_scores_gemma":[0.02165342,0.0011432497,0.041424595,0.0029424361,0.0008010383,0.0018272436,0.0013383714,0.0017709798,0.0004666027],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19425485,0.00022670992,0.005238922,0.018772759,0.7721271,0.00016584442,0.00007766066,0.0010618771,0.0015176788,0.00008131901,0.00043095736,0.006044338],"study_design_scores_gemma":[0.04296273,0.016076712,0.025655072,0.00078864064,0.90931726,0.00012446706,0.0001175631,0.0020461127,0.00100891,0.00020557505,0.0016178091,0.000079099635],"about_ca_topic_score_codex":0.0018179042,"about_ca_topic_score_gemma":0.00263372,"teacher_disagreement_score":0.025612904,"about_ca_system_score_codex":0.00126532,"about_ca_system_score_gemma":0.0011294623,"threshold_uncertainty_score":0.13545561},"labels":[],"label_agreement":null},{"id":"W3159176128","doi":"10.1007/s12325-021-01732-8","title":"Strategies to Prolong Ketamine’s Efficacy in Adults with Treatment-Resistant Depression","year":2021,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Treatment of Major Depression","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Auto Workers; University of Toronto; Brain and Cognition Discovery Foundation; University Health Network","funders":"","keywords":"Medicine; Depression (economics); Ketamine; Rheumatology; Treatment-resistant depression; Internal medicine; Psychiatry; Intensive care medicine; Physical therapy; Major depressive disorder; Mood","score_opus":0.029440755236178173,"score_gpt":0.38051257478142037,"score_spread":0.3510718195452422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159176128","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002139832,0.9969216,0.00010273182,0.0002636652,0.000084075626,0.0001006551,0.000046690555,0.0000034158807,0.00033728874],"genre_scores_gemma":[0.03866751,0.9592166,0.0009878372,0.0005545637,0.00016897889,0.0002571848,0.00007018419,0.0000019942713,0.00007517446],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975026,0.0010213742,0.0009413936,0.00016470315,0.00031231626,0.00005761232],"domain_scores_gemma":[0.9921387,0.005231013,0.0020928583,0.00007484941,0.00037195598,0.000090613416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038403543,0.00069481315,0.0024776256,0.002095816,0.0002314994,0.0011895751,0.00076641765,0.0011975197,0.0021898856],"category_scores_gemma":[0.012913128,0.00035672486,0.0029136587,0.0016756696,0.0003872854,0.0011973936,0.00051208335,0.0007506215,0.00020218708],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001314401,0.00012263998,0.0016121082,0.6592917,0.0069759865,0.00020571105,0.00022277843,0.00017370997,0.00091674784,0.00051662663,0.0015801176,0.32706752],"study_design_scores_gemma":[0.0063383793,0.0066076815,0.023235215,0.77809465,0.099778585,0.0028327906,0.0009871257,0.0004246925,0.0029059344,0.0015375081,0.07715193,0.00010543634],"about_ca_topic_score_codex":0.0011129312,"about_ca_topic_score_gemma":0.0033967642,"teacher_disagreement_score":0.0038403543,"about_ca_system_score_codex":0.0009498536,"about_ca_system_score_gemma":0.002504921,"threshold_uncertainty_score":0.020309985},"labels":[],"label_agreement":null},{"id":"W3160202558","doi":"10.1007/s12325-021-01753-3","title":"Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Gilead Sciences; AbbVie; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Rheumatology; Hepatitis C virus; Clinical trial; Hepatitis C; Virology; Virus","score_opus":0.05627558918075966,"score_gpt":0.41988705088490674,"score_spread":0.3636114617041471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160202558","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98194194,0.0071498887,0.0009517565,0.00047607953,0.00007227711,0.0011596476,0.0043130433,0.00002721472,0.003908192],"genre_scores_gemma":[0.9935824,0.0008501587,0.0003484,0.00030537896,0.00006816688,0.0005941203,0.0037844388,0.000005786735,0.00046101242],"study_design_codex":"observational","study_design_gemma":"systematic_review","domain_scores_codex":[0.99309725,0.0038213765,0.001004365,0.0008607371,0.00093975104,0.0002764861],"domain_scores_gemma":[0.9896415,0.0036614516,0.0041907327,0.0008287967,0.0011267539,0.00055081805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009945035,0.00040750534,0.00084942736,0.0005448472,0.000418564,0.0015459019,0.00047052535,0.0006109157,0.0036483437],"category_scores_gemma":[0.013706331,0.00019699166,0.0019109506,0.0006263595,0.00053010415,0.0008273756,0.0005908729,0.0009932256,0.00040636308],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24626483,0.0026297471,0.6309056,0.0027231062,0.013828955,0.00050211913,0.0005320598,0.0024279912,0.0042894026,0.0008625854,0.005038693,0.089995],"study_design_scores_gemma":[0.037673775,0.13356547,0.7822331,0.0008035007,0.008861008,0.0030581253,0.0005888412,0.0035283433,0.005836312,0.0017711245,0.021931432,0.00014883325],"about_ca_topic_score_codex":0.00022457562,"about_ca_topic_score_gemma":0.00038068517,"teacher_disagreement_score":0.009945035,"about_ca_system_score_codex":0.0006155288,"about_ca_system_score_gemma":0.0011185121,"threshold_uncertainty_score":0.05259502},"labels":[],"label_agreement":null},{"id":"W3162743464","doi":"10.1007/s12325-021-01756-0","title":"Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"National Cancer Institute; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Medicine; Odds ratio; Internal medicine; Hazard ratio; Confidence interval; Salvage therapy; Oncology; Refractory (planetary science); Chemotherapy","score_opus":0.025367968608400935,"score_gpt":0.35202477845148494,"score_spread":0.326656809843084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162743464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97195834,0.015807629,0.0028034723,0.00024855637,0.0005378693,0.0018129136,0.0018325255,0.000049698232,0.004949041],"genre_scores_gemma":[0.99197114,0.0016854092,0.0018167794,0.000284342,0.0001879712,0.0014324775,0.0012318329,0.000021354488,0.0013685145],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9900988,0.0075081186,0.0007137955,0.0007576147,0.00064978807,0.00027192355],"domain_scores_gemma":[0.9897377,0.0071133315,0.0016382388,0.0007885,0.0003995756,0.00032261817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00930664,0.0012829395,0.0029062706,0.0009387781,0.0001630587,0.0011495223,0.0009548723,0.0010241859,0.0052229073],"category_scores_gemma":[0.013719609,0.00037792875,0.0049241595,0.0005797855,0.000705837,0.0008152949,0.0010850898,0.0018805884,0.00043208065],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8864289,0.0022047434,0.010616824,0.0048789233,0.046349905,0.00009751292,0.00022659943,0.0024809563,0.0034658734,0.0011883812,0.0008497288,0.041211702],"study_design_scores_gemma":[0.30972436,0.46607986,0.068706356,0.0012800057,0.11404098,0.0004813475,0.00063839386,0.009702752,0.01243359,0.0048648585,0.011857732,0.00018981691],"about_ca_topic_score_codex":0.0003755818,"about_ca_topic_score_gemma":0.00073218264,"teacher_disagreement_score":0.00930664,"about_ca_system_score_codex":0.0006769561,"about_ca_system_score_gemma":0.00057080976,"threshold_uncertainty_score":0.049218774},"labels":[],"label_agreement":null},{"id":"W3164078411","doi":"10.1007/s12325-021-01746-2","title":"Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US)","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Pharmaceuticals; Janssen Scientific Affairs","keywords":"Rivaroxaban; Medicine; Polypharmacy; Warfarin; Atrial fibrillation; Internal medicine; Stroke (engine); Hazard ratio; Population; Confidence interval; Environmental health","score_opus":0.023315740702173942,"score_gpt":0.33370449795192714,"score_spread":0.3103887572497532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164078411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954444,0.0039568213,0.00005426815,0.00007104241,0.000011419154,0.000015729636,0.00016365101,0.0000019879276,0.0002807288],"genre_scores_gemma":[0.99895835,0.00062727986,0.00006997702,0.00005462653,0.00002059706,0.000013379774,0.00021333028,6.614199e-7,0.00004183946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975587,0.0012791516,0.00032011318,0.00028449253,0.0004213912,0.00013608002],"domain_scores_gemma":[0.99589705,0.0015092915,0.0018114366,0.0001739811,0.00020695513,0.0004013269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030494537,0.00026033408,0.00066684687,0.0005941588,0.00017661341,0.00067635963,0.00022317386,0.0005748267,0.00091554574],"category_scores_gemma":[0.0058228187,0.0002247592,0.0016529968,0.00074125436,0.00032548702,0.00044286874,0.00029590886,0.00039461118,0.00007822657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051327627,0.0011098143,0.9064704,0.0003438518,0.007947412,0.00009738909,0.00012819684,0.000674535,0.0005574776,0.00011795987,0.0002959917,0.030929284],"study_design_scores_gemma":[0.0034281854,0.017871872,0.9719605,0.00009139939,0.0037367544,0.0004440977,0.00012875571,0.0012387112,0.00033323295,0.00019850636,0.0005433234,0.000024757263],"about_ca_topic_score_codex":0.0016155198,"about_ca_topic_score_gemma":0.0029801712,"teacher_disagreement_score":0.0030494537,"about_ca_system_score_codex":0.0004982539,"about_ca_system_score_gemma":0.00046373493,"threshold_uncertainty_score":0.016127229},"labels":[],"label_agreement":null},{"id":"W3171967615","doi":"10.1007/s12325-021-01790-y","title":"Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Windsor; Queen's University","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Spirometry; Interstitial lung disease; Idiopathic pulmonary fibrosis; Vital capacity; Quartile; Internal medicine; Physical therapy; Lung; Diffusing capacity; Asthma; Lung function; Confidence interval","score_opus":0.003816640828764195,"score_gpt":0.25071091482226937,"score_spread":0.24689427399350516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171967615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941553,0.0025587578,0.00019814548,0.00017727446,0.000025113317,0.00015142206,0.0018928761,0.000008145741,0.0008329231],"genre_scores_gemma":[0.9966804,0.00046916984,0.00028727463,0.00017460948,0.000048516486,0.00014552998,0.0019754579,0.000003955658,0.0002152078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979825,0.0010147414,0.00024827212,0.0004276287,0.00020805451,0.000118743665],"domain_scores_gemma":[0.9960444,0.0006476518,0.0021827084,0.00032719385,0.00034409974,0.0004539562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003362526,0.00043159322,0.00090552244,0.00039787023,0.0003279793,0.0009363596,0.00069553667,0.00082133495,0.0009480575],"category_scores_gemma":[0.003625554,0.0002933144,0.0012090241,0.00070481695,0.0003337681,0.00067436526,0.00071971025,0.0007769353,0.0003938967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003735741,0.00020716504,0.99074847,0.00026034965,0.0006062185,0.00008576362,0.00019374539,0.00007062525,0.0003124849,0.00003407598,0.00046325807,0.00328218],"study_design_scores_gemma":[0.0005057653,0.0019272602,0.9955745,0.00010309162,0.000354499,0.00036124032,0.00014095551,0.00016577113,0.00007859913,0.00004183511,0.00073285546,0.000013584047],"about_ca_topic_score_codex":0.0012935719,"about_ca_topic_score_gemma":0.002016694,"teacher_disagreement_score":0.003362526,"about_ca_system_score_codex":0.00035443399,"about_ca_system_score_gemma":0.000372478,"threshold_uncertainty_score":0.017782927},"labels":[],"label_agreement":null},{"id":"W3173241664","doi":"10.1007/s12325-021-01818-3","title":"Subcutaneously Administered Anti-TNFs for the Treatment of Ulcerative Colitis: A Retrospective, Propensity Score-Matched, US Health Claims Analysis","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bell (Canada); Western University; Merck Canada Inc. (Canada); McGill University Health Centre; Montreal General Hospital; Dalhousie University","funders":"Janssen Canada","keywords":"Golimumab; Medicine; Adalimumab; Propensity score matching; Concomitant; Ulcerative colitis; Internal medicine; Infliximab; Retrospective cohort study; Vedolizumab; Tumor necrosis factor alpha","score_opus":0.02185147195618798,"score_gpt":0.3073743124811265,"score_spread":0.28552284052493854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173241664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973411,0.00062634854,0.0005777026,0.000035419467,0.000015407886,0.000030107796,0.0010234601,0.000007231165,0.0003432482],"genre_scores_gemma":[0.99851745,0.000138211,0.00019667587,0.000033718494,0.000018353487,0.000014368812,0.00097453356,0.000003725051,0.00010312358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804,0.0005651286,0.00035300368,0.00049574766,0.00038570486,0.00016038514],"domain_scores_gemma":[0.99624026,0.0007072587,0.0019396278,0.00065952935,0.00026405853,0.00018932088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015467177,0.00037895155,0.0006220224,0.0010968125,0.0005965454,0.00096977735,0.0004815772,0.0006298798,0.0017715734],"category_scores_gemma":[0.004351527,0.00055873924,0.0014394637,0.0024991503,0.00047204786,0.00057572406,0.0006031374,0.00081631873,0.00029909433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002529119,0.00012574966,0.9928786,0.00004017081,0.001214093,0.0001607136,0.000041508705,0.0002761509,0.0004326561,0.00011938871,0.00028946082,0.001892315],"study_design_scores_gemma":[0.00038178323,0.00073568226,0.9917529,0.000026168243,0.0015185014,0.0010346263,0.00018703929,0.0029536225,0.00028146955,0.00024394243,0.0008630959,0.00002121893],"about_ca_topic_score_codex":0.0038709096,"about_ca_topic_score_gemma":0.0040105106,"teacher_disagreement_score":0.0038709096,"about_ca_system_score_codex":0.00056310586,"about_ca_system_score_gemma":0.000565047,"threshold_uncertainty_score":0.008179903},"labels":[],"label_agreement":null},{"id":"W3180183107","doi":"10.1007/s12325-021-01846-z","title":"Effectiveness of Radiofrequency Catheter Ablation Using Ablation Index Versus Second Generation Cryoballoon in the Treatment of Persistent Atrial Fibrillation: A Matching-Adjusted Indirect Comparison","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Biosense Webster","keywords":"Medicine; Atrial fibrillation; Ablation; Catheter ablation; Internal medicine; Radiofrequency ablation; Cardiology; Radiofrequency catheter ablation","score_opus":0.09545926004276585,"score_gpt":0.3690812414886553,"score_spread":0.27362198144588945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180183107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7663965,0.18062341,0.018452477,0.001157533,0.003338832,0.010316818,0.010894087,0.00025391777,0.008566387],"genre_scores_gemma":[0.97874373,0.006270984,0.0059833927,0.00065310113,0.0002748742,0.005267031,0.0017589198,0.000029794075,0.0010181366],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9755434,0.017266383,0.003187182,0.0019910259,0.0013838158,0.000628226],"domain_scores_gemma":[0.981344,0.013311585,0.0033229461,0.0009256927,0.0007645691,0.00033117828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01687131,0.0022860852,0.0074465857,0.0020853728,0.00031648696,0.0019760383,0.0018661638,0.002578736,0.007046769],"category_scores_gemma":[0.03057099,0.0007347658,0.023890376,0.0014948052,0.000902408,0.0016348821,0.0018464096,0.0025467714,0.0005132449],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41287765,0.0011072045,0.018559547,0.05671322,0.46538782,0.0001922919,0.00041119644,0.004273545,0.0016737909,0.0017725365,0.0015711054,0.035460167],"study_design_scores_gemma":[0.1527029,0.057813447,0.04440675,0.0052862703,0.7158695,0.0003778608,0.0004513571,0.009995085,0.0025212003,0.0046420908,0.00566349,0.0002701114],"about_ca_topic_score_codex":0.0017633664,"about_ca_topic_score_gemma":0.0014532517,"teacher_disagreement_score":0.01687131,"about_ca_system_score_codex":0.0014105473,"about_ca_system_score_gemma":0.0010601095,"threshold_uncertainty_score":0.08922511},"labels":[],"label_agreement":null},{"id":"W3184516018","doi":"10.1007/s12325-021-01823-6","title":"Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Merck Sharp and Dohme; AstraZeneca","keywords":"Medicine; Prostate cancer; Internal medicine; Chemotherapy; Oncology; Cancer; Overall survival; Enzalutamide; Hormonal therapy","score_opus":0.02342395738069975,"score_gpt":0.34929700075028364,"score_spread":0.3258730433695839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184516018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95585704,0.0031450114,0.0003000161,0.0006528746,0.000019970568,0.000028863948,0.038345195,0.000033301345,0.0016176887],"genre_scores_gemma":[0.9789034,0.0011136272,0.0003514113,0.00026567385,0.000026635766,0.000032517604,0.019086914,0.000009061022,0.00021077166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895453,0.00021416297,0.0002673835,0.00027465782,0.0001746999,0.00011456323],"domain_scores_gemma":[0.9954965,0.00066509226,0.0030250228,0.00016517569,0.0003971416,0.00025093355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000610074,0.00013743063,0.0003082205,0.0012955397,0.00025695525,0.00057381263,0.00033222177,0.00031347148,0.0019061782],"category_scores_gemma":[0.0039068917,0.00013256642,0.00042848103,0.0035224643,0.00017985694,0.00055715686,0.0004235721,0.00042060288,0.00029238214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029842422,0.000029242774,0.98978007,0.0000927016,0.00012885682,0.000058887028,0.00006571622,0.00021246824,0.00015239316,0.000048722315,0.002000947,0.0071316063],"study_design_scores_gemma":[0.000015741547,0.00006448182,0.9955049,0.00007412949,0.00006225053,0.0003946071,0.00020570897,0.00040467133,0.00017582673,0.00007890983,0.0030068464,0.000012018648],"about_ca_topic_score_codex":0.017845964,"about_ca_topic_score_gemma":0.030988608,"teacher_disagreement_score":0.017845964,"about_ca_system_score_codex":0.00082749897,"about_ca_system_score_gemma":0.0007071401,"threshold_uncertainty_score":0.035484195},"labels":[],"label_agreement":null},{"id":"W3184889104","doi":"10.1007/s12325-021-01825-4","title":"Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Apellis Pharmaceuticals","keywords":"Eculizumab; Medicine; Paroxysmal nocturnal hemoglobinuria; Discontinuation; Cohort; Population; Internal medicine; Pediatrics; Retrospective cohort study; Immunology","score_opus":0.015182163423706355,"score_gpt":0.2951789799775904,"score_spread":0.27999681655388403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184889104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912252,0.0009682938,0.00006691789,0.00028055967,0.0000077755285,0.000012444412,0.007064694,0.0000042570446,0.00036979726],"genre_scores_gemma":[0.99513644,0.00047805367,0.00010877711,0.00008724481,0.000015167324,0.000023272612,0.0040752515,0.0000015843028,0.00007416201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987686,0.0003759745,0.00028485988,0.00020923678,0.00019585097,0.00016533738],"domain_scores_gemma":[0.99671245,0.00035856344,0.0024284176,0.00009575238,0.00017844257,0.00022644807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088719017,0.000244632,0.00034734316,0.0013348629,0.0002298021,0.00087918184,0.00046245015,0.0005091499,0.0012971028],"category_scores_gemma":[0.0036938214,0.00025824612,0.00092096976,0.0025322638,0.00021941487,0.0007822731,0.00057056884,0.00054686074,0.00015253297],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013257081,0.000040892806,0.99700314,0.000028609813,0.00023938603,0.000040126317,0.000032522254,0.0003379621,0.000028584614,0.000037695583,0.0005332194,0.0015452851],"study_design_scores_gemma":[0.0000225834,0.00006972835,0.99763024,0.000038532296,0.000082093335,0.00017782915,0.0002102696,0.001219267,0.00003364965,0.000050887473,0.00045710805,0.00000776066],"about_ca_topic_score_codex":0.026976863,"about_ca_topic_score_gemma":0.026372185,"teacher_disagreement_score":0.026976863,"about_ca_system_score_codex":0.001436735,"about_ca_system_score_gemma":0.0006094929,"threshold_uncertainty_score":0.05363965},"labels":[],"label_agreement":null},{"id":"W3187202922","doi":"10.1007/s12325-021-01855-y","title":"Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Lunds Universitet; GlaxoSmithKline","keywords":"Medicine; COPD; Internal medicine; Rheumatology; Family medicine; Intensive care medicine; Physical therapy","score_opus":0.024221451868375328,"score_gpt":0.34524699674950515,"score_spread":0.32102554488112983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187202922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815652,0.011189029,0.0005119807,0.000558383,0.00020519197,0.0010344086,0.0017046846,0.00004963392,0.0031814552],"genre_scores_gemma":[0.9923805,0.0021507728,0.00045623162,0.0007335541,0.00031761348,0.000846245,0.0018415826,0.0000208252,0.0012527419],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9973992,0.0015575076,0.0002733933,0.00029822192,0.00025856702,0.00021310439],"domain_scores_gemma":[0.99773633,0.00095306255,0.0005512642,0.0002539183,0.00015668565,0.00034870376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004507567,0.0011898092,0.0033896482,0.00028046113,0.00033826663,0.0014577501,0.0006233919,0.0014115974,0.0032143935],"category_scores_gemma":[0.0042354227,0.00038429705,0.005782461,0.00040018454,0.00047142754,0.00090397376,0.000593285,0.00207937,0.0005135826],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9659074,0.0009972573,0.0061758133,0.00081391516,0.00881601,0.00006919142,0.000050763512,0.00033787068,0.0026529792,0.00012056133,0.0006223536,0.013435923],"study_design_scores_gemma":[0.7794888,0.09263698,0.09116104,0.0003614415,0.02692914,0.00034667816,0.00013522513,0.0018783732,0.0019779066,0.00080829946,0.0041791676,0.000096912954],"about_ca_topic_score_codex":0.0003115661,"about_ca_topic_score_gemma":0.0011143172,"teacher_disagreement_score":0.004507567,"about_ca_system_score_codex":0.0004886027,"about_ca_system_score_gemma":0.0005115599,"threshold_uncertainty_score":0.02383858},"labels":[],"label_agreement":null},{"id":"W3187334250","doi":"10.1007/s12325-021-01862-z","title":"Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug–Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Treatment of Major Depression","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; Drug; Depression (economics); Adverse effect; Intensive care medicine; Rheumatology; Internal medicine; Psychiatry","score_opus":0.01014274449460175,"score_gpt":0.30348813988688,"score_spread":0.2933453953922783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187334250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987204,0.00033493974,0.000029707157,0.0000375802,0.000003010678,0.0000125674715,0.00053772173,0.000002089479,0.00032207737],"genre_scores_gemma":[0.9993886,0.0001424741,0.000034562785,0.000024381303,0.0000069621756,0.0000069296048,0.00032240906,5.705688e-7,0.000073273244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995468,0.00007038486,0.000091965296,0.0001259318,0.00011007635,0.00005473659],"domain_scores_gemma":[0.99833316,0.00017758519,0.0011693828,0.00005303623,0.0000918277,0.00017497929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040076082,0.00012674223,0.00028920497,0.0007004277,0.00027422083,0.00049434166,0.00026828377,0.00030955247,0.002461227],"category_scores_gemma":[0.0014935427,0.00016651458,0.00039919806,0.000764551,0.00017008797,0.00039056607,0.0003931232,0.0004451603,0.00025891274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060400882,0.000017651977,0.99889755,0.000008475368,0.000026173531,0.000031260348,0.000021431693,0.00000782776,0.000090573245,0.0000064234227,0.000049922604,0.00078221265],"study_design_scores_gemma":[0.0000039211614,0.00005102853,0.9995678,0.0000049301184,0.00001025928,0.00020737352,0.000046048102,0.000032537017,0.000016675753,0.0000050129415,0.000053363987,0.0000011140097],"about_ca_topic_score_codex":0.0026688068,"about_ca_topic_score_gemma":0.0044163354,"teacher_disagreement_score":0.0026688068,"about_ca_system_score_codex":0.00021410995,"about_ca_system_score_gemma":0.0001971337,"threshold_uncertainty_score":0.008233607},"labels":[],"label_agreement":null},{"id":"W3192547636","doi":"10.1007/bf02849868","title":"Rotavirus gastroenteritis","year":2005,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Viral gastroenteritis research and epidemiology","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"Merck Canada","keywords":"Medicine; Rotavirus; Vomiting; Diarrhea; Serotype; Rotavirus vaccine; Vaccination; Rotavirus gastroenteritis; Feces; Pediatrics; Virology; Internal medicine; Microbiology; Biology","score_opus":0.08661154738774483,"score_gpt":0.4706059393184704,"score_spread":0.38399439193072554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192547636","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000070039,0.99853384,0.00006776453,0.000144123,0.00028315064,0.000007265848,0.000016837917,0.0000055227288,0.0008714791],"genre_scores_gemma":[0.00043776247,0.99851507,0.00015584145,0.00021569298,0.00021998743,0.0000063547805,0.000030789808,9.129218e-7,0.00041763202],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997211,0.00006225543,0.000062006875,0.000040919444,0.00008769148,0.00002601375],"domain_scores_gemma":[0.99959713,0.00015668174,0.000099293946,0.000014254739,0.00009998162,0.000032702414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066252216,0.001048669,0.0026065712,0.002291799,0.00021030738,0.0009482494,0.00064630894,0.0008773249,0.0047089513],"category_scores_gemma":[0.0011575355,0.00027491717,0.00060604827,0.0021955266,0.0003988312,0.0010557601,0.00069838046,0.0013594979,0.0020472081],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001072558,0.000051341944,0.00027090948,0.027207077,0.00011211737,0.00021014252,0.000035472847,0.00013636962,0.000668645,0.00073832454,0.035880677,0.9345817],"study_design_scores_gemma":[0.00010956429,0.00020849607,0.002075109,0.018936591,0.0005771975,0.003150855,0.00011928326,0.000086874985,0.00038606668,0.0009189664,0.97340864,0.000022312064],"about_ca_topic_score_codex":0.0015969208,"about_ca_topic_score_gemma":0.0032909175,"teacher_disagreement_score":0.0047089513,"about_ca_system_score_codex":0.0005455116,"about_ca_system_score_gemma":0.0014094999,"threshold_uncertainty_score":0.015752971},"labels":[],"label_agreement":null},{"id":"W3198178766","doi":"10.1007/s12325-021-01897-2","title":"Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Migraine; Quality of life (healthcare); Pediatrics; Internal medicine; Physical therapy","score_opus":0.0662035492485772,"score_gpt":0.3728287766856725,"score_spread":0.3066252274370953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198178766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99806577,0.00031987048,0.00034426793,0.000038816685,0.0000037016134,0.000041916646,0.0007544389,0.000005295045,0.00042596273],"genre_scores_gemma":[0.9987061,0.000082366336,0.000304459,0.000020396139,0.000004030973,0.00006195998,0.0007618494,0.0000011852248,0.00005760882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99914396,0.0004225941,0.00007879313,0.00012692885,0.00012383326,0.00010381924],"domain_scores_gemma":[0.99880266,0.0003935082,0.0005266666,0.00006800882,0.000099075,0.000110091045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019938813,0.00027653624,0.0006145053,0.0006777343,0.00013686542,0.0005638575,0.00023799422,0.00021631892,0.0015171703],"category_scores_gemma":[0.004939738,0.00011152562,0.00097464345,0.00085599325,0.00015250925,0.00039084634,0.0005502483,0.0003898552,0.00019515205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007854031,0.00026282296,0.95996255,0.00013330807,0.00079248956,0.00004660252,0.0002004404,0.0020479634,0.00073885446,0.00010181761,0.00053983985,0.02731927],"study_design_scores_gemma":[0.00034409738,0.0018713969,0.9927307,0.0000215402,0.00019013757,0.00011449612,0.00012179276,0.0035574874,0.0003172305,0.0002119797,0.00050439616,0.000014815916],"about_ca_topic_score_codex":0.00095746625,"about_ca_topic_score_gemma":0.00069807435,"teacher_disagreement_score":0.0019938813,"about_ca_system_score_codex":0.00034873124,"about_ca_system_score_gemma":0.00022527948,"threshold_uncertainty_score":0.010544777},"labels":[],"label_agreement":null},{"id":"W3200209831","doi":"10.1007/s12325-021-01878-5","title":"Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Propeller Health; Pearl Therapeutics; Allergan; Forest Laboratories; Esperion Therapeutics; AstraZeneca; Galderma; Novo Nordisk; Eisai; Brigham and Women's Hospital; Kiniksa Pharmaceuticals; Sunovion; Pfizer","keywords":"Medicine; COPD; Placebo; Internal medicine; Formoterol; Exacerbation; Maintenance therapy; Randomized controlled trial; Mace; Asthma; Conventional PCI; Myocardial infarction; Chemotherapy; Budesonide","score_opus":0.02147761966077214,"score_gpt":0.3626173923779226,"score_spread":0.34113977271715046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200209831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98156184,0.00809663,0.0010266779,0.00097054715,0.0012069264,0.0027105003,0.0016924051,0.00019326575,0.0025410908],"genre_scores_gemma":[0.98649955,0.0018149216,0.0011736318,0.0010372223,0.0007398004,0.0036234432,0.001828408,0.000042095253,0.0032408966],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975212,0.0015932156,0.0001464792,0.0003594507,0.00010871331,0.0002709266],"domain_scores_gemma":[0.997127,0.0013577818,0.0005419002,0.00026813193,0.00020464046,0.0005005085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00381997,0.0020814836,0.007447432,0.00041267712,0.0004154926,0.00157274,0.0011610847,0.0018573216,0.007219799],"category_scores_gemma":[0.0044531613,0.0006893556,0.004561006,0.00038484493,0.0009139617,0.0014978012,0.0006405498,0.003113,0.0007867823],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9960305,0.00041024236,0.00030165183,0.00015396379,0.0011868678,0.000012453757,0.000007688578,0.0001153195,0.0002452564,0.000031361276,0.00020040853,0.0013042336],"study_design_scores_gemma":[0.9661194,0.026708858,0.0025756904,0.000032618136,0.0028451025,0.00001725316,0.000017340604,0.00091406546,0.00020627354,0.00020152675,0.0003449451,0.000016956978],"about_ca_topic_score_codex":0.0008008704,"about_ca_topic_score_gemma":0.0013992292,"teacher_disagreement_score":0.007447432,"about_ca_system_score_codex":0.0007910478,"about_ca_system_score_gemma":0.001174886,"threshold_uncertainty_score":0.024152637},"labels":[],"label_agreement":null},{"id":"W3208029444","doi":"10.1007/s12325-021-01898-1","title":"Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Actelion Pharmaceuticals; Seoul St. Mary's Hospital, Catholic University of Korea; Universitaire Ziekenhuizen Leuven, KU Leuven; Guangdong Provincial People's Hospital; Universität Wien; Peking Union Medical College; Karl-Franzens-Universität Graz; University of Ottawa; Medizinische Universität Graz; Peking Union Medical College Hospital; Changi General Hospital; Royal Adelaide Hospital; Samsung; Aarhus Universitetshospital; Shanghai Pulmonary Hospital; Centre Hospitalier Universitaire de Toulouse; Universität Greifswald; Seoul National University Hospital; Renji Hospital; Seoul National University; Catholic University of Korea; Aarhus Universitet; Jewish General Hospital; Medizinische Universität Wien; University of Alberta; Rigshospitalet","keywords":"Tolerability; Medicine; Discontinuation; Internal medicine; Clinical endpoint; Adverse effect; Placebo; Pulmonary hypertension; Clinical trial; Pathology","score_opus":0.035486699790773686,"score_gpt":0.3073673866782115,"score_spread":0.27188068688743783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208029444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951774,0.0033038568,0.00013591904,0.000095101765,0.000024958614,0.0001297421,0.00053733727,0.00001569075,0.0005800216],"genre_scores_gemma":[0.9959592,0.001373072,0.0003008824,0.0002714174,0.00012779846,0.0002543838,0.0011348383,0.000005906962,0.0005725238],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9991265,0.00052366854,0.0000791895,0.00009991044,0.00008889702,0.00008188664],"domain_scores_gemma":[0.9982175,0.000573834,0.0005698244,0.00018552796,0.00007831721,0.00037494014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031112868,0.0006688515,0.0012760758,0.00026872073,0.00014775856,0.0005870887,0.0003680375,0.0006659901,0.0031991499],"category_scores_gemma":[0.0019326104,0.00016118483,0.0015966843,0.0002836369,0.0005339261,0.0007110034,0.00041351453,0.0010432961,0.0003281413],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.851191,0.008370395,0.017368235,0.0013209741,0.002293243,0.00020936906,0.00021695037,0.000828924,0.008533065,0.0001059417,0.0009446994,0.10861721],"study_design_scores_gemma":[0.3778916,0.4751318,0.1381498,0.00017123431,0.0025088224,0.0004969785,0.00015194243,0.0007417111,0.0024343117,0.00020505177,0.0020487886,0.00006795654],"about_ca_topic_score_codex":0.00018608465,"about_ca_topic_score_gemma":0.00033774012,"teacher_disagreement_score":0.0031991499,"about_ca_system_score_codex":0.00027024743,"about_ca_system_score_gemma":0.00032910155,"threshold_uncertainty_score":0.01645428},"labels":[],"label_agreement":null},{"id":"W3209198105","doi":"10.1007/s12325-021-01934-0","title":"Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Novartis Pharma","keywords":"Medicine; Immune thrombocytopenia; Rheumatology; Quality of life (healthcare); Index (typography); Internal medicine; Health related quality of life; Immunology; Intensive care medicine; Physical therapy; Platelet; Disease; Nursing","score_opus":0.05389147020717946,"score_gpt":0.3971491396144844,"score_spread":0.34325766940730496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209198105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99727064,0.00025068506,0.00036633146,0.00016751191,0.000010630603,0.00010390265,0.0009016047,0.000008885142,0.0009198749],"genre_scores_gemma":[0.998569,0.00007623062,0.00038793377,0.000053427928,0.000005530766,0.000084125466,0.0007577038,0.000001939801,0.00006412005],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982046,0.0007630458,0.00029627368,0.00013153648,0.0004326048,0.00017197034],"domain_scores_gemma":[0.9939646,0.0019578517,0.0022853576,0.0002769385,0.0009252454,0.00059001724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046552736,0.00027353698,0.00042663165,0.0012103871,0.0002357718,0.0006527158,0.00043919645,0.00041546626,0.0010765042],"category_scores_gemma":[0.014608811,0.00016475552,0.0008316165,0.0016037907,0.00036567243,0.0007146363,0.0010144956,0.0007002809,0.0001534889],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000708247,0.00006861129,0.99459016,0.000033453274,0.00008727171,0.000020964031,0.00017325109,0.00020276906,0.000057839625,0.00003070583,0.00027208464,0.0043921135],"study_design_scores_gemma":[0.000016699032,0.00027685246,0.9981654,0.000018909564,0.000019452524,0.000085188905,0.00034090757,0.0006513195,0.00004456138,0.000038371363,0.0003370019,0.0000054256543],"about_ca_topic_score_codex":0.001757162,"about_ca_topic_score_gemma":0.0015217656,"teacher_disagreement_score":0.0046552736,"about_ca_system_score_codex":0.00046907554,"about_ca_system_score_gemma":0.00039050743,"threshold_uncertainty_score":0.024619699},"labels":[],"label_agreement":null},{"id":"W3209696856","doi":"10.1007/s12325-021-01938-w","title":"Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Neurogenetic and Muscular Disorders Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"SMA*; Spinal muscular atrophy; Medicine; Discontinuation; Neuromuscular disease; Retrospective cohort study; Weakness; Regimen; Internal medicine; Pediatrics; Physical therapy; Surgery; Disease","score_opus":0.029409359234226495,"score_gpt":0.36863691277718974,"score_spread":0.33922755354296324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209696856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98701847,0.001357536,0.00017459074,0.00021527376,0.000014252337,0.000063503,0.010374381,0.00000944557,0.00077260827],"genre_scores_gemma":[0.99298495,0.00053854845,0.00016105195,0.00013458153,0.000019989588,0.00007135441,0.005998496,0.000003529752,0.000087482134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970251,0.0007398527,0.0007881654,0.00051800744,0.00068668346,0.00024222773],"domain_scores_gemma":[0.9890298,0.002158624,0.0068610576,0.0006173553,0.000841938,0.0004912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024972314,0.00032440491,0.00059937756,0.0028456294,0.0006525114,0.0011417043,0.00073488936,0.00062392594,0.001347588],"category_scores_gemma":[0.0072174543,0.00043470715,0.0010788435,0.006510571,0.0003457697,0.00073726766,0.0009300683,0.000811794,0.00018539502],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005467903,0.000029343484,0.9988424,0.00002677394,0.000110138695,0.00004851275,0.000041568186,0.00003742998,0.000019927542,0.000023249782,0.00028107179,0.00048487747],"study_design_scores_gemma":[0.000015403493,0.00004357708,0.998228,0.000044530992,0.000116262745,0.000279934,0.0003007378,0.0005303396,0.00003155719,0.000029176303,0.00037330977,0.000007146204],"about_ca_topic_score_codex":0.018571189,"about_ca_topic_score_gemma":0.020493528,"teacher_disagreement_score":0.018571189,"about_ca_system_score_codex":0.0009011196,"about_ca_system_score_gemma":0.0011231124,"threshold_uncertainty_score":0.03692621},"labels":[],"label_agreement":null},{"id":"W3210334482","doi":"10.1007/s12325-021-01957-7","title":"Economic Evaluation of Budesonide Orodispersible Tablets for the Treatment of Eosinophilic Esophagitis: A Cost–Utility Analysis","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Eosinophilic Esophagitis","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; London Health Sciences Centre; Western University; University of British Columbia; University of Calgary; McGill University; BC Children's Hospital; HEC Montréal","funders":"","keywords":"Medicine; Eosinophilic esophagitis; Budesonide; Internal medicine; Dermatology; Rheumatology; Gastroenterology; Asthma; Physical therapy; Intensive care medicine; Disease","score_opus":0.046110964182576264,"score_gpt":0.37735550063562195,"score_spread":0.3312445364530457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210334482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.851001,0.10556532,0.016561976,0.004597171,0.00058883114,0.0039899605,0.0049843346,0.00012486697,0.012586667],"genre_scores_gemma":[0.9893847,0.006186821,0.0023848147,0.00026027858,0.000060733193,0.00035512986,0.00060664077,0.000011193434,0.00074976677],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9917368,0.0069862185,0.0002433297,0.00018210689,0.0005676333,0.0002839711],"domain_scores_gemma":[0.9900131,0.008498652,0.0006671371,0.0001425276,0.00031421884,0.0003643765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006481943,0.0015958073,0.0030782905,0.0020640995,0.0002951999,0.0023238622,0.0010139269,0.0015317635,0.0053547304],"category_scores_gemma":[0.02131646,0.0007403493,0.006047015,0.0016084716,0.00069311186,0.001269596,0.00084550766,0.0021535791,0.00019083772],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34722215,0.0044150464,0.029520987,0.0140985055,0.042586442,0.0016540334,0.0002665064,0.29401633,0.003056939,0.013859491,0.006136844,0.24316679],"study_design_scores_gemma":[0.09361757,0.061369076,0.06887464,0.005406643,0.09233416,0.0026377921,0.0014509441,0.6417748,0.00284708,0.012321497,0.016831718,0.00053412234],"about_ca_topic_score_codex":0.008419659,"about_ca_topic_score_gemma":0.005025881,"teacher_disagreement_score":0.008419659,"about_ca_system_score_codex":0.006260195,"about_ca_system_score_gemma":0.0027330115,"threshold_uncertainty_score":0.045421124},"labels":[],"label_agreement":null},{"id":"W3213116899","doi":"10.1007/s12325-021-01944-y","title":"A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar","year":2021,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nexus Clinical Research (Canada); Memorial University of Newfoundland","funders":"Amgen","keywords":"Infliximab; Medicine; Biosimilar; Rheumatoid arthritis; Pharmacology; Internal medicine; Monoclonal antibody; Tumor necrosis factor alpha; Immunology; Antibody","score_opus":0.29922630501509223,"score_gpt":0.4893622988553286,"score_spread":0.19013599384023638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213116899","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001380268,0.9984237,0.00008895029,0.00062781444,0.00020149176,0.00001735167,0.00006697954,0.0000039756887,0.00043170576],"genre_scores_gemma":[0.0017877163,0.9966229,0.00035073524,0.00084972335,0.0001495426,0.000029164301,0.00009272693,0.0000026328344,0.000114990195],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99554473,0.0009999191,0.001807909,0.00040228583,0.0011146573,0.00013056518],"domain_scores_gemma":[0.97424906,0.016935278,0.004268216,0.00035634162,0.0037567664,0.0004343488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075033507,0.0011271584,0.0033153284,0.00899177,0.0005699079,0.0030475352,0.001785337,0.0026175876,0.004024966],"category_scores_gemma":[0.021896081,0.00088400306,0.0028330295,0.008732906,0.0010409539,0.0025877405,0.0010885736,0.0025755432,0.0009543302],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043122363,0.000054123495,0.0007128013,0.378872,0.0021458173,0.00038468186,0.00023458517,0.00027575486,0.00094244326,0.0032870588,0.025702091,0.5869574],"study_design_scores_gemma":[0.00013167672,0.00039786252,0.0040218383,0.4405691,0.009263439,0.0016596834,0.00034311932,0.000117805845,0.000604542,0.002442002,0.5403884,0.00006057212],"about_ca_topic_score_codex":0.0029271813,"about_ca_topic_score_gemma":0.00627577,"teacher_disagreement_score":0.00899177,"about_ca_system_score_codex":0.0028592546,"about_ca_system_score_gemma":0.008194039,"threshold_uncertainty_score":0.03968197},"labels":[],"label_agreement":null},{"id":"W3213710096","doi":"10.1007/s12325-021-01958-6","title":"Concomitant Treatment of Hypertensive Patients with Bisoprolol and Perindopril in Routine Clinical Practice: A Post Hoc Analysis of the CONFIDENCE II, PROTECT I, and PROTECT III Observational Studies","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Trillium Health Centre","funders":"Servier","keywords":"Medicine; Perindopril; Bisoprolol; Concomitant; Observational study; Post-hoc analysis; Internal medicine; Rheumatology; Confidence interval; Intensive care medicine; Cardiology; Blood pressure","score_opus":0.07411408436144089,"score_gpt":0.3839858495488002,"score_spread":0.3098717651873593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213710096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969535,0.0010530333,0.00070650765,0.000041126284,0.000039273677,0.00020381765,0.000748046,0.000012481737,0.00024217337],"genre_scores_gemma":[0.99828917,0.000098715456,0.00058204524,0.000039395516,0.000030989202,0.00019499412,0.00063779386,0.000007920153,0.000118986616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97898877,0.014050244,0.0020367936,0.0018233757,0.0020685713,0.001032151],"domain_scores_gemma":[0.9521956,0.033444636,0.0066191377,0.0043084123,0.0022968317,0.0011353211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01768461,0.00096000254,0.0019318848,0.0009935077,0.00040102546,0.0011781063,0.0009538306,0.0005715698,0.001339519],"category_scores_gemma":[0.018617602,0.00038427082,0.007013698,0.0008955269,0.0004396409,0.0005631523,0.0008245261,0.00086264394,0.00010604483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10119407,0.0006026615,0.82270455,0.0007807954,0.06199343,0.00030894563,0.00034728803,0.00077636784,0.0029791906,0.00014199394,0.0007908058,0.007379938],"study_design_scores_gemma":[0.005166831,0.017641291,0.93640196,0.00010927514,0.033208076,0.0003145349,0.00044008959,0.0035020374,0.001691107,0.00009935648,0.0013773493,0.00004807604],"about_ca_topic_score_codex":0.0026916307,"about_ca_topic_score_gemma":0.0033516244,"teacher_disagreement_score":0.01768461,"about_ca_system_score_codex":0.0005063209,"about_ca_system_score_gemma":0.0014000703,"threshold_uncertainty_score":0.093526244},"labels":[],"label_agreement":null},{"id":"W3214276446","doi":"10.1007/s12325-021-01936-y","title":"Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review","year":2021,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Bone health and treatments","field":"Medicine","cited_by":212,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Amgen","keywords":"Denosumab; Medicine; Osteoporosis; Discontinuation; Osteonecrosis of the jaw; Bone remodeling; Internal medicine; Bone mineral; Oncology; Bisphosphonate","score_opus":0.05126907684742239,"score_gpt":0.4286028167517308,"score_spread":0.3773337399043084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214276446","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000053013988,0.99798006,0.00002968576,0.0011627938,0.00052487955,0.0000034013199,0.0000128840575,0.0000017703293,0.00023145469],"genre_scores_gemma":[0.0006520934,0.9958722,0.00010379604,0.001956758,0.0011151003,0.000008202855,0.000032375105,0.000001825935,0.00025767673],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992912,0.00020188023,0.00015224513,0.00011561241,0.00019007498,0.000048951977],"domain_scores_gemma":[0.9972366,0.0017027984,0.00029335465,0.000055224307,0.0005634243,0.00014852658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017769219,0.0008748073,0.0018707188,0.0027465431,0.00040167646,0.002272269,0.00093724945,0.0021050682,0.0037156933],"category_scores_gemma":[0.004095183,0.00033594694,0.0013082486,0.0035777893,0.0008440724,0.0037393724,0.0011011059,0.003185232,0.0009550597],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002930728,0.00007217044,0.00041177968,0.08735118,0.00042109116,0.00051897246,0.0003921774,0.0003583177,0.00078472146,0.011393656,0.113420844,0.784582],"study_design_scores_gemma":[0.000044096614,0.00012894657,0.0009504276,0.04936355,0.0005393016,0.0017704432,0.0002528449,0.00010218838,0.00011649975,0.0028465255,0.9438489,0.00003637178],"about_ca_topic_score_codex":0.0023813818,"about_ca_topic_score_gemma":0.004509281,"teacher_disagreement_score":0.0037156933,"about_ca_system_score_codex":0.0012444035,"about_ca_system_score_gemma":0.0030329821,"threshold_uncertainty_score":0.012430251},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W3214657680","doi":"10.1007/s12325-021-01951-z","title":"The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review","year":2021,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; HEC Montréal; ABB (Canada); Université de Montréal","funders":"AbbVie Canada; AbbVie","keywords":"Biosimilar; Medicine; Systematic review; MEDLINE; Health care; Actuarial science; Business; Internal medicine","score_opus":0.020731650380400847,"score_gpt":0.41975871676771204,"score_spread":0.39902706638731117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214657680","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002633038,0.9946426,0.00018120895,0.00057933846,0.0001380757,0.000386366,0.00088653836,0.0000065159516,0.00054621114],"genre_scores_gemma":[0.029461347,0.9677635,0.00073448266,0.00066858565,0.00012583853,0.0006888872,0.00041615934,0.000007645084,0.0001334925],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.983761,0.005993168,0.005712773,0.0009693092,0.0030464681,0.00051734096],"domain_scores_gemma":[0.91549844,0.0652603,0.013112681,0.0007349889,0.004864531,0.00052907976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015797071,0.0017281865,0.0077029956,0.018481398,0.0006868656,0.0045005777,0.0020850543,0.002515691,0.0063304035],"category_scores_gemma":[0.07518466,0.0011856497,0.009686006,0.018640624,0.0010065368,0.0033533147,0.0017736086,0.0015828573,0.00035999014],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002741283,0.000024486626,0.0015753076,0.9588019,0.013493544,0.00018569351,0.0001347777,0.00017073117,0.000070494956,0.0004136637,0.001124571,0.023730656],"study_design_scores_gemma":[0.00023642836,0.0002157578,0.0056075156,0.9108671,0.07018084,0.0005424678,0.00039757474,0.00017262416,0.00013473247,0.00044531297,0.01116108,0.000038510643],"about_ca_topic_score_codex":0.009957527,"about_ca_topic_score_gemma":0.021583887,"teacher_disagreement_score":0.018481398,"about_ca_system_score_codex":0.007821301,"about_ca_system_score_gemma":0.017433433,"threshold_uncertainty_score":0.08354384},"labels":[],"label_agreement":null},{"id":"W3214922391","doi":"10.1007/s12325-021-01953-x","title":"A Qualitative Study to Characterize the Humanistic Burden of Kabuki Syndrome in the United States and Canada","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Kabuki syndrome; Medicine; Psychosocial; Quality of life (healthcare); Presentation (obstetrics); Gerontology; Psychiatry; Developmental psychology; Pediatrics; Psychology; Nursing","score_opus":0.013931039726425835,"score_gpt":0.3117162852945852,"score_spread":0.2977852455681594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214922391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864581,0.00083648885,0.00041015723,0.0033304929,0.00007964192,0.0003355275,0.00039320454,0.000010023426,0.008146251],"genre_scores_gemma":[0.99472034,0.00092443964,0.00035975702,0.0014768834,0.000010184213,0.00019721244,0.000116202544,0.000013569236,0.002181429],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9955835,0.001960732,0.00015298263,0.00035130495,0.0006051608,0.0013464051],"domain_scores_gemma":[0.9916677,0.0021500047,0.00060272537,0.00016033385,0.0024271053,0.0029921087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049057943,0.00050780113,0.0008134553,0.002260657,0.024900604,0.0045596487,0.0018687305,0.0013341086,0.003689651],"category_scores_gemma":[0.0072221374,0.0004336805,0.00043158318,0.002812605,0.008854571,0.0018154779,0.0051467526,0.0026136031,0.00023029318],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003114091,0.000055293865,0.020605696,0.0001318259,0.0000072812327,0.0010610218,0.9716593,0.000033972356,0.00036748222,0.0010860838,0.0017927341,0.0031682258],"study_design_scores_gemma":[0.0000021973497,0.000013494382,0.0061314036,0.00010417835,0.0000019377585,0.00009015352,0.9891236,0.000041985655,0.000033515764,0.000056328943,0.004390209,0.000011030959],"about_ca_topic_score_codex":0.93828964,"about_ca_topic_score_gemma":0.96373516,"teacher_disagreement_score":0.061710358,"about_ca_system_score_codex":0.060281005,"about_ca_system_score_gemma":0.080101326,"threshold_uncertainty_score":0.43737137},"labels":[],"label_agreement":null},{"id":"W4212819218","doi":"10.1007/s12325-015-0202-8","title":"Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users","year":2015,"lang":"en","type":"erratum","venue":"Advances in Therapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Rivaroxaban; Medicine; Warfarin; Atrial fibrillation; Internal medicine; Cardiology","score_opus":0.04481134226210652,"score_gpt":0.35536020803725427,"score_spread":0.31054886577514773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212819218","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021604054,0.011451304,0.000967604,0.18407622,0.71786433,0.0001800533,0.05148683,0.0003235132,0.012045995],"genre_scores_gemma":[0.22300015,0.024608478,0.0093052145,0.30550697,0.17326647,0.00075391267,0.05898123,0.0009980311,0.20357955],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972344,0.00043184112,0.0010675397,0.00021793066,0.0008962201,0.00015201511],"domain_scores_gemma":[0.9783489,0.010330634,0.0030071025,0.0009154577,0.006805599,0.0005922912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027706574,0.0010277741,0.0012279868,0.0021440417,0.0010813526,0.0013120183,0.00114477,0.0025025287,0.015592531],"category_scores_gemma":[0.050270896,0.00059452077,0.0020380993,0.0027789895,0.0004261524,0.0011193217,0.00042823522,0.0033400103,0.0051732743],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050535036,0.00007132814,0.011609948,0.00032699518,0.00016754004,0.00037968045,0.00006768603,0.00011634337,0.000043119733,0.00044832192,0.9760334,0.010230204],"study_design_scores_gemma":[0.0017637495,0.0006298067,0.2410523,0.0026668194,0.0019212519,0.0037237122,0.0013767885,0.0016827183,0.001111278,0.0030360566,0.7407465,0.0002890333],"about_ca_topic_score_codex":0.022345688,"about_ca_topic_score_gemma":0.029192226,"teacher_disagreement_score":0.022345688,"about_ca_system_score_codex":0.0015149941,"about_ca_system_score_gemma":0.0028242306,"threshold_uncertainty_score":0.05216229},"labels":[],"label_agreement":null},{"id":"W4213360317","doi":"10.1007/s12325-021-02031-y","title":"A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Université de Montréal","funders":"Amryt Pharma","keywords":"Medicine; Familial hypercholesterolemia; Internal medicine; PCSK9; Intima-media thickness; Cardiology; Triglyceride; Lipoprotein; LDL receptor; Cholesterol; Gastroenterology","score_opus":0.007816532930660992,"score_gpt":0.2772037853522879,"score_spread":0.2693872524216269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213360317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99672323,0.000842999,0.00046610224,0.0001721825,0.00003556916,0.000050815474,0.00006302064,0.000017418726,0.0016287102],"genre_scores_gemma":[0.99894816,0.00028357466,0.00028995468,0.00009012151,0.00008826427,0.00001077079,0.000043327833,0.000005255385,0.00024053382],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9994349,0.00009519189,0.00008895753,0.0001387808,0.00010337093,0.00013872971],"domain_scores_gemma":[0.998448,0.0004048209,0.00044041654,0.00015830291,0.00009815388,0.00045028963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039931835,0.0011163162,0.00087169535,0.0016328869,0.0014401198,0.00090541755,0.0006563184,0.0024995855,0.0015564102],"category_scores_gemma":[0.0027835947,0.00069461553,0.00084405503,0.00096745824,0.0010739696,0.0006988508,0.00073437655,0.0011316335,0.00049497583],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000121323654,0.000092725095,0.093228035,0.000037734942,0.00003642359,0.90248716,0.00064317713,0.000067967936,0.0010121858,0.00005384824,0.00013227206,0.0020871935],"study_design_scores_gemma":[0.000022365619,0.00031946882,0.051465753,0.000013586251,0.00004199729,0.94676405,0.00041680422,0.00014800184,0.00038126283,0.000051387746,0.00035346436,0.000021865944],"about_ca_topic_score_codex":0.0018861269,"about_ca_topic_score_gemma":0.0023566047,"teacher_disagreement_score":0.0024995855,"about_ca_system_score_codex":0.00057529646,"about_ca_system_score_gemma":0.00051890605,"threshold_uncertainty_score":0.0052066445},"labels":[],"label_agreement":null},{"id":"W4214530973","doi":"10.1007/s12325-022-02061-0","title":"Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Ticagrelor; Medicine; Clopidogrel; Cardiology; Internal medicine; Myocardial infarction; Acute coronary syndrome; Anesthesia","score_opus":0.002332707193131385,"score_gpt":0.21613047412250017,"score_spread":0.21379776692936878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214530973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962878,0.0026825103,0.000043681976,0.0001477879,0.000024521974,0.000019363933,0.000050556035,0.0000036099823,0.0007402425],"genre_scores_gemma":[0.99905795,0.00048463742,0.000087894696,0.0000923595,0.00008576148,0.000027995693,0.00006880104,7.206333e-7,0.00009381341],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99947864,0.00026846482,0.00003387555,0.000059100406,0.00008798909,0.00007203052],"domain_scores_gemma":[0.99926215,0.00029137437,0.00016779907,0.000029628578,0.000054298576,0.00019465291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065555295,0.00024828833,0.0006930643,0.00021153332,0.00017799751,0.0003578153,0.00012404,0.00033062458,0.0008586387],"category_scores_gemma":[0.0020056046,0.00009081937,0.0003790057,0.00024952783,0.00020109159,0.00018982073,0.00019649998,0.00052921637,0.00011805579],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10215408,0.003688819,0.7573244,0.00039544952,0.0020596331,0.0007986445,0.00032767974,0.00067002524,0.011189032,0.00016229649,0.0012695392,0.1199604],"study_design_scores_gemma":[0.0008630362,0.01323191,0.9830403,0.000024395145,0.00044940738,0.0003214056,0.000084238294,0.0005074501,0.00080804585,0.000067525085,0.0005885373,0.000013780078],"about_ca_topic_score_codex":0.0004400262,"about_ca_topic_score_gemma":0.00074384,"teacher_disagreement_score":0.0008586387,"about_ca_system_score_codex":0.0002941865,"about_ca_system_score_gemma":0.0002817981,"threshold_uncertainty_score":0.0034669042},"labels":[],"label_agreement":null},{"id":"W4214695698","doi":"10.1007/s12325-022-02068-7","title":"Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"Janssen Pharmaceuticals; EMD Serono; Genentech; H. Lundbeck A/S; Biogen; Celgene; Alexion Pharmaceuticals; Bundesministerium für Bildung und Forschung; Teva Pharmaceutical Industries; Sanofi; Deutsche Forschungsgemeinschaft; Bristol-Myers Squibb; TG Therapeutics; Amgen","keywords":"Medicine; Glatiramer acetate; Tolerability; Discontinuation; Dimethyl fumarate; Adverse effect; Multiple sclerosis; Internal medicine; Natalizumab; Immunology","score_opus":0.034226654165303114,"score_gpt":0.3606155336236517,"score_spread":0.32638887945834855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214695698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941227,0.0024767045,0.00018740272,0.00012598444,0.000023634424,0.00041899187,0.0013342985,0.000032308086,0.0012781194],"genre_scores_gemma":[0.99463934,0.0007534207,0.00043389146,0.00036305652,0.0000594849,0.00030064242,0.0028159856,0.000010724976,0.00062347366],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99893206,0.0004890427,0.00009795528,0.00017868957,0.0001676352,0.00013453806],"domain_scores_gemma":[0.997919,0.00044660302,0.00073358795,0.00017727265,0.00020574502,0.0005176224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004168851,0.0006934151,0.0016055807,0.00027223403,0.0004913002,0.0010240927,0.00048001256,0.00097476103,0.0016003014],"category_scores_gemma":[0.002357928,0.00021261553,0.0019120668,0.00038312539,0.00045831397,0.0006707467,0.00036177368,0.0016859343,0.00034092058],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7302285,0.021196263,0.10031505,0.0009337042,0.005448532,0.0003277363,0.00038961353,0.0016705213,0.014586463,0.00016175352,0.003479317,0.121262535],"study_design_scores_gemma":[0.25911593,0.39932668,0.31977025,0.0001404776,0.0060882666,0.0010938733,0.00018852719,0.001662469,0.008054007,0.00030493256,0.0041545224,0.00009989495],"about_ca_topic_score_codex":0.0009704941,"about_ca_topic_score_gemma":0.0020991885,"teacher_disagreement_score":0.004168851,"about_ca_system_score_codex":0.0006048988,"about_ca_system_score_gemma":0.0008059503,"threshold_uncertainty_score":0.022047281},"labels":[],"label_agreement":null},{"id":"W4220654595","doi":"10.1007/s12325-022-02090-9","title":"Opioid-Induced Constipation: Cost Impact of Approved Medications in the Emergency Department","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Bausch Health","keywords":"Medicine; Cohort; Emergency department; Emergency medicine; Opioid; Constipation; Odds ratio; Health care; Medical prescription; Internal medicine; Retrospective cohort study; Pharmacology; Psychiatry","score_opus":0.02967051343816279,"score_gpt":0.3641262994304634,"score_spread":0.3344557859923006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220654595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99535626,0.0018864956,0.00008923437,0.0006237788,0.00001750479,0.000020584732,0.00088574534,0.0000028047966,0.0011174484],"genre_scores_gemma":[0.99841166,0.0006899085,0.0001507857,0.000094391755,0.000030262552,0.000008692463,0.0005159947,0.0000012197297,0.000097106604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991891,0.00027566557,0.000119399454,0.00008365032,0.00021607481,0.000116227835],"domain_scores_gemma":[0.9977883,0.00037666902,0.0014348534,0.000041670188,0.00016544611,0.00019301589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006448268,0.00015378777,0.00025396334,0.00063464814,0.00024064128,0.0007225757,0.00020476876,0.00022226395,0.001938633],"category_scores_gemma":[0.0045571863,0.000091592374,0.0006120691,0.0009227071,0.0001708886,0.0004422191,0.00068806065,0.0003729099,0.00009062109],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043951673,0.000066022076,0.98304075,0.00012497844,0.00017491331,0.00017685434,0.000043726704,0.00046284587,0.00014390516,0.00011826675,0.00046084842,0.014747367],"study_design_scores_gemma":[0.00002272929,0.00019771434,0.997324,0.00008680167,0.00007356028,0.00043894636,0.00023959922,0.00088900595,0.00006812842,0.00006877509,0.00058619917,0.000004534223],"about_ca_topic_score_codex":0.007962692,"about_ca_topic_score_gemma":0.01550597,"teacher_disagreement_score":0.007962692,"about_ca_system_score_codex":0.0013503374,"about_ca_system_score_gemma":0.0009161064,"threshold_uncertainty_score":0.015832722},"labels":[],"label_agreement":null},{"id":"W4220690582","doi":"10.1007/s12325-021-02030-z","title":"Beyond Response: Aiming for Quality Remission in Depression","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Treatment of Major Depression","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Servier","keywords":"Escitalopram; Agomelatine; Medicine; Mood; Depression (economics); Discontinuation; Antidepressant; Internal medicine; Quality of life (healthcare); Psychiatry; Anxiety","score_opus":0.032057109669494134,"score_gpt":0.40205237874683236,"score_spread":0.3699952690773382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220690582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40003288,0.103137806,0.10722017,0.2996709,0.006891139,0.004726642,0.0013650396,0.0020665808,0.07488887],"genre_scores_gemma":[0.8757267,0.013949772,0.0614241,0.034034565,0.0024297219,0.0028117492,0.00080430455,0.00028387966,0.00853529],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99317074,0.0036903403,0.00083584624,0.0006035842,0.0011196033,0.00057994504],"domain_scores_gemma":[0.9900855,0.0047753844,0.0017997328,0.00078639534,0.0009772714,0.001575771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014712285,0.00036448287,0.0012576334,0.00085334445,0.00094408955,0.0018522032,0.0009575457,0.0017154497,0.0048967223],"category_scores_gemma":[0.02604345,0.00023625314,0.0014241474,0.0007200598,0.0009227018,0.0029597625,0.0021691548,0.0042742756,0.0011638857],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002474347,0.0012401296,0.016440881,0.002234055,0.0005341353,0.00023132838,0.0016073426,0.0013344262,0.0022212805,0.012408849,0.030456282,0.9288169],"study_design_scores_gemma":[0.015790941,0.028518911,0.2581875,0.01846365,0.0036178846,0.0077197603,0.0071943915,0.022850486,0.013193496,0.23074867,0.39314997,0.00056427915],"about_ca_topic_score_codex":0.0011280483,"about_ca_topic_score_gemma":0.002116092,"teacher_disagreement_score":0.014712285,"about_ca_system_score_codex":0.0021603473,"about_ca_system_score_gemma":0.0019943747,"threshold_uncertainty_score":0.07780695},"labels":[],"label_agreement":null},{"id":"W4221019027","doi":"10.1007/s12325-022-02104-6","title":"Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Infliximab; Medicine; Biosimilar; Inflammatory bowel disease; Internal medicine; Ulcerative colitis; Observational study; Adverse effect; Disease","score_opus":0.03858910153886844,"score_gpt":0.35364014621390394,"score_spread":0.31505104467503553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221019027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99859947,0.00027124272,0.000028702256,0.000026560085,0.0000031399568,0.00002651046,0.00084349234,0.0000014272347,0.00019945575],"genre_scores_gemma":[0.9981762,0.00015493306,0.00006334074,0.000036171747,0.000005695265,0.000022046199,0.0014474766,0.0000010997426,0.0000929785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980862,0.0005128484,0.00019923749,0.0003433695,0.00054184353,0.00031650576],"domain_scores_gemma":[0.9949344,0.0005766021,0.002355937,0.00029775116,0.0010458526,0.0007894614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020410323,0.00033067437,0.0005556459,0.0006960124,0.00081818155,0.0011038213,0.00070980296,0.0005580396,0.00081294123],"category_scores_gemma":[0.0036772892,0.00024233216,0.00086696557,0.0016068814,0.00058450864,0.0004372527,0.0007225451,0.00064962206,0.00016893957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045501415,0.000071516115,0.99837613,0.000012874895,0.00014496391,0.000022901366,0.00009879629,0.00003337867,0.000055203007,0.000006447226,0.00007695496,0.00064575055],"study_design_scores_gemma":[0.00003837153,0.00015610358,0.99935275,0.000006702745,0.000055588247,0.000035810568,0.00013779772,0.00007904285,0.00002377601,0.0000034445009,0.000106424566,0.0000042552374],"about_ca_topic_score_codex":0.27853787,"about_ca_topic_score_gemma":0.30906427,"teacher_disagreement_score":0.27853787,"about_ca_system_score_codex":0.0029244325,"about_ca_system_score_gemma":0.0029209158,"threshold_uncertainty_score":0.5538332},"labels":[],"label_agreement":null},{"id":"W4221029922","doi":"10.1007/s12325-022-02105-5","title":"The Economic Burden of Insulin Injection-Induced Lipohypertophy. Role of Education: The ISTERP-3 Study","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Diabetes Management and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Advanced Micro Devices (Canada)","funders":"","keywords":"Medicine; Insulin; Hypoglycemia; Diabetes mellitus; Insulin pen; Psychological intervention; Rehabilitation; Internal medicine; Type 2 diabetes; Physical therapy; Endocrinology; Nursing","score_opus":0.014228393782122786,"score_gpt":0.32699597709322403,"score_spread":0.31276758331110127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221029922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99347794,0.0030168933,0.00008107655,0.0004738171,0.000031944015,0.000058897094,0.0018571285,0.0000031110064,0.0009991388],"genre_scores_gemma":[0.9963213,0.001479666,0.00006771809,0.00015470342,0.000058790796,0.000077777746,0.0014415641,0.000004033569,0.00039434907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871933,0.0007266623,0.0000841078,0.00012263759,0.00015679366,0.00019049922],"domain_scores_gemma":[0.9968432,0.00076879206,0.0015089192,0.00018781828,0.00012137914,0.0005698817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002787925,0.00091721653,0.00070571055,0.000820358,0.00037308005,0.0014979072,0.0008851384,0.0013501432,0.002449642],"category_scores_gemma":[0.0033486185,0.0004345321,0.0024275836,0.0021105402,0.0005438987,0.00092939957,0.0012707562,0.0015180288,0.00033417472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02452944,0.0013411721,0.9606436,0.00041706805,0.002384226,0.00058566104,0.00016324787,0.00034944777,0.00011248091,0.00031881614,0.0011866775,0.007968184],"study_design_scores_gemma":[0.0019093992,0.002364225,0.991434,0.00016795038,0.0014908385,0.00029658875,0.00049476547,0.00086552487,0.000050456714,0.00017486808,0.00073239126,0.000018964116],"about_ca_topic_score_codex":0.0072643934,"about_ca_topic_score_gemma":0.0047752787,"teacher_disagreement_score":0.0072643934,"about_ca_system_score_codex":0.0008777343,"about_ca_system_score_gemma":0.0011592739,"threshold_uncertainty_score":0.014744103},"labels":[],"label_agreement":null},{"id":"W4221036987","doi":"10.1007/s12325-022-02097-2","title":"P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease","year":2022,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Atuka (Canada); Toronto Western Hospital","funders":"Parkinsonfonden; Ipsen; H. Lundbeck A/S; Sage Therapeutics; Acorda Therapeutics; Sunovion; European Commission; Sanofi; University of South Florida; Israel Science Foundation; University of Cambridge; Boston Scientific Corporation; International Parkinson and Movement Disorder Society; Biogen; University of Oxford; Adamas Pharmaceuticals; Jazz Pharmaceuticals; National Parkinson Foundation; Teva Pharmaceutical Industries; AstraZeneca","keywords":"Rasagiline; Pramipexole; Tolerability; Levodopa; Medicine; Parkinson's disease; Selegiline; Pharmacology; Dopamine; Internal medicine; Adverse effect; Disease","score_opus":0.061359160184941836,"score_gpt":0.3735306502470583,"score_spread":0.3121714900621164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221036987","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017084118,0.96134436,0.0045895367,0.0031181627,0.00076198677,0.0001041815,0.00026775585,0.00023505843,0.012494909],"genre_scores_gemma":[0.05867412,0.9224629,0.005839105,0.0026980261,0.0007693632,0.000107569984,0.00053414376,0.000029954032,0.008884907],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998833,0.000016585316,0.00001092655,0.000021196623,0.000052781517,0.000015159079],"domain_scores_gemma":[0.9998944,0.000026642683,0.000032398468,0.0000018419215,0.000018413692,0.000026351228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003638923,0.00046980445,0.0004361687,0.00058176334,0.00015482845,0.0006251512,0.00041415956,0.0007181557,0.0023224994],"category_scores_gemma":[0.00029584003,0.00015760298,0.00041612206,0.0002563166,0.00023979979,0.0007277279,0.00033849117,0.0017945307,0.00126161],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042581995,0.00021435968,0.0004093825,0.003987535,0.00008083268,0.001099758,0.00012309347,0.00056157366,0.034449257,0.0037456437,0.020175256,0.9347275],"study_design_scores_gemma":[0.0004740952,0.005103921,0.0036967197,0.001347712,0.0002342791,0.009981819,0.00008702927,0.0010138657,0.014396943,0.002375961,0.9612157,0.000071881324],"about_ca_topic_score_codex":0.00030506146,"about_ca_topic_score_gemma":0.0010037262,"teacher_disagreement_score":0.0023224994,"about_ca_system_score_codex":0.00023359554,"about_ca_system_score_gemma":0.00036866064,"threshold_uncertainty_score":0.007769525},"labels":[],"label_agreement":null},{"id":"W4224992031","doi":"10.1007/s12325-022-02137-x","title":"Quality Standard Position Statements for Health System Policy Changes in Diagnosis and Management of COPD: A Global Perspective","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"AstraZeneca","keywords":"Medicine; COPD; Health care; Multidisciplinary approach; Position paper; Quality (philosophy); Evidence-based practice; Nursing; Intensive care medicine; Alternative medicine; Pathology","score_opus":0.03626643249394235,"score_gpt":0.4619851468467,"score_spread":0.42571871435275765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224992031","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010062259,0.008659117,0.016277216,0.9548601,0.011963436,0.0005533886,0.00021987586,0.000128842,0.006331926],"genre_scores_gemma":[0.07924881,0.02581167,0.2755016,0.5905208,0.0145067405,0.0041217715,0.0019568873,0.00035112153,0.0079805115],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.6103599,0.18575966,0.07059928,0.012035591,0.10506666,0.016178869],"domain_scores_gemma":[0.30246884,0.29770517,0.06564461,0.024742309,0.27129892,0.03814021],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.48611823,0.0038790647,0.0037169112,0.009650741,0.008525809,0.032319166,0.014515839,0.050486643,0.0046524927],"category_scores_gemma":[0.5100239,0.0026284496,0.008105828,0.008122065,0.022882212,0.021651262,0.021088803,0.054426074,0.002277101],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022374434,0.00065087056,0.004616343,0.009764039,0.0005380806,0.00049503415,0.008460382,0.007201716,0.0014084892,0.3682686,0.46746767,0.13090514],"study_design_scores_gemma":[0.00046304544,0.00080972834,0.0061640586,0.03095116,0.00048584997,0.00043809376,0.007244382,0.0061400766,0.0018984835,0.2769588,0.6677808,0.0006655078],"about_ca_topic_score_codex":0.024452066,"about_ca_topic_score_gemma":0.01266734,"teacher_disagreement_score":0.48611823,"about_ca_system_score_codex":0.041169856,"about_ca_system_score_gemma":0.20811695,"threshold_uncertainty_score":0.6337077},"labels":[],"label_agreement":null},{"id":"W4225103600","doi":"10.1007/s12325-022-02084-7","title":"Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Tofacitinib; Medicine; Psoriatic arthritis; Rheumatology; Health care; Database; Dermatology; Arthritis; Internal medicine; Family medicine; Rheumatoid arthritis","score_opus":0.06083006821720849,"score_gpt":0.38085236416649143,"score_spread":0.32002229594928294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225103600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98495156,0.0007257532,0.00018698811,0.00017465849,0.000008793162,0.000038098875,0.013140083,0.000010347833,0.00076367543],"genre_scores_gemma":[0.9856529,0.00035884226,0.00035318878,0.00012673304,0.00003837775,0.000047900277,0.013317765,0.000004771997,0.00009940504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996621,0.0009761684,0.00082924,0.0004980332,0.00083853723,0.00023694395],"domain_scores_gemma":[0.9829213,0.00319144,0.0111174,0.0010247598,0.0010300159,0.0007149822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023734912,0.00027209855,0.0006172739,0.0017116641,0.0004109555,0.0012911666,0.00052691734,0.00058259896,0.0008844252],"category_scores_gemma":[0.01002698,0.00027891638,0.00058909564,0.0034698315,0.00024448722,0.0008941167,0.0008188449,0.0007538541,0.0003134891],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000153076,0.000056963137,0.9971711,0.00003722227,0.00011573696,0.00008412964,0.00010369095,0.00006890667,0.000061272134,0.000034093617,0.00056825863,0.0015456545],"study_design_scores_gemma":[0.000025735186,0.00007978911,0.9968953,0.000040003535,0.00007394263,0.0006358398,0.00027259512,0.0007245457,0.00008484019,0.000040487826,0.0011141003,0.000012756728],"about_ca_topic_score_codex":0.008609811,"about_ca_topic_score_gemma":0.012976877,"teacher_disagreement_score":0.008609811,"about_ca_system_score_codex":0.0006569815,"about_ca_system_score_gemma":0.0007772919,"threshold_uncertainty_score":0.017119348},"labels":[],"label_agreement":null},{"id":"W4239984345","doi":"10.1007/s12325-014-0150-8","title":"Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis","year":2014,"lang":"en","type":"erratum","venue":"Advances in Therapy","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Exemestane; Medicine; Everolimus; Internal medicine; Oncology; Breast cancer; Postmenopausal women; Progression-free survival; Aromatase; Overall survival; Cancer","score_opus":0.007630919257924771,"score_gpt":0.2911378448630639,"score_spread":0.2835069256051391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239984345","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0331057,0.026993744,0.0038602047,0.14896171,0.7312309,0.00038026794,0.028457684,0.00068066904,0.02632906],"genre_scores_gemma":[0.23814732,0.031509466,0.015583535,0.19340502,0.10978027,0.00056904205,0.03256638,0.0014722376,0.37696674],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993292,0.000085597705,0.00016389001,0.00008012906,0.00026738687,0.00007373763],"domain_scores_gemma":[0.99755484,0.0009653526,0.0002527054,0.00013383095,0.00091308705,0.00018030989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001466728,0.0005940795,0.0010256085,0.0010793878,0.00052467384,0.0009077031,0.000641801,0.0012150082,0.01089174],"category_scores_gemma":[0.009133639,0.00029744615,0.0009983149,0.0007062649,0.0002932087,0.0005456876,0.00027512273,0.0021279643,0.003993807],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024262862,0.0001067205,0.010271279,0.0006237654,0.0002711808,0.001582501,0.00003890771,0.00047847469,0.0003613472,0.00079614966,0.92224514,0.060798224],"study_design_scores_gemma":[0.0012851397,0.00087344955,0.052346688,0.0012228134,0.0016426467,0.006187489,0.00029659466,0.0020865963,0.0025179216,0.0019252329,0.92950356,0.00011170178],"about_ca_topic_score_codex":0.004914072,"about_ca_topic_score_gemma":0.010264639,"teacher_disagreement_score":0.01089174,"about_ca_system_score_codex":0.0012159293,"about_ca_system_score_gemma":0.0014040485,"threshold_uncertainty_score":0.0364365},"labels":[],"label_agreement":null},{"id":"W4246924398","doi":"10.1007/s12325-016-0442-2","title":"Erratum to: nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial","year":2016,"lang":"en","type":"erratum","venue":"Advances in Therapy","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Québec; Hôpital du Sacré-Cœur de Montréal; Royal Victoria Regional Health Centre; BC Cancer Agency; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Gemcitabine; Medicine; Nab-paclitaxel; Internal medicine; Oncology; Subgroup analysis; Metastatic adenocarcinoma; Paclitaxel; Adenocarcinoma; Chemotherapy; Cancer; Meta-analysis","score_opus":0.028275468941952153,"score_gpt":0.3569516600612091,"score_spread":0.32867619111925694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246924398","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08117649,0.13688108,0.0016223344,0.2912868,0.2960439,0.0038470805,0.14190863,0.0004642136,0.046769433],"genre_scores_gemma":[0.44284523,0.052027624,0.0053890496,0.24396957,0.061431497,0.0025455414,0.04961419,0.0009995971,0.1411777],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978946,0.00048255044,0.00047441947,0.00023997122,0.00066549645,0.00024312176],"domain_scores_gemma":[0.993363,0.0033087125,0.0009783315,0.0003252263,0.0015530897,0.00047166375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042010327,0.0010588347,0.0027670735,0.0009772787,0.0008924383,0.0017314325,0.001201857,0.0020580862,0.015618074],"category_scores_gemma":[0.030184623,0.00056548044,0.0051904833,0.0018896024,0.0006340532,0.00083368894,0.00043519703,0.00418247,0.0015148362],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054644194,0.0001021466,0.009112814,0.0045802253,0.006660516,0.0004301029,0.00008857731,0.0006755504,0.0002996266,0.0010450693,0.8839362,0.03842491],"study_design_scores_gemma":[0.28483248,0.0038330099,0.10450409,0.009740141,0.08535005,0.0019142536,0.0007373443,0.003196616,0.0015962676,0.0059694196,0.49770537,0.0006209097],"about_ca_topic_score_codex":0.21703227,"about_ca_topic_score_gemma":0.47661126,"teacher_disagreement_score":0.78296775,"about_ca_system_score_codex":0.007968883,"about_ca_system_score_gemma":0.013437349,"threshold_uncertainty_score":0.431538},"labels":[],"label_agreement":null},{"id":"W4254619169","doi":"10.1007/s12325-015-0230-4","title":"Erratum to: Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study","year":2015,"lang":"en","type":"erratum","venue":"Advances in Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Tolerability; Relapsing remitting; Fingolimod; Multiple sclerosis; Internal medicine; Rheumatology; Adverse effect; Immunology","score_opus":0.0726722418288143,"score_gpt":0.35049807896330554,"score_spread":0.27782583713449127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254619169","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025052198,0.009870301,0.0007296827,0.11924247,0.8546626,0.00015513263,0.004544993,0.000214467,0.008075091],"genre_scores_gemma":[0.04927149,0.030516885,0.007739517,0.41524395,0.2596985,0.00065114215,0.01048746,0.0008580835,0.22553298],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99788326,0.0004375245,0.0006533507,0.00016111814,0.0007292816,0.00013542068],"domain_scores_gemma":[0.98913443,0.004472559,0.0012045193,0.00042035937,0.004331967,0.00043615105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00384075,0.0011101934,0.0016791063,0.0016466767,0.0014781852,0.0016983907,0.0010423621,0.0030561774,0.01704984],"category_scores_gemma":[0.026134234,0.00055729254,0.0013341588,0.0009910719,0.0006712292,0.0010618131,0.00056799577,0.0031481662,0.007828801],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053144,0.00005484499,0.0008156063,0.00035135707,0.000062101775,0.0004045345,0.000027442338,0.000045403875,0.00008152917,0.0003379904,0.98262537,0.014662361],"study_design_scores_gemma":[0.001597245,0.00040799333,0.009634784,0.0023080627,0.0006443469,0.0015408194,0.00025717219,0.00046873657,0.0010701609,0.0013888829,0.9805906,0.00009123839],"about_ca_topic_score_codex":0.0076540075,"about_ca_topic_score_gemma":0.011702728,"teacher_disagreement_score":0.01704984,"about_ca_system_score_codex":0.0019470766,"about_ca_system_score_gemma":0.0031960602,"threshold_uncertainty_score":0.057037413},"labels":[],"label_agreement":null},{"id":"W4280570876","doi":"10.1007/s12325-022-02158-6","title":"Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Barrie Urology Group; Simon Fraser University","funders":"AbbVie","keywords":"Medicine; Internal medicine; Gastroenterology; Regimen; Hepatitis C; Sofosbuvir; Cirrhosis; Clinical endpoint; Adverse effect; Incidence (geometry); Hepatitis C virus; Surgery; Randomized controlled trial; Ribavirin; Immunology; Virus","score_opus":0.023043689408431274,"score_gpt":0.3430762373618999,"score_spread":0.32003254795346864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280570876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997389,0.0015762475,0.00009795724,0.00008463365,0.000011579211,0.00013645721,0.00022025043,0.0000100876605,0.00047398268],"genre_scores_gemma":[0.9984005,0.00045524118,0.000358155,0.00012485814,0.00003125576,0.00012902271,0.00033624764,0.0000026964187,0.00016196721],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9974427,0.0018985642,0.00015964171,0.00016170308,0.00023638876,0.0001009123],"domain_scores_gemma":[0.9974005,0.00070758763,0.0010064687,0.00023613205,0.00021716587,0.0004321273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003950404,0.00061734184,0.001112867,0.000334929,0.00021680437,0.00049604423,0.0004141544,0.0006281132,0.00076962326],"category_scores_gemma":[0.0033227657,0.0002077341,0.001358273,0.00038077086,0.00044726217,0.00046409512,0.00033636784,0.0008164358,0.000116637944],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8352057,0.0037096855,0.05459986,0.00078596076,0.004014641,0.000154055,0.00027953493,0.00349047,0.008688641,0.00019228962,0.0008734163,0.0880057],"study_design_scores_gemma":[0.33431628,0.33535722,0.3139104,0.00014866475,0.004229491,0.00044260325,0.00017753705,0.0054247514,0.0027070793,0.000260574,0.0028600625,0.00016536337],"about_ca_topic_score_codex":0.001684285,"about_ca_topic_score_gemma":0.00469326,"teacher_disagreement_score":0.003950404,"about_ca_system_score_codex":0.00052154384,"about_ca_system_score_gemma":0.0009403913,"threshold_uncertainty_score":0.020891964},"labels":[],"label_agreement":null},{"id":"W4281298326","doi":"10.1007/s12325-022-02130-4","title":"Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Amgen (Canada); Université de Montréal; Montreal Heart Institute","funders":"Amgen Canada; Amgen","keywords":"Evolocumab; Medicine; Ezetimibe; Statin; Dyslipidemia; Internal medicine; Context (archaeology); Cohort; Quality-adjusted life year; Cardiology; Physical therapy; Cost effectiveness; Disease; Cholesterol; Apolipoprotein B","score_opus":0.010983426101665434,"score_gpt":0.255251527536024,"score_spread":0.24426810143435854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281298326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95462114,0.0070521235,0.0047730505,0.0037850267,0.00011347004,0.0012876204,0.014689165,0.00009467712,0.013583709],"genre_scores_gemma":[0.9927401,0.0014271296,0.0019634855,0.00025320202,0.0000164059,0.00012044628,0.0025330817,0.000009791414,0.0009363653],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99869365,0.00044895432,0.00005542453,0.0001192249,0.0002951334,0.00038754675],"domain_scores_gemma":[0.9970682,0.0012202763,0.00030093256,0.00007124025,0.00090504775,0.00043428867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022646291,0.0010188989,0.0009709796,0.001384821,0.0007674657,0.0016597006,0.0014488796,0.00066098996,0.00332356],"category_scores_gemma":[0.008135022,0.00043984503,0.0022566768,0.002015889,0.00065979006,0.00053827383,0.00083762454,0.0010975228,0.00013609666],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009137946,0.00090609095,0.12506768,0.0013890981,0.0031813486,0.0006273423,0.00016651445,0.7980825,0.0006756731,0.010098727,0.009237329,0.041429877],"study_design_scores_gemma":[0.004255402,0.0024865523,0.10678668,0.00069098803,0.0032216224,0.0003726442,0.0007681123,0.869589,0.0007775013,0.004584155,0.006293057,0.00017440532],"about_ca_topic_score_codex":0.9329913,"about_ca_topic_score_gemma":0.91553795,"teacher_disagreement_score":0.067008674,"about_ca_system_score_codex":0.05932438,"about_ca_system_score_gemma":0.050768916,"threshold_uncertainty_score":0.43043053},"labels":[],"label_agreement":null},{"id":"W4281729595","doi":"10.1007/s12325-022-02176-4","title":"Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review","year":2022,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Rheumatology; Narrative; Fibromyalgia; Internal medicine; Physical therapy","score_opus":0.024514767142040907,"score_gpt":0.34961538552925664,"score_spread":0.3251006183872157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281729595","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00060648605,0.9988825,0.00003538197,0.00009869588,0.0000479056,0.000037973652,0.0000854774,0.0000020595285,0.00020356588],"genre_scores_gemma":[0.005946737,0.9933169,0.00012978034,0.00030964555,0.00007927065,0.00007284815,0.00008394693,0.0000013153146,0.000059622507],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9986546,0.0003237054,0.00059266266,0.00016488126,0.00021745758,0.000046661586],"domain_scores_gemma":[0.994925,0.00370306,0.0009632448,0.000044192067,0.00031199446,0.000052421954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018151366,0.0008933559,0.0030973726,0.004186488,0.00041508384,0.0018730377,0.00092092366,0.0010539849,0.0031602234],"category_scores_gemma":[0.00649234,0.00041546524,0.0027112593,0.00434949,0.00049972936,0.0013523194,0.00074799056,0.0007214758,0.0002457052],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038823258,0.000048860387,0.00082350225,0.83645433,0.0030679232,0.00025673187,0.00033856064,0.000108073364,0.0003480851,0.00043873186,0.0040434804,0.15368342],"study_design_scores_gemma":[0.0004102611,0.0007302585,0.0099909175,0.8255953,0.03798166,0.003535318,0.0009666003,0.00015526333,0.0004936198,0.0006579266,0.11938516,0.00009771253],"about_ca_topic_score_codex":0.0018474463,"about_ca_topic_score_gemma":0.005000849,"teacher_disagreement_score":0.004186488,"about_ca_system_score_codex":0.0009620076,"about_ca_system_score_gemma":0.0026675456,"threshold_uncertainty_score":0.010571957},"labels":[],"label_agreement":null},{"id":"W4281761508","doi":"10.1007/s12325-022-02183-5","title":"Clinical Radiofrequency Ablation Outcomes of Combined Sensory Nerve Branch and Dorsal Entry Root Zone Complex Lesions for Sacroiliac Joint Complex Pain","year":2022,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Spine and Intervertebral Disc Pathology","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; McMaster University; Mount Sinai Hospital; Health Sciences Centre; The Scarborough Hospital; St. Michael's Hospital","funders":"","keywords":"Medicine; Pulsed radiofrequency; Interventional pain management; Sacroiliac joint; Radiofrequency ablation; Low back pain; Ablation; Chronic pain; Nerve root; Surgery; Radiology; Anesthesia; Physical therapy; Internal medicine; Pain relief; Pathology","score_opus":0.17937227242068968,"score_gpt":0.444489794070084,"score_spread":0.2651175216493943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281761508","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045961107,0.9990551,0.00006057038,0.00005846785,0.000045084904,0.0000045267293,0.000018008945,0.0000019648135,0.00029669725],"genre_scores_gemma":[0.0046138274,0.994638,0.0001854222,0.00015559798,0.00012009413,0.000009207862,0.00005496575,0.0000017484277,0.00022101965],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9998099,0.00003548247,0.000048072332,0.000037498085,0.000053558233,0.000015531952],"domain_scores_gemma":[0.999605,0.0002617917,0.0000599619,0.000007205739,0.000055214216,0.000010972665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068776397,0.0004763483,0.001537068,0.0008837003,0.00010274831,0.00062413083,0.0007086185,0.0005167193,0.002362063],"category_scores_gemma":[0.0010739567,0.00014084078,0.00095208787,0.00089555414,0.00022291971,0.00042083606,0.00026629653,0.0005839894,0.0005984329],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003968306,0.00008300128,0.00066449074,0.035997298,0.0007694475,0.00015522099,0.0000400722,0.00020877687,0.0014367956,0.00042690188,0.0062697786,0.9535514],"study_design_scores_gemma":[0.001343774,0.0031997664,0.043603685,0.07834971,0.013498463,0.011313727,0.00041328146,0.0008867036,0.0038771143,0.004192713,0.8390808,0.0002401755],"about_ca_topic_score_codex":0.0005915657,"about_ca_topic_score_gemma":0.0013945445,"teacher_disagreement_score":0.002362063,"about_ca_system_score_codex":0.00023897445,"about_ca_system_score_gemma":0.0005835685,"threshold_uncertainty_score":0.007901907},"labels":[],"label_agreement":null},{"id":"W4281933688","doi":"10.1007/s12325-022-02160-y","title":"A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus","year":2022,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Rheumatology; Internal medicine; Clinical trial; Adverse effect; Rash; Systemic lupus erythematosus; Rheumatoid arthritis; Arthritis; Lupus erythematosus; Disease; Immunology","score_opus":0.05548976719446784,"score_gpt":0.40008612301153196,"score_spread":0.3445963558170641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281933688","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012180528,0.9987834,0.000052395942,0.0002286508,0.00016247621,0.000026557402,0.000065939406,0.000003279794,0.0005555509],"genre_scores_gemma":[0.00077031885,0.9983419,0.00013202967,0.00030607634,0.00018152178,0.000035725283,0.00007115841,0.0000014159247,0.00015980835],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9993,0.00020498219,0.00024301415,0.00008228871,0.00014249844,0.000027194226],"domain_scores_gemma":[0.9977767,0.0015318298,0.00037455768,0.000023012743,0.00023962592,0.000054198215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095872284,0.00082203065,0.002145391,0.0041265227,0.0003406748,0.0013552377,0.0010073867,0.0011380005,0.009295757],"category_scores_gemma":[0.0037939926,0.0002929251,0.0014656041,0.0038912706,0.00035038497,0.0012211592,0.00062826736,0.001074922,0.0012045583],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002291645,0.00005702993,0.0002872743,0.4234332,0.0006840072,0.00046435895,0.0002027261,0.00022024113,0.00060797675,0.0019400702,0.041967716,0.5299062],"study_design_scores_gemma":[0.00015501233,0.00033138908,0.0025543992,0.29844737,0.0032932754,0.0036684733,0.00023856213,0.00014581224,0.0002711303,0.0012061147,0.689636,0.000052527255],"about_ca_topic_score_codex":0.001967281,"about_ca_topic_score_gemma":0.00380166,"teacher_disagreement_score":0.009295757,"about_ca_system_score_codex":0.0008629342,"about_ca_system_score_gemma":0.0021845326,"threshold_uncertainty_score":0.031097412},"labels":[],"label_agreement":null},{"id":"W4283785207","doi":"10.1007/s12325-022-02229-8","title":"The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD","year":2022,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton","funders":"United Therapeutics Corporation","keywords":"Treprostinil; Medicine; Idiopathic pulmonary fibrosis; Pharmacology; Fibrosis; Inflammation; Pulmonary fibrosis; In vivo; Lung; Internal medicine; Pulmonary hypertension; Biology","score_opus":0.040566566312500385,"score_gpt":0.39908404381166745,"score_spread":0.35851747749916707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283785207","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009690798,0.9993043,0.000042184423,0.00014309661,0.000088056666,0.000002003613,0.0000078674475,0.0000041264934,0.0003113662],"genre_scores_gemma":[0.00078369636,0.9984629,0.000106793115,0.00017283029,0.00013708962,0.0000043340683,0.000022660868,0.0000010711572,0.00030870477],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998585,0.000026403686,0.000021425447,0.000023353161,0.00005456636,0.000015640906],"domain_scores_gemma":[0.9997956,0.0000980753,0.000033712167,0.0000057514226,0.000047454174,0.00001942748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004072123,0.00067301444,0.0013908533,0.0016391488,0.00021256729,0.0008162428,0.0006631593,0.0008945082,0.0029823198],"category_scores_gemma":[0.00045248898,0.00018317488,0.0005718684,0.001353508,0.00030535797,0.00092722505,0.0004585353,0.0018118297,0.0011999323],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014886442,0.00008221035,0.00013047253,0.016012717,0.00011431129,0.00015913958,0.000039177015,0.00020318113,0.0016317244,0.0020010837,0.016939951,0.9625372],"study_design_scores_gemma":[0.000087610795,0.0002628353,0.0015784155,0.007074676,0.00028265044,0.002199625,0.00007438843,0.00018036466,0.00069205026,0.0023822205,0.9851599,0.000025291294],"about_ca_topic_score_codex":0.0006417267,"about_ca_topic_score_gemma":0.0014514958,"teacher_disagreement_score":0.0029823198,"about_ca_system_score_codex":0.00033209604,"about_ca_system_score_gemma":0.0006149506,"threshold_uncertainty_score":0.009976864},"labels":[],"label_agreement":null},{"id":"W4285040754","doi":"10.1007/s12325-022-02199-x","title":"Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"Actelion Pharmaceuticals; Faculty of Medicine Siriraj Hospital, Mahidol University; National Taiwan University; Taichung Veterans General Hospital; Ministry of Health of the Russian Federation; National Taiwan University Hospital; NIH Clinical Center; Akademiska Sjukhuset","keywords":"Medicine; Tolerability; Internal medicine; Adverse effect; Clinical endpoint; Placebo; Pulmonary hypertension; Safety profile; Clinical trial","score_opus":0.030064565627307947,"score_gpt":0.29443968968871104,"score_spread":0.26437512406140307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285040754","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99794656,0.001129387,0.00010378387,0.00005196599,0.0000142250265,0.00015296803,0.00029325316,0.0000054909824,0.00030240824],"genre_scores_gemma":[0.9974196,0.0007393775,0.00028921405,0.000111931644,0.00006259359,0.00022970606,0.0007248371,0.0000033608662,0.00041952895],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99891186,0.0007595512,0.000062938714,0.00009257702,0.00008784179,0.00008510111],"domain_scores_gemma":[0.99749064,0.0008171975,0.00078233273,0.00021625584,0.00015893842,0.0005345792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031731187,0.00064279546,0.001060452,0.00023565922,0.00016547722,0.00045606348,0.0004113284,0.0005041117,0.0026338324],"category_scores_gemma":[0.0022472045,0.00021958018,0.001150911,0.00024085153,0.00049425353,0.00047983913,0.00036599924,0.0010891826,0.00024011526],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9210973,0.0053711394,0.020938816,0.0005035801,0.00086594734,0.00008442392,0.0001848393,0.00045333814,0.006418767,0.000048600752,0.00031753417,0.043715775],"study_design_scores_gemma":[0.45543757,0.33504382,0.20181456,0.00013837602,0.0015779522,0.00030175716,0.00015470423,0.0011346232,0.002467638,0.0001644256,0.0016992799,0.000065275],"about_ca_topic_score_codex":0.00054996123,"about_ca_topic_score_gemma":0.0009354813,"teacher_disagreement_score":0.0031731187,"about_ca_system_score_codex":0.00043596374,"about_ca_system_score_gemma":0.00059662416,"threshold_uncertainty_score":0.01678121},"labels":[],"label_agreement":null},{"id":"W4285732351","doi":"10.1007/s12325-022-02231-0","title":"Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis","year":2022,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"GlaxoSmithKline","keywords":"Medicine; Fluticasone propionate; COPD; Meta-analysis; Internal medicine; Pharmacology; Physical therapy; Corticosteroid","score_opus":0.17133879769135232,"score_gpt":0.41856365797525713,"score_spread":0.2472248602839048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285732351","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.049077768,0.9402089,0.0038494552,0.00076894776,0.00084616285,0.0019099094,0.0018951731,0.00017338597,0.0012702779],"genre_scores_gemma":[0.7216498,0.2571923,0.009625745,0.0020339405,0.000569048,0.004552529,0.0028186138,0.0001276669,0.0014303218],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9850167,0.009841151,0.002343222,0.0014351013,0.0009913084,0.0003725999],"domain_scores_gemma":[0.986605,0.009914989,0.0017509599,0.0006163493,0.0007958939,0.00031673888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020841299,0.0038053617,0.01536475,0.0042068674,0.00056302914,0.0034086832,0.0022975588,0.0021021653,0.004121472],"category_scores_gemma":[0.025384236,0.0016455655,0.05296273,0.0035791611,0.00057243335,0.0020235751,0.001977329,0.002402717,0.00049254956],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008349932,0.000047254704,0.0021264812,0.054446466,0.92986757,0.000064623964,0.00004366971,0.00081988977,0.00023597921,0.00009406014,0.00028446154,0.0036195228],"study_design_scores_gemma":[0.0021310558,0.00026539405,0.0012706463,0.0018496622,0.99344134,0.000026987525,0.0000130773615,0.0003721179,0.00008270541,0.00011426022,0.00041968617,0.000013039738],"about_ca_topic_score_codex":0.007389554,"about_ca_topic_score_gemma":0.01238831,"teacher_disagreement_score":0.020841299,"about_ca_system_score_codex":0.0029611504,"about_ca_system_score_gemma":0.0025349606,"threshold_uncertainty_score":0.11022067},"labels":[],"label_agreement":null},{"id":"W4285891556","doi":"10.1007/s12325-022-02247-6","title":"Correction to: Beyond Response: Aiming for Quality Remission in Depression","year":2022,"lang":"en","type":"erratum","venue":"Advances in Therapy","topic":"Health Policy Implementation Science","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto","funders":"","keywords":"Medicine; Depression (economics); Rheumatology; Quality (philosophy); Alternative medicine; Internal medicine; Medical physics; Physical therapy; Epistemology; Pathology","score_opus":0.3897808584831003,"score_gpt":0.6942229551170802,"score_spread":0.3044420966339799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285891556","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003307651,0.00049236714,0.00019724674,0.11364383,0.88277173,0.000018367902,0.0005608739,0.00009780844,0.0021847691],"genre_scores_gemma":[0.004433132,0.0046017575,0.002444628,0.30185905,0.47863403,0.00040122183,0.0010840641,0.0009010001,0.20564114],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9899593,0.0020213025,0.0020210703,0.0011651467,0.0038733229,0.0009598623],"domain_scores_gemma":[0.9364652,0.023910062,0.0023963503,0.0035175325,0.030146742,0.0035640572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008874244,0.0025651155,0.0025809791,0.0037130974,0.006194376,0.008101187,0.0044592028,0.017006956,0.07151436],"category_scores_gemma":[0.12861072,0.001465849,0.0018145562,0.0033809396,0.0049181865,0.0038106656,0.0033018715,0.02617622,0.045078937],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000071825634,0.0000020676255,0.000017856077,0.000034890323,0.0000027069939,0.000042801053,0.000015461841,0.000008305651,0.0000034721545,0.00044179588,0.99825233,0.0011710998],"study_design_scores_gemma":[0.000063604515,0.000009862544,0.00042688922,0.00052789284,0.000027207087,0.00019457987,0.00017078996,0.00015176892,0.00009388696,0.0028414885,0.9954542,0.000037885897],"about_ca_topic_score_codex":0.05743012,"about_ca_topic_score_gemma":0.07118214,"teacher_disagreement_score":0.07151436,"about_ca_system_score_codex":0.009544999,"about_ca_system_score_gemma":0.01810847,"threshold_uncertainty_score":0.2392394},"labels":[],"label_agreement":null},{"id":"W4292470370","doi":"10.1007/s12325-022-02269-0","title":"The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; University of Toronto; Toronto Western Hospital; Memorial University of Newfoundland","funders":"Janssen Research and Development","keywords":"Medicine; Psoriatic arthritis; Placebo; Dermatology Life Quality Index; Visual analogue scale; Crossover study; Internal medicine; Quality of life (healthcare); EQ-5D; Physical therapy; Randomized controlled trial; Arthritis; Health related quality of life; Disease","score_opus":0.007456155231777105,"score_gpt":0.30305885108802405,"score_spread":0.29560269585624693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292470370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919642,0.0034619002,0.0003557584,0.0006191846,0.00032935268,0.0005686375,0.00084120804,0.00013070034,0.0017290174],"genre_scores_gemma":[0.9925029,0.0015422689,0.00057680387,0.00074785086,0.00025180884,0.00080188166,0.0008988574,0.000028621609,0.002649078],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99948776,0.0002412626,0.00002333484,0.00009401592,0.00003320186,0.000120320125],"domain_scores_gemma":[0.9992761,0.00021172795,0.00015972237,0.00007010638,0.00003839619,0.00024395385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012632043,0.0015689976,0.003654101,0.00038824853,0.0004819758,0.0010380929,0.00083417096,0.0016055147,0.005443745],"category_scores_gemma":[0.0014940731,0.0006657683,0.0022167102,0.00035195678,0.0010085885,0.0014906029,0.00047110274,0.0042482545,0.001090443],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9793834,0.0034429245,0.00095336733,0.00036603108,0.0007777893,0.000031012896,0.000048738235,0.00029780713,0.0017777086,0.00006974709,0.00061257766,0.012238906],"study_design_scores_gemma":[0.93318033,0.057687555,0.0068663717,0.00004230483,0.00068358786,0.00003314501,0.000039792263,0.0004655802,0.0003782951,0.00019742089,0.00040462674,0.000020860403],"about_ca_topic_score_codex":0.0011726046,"about_ca_topic_score_gemma":0.0029554218,"teacher_disagreement_score":0.005443745,"about_ca_system_score_codex":0.0005987652,"about_ca_system_score_gemma":0.00078000023,"threshold_uncertainty_score":0.018211186},"labels":[],"label_agreement":null},{"id":"W4292656895","doi":"10.1007/s12325-022-02248-5","title":"Patient Preferences in the Management of Wet Age-Related Macular Degeneration: A Conjoint Analysis","year":2022,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Pharma","keywords":"Medicine; Conjoint analysis; Macular degeneration; Preference; Demography; Physical therapy; Active listening; Family medicine; Internal medicine; Ophthalmology","score_opus":0.04598254760328476,"score_gpt":0.3677459512750403,"score_spread":0.32176340367175554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292656895","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99546754,0.00042058126,0.002593727,0.00014468655,0.000006897659,0.00027965868,0.00032078105,0.0000056523327,0.0007604261],"genre_scores_gemma":[0.99646914,0.00013532372,0.0030239227,0.000028018701,0.0000037532784,0.00012526418,0.00012174659,0.0000011908476,0.000091631344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99136204,0.006289658,0.00053174846,0.00020897874,0.0013293312,0.00027835797],"domain_scores_gemma":[0.98432577,0.01066832,0.0024200417,0.000564882,0.0015329152,0.0004880734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013742198,0.00032778893,0.0005943615,0.0029511184,0.0005455199,0.0012757296,0.00039422745,0.00033740507,0.0019157121],"category_scores_gemma":[0.019591361,0.00017240216,0.0015172088,0.0028668246,0.00048411184,0.0005634473,0.0012502922,0.00047824846,0.0002009716],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021242525,0.00082511385,0.86126816,0.0007277355,0.0012893523,0.00024532387,0.0066198893,0.0043644337,0.0013276876,0.00055978476,0.0007175683,0.11993066],"study_design_scores_gemma":[0.00016825146,0.0036639557,0.93219954,0.0004236007,0.000841437,0.001276953,0.020685272,0.033057835,0.002206699,0.003014046,0.0022922712,0.00017019935],"about_ca_topic_score_codex":0.001198174,"about_ca_topic_score_gemma":0.0016755947,"teacher_disagreement_score":0.013742198,"about_ca_system_score_codex":0.0009708372,"about_ca_system_score_gemma":0.00083749165,"threshold_uncertainty_score":0.07267654},"labels":[],"label_agreement":null},{"id":"W4293037425","doi":"10.1007/s12325-022-02241-y","title":"The Role of Interleukins in the Pathogenesis of Dermatological Immune-Mediated Diseases","year":2022,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; Dalhousie University; Université de Sherbrooke; Government of New Brunswick; University of New Brunswick","funders":"Health Canada; Bausch Health","keywords":"Medicine; Psoriasis; Pathogenesis; Atopic dermatitis; Immunology; Cytokine; Interleukin; Immune system; Tumor necrosis factor alpha; Interleukin 20; Chemokine; Interleukin 23; Interleukin 5","score_opus":0.022295024573765997,"score_gpt":0.3424399022226569,"score_spread":0.32014487764889094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293037425","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006977031,0.999243,0.000064087864,0.00012126394,0.00012379487,0.0000021711744,0.000008921838,0.0000027999583,0.00036414986],"genre_scores_gemma":[0.00061404234,0.9986236,0.00012703151,0.00012136631,0.00023511166,0.0000039493684,0.000015360532,5.057105e-7,0.00025906545],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998049,0.00003723555,0.000028623723,0.000025401787,0.00008246065,0.000021387186],"domain_scores_gemma":[0.9996767,0.00017241375,0.000055958706,0.0000075157573,0.000062467,0.000024870676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005532438,0.00079745677,0.0012047855,0.0013757744,0.00019745105,0.0010193222,0.00058883044,0.0007377013,0.0025734517],"category_scores_gemma":[0.00059149915,0.00016638951,0.00042981605,0.0015355927,0.0003910998,0.0008706565,0.0006069694,0.0018144319,0.0012281716],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015110507,0.000083924526,0.00028377876,0.014567252,0.0000920759,0.00024213236,0.00004763473,0.00030347847,0.0024570671,0.002646671,0.01918174,0.9599431],"study_design_scores_gemma":[0.00006741258,0.00015170667,0.0016421174,0.005271221,0.00024438804,0.0015008544,0.000088464905,0.00015292494,0.00074911723,0.0031241183,0.98698413,0.000023534609],"about_ca_topic_score_codex":0.000584575,"about_ca_topic_score_gemma":0.0011229486,"teacher_disagreement_score":0.0025734517,"about_ca_system_score_codex":0.00035514412,"about_ca_system_score_gemma":0.0009871047,"threshold_uncertainty_score":0.0086090565},"labels":[],"label_agreement":null},{"id":"W4294238099","doi":"10.1007/s12325-022-02250-x","title":"The Patient and Clinician Assessment of Gastrointestinal (GI) Related Adverse Events Associated with Oral Disease-Modifying Therapies in Multiple Sclerosis: A Qualitative Study","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Biogen","keywords":"Medicine; Fingolimod; Teriflunomide; Adverse effect; Nausea; Qualitative research; Clinical trial; Disease; Internal medicine; Diarrhea; Multiple sclerosis; Physical therapy; Psychiatry","score_opus":0.09518329872803062,"score_gpt":0.4116198257491791,"score_spread":0.3164365270211485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294238099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98384976,0.001063153,0.003218898,0.0062326365,0.00012955765,0.00061679626,0.00037071537,0.000025167159,0.0044933073],"genre_scores_gemma":[0.9929495,0.0009906301,0.0018770525,0.0019228376,0.000029755116,0.00059601566,0.000108815104,0.00002861617,0.0014968793],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9675186,0.025603887,0.000908811,0.0014784408,0.0018174037,0.0026728797],"domain_scores_gemma":[0.92827666,0.05500958,0.003648461,0.0012659716,0.0067295483,0.0050698565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025475852,0.0007479232,0.0011597307,0.0021909028,0.011670483,0.0054003187,0.002515241,0.0025132978,0.002881477],"category_scores_gemma":[0.045552075,0.00084242196,0.00066019077,0.0022534537,0.014085019,0.0049112653,0.0062234155,0.004107621,0.00038915992],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002348787,0.000030588795,0.0021818497,0.000145212,0.0000038889475,0.00026722558,0.99481577,0.000023035132,0.00020888982,0.00034265278,0.00033101183,0.0016264609],"study_design_scores_gemma":[0.0000050781327,0.000031653213,0.00071187783,0.00013869227,0.0000026082143,0.000115200106,0.9955422,0.000059020207,0.00008728995,0.000113890674,0.0031797457,0.0000128462],"about_ca_topic_score_codex":0.03918383,"about_ca_topic_score_gemma":0.051493574,"teacher_disagreement_score":0.03918383,"about_ca_system_score_codex":0.014154263,"about_ca_system_score_gemma":0.016188724,"threshold_uncertainty_score":0.13473076},"labels":[],"label_agreement":null},{"id":"W4295470189","doi":"10.1007/s12325-022-02270-7","title":"The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; University of Toronto; Toronto Western Hospital; Memorial University of Newfoundland","funders":"Janssen Research and Development; Janssen Scientific Affairs","keywords":"Medicine; Psoriatic arthritis; Placebo; Presenteeism; Internal medicine; Physical therapy; Absenteeism; Arthritis","score_opus":0.007089833713171946,"score_gpt":0.2797830670537712,"score_spread":0.27269323334059925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295470189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98850596,0.006053072,0.00040679987,0.00082536094,0.0004966847,0.0006049496,0.0009003748,0.00015980344,0.0020469634],"genre_scores_gemma":[0.99229175,0.002040913,0.00048129575,0.0007683602,0.0002753024,0.0006985023,0.00073202484,0.000028403938,0.0026835203],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994684,0.0002337982,0.000027675225,0.00009585318,0.00003760695,0.00013673349],"domain_scores_gemma":[0.9991779,0.0002412244,0.00017787161,0.0000723413,0.00004419985,0.00028652337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012637904,0.0017291898,0.0035229279,0.00043471172,0.00057594577,0.0012114367,0.0009903904,0.001735963,0.0058710934],"category_scores_gemma":[0.0016874905,0.0006801316,0.0023585698,0.00036762582,0.0010443163,0.0014714873,0.00047369627,0.0047388803,0.0012394299],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97583175,0.0036282535,0.0008112871,0.0005193363,0.0009277023,0.00003544962,0.00005305423,0.0003324908,0.0017324244,0.00007348632,0.0007471589,0.015307571],"study_design_scores_gemma":[0.93297815,0.05841357,0.0063147955,0.00005871712,0.0006779162,0.00003704083,0.00004683199,0.00043481804,0.00035133475,0.00020373623,0.00046074786,0.000022412663],"about_ca_topic_score_codex":0.0012021294,"about_ca_topic_score_gemma":0.0024685522,"teacher_disagreement_score":0.0058710934,"about_ca_system_score_codex":0.0006471592,"about_ca_system_score_gemma":0.0008232484,"threshold_uncertainty_score":0.019640744},"labels":[],"label_agreement":null},{"id":"W4296642322","doi":"10.1007/s12325-022-02303-1","title":"Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational Study","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada); University of Saskatchewan; Université de Montréal; University of Toronto; St. Joseph's Hospital; Mount Sinai Hospital; Western University","funders":"","keywords":"Medicine; Etanercept; Rheumatoid arthritis; Internal medicine; Rheumatology; Erythrocyte sedimentation rate; Adverse effect; Observational study; Biosimilar; Methotrexate; Concomitant; Prospective cohort study; Physical therapy","score_opus":0.01895463268009967,"score_gpt":0.3013498490173185,"score_spread":0.2823952163372188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296642322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991009,0.0004015993,0.00003742025,0.000025609645,0.000012602606,0.000017937198,0.00024341753,0.0000015078936,0.00015903582],"genre_scores_gemma":[0.9988073,0.00014409718,0.00005963092,0.00008835381,0.000036847825,0.000024922905,0.0006727956,0.0000021739088,0.00016394242],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978218,0.0007777711,0.00026009002,0.00051729113,0.00030942584,0.00031363836],"domain_scores_gemma":[0.99329317,0.0018313474,0.0029745298,0.0005927851,0.00040656363,0.0009015114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029991814,0.00063659454,0.0012244198,0.0005233248,0.00060506194,0.0013758177,0.0006346542,0.0013100492,0.0017640556],"category_scores_gemma":[0.004996243,0.00046610885,0.0023245874,0.0009620517,0.00065333873,0.0012788165,0.0006074906,0.0019984066,0.00033663123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053244717,0.0012388494,0.9370946,0.00013992192,0.0021906118,0.00015609061,0.00020448415,0.0001794484,0.0010713714,0.000049046484,0.000260658,0.0041702837],"study_design_scores_gemma":[0.0021944349,0.008098348,0.9866933,0.000031866442,0.0013131214,0.00025551047,0.00025510995,0.0004240116,0.00021658975,0.00005654911,0.00043282934,0.00002821488],"about_ca_topic_score_codex":0.00236476,"about_ca_topic_score_gemma":0.0018878856,"teacher_disagreement_score":0.0029991814,"about_ca_system_score_codex":0.00089663855,"about_ca_system_score_gemma":0.00058813824,"threshold_uncertainty_score":0.015861392},"labels":[],"label_agreement":null},{"id":"W4296667915","doi":"10.1007/s12325-022-02277-0","title":"Educational and Emotional Needs of Patients with Myelodysplastic Syndromes: An AI Analysis of Multi-Country Social Media","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Social media; Myelodysplastic syndromes; Rheumatology; Family medicine; Psychiatry; Internal medicine; World Wide Web","score_opus":0.037495158081482065,"score_gpt":0.37385490940713384,"score_spread":0.33635975132565177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296667915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986045,0.000072836476,0.00005016291,0.00014694736,0.00000417023,0.000025917403,0.00056989584,0.000002280787,0.0005233155],"genre_scores_gemma":[0.99836177,0.00015570386,0.00015576952,0.00015306669,0.000017132123,0.00007785286,0.0007539921,0.0000041639,0.0003204894],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.99918395,0.00030129633,0.00010437407,0.000092179136,0.00014492079,0.00017322168],"domain_scores_gemma":[0.99569017,0.0019159573,0.0012173828,0.000091870126,0.00065916334,0.0004255566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000936013,0.00022044718,0.00026376918,0.0023103599,0.0008159038,0.0012670254,0.00026423106,0.00037318427,0.0015825756],"category_scores_gemma":[0.005707712,0.00011619424,0.00035704466,0.0019974483,0.00038270943,0.0012089561,0.0015683868,0.0005035292,0.00025464562],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020848475,0.00015489015,0.9434357,0.00024292675,0.000072971765,0.0004841414,0.0323953,0.00007571223,0.00046741945,0.00013689986,0.0013502599,0.02097526],"study_design_scores_gemma":[0.000007949996,0.000099314566,0.9128284,0.00010676094,0.000047203775,0.0003060557,0.083367035,0.00054751884,0.00014484883,0.0000880397,0.0024297228,0.000027201862],"about_ca_topic_score_codex":0.010360244,"about_ca_topic_score_gemma":0.018184898,"teacher_disagreement_score":0.010360244,"about_ca_system_score_codex":0.000771434,"about_ca_system_score_gemma":0.0006537429,"threshold_uncertainty_score":0.020599902},"labels":[],"label_agreement":null},{"id":"W4304165795","doi":"10.1007/s12325-022-02329-5","title":"Reasons for Treatment Changes in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Chart Review Study","year":2022,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Otsuka Pharmaceutical Development and Commercialization; Otsuka Pharmaceutical","keywords":"Medicine; Discontinuation; Pediatrics; Complication; Attention deficit hyperactivity disorder; Medical record; Psychiatry; Physical therapy; Internal medicine","score_opus":0.04816910701679069,"score_gpt":0.3875172918370127,"score_spread":0.33934818482022205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304165795","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99415225,0.002256282,0.00021931448,0.00020330757,0.000014369358,0.00022338619,0.0017997579,0.000013069295,0.0011182744],"genre_scores_gemma":[0.99652463,0.0012516775,0.00059711805,0.00012523521,0.000020875044,0.00016089492,0.0011630208,0.000005202303,0.00015121399],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964533,0.0010303723,0.0007433224,0.00040622902,0.0011063195,0.00026041313],"domain_scores_gemma":[0.97727793,0.00420333,0.015269995,0.0003671517,0.002113933,0.0007676845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028118358,0.00016467871,0.00036786683,0.002743615,0.0006038075,0.0009575671,0.0004149143,0.0003292754,0.0012905853],"category_scores_gemma":[0.0118029,0.00029714996,0.00065175095,0.0037187096,0.00034620063,0.0007249798,0.0006275244,0.0005764013,0.0001581131],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029098119,0.000034028104,0.99564326,0.00007771592,0.000025642414,0.000114210925,0.00053449196,0.000012712026,0.000035366116,0.000017216258,0.000287653,0.0031886536],"study_design_scores_gemma":[0.000007689218,0.000074935575,0.9970619,0.00010886189,0.000028709926,0.00048507735,0.00123059,0.00007613888,0.0000669289,0.00000826681,0.0008456289,0.000005304015],"about_ca_topic_score_codex":0.014099667,"about_ca_topic_score_gemma":0.021516262,"teacher_disagreement_score":0.014099667,"about_ca_system_score_codex":0.001801022,"about_ca_system_score_gemma":0.002484593,"threshold_uncertainty_score":0.028035164},"labels":[],"label_agreement":null},{"id":"W4306377497","doi":"10.1007/s12325-022-02340-w","title":"A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"AstraZeneca","keywords":"Medicine; Asthma; Charter; Referral; Intensive care medicine; Health care; Disease; Family medicine; Internal medicine","score_opus":0.008567164779409284,"score_gpt":0.27349466121056665,"score_spread":0.26492749643115737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306377497","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00078130554,0.009924281,0.016888566,0.9303181,0.03194262,0.00039515554,0.00017664453,0.00081502664,0.008758226],"genre_scores_gemma":[0.045802686,0.034438547,0.13728984,0.7026853,0.055873055,0.0022687162,0.0015167155,0.0015023276,0.018622749],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.88591427,0.05383638,0.010701339,0.005142534,0.037475064,0.006930316],"domain_scores_gemma":[0.7451892,0.07354692,0.0140880905,0.016094053,0.08099778,0.070084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.103511125,0.0018054293,0.0022794616,0.003641005,0.009209657,0.020459872,0.008283839,0.015581913,0.0071448684],"category_scores_gemma":[0.22757615,0.0012668335,0.0028890413,0.003434985,0.014483228,0.022736441,0.017488996,0.05879885,0.0059844474],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004742845,0.00021475402,0.0011858927,0.0005961778,0.000050282575,0.0001985934,0.004131092,0.00057410786,0.00017687047,0.030906022,0.84810406,0.11381464],"study_design_scores_gemma":[0.00009202758,0.0002466097,0.0020964677,0.0028738277,0.00004021461,0.00031637307,0.0023386916,0.00065367424,0.00025432833,0.029718531,0.96116394,0.00020528285],"about_ca_topic_score_codex":0.015304787,"about_ca_topic_score_gemma":0.027242845,"teacher_disagreement_score":0.103511125,"about_ca_system_score_codex":0.015615441,"about_ca_system_score_gemma":0.07649079,"threshold_uncertainty_score":0.5474257},"labels":[],"label_agreement":null},{"id":"W4306898284","doi":"10.1007/s12325-022-02332-w","title":"Cost-Effectiveness of Acthar Gel Versus Standard of Care for the Treatment of Exacerbations in Moderate-to-Severe Systemic Lupus Erythematosus","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Exacerbation; Internal medicine; Systemic lupus erythematosus; Rheumatology; Cohort; Quality of life (healthcare); Disease","score_opus":0.05126373379941145,"score_gpt":0.3779763090322955,"score_spread":0.32671257523288405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306898284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9534444,0.023846777,0.008396953,0.0022362971,0.00018273745,0.0009445446,0.002482414,0.00013573084,0.008330047],"genre_scores_gemma":[0.9971949,0.0010083434,0.0009935244,0.0001313611,0.00001683835,0.00014421786,0.00029004068,0.0000044003705,0.00021619894],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9976115,0.0017651576,0.00009258197,0.00016583725,0.00017736429,0.00018768593],"domain_scores_gemma":[0.99608046,0.0030768707,0.00045495128,0.00006328525,0.00010639563,0.00021812777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037623812,0.0008236989,0.0017052371,0.0009398937,0.0001718317,0.0013286384,0.0009159087,0.0012814288,0.0034490202],"category_scores_gemma":[0.009677379,0.00042330087,0.0038063002,0.0005665603,0.0004777769,0.00094238564,0.0007222064,0.0012066759,0.0001505697],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07704399,0.0013845115,0.024817135,0.004163763,0.009815275,0.0005542246,0.00013752877,0.7881679,0.0011857039,0.006311061,0.0026002568,0.08381859],"study_design_scores_gemma":[0.021006074,0.031474117,0.045254897,0.0031694095,0.017941494,0.0014193116,0.00035175885,0.8604306,0.0022423826,0.011944607,0.004559008,0.00020645575],"about_ca_topic_score_codex":0.005929433,"about_ca_topic_score_gemma":0.0040478734,"teacher_disagreement_score":0.005929433,"about_ca_system_score_codex":0.0035032204,"about_ca_system_score_gemma":0.002048364,"threshold_uncertainty_score":0.025417745},"labels":[],"label_agreement":null},{"id":"W4307582617","doi":"10.1007/s12325-022-02345-5","title":"Examining the Systemic Bioavailability of Cannabidiol and Tetrahydrocannabinol from a Novel Transdermal Delivery System in Healthy Adults: A Single-Arm, Open-Label, Exploratory Study","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BGC Engineering (Canada)","funders":"","keywords":"Cannabidiol; Cmax; Medicine; Transdermal; Pharmacokinetics; Bioavailability; Pharmacology; Area under the curve; Adverse effect; Bioequivalence; Cannabis","score_opus":0.05866162924438281,"score_gpt":0.3197853359846563,"score_spread":0.2611237067402735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307582617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983418,0.00035791253,0.00058585434,0.00002550849,0.000018522353,0.00038380377,0.00010590181,0.0000124663575,0.00016816796],"genre_scores_gemma":[0.99398476,0.0006585277,0.0028029445,0.00017061885,0.00006467795,0.0007838739,0.00023566675,0.000010949403,0.0012879743],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99961483,0.00010620363,0.000029142147,0.0001117916,0.000094581694,0.000043353233],"domain_scores_gemma":[0.99960107,0.00008898472,0.00012447507,0.000043859523,0.000062689345,0.00007895091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011227968,0.00066220213,0.0010460016,0.00019710927,0.00034596492,0.00045577664,0.00031808173,0.00072923995,0.0014399196],"category_scores_gemma":[0.00069695263,0.0004126913,0.00058945763,0.00016950657,0.00043422863,0.00055284606,0.0002413577,0.00086681684,0.00038489813],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22487028,0.06958806,0.01536598,0.001298903,0.0008144541,0.00040148906,0.0008667508,0.00075866294,0.6042521,0.00016193073,0.00081182254,0.08080948],"study_design_scores_gemma":[0.015580705,0.8800624,0.05413455,0.000021334443,0.0009152403,0.00051678665,0.00030335793,0.002241962,0.043925602,0.00010335181,0.002145552,0.00004916067],"about_ca_topic_score_codex":0.00060858415,"about_ca_topic_score_gemma":0.0010150621,"teacher_disagreement_score":0.0014399196,"about_ca_system_score_codex":0.00031647793,"about_ca_system_score_gemma":0.0005336031,"threshold_uncertainty_score":0.0059379935},"labels":[],"label_agreement":null},{"id":"W4307730286","doi":"10.1007/s12325-022-02353-5","title":"Projecting the Epidemiological and Economic Impact of Chronic Kidney Disease Using Patient-Level Microsimulation Modelling: Rationale and Methods of Inside CKD","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"AstraZeneca","keywords":"Medicine; Microsimulation; Epidemiology; Kidney disease; Rheumatology; Intensive care medicine; Internal medicine","score_opus":0.07483301571167904,"score_gpt":0.40650440792095754,"score_spread":0.3316713922092785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307730286","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.069861986,0.00067861174,0.9118406,0.0034757843,0.00012076295,0.00041305672,0.0014039421,0.00023359414,0.011971649],"genre_scores_gemma":[0.7949564,0.0010418815,0.19679116,0.00040346076,0.00013188111,0.0011317048,0.0007466495,0.000098873155,0.0046978947],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99824166,0.0012974442,0.000050130435,0.00015837378,0.00013540564,0.00011697468],"domain_scores_gemma":[0.9942834,0.0045490945,0.0004198134,0.00023351188,0.00034981483,0.00016437574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033827526,0.0009185121,0.00082618167,0.0008763094,0.00043170084,0.0015101065,0.0025094647,0.001289561,0.0030170497],"category_scores_gemma":[0.01252917,0.00070723816,0.001740171,0.001118339,0.0011040274,0.0012511428,0.0021841407,0.0016679108,0.0002689327],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015088701,0.0000144186515,0.0016192447,0.00003005535,0.000036601003,0.00003401021,0.000044121414,0.97355497,0.000056794797,0.022396034,0.00021172685,0.0019869877],"study_design_scores_gemma":[0.000013451461,0.000022121712,0.00033276388,0.000034285233,0.000019636598,0.000022395863,0.000030237576,0.9769546,0.00007704583,0.021402147,0.0010754418,0.000015755053],"about_ca_topic_score_codex":0.025712013,"about_ca_topic_score_gemma":0.011029423,"teacher_disagreement_score":0.025712013,"about_ca_system_score_codex":0.0017497553,"about_ca_system_score_gemma":0.0026535972,"threshold_uncertainty_score":0.051124692},"labels":[],"label_agreement":null},{"id":"W4307852697","doi":"10.1007/s12325-022-02322-y","title":"No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; Eli Lilly and Company; Ortho Dermatologics; Galderma; Incyte; Dermira; Les Laboratories Pierre Fabre; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer","keywords":"Medicine; Dupilumab; Atopic dermatitis; Discontinuation; Incidence (geometry); Placebo; Dosing; Internal medicine; Adverse effect; Regimen; Cumulative incidence; Dermatology; Cohort","score_opus":0.005435478724070912,"score_gpt":0.25447065783412526,"score_spread":0.24903517911005435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307852697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550456,0.0029581725,0.000119177974,0.00005387831,0.000015392809,0.0000274837,0.00024489322,0.000006980731,0.0010695034],"genre_scores_gemma":[0.9988644,0.00047971483,0.00009389288,0.00009043491,0.000023040117,0.000012861429,0.00021410403,0.0000015116123,0.00022007783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900985,0.00038356078,0.0001052163,0.00015859545,0.00021608632,0.00012680521],"domain_scores_gemma":[0.99826056,0.0002966669,0.00094761816,0.00011783938,0.0001488654,0.00022840234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001002267,0.00026661536,0.0005216467,0.00022647214,0.0002298196,0.0004762741,0.00013964686,0.00044919428,0.0012409773],"category_scores_gemma":[0.0017277951,0.00017829868,0.00097266666,0.00025429213,0.00014835899,0.00029907894,0.00035151368,0.0006857056,0.00011982162],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009406864,0.0002988816,0.96347094,0.00017172398,0.00056805456,0.00038975678,0.0001080011,0.00012080482,0.0022045644,0.000049336893,0.0004734669,0.022737652],"study_design_scores_gemma":[0.00032522192,0.0045127105,0.99217564,0.00004775315,0.0003777124,0.001115901,0.00006866407,0.00021506417,0.00032365846,0.00003208145,0.000794159,0.00001141],"about_ca_topic_score_codex":0.0010593841,"about_ca_topic_score_gemma":0.0021912656,"teacher_disagreement_score":0.0012409773,"about_ca_system_score_codex":0.00018843616,"about_ca_system_score_gemma":0.00030284663,"threshold_uncertainty_score":0.0053005815},"labels":[],"label_agreement":null},{"id":"W4309722656","doi":"10.1007/s12325-022-02369-x","title":"Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305)","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"Biohaven Pharmaceuticals","keywords":"Medicine; Migraine; Rheumatology; Open label; Migraine Disorders; Physical therapy; Internal medicine; Clinical trial","score_opus":0.18313469768657126,"score_gpt":0.4694301944779297,"score_spread":0.28629549679135846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309722656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99106836,0.00093545555,0.003281147,0.00006068773,0.0000286303,0.0020046188,0.0014030389,0.000104307546,0.0011137424],"genre_scores_gemma":[0.9935516,0.00026699473,0.0028923275,0.00005442842,0.000023678469,0.0016982965,0.001117254,0.000014262286,0.00038110986],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.998212,0.0013451509,0.00006740012,0.00013239704,0.00016957756,0.00007355833],"domain_scores_gemma":[0.99781704,0.0007550569,0.0008045407,0.0003251091,0.00016141486,0.00013685782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051431037,0.0004363818,0.0012913382,0.00032713675,0.00012301358,0.0004195219,0.0004181901,0.0003385483,0.003647196],"category_scores_gemma":[0.004526573,0.00025917703,0.0011049138,0.00043286334,0.00040378858,0.00035942622,0.00039164117,0.00065349037,0.0004093483],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83372164,0.0065389527,0.013912336,0.00095259945,0.0014929482,0.00003215429,0.00023653069,0.002836454,0.019522004,0.00026950665,0.0010743216,0.11941055],"study_design_scores_gemma":[0.4306766,0.3010567,0.24104,0.00015516744,0.0025647043,0.00019665367,0.00013862718,0.009225224,0.01077413,0.0007003092,0.0033489089,0.00012293826],"about_ca_topic_score_codex":0.00070708955,"about_ca_topic_score_gemma":0.0009538493,"teacher_disagreement_score":0.0051431037,"about_ca_system_score_codex":0.00037674507,"about_ca_system_score_gemma":0.0007188037,"threshold_uncertainty_score":0.027199686},"labels":[],"label_agreement":null},{"id":"W4311052876","doi":"10.1007/s12325-022-02360-6","title":"PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Center for Advancing Translational Sciences; Feinberg School of Medicine; Ipsen; Carcinoid Cancer Foundation; Neuroendocrine Tumor Research Foundation; Northwestern University","keywords":"Acromegaly; Medicine; Somatostatin; Somatostatin Analogue; Rheumatology; Internal medicine; Octreotide; Medical physics; Growth hormone; Hormone","score_opus":0.034876949359028304,"score_gpt":0.3551121762573508,"score_spread":0.3202352268983225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311052876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926198,0.000370048,0.00020180327,0.0002062316,0.000024726452,0.00026395262,0.002408728,0.0000104717265,0.003894167],"genre_scores_gemma":[0.9905872,0.0008620748,0.0008483774,0.00082388276,0.000044965334,0.0005176681,0.004104632,0.000026134245,0.0021850301],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910104,0.00018191985,0.00018644205,0.000079960926,0.00024734705,0.00020329107],"domain_scores_gemma":[0.994341,0.0008236468,0.0031681606,0.00012396717,0.0006581581,0.0008850482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012738736,0.000349964,0.0004189482,0.0018106755,0.00055896747,0.0008496759,0.00030189764,0.0005710971,0.0033055423],"category_scores_gemma":[0.0032666216,0.00024330849,0.00085519266,0.0015355167,0.0003663347,0.0010251113,0.0012012589,0.000966728,0.00090045313],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023064428,0.0003810639,0.98772484,0.000104117076,0.00009260488,0.00013431901,0.0013184006,0.000048361206,0.00049965474,0.000044814973,0.0013570689,0.008064111],"study_design_scores_gemma":[0.000023920977,0.0006231786,0.99088365,0.00007683243,0.00004743396,0.000609402,0.0038573379,0.00011144989,0.000181212,0.000022188344,0.0035415057,0.00002184972],"about_ca_topic_score_codex":0.0021618467,"about_ca_topic_score_gemma":0.0036316966,"teacher_disagreement_score":0.0033055423,"about_ca_system_score_codex":0.00054376014,"about_ca_system_score_gemma":0.000693936,"threshold_uncertainty_score":0.011058152},"labels":[],"label_agreement":null},{"id":"W4311476820","doi":"10.1007/s12325-022-02379-9","title":"Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting","year":2022,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lynde Centre for Dermatology","funders":"Eli Lilly and Company","keywords":"Medicine; Plaque psoriasis; Psoriasis; Rheumatology; Internal medicine; Dermatology; Physical therapy","score_opus":0.026024946539772983,"score_gpt":0.299438510484854,"score_spread":0.273413563945081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311476820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99896014,0.00049655454,0.000096333446,0.000026969125,0.0000043192144,0.00004875446,0.00014775728,0.0000027993951,0.00021633353],"genre_scores_gemma":[0.9993468,0.0000897856,0.0001459676,0.000028730281,0.000010192479,0.000050244842,0.00024789467,0.0000017917458,0.000078532874],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9959265,0.002778752,0.00033903064,0.00038198626,0.00032420142,0.00024943613],"domain_scores_gemma":[0.9945029,0.0024727667,0.0016872068,0.0005371295,0.0003057534,0.0004942103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007071746,0.0004232837,0.0011745403,0.0004181646,0.00023089319,0.0007713476,0.00038358147,0.0007262961,0.001714143],"category_scores_gemma":[0.0054757553,0.00018254666,0.0022620833,0.000306791,0.0003625161,0.00054159976,0.00054888614,0.0007906932,0.00019285573],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67313224,0.009196836,0.23381324,0.0007337057,0.011181256,0.00016330527,0.0005834853,0.0036275513,0.006735659,0.00017951078,0.00063528947,0.06001796],"study_design_scores_gemma":[0.04801401,0.2648387,0.6677915,0.000115853494,0.0067964117,0.0006606216,0.0006342176,0.00477626,0.004244475,0.00037575964,0.0016475291,0.00010469466],"about_ca_topic_score_codex":0.00042076388,"about_ca_topic_score_gemma":0.00065442803,"teacher_disagreement_score":0.007071746,"about_ca_system_score_codex":0.00042486333,"about_ca_system_score_gemma":0.00041193233,"threshold_uncertainty_score":0.03739941},"labels":[],"label_agreement":null},{"id":"W4317438721","doi":"10.1007/s12325-022-02422-9","title":"Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; Rivaroxaban; Warfarin; Atrial fibrillation; Internal medicine; Poisson regression; Retrospective cohort study; Cohort; Population; Confidence interval; Odds ratio; Emergency medicine","score_opus":0.03983527937279056,"score_gpt":0.34376283745290837,"score_spread":0.3039275580801178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317438721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944723,0.0010924322,0.00011345385,0.00017295027,0.000009609783,0.000009206249,0.003737009,0.0000051963248,0.0003877604],"genre_scores_gemma":[0.9965223,0.00046814483,0.00011338217,0.00006531794,0.000014005322,0.00001549726,0.0027142533,0.0000017411205,0.00008529016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987897,0.00039366187,0.00023001195,0.00022723315,0.00023874319,0.00012058828],"domain_scores_gemma":[0.9981213,0.0003206366,0.0012008786,0.00007762204,0.0001245204,0.00015490962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010811357,0.00023260676,0.00043713415,0.0010521605,0.00017666612,0.0007886975,0.0003696136,0.0002973883,0.00095734734],"category_scores_gemma":[0.003926561,0.00019237676,0.0011788006,0.0021328046,0.00017508773,0.00045850824,0.0004714253,0.00041937036,0.00008609806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001824714,0.000035802066,0.9960388,0.000033867473,0.00047816854,0.000037380953,0.000029236935,0.00042562297,0.00003791928,0.00005458169,0.00038738965,0.002258747],"study_design_scores_gemma":[0.00002738546,0.000108706685,0.9973634,0.00003953798,0.00019839682,0.00017346034,0.00014936399,0.0013864936,0.000050115283,0.00011627354,0.0003806412,0.0000062889494],"about_ca_topic_score_codex":0.020141667,"about_ca_topic_score_gemma":0.018353218,"teacher_disagreement_score":0.020141667,"about_ca_system_score_codex":0.00082710723,"about_ca_system_score_gemma":0.00054828875,"threshold_uncertainty_score":0.040048838},"labels":[],"label_agreement":null},{"id":"W4321169417","doi":"10.1007/s12325-023-02450-z","title":"Breast Cancer Screening Should Embrace Precision Medicine: Evidence by Reviewing Economic Evaluations in China","year":2023,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China; China Medical Board","keywords":"Medicine; Breast cancer; Rheumatology; Alternative medicine; Cancer; China; Family medicine; Internal medicine; Precision medicine; Medical physics; Oncology; Traditional medicine; Intensive care medicine; Pathology","score_opus":0.2995815257093418,"score_gpt":0.5379578317870879,"score_spread":0.23837630607774607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321169417","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00086361245,0.99756134,0.00013113319,0.0006017131,0.00008158101,0.0001278475,0.000090296606,0.0000029838675,0.0005394616],"genre_scores_gemma":[0.014747849,0.9837556,0.0005576358,0.0005328518,0.00007449736,0.00017462701,0.00008307524,0.0000024636572,0.0000713822],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9922483,0.0034504686,0.002258822,0.00027951383,0.001526451,0.00023643],"domain_scores_gemma":[0.974595,0.019585522,0.0032083942,0.00029084706,0.002115569,0.00020462224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015387975,0.0015816453,0.004833897,0.00760854,0.00045648208,0.0025909534,0.0014323116,0.0016063635,0.0033338158],"category_scores_gemma":[0.040372495,0.00059964013,0.0049067372,0.00877372,0.000685942,0.001655304,0.0010011528,0.0012047763,0.00015340273],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004892018,0.00006767296,0.001491514,0.67685884,0.008259511,0.0001491634,0.00014901411,0.0011541574,0.00019583781,0.0019852638,0.0032666046,0.30593318],"study_design_scores_gemma":[0.0007916331,0.0006347407,0.013224232,0.8607947,0.057076536,0.00047423097,0.0003311466,0.0010328669,0.0005309879,0.0029234402,0.06210321,0.000082271414],"about_ca_topic_score_codex":0.014672228,"about_ca_topic_score_gemma":0.02692209,"teacher_disagreement_score":0.015387975,"about_ca_system_score_codex":0.007030273,"about_ca_system_score_gemma":0.013674659,"threshold_uncertainty_score":0.08138031},"labels":[],"label_agreement":null},{"id":"W4321604810","doi":"10.1007/s12325-022-02391-z","title":"Venous Thromboembolism Recurrence Among Patients Who Abandon Oral Anticoagulant Therapy in the USA: A Retrospective Longitudinal Study","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; Venous thromboembolism; Anticoagulant therapy; Retrospective cohort study; Rheumatology; Internal medicine; Oral anticoagulant; Intensive care medicine; Warfarin; Atrial fibrillation; Thrombosis","score_opus":0.042814122044271576,"score_gpt":0.34948516422770154,"score_spread":0.30667104218342994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321604810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982845,0.00034866916,0.000111018955,0.000081450555,0.000008990507,0.0000180905,0.0008907523,0.0000030491758,0.00025335493],"genre_scores_gemma":[0.99800485,0.00028093814,0.00013347852,0.000115663956,0.000015415815,0.00003071909,0.0012840183,0.0000022059564,0.0001326056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915123,0.0002267756,0.00012183131,0.00022291597,0.00015739418,0.00011994226],"domain_scores_gemma":[0.99762565,0.00028483794,0.001201985,0.00026245782,0.00033046634,0.0002945517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013617164,0.00023973624,0.00041109163,0.00083521917,0.00062117697,0.0007467908,0.00041594714,0.00057521445,0.00077928515],"category_scores_gemma":[0.0027336448,0.00044376825,0.00068293104,0.0016777017,0.00025917604,0.00066380773,0.00048398512,0.00096914836,0.00020791242],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060447415,0.00002927331,0.9992106,0.0000050723133,0.000065582455,0.00002672222,0.000054423093,0.000010446743,0.000031665673,0.000007853254,0.00011717937,0.0003806687],"study_design_scores_gemma":[0.00001496648,0.000116823656,0.9987447,0.000016640059,0.00008324577,0.0002200993,0.00023560079,0.00015662907,0.000025980687,0.00001912908,0.0003602513,0.0000058483784],"about_ca_topic_score_codex":0.014329446,"about_ca_topic_score_gemma":0.01750476,"teacher_disagreement_score":0.014329446,"about_ca_system_score_codex":0.0004705671,"about_ca_system_score_gemma":0.00072243216,"threshold_uncertainty_score":0.028492033},"labels":[],"label_agreement":null},{"id":"W4324017399","doi":"10.1007/s12325-023-02458-5","title":"Treatment Patterns Among Patients with Attention-Deficit/Hyperactivity Disorder and Comorbid Anxiety and/or Depression in the United States: A Retrospective Claims Analysis","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Allergan; Otsuka Pharmaceutical; Neos Therapeutics; Pfizer","keywords":"Comorbidity; Anxiety; Depression (economics); Medicine; Discontinuation; Psychiatry; Attention deficit hyperactivity disorder; Odds ratio; Internal medicine","score_opus":0.01650501657985638,"score_gpt":0.3147274902662078,"score_spread":0.2982224736863514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324017399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964864,0.0006126824,0.00010430883,0.00007745618,0.0000054723437,0.00002380744,0.0023256466,0.000005847789,0.00035840628],"genre_scores_gemma":[0.9974595,0.00032001722,0.000117153424,0.000057537516,0.000010746291,0.000020905889,0.0019603078,0.0000021112005,0.000051877556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869484,0.0002963584,0.0003127191,0.00025608603,0.00031023845,0.00012979194],"domain_scores_gemma":[0.996714,0.00043453494,0.0021972973,0.00017775987,0.00025698688,0.00021937232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012282857,0.00025918247,0.00043616057,0.0019464839,0.00053999876,0.00089844165,0.0005208721,0.0004355139,0.0008221062],"category_scores_gemma":[0.0029267527,0.0004472969,0.0007630977,0.003503988,0.00033642462,0.0006088388,0.0006755927,0.000621846,0.00014297996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002806722,0.000016071845,0.99931,0.0000075625653,0.000051741168,0.000026163896,0.000026991696,0.000028792696,0.000017918159,0.000008099618,0.00009675912,0.0003818769],"study_design_scores_gemma":[0.0000058523824,0.000028851002,0.9990883,0.000016067497,0.0000433717,0.00020650319,0.00013699169,0.0003076639,0.000024939427,0.000013469796,0.00012430984,0.0000037101865],"about_ca_topic_score_codex":0.025670428,"about_ca_topic_score_gemma":0.022492515,"teacher_disagreement_score":0.025670428,"about_ca_system_score_codex":0.0009454344,"about_ca_system_score_gemma":0.00070136285,"threshold_uncertainty_score":0.05104202},"labels":[],"label_agreement":null},{"id":"W4324311138","doi":"10.1007/s12325-023-02470-9","title":"Cost-Effectiveness of Brentuximab Vedotin Versus Physician’s Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"Seagen","keywords":"Bexarotene; Medicine; Brentuximab vedotin; Methotrexate; Internal medicine; Oncology; Cutaneous T-cell lymphoma; Lymphoma; Mycosis fungoides; Dermatology; Hodgkin lymphoma","score_opus":0.08365397874228304,"score_gpt":0.4042393616517976,"score_spread":0.32058538290951455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324311138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744168,0.005741229,0.0026669127,0.0030447326,0.000046951092,0.0004953739,0.005137744,0.000067603316,0.008382667],"genre_scores_gemma":[0.9971334,0.0007090562,0.00070306176,0.000105322266,0.000004977594,0.00003389567,0.0007060784,0.0000050059953,0.0005992392],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9989876,0.000418615,0.000036027737,0.000093844836,0.00014926448,0.0003146022],"domain_scores_gemma":[0.99819106,0.0009513574,0.00016452049,0.000033093485,0.00033132278,0.0003286482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016794341,0.0007392601,0.000829407,0.00073065405,0.00058147,0.0013468458,0.0011731543,0.00071744533,0.0032328472],"category_scores_gemma":[0.0054077255,0.00038988065,0.0015086519,0.00093463744,0.0005512767,0.00046032082,0.00059780525,0.0008471419,0.00010058156],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007470605,0.0004638208,0.048085447,0.0007335091,0.0013968971,0.0005508476,0.00014105269,0.89648044,0.0010545027,0.00566214,0.0042551127,0.033705655],"study_design_scores_gemma":[0.0022773275,0.0018947113,0.05540729,0.0003617008,0.0019030307,0.00035739873,0.00056585757,0.92937523,0.0010668531,0.0025113223,0.0041608186,0.00011851277],"about_ca_topic_score_codex":0.94471586,"about_ca_topic_score_gemma":0.9151389,"teacher_disagreement_score":0.055898577,"about_ca_system_score_codex":0.055898577,"about_ca_system_score_gemma":0.032610573,"threshold_uncertainty_score":0.40557444},"labels":[],"label_agreement":null},{"id":"W4327680697","doi":"10.1007/s12325-023-02457-6","title":"Dose Escalation Patterns of Advanced Therapies in Crohn’s Disease and Ulcerative Colitis: A Systematic Literature Review","year":2023,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"AbbVie","keywords":"Medicine; Ustekinumab; Infliximab; Adalimumab; Vedolizumab; Certolizumab pegol; Systematic review; Golimumab; De-escalation; Internal medicine; MEDLINE; Cochrane Library; Ulcerative colitis; Guideline; Tofacitinib; Meta-analysis; Disease; Pathology","score_opus":0.013942766061465902,"score_gpt":0.3245184971234345,"score_spread":0.3105757310619686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327680697","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002599089,0.9959305,0.0001409247,0.0002279868,0.00004966952,0.0003547125,0.0004216807,0.000007530876,0.00026786712],"genre_scores_gemma":[0.03545975,0.96105975,0.0012923569,0.0006384949,0.00008120332,0.0008983598,0.00044030024,0.000008925164,0.00012094161],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98298633,0.006172096,0.0072633326,0.0010965993,0.0021562185,0.00032539005],"domain_scores_gemma":[0.9289771,0.047853634,0.01739372,0.000921258,0.00438831,0.00046605075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0139780855,0.0013066679,0.007626651,0.018230826,0.00060591975,0.0028279098,0.0016421996,0.0015685136,0.0031125587],"category_scores_gemma":[0.0568493,0.001125891,0.009450849,0.018357294,0.0009238243,0.0031804813,0.0016619926,0.0012106639,0.00027366113],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003099835,0.000019922394,0.002053315,0.94887316,0.011843975,0.00009184469,0.0002697183,0.000114280105,0.00012962581,0.00014470682,0.0008591984,0.03529037],"study_design_scores_gemma":[0.00046832682,0.00030681127,0.010081622,0.9020495,0.075434215,0.0005425828,0.0004555935,0.00010572448,0.0001706882,0.00021472812,0.010122832,0.00004741287],"about_ca_topic_score_codex":0.006827492,"about_ca_topic_score_gemma":0.019006781,"teacher_disagreement_score":0.018230826,"about_ca_system_score_codex":0.0048356843,"about_ca_system_score_gemma":0.009905772,"threshold_uncertainty_score":0.073924005},"labels":[],"label_agreement":null},{"id":"W4353015402","doi":"10.1007/s12325-023-02483-4","title":"Ischemic Stroke and Systemic Embolism Among One-and-Done Direct Oral Anticoagulant Users with Non-valvular Atrial Fibrillation","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; Atrial fibrillation; Internal medicine; Cardiology; Stroke (engine); Embolism; Rheumatology; Oral anticoagulant; Anticoagulant; Ischemic stroke; Rivaroxaban; Warfarin; Ischemia","score_opus":0.03123094527149826,"score_gpt":0.3188026856673539,"score_spread":0.28757174039585565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353015402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990177,0.00022467114,0.00008705462,0.000039058636,0.000008552563,0.000009609138,0.00035207527,0.0000020850343,0.00025915087],"genre_scores_gemma":[0.9988544,0.00016009636,0.000073398674,0.000034524484,0.000024515399,0.000013492636,0.0006089576,0.0000012268027,0.00022932373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993292,0.00015208259,0.00007269511,0.00021614882,0.00012198801,0.00010790083],"domain_scores_gemma":[0.9983908,0.00025992875,0.0008479621,0.00015818518,0.00012614703,0.00021701692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093287905,0.0003113808,0.00037561884,0.0004777432,0.00037233197,0.0006794345,0.00039145583,0.00041019946,0.0020071466],"category_scores_gemma":[0.0022197224,0.0002527348,0.0009544384,0.0005196522,0.00019317781,0.00041900954,0.00048294917,0.0005722184,0.00023356013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042635264,0.000057792964,0.9974443,0.0000118552425,0.00013690289,0.000031490366,0.000027658796,0.000028139406,0.000081223356,0.000019265965,0.00008395357,0.0016510924],"study_design_scores_gemma":[0.00005451202,0.00032094214,0.99864846,0.000012836864,0.00012728109,0.00020986966,0.00006732139,0.0002465315,0.00007602896,0.00005875371,0.00017292918,0.0000045632128],"about_ca_topic_score_codex":0.0026405777,"about_ca_topic_score_gemma":0.003489128,"teacher_disagreement_score":0.0026405777,"about_ca_system_score_codex":0.00021880252,"about_ca_system_score_gemma":0.00035356634,"threshold_uncertainty_score":0.0067145824},"labels":[],"label_agreement":null},{"id":"W4360815487","doi":"10.1007/s12325-023-02443-y","title":"Interview-Based Patient- and Caregiver-Reported Experiences of Hunger and Improved Quality of Life with Setmelanotide Treatment in Bardet-Biedl Syndrome","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Genetic and Kidney Cyst Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Bardet–Biedl syndrome; Rheumatology; Quality of life (healthcare); Internal medicine; Pediatrics; Gerontology; Nursing; Phenotype; Genetics","score_opus":0.01580107757091467,"score_gpt":0.2864216264118373,"score_spread":0.2706205488409227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360815487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979808,0.00026019246,0.00036945607,0.000286587,0.000017411074,0.000078493315,0.00011027249,0.000004152387,0.0008927001],"genre_scores_gemma":[0.99866366,0.00024038967,0.00042151715,0.00015830707,0.0000070935853,0.00015608463,0.0000670517,0.000003148888,0.0002826689],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99551165,0.0034041018,0.0002105505,0.00017539818,0.000198381,0.0004999263],"domain_scores_gemma":[0.99377763,0.0037236104,0.0010647678,0.00014649867,0.0005022849,0.00078521465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053265584,0.00043949296,0.00059493823,0.0006706949,0.0022699353,0.0012602191,0.0005997139,0.00069042534,0.0022654717],"category_scores_gemma":[0.011593788,0.00035114674,0.0005422687,0.0005067702,0.0016082902,0.0011556762,0.0026443528,0.0015481949,0.0002159451],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052911456,0.000304486,0.04727073,0.00048581377,0.000050785624,0.0019577895,0.9337505,0.00018449895,0.0019044764,0.0002996739,0.0010621733,0.01220004],"study_design_scores_gemma":[0.00007316369,0.000741122,0.036906447,0.00032806926,0.000043372034,0.0017956101,0.9526089,0.00042353326,0.0009653201,0.0002419811,0.0058011534,0.00007139385],"about_ca_topic_score_codex":0.0031067878,"about_ca_topic_score_gemma":0.006576758,"teacher_disagreement_score":0.0053265584,"about_ca_system_score_codex":0.0020075687,"about_ca_system_score_gemma":0.001685611,"threshold_uncertainty_score":0.02816987},"labels":[],"label_agreement":null},{"id":"W4361303012","doi":"10.1007/s12325-023-02475-4","title":"Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Janssen Research and Development; Janssen Scientific Affairs","keywords":"Medicine; Ustekinumab; Psoriatic arthritis; Secukinumab; Sacroiliitis; Internal medicine; Axial spondyloarthritis; Ankylosing spondylitis; Human leukocyte antigen; Immunology; Oncology; Rheumatology; Adalimumab; Arthritis; Rheumatoid arthritis; Antigen","score_opus":0.10104494604942928,"score_gpt":0.4457693522950448,"score_spread":0.3447244062456155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361303012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814299,0.0055367528,0.0024989573,0.00025091172,0.00023585884,0.0053397384,0.0024383827,0.00011342864,0.0021561505],"genre_scores_gemma":[0.9875946,0.0008527341,0.0022275052,0.00030133905,0.00012580311,0.006215957,0.0015979504,0.00004549587,0.0010386531],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.98868924,0.0074314405,0.0008941995,0.0011675435,0.00092004606,0.0008975811],"domain_scores_gemma":[0.9843255,0.008850011,0.002948447,0.0017929386,0.0011595151,0.0009235904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022606121,0.0019500323,0.003726411,0.0006245661,0.0007778888,0.0017748163,0.0010465806,0.0011280967,0.0042755706],"category_scores_gemma":[0.01497881,0.0006083814,0.0073457677,0.0008753247,0.0013305378,0.0013198785,0.0009492253,0.002255407,0.0005318135],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9274475,0.0036598458,0.018479861,0.0012568416,0.028966518,0.00009128029,0.00017222449,0.0012595186,0.0067921607,0.00013970301,0.0008080226,0.0109266145],"study_design_scores_gemma":[0.40063542,0.34083128,0.16955261,0.00022406355,0.06933028,0.00034345305,0.00034459858,0.00398789,0.007308902,0.0013351869,0.005935177,0.00017109161],"about_ca_topic_score_codex":0.0005540293,"about_ca_topic_score_gemma":0.001474876,"teacher_disagreement_score":0.022606121,"about_ca_system_score_codex":0.0009642499,"about_ca_system_score_gemma":0.0020658013,"threshold_uncertainty_score":0.11955404},"labels":[],"label_agreement":null},{"id":"W4362507047","doi":"10.1007/s12325-023-02495-0","title":"A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”","year":2023,"lang":"en","type":"letter","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Fluticasone propionate; COPD; Meta-analysis; Internal medicine; Pharmacology; Corticosteroid","score_opus":0.0768440390173844,"score_gpt":0.3648680601505049,"score_spread":0.2880240211331205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362507047","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014820856,0.00087384495,0.00010037335,0.9419804,0.055730294,0.000019878331,0.00032043885,0.00003973428,0.0007867474],"genre_scores_gemma":[0.00077418407,0.0005312541,0.00013872726,0.95421106,0.041758496,0.00004573379,0.00007009937,0.000027851467,0.0024425816],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936661,0.0020206578,0.0012451346,0.00086095266,0.0016347158,0.00057241047],"domain_scores_gemma":[0.9750489,0.014675528,0.0022868915,0.0005846369,0.0052149105,0.002189106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008175729,0.0012496855,0.0033800867,0.0012434319,0.0030736744,0.0044622603,0.002534371,0.04016936,0.009973018],"category_scores_gemma":[0.057494894,0.0011245228,0.0029475414,0.0012319877,0.0016734176,0.002799388,0.0015691381,0.035098456,0.011459351],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011875258,0.000021124188,0.00021279443,0.00010028469,0.000034847068,0.00027082316,0.000031560463,0.00003074979,0.00006804394,0.0003253872,0.9958925,0.0028930728],"study_design_scores_gemma":[0.0007237397,0.0001907121,0.0021309974,0.0012690355,0.0002811825,0.0010915416,0.0003027952,0.00062214566,0.000390913,0.0046286066,0.9882172,0.00015121745],"about_ca_topic_score_codex":0.0068375417,"about_ca_topic_score_gemma":0.009697045,"teacher_disagreement_score":0.04016936,"about_ca_system_score_codex":0.004519003,"about_ca_system_score_gemma":0.006756055,"threshold_uncertainty_score":0.043237925},"labels":[],"label_agreement":null},{"id":"W4366238420","doi":"10.1007/s12325-023-02503-3","title":"The Role of Expert Opinion in Projecting Long-Term Survival Outcomes Beyond the Horizon of a Clinical Trial","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Advanced Causal Inference Techniques","field":"Mathematics","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Defense Acquisition Program Administration; AstraZeneca","keywords":"Frequentist inference; Medicine; Bayesian probability; Expert opinion; Population; Survival analysis; Placebo; Relative survival; Statistics; Bayesian inference; Internal medicine; Intensive care medicine; Mathematics","score_opus":0.26403437545403435,"score_gpt":0.5460801964420338,"score_spread":0.2820458209879994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366238420","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28353783,0.0054969313,0.6790518,0.009406885,0.00021728098,0.0008050564,0.0011000324,0.00031859113,0.02006562],"genre_scores_gemma":[0.87126917,0.0008398717,0.12596464,0.00088048686,0.00014359647,0.00031993634,0.00030321025,0.00003436384,0.0002446953],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.79067934,0.18912722,0.0045264005,0.0051271133,0.009364776,0.0011751904],"domain_scores_gemma":[0.31384593,0.6434232,0.020724354,0.00896019,0.011458127,0.0015882672],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.17087755,0.0011465952,0.0011373346,0.0034060278,0.0008506395,0.003993723,0.0014533243,0.0021041278,0.0019689333],"category_scores_gemma":[0.40851095,0.00066708395,0.0017060685,0.001780237,0.001904179,0.0048633493,0.0037603942,0.002105046,0.0003803148],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004175043,0.00036699127,0.2106822,0.00434236,0.0030921777,0.00046350338,0.009252594,0.13012466,0.002937521,0.029675085,0.0050903265,0.5997975],"study_design_scores_gemma":[0.00061079086,0.0016755402,0.090685695,0.004461143,0.0017219975,0.00067912595,0.0032096684,0.71836597,0.004544888,0.1622995,0.011258715,0.00048699282],"about_ca_topic_score_codex":0.0032196916,"about_ca_topic_score_gemma":0.003680897,"teacher_disagreement_score":0.8291224,"about_ca_system_score_codex":0.002155254,"about_ca_system_score_gemma":0.0030620699,"threshold_uncertainty_score":0.9036976},"labels":[],"label_agreement":null},{"id":"W4367834624","doi":"10.1007/s12325-023-02482-5","title":"Patient Management and Clinical Outcomes Associated with a Recorded Diagnosis of Stage 3 Chronic Kidney Disease: The REVEAL-CKD Study","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Seven Oaks General Hospital","funders":"AstraZeneca","keywords":"Medicine; Kidney disease; Rheumatology; Internal medicine; Stage (stratigraphy); Intensive care medicine; Disease; Disease management; Nephrology","score_opus":0.02155464134305796,"score_gpt":0.3464925788264291,"score_spread":0.32493793748337113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367834624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99120927,0.00091737835,0.00013648596,0.00018460247,0.000026422447,0.0000963074,0.0066459454,0.0000073516494,0.00077614986],"genre_scores_gemma":[0.9912299,0.00038403846,0.00016074722,0.00016961829,0.000052758405,0.00015073307,0.0074057374,0.000008070272,0.00043846044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848217,0.00055266183,0.0002433097,0.00032220053,0.00019689562,0.00020283854],"domain_scores_gemma":[0.9960187,0.0006834045,0.001909456,0.00050371,0.00035098894,0.00053365907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024342742,0.000508984,0.0008703542,0.00054153963,0.000516137,0.0012181869,0.00094523706,0.0010298402,0.0015311168],"category_scores_gemma":[0.0049072797,0.00071994826,0.0015963317,0.0014911501,0.00031604615,0.0011025144,0.0019283225,0.0015370211,0.00040515434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028523626,0.00024134557,0.9943144,0.00008633892,0.00069275405,0.00005464841,0.00012894013,0.000070055146,0.000112205715,0.000057304645,0.0007260703,0.00066349976],"study_design_scores_gemma":[0.0006458529,0.0005415024,0.99666303,0.000051059364,0.00058211526,0.00019690217,0.00026395379,0.000310505,0.000054804565,0.000054880926,0.0006148284,0.000020472135],"about_ca_topic_score_codex":0.010667512,"about_ca_topic_score_gemma":0.015764838,"teacher_disagreement_score":0.010667512,"about_ca_system_score_codex":0.000670101,"about_ca_system_score_gemma":0.0008706105,"threshold_uncertainty_score":0.02121085},"labels":[],"label_agreement":null},{"id":"W4379792157","doi":"10.1007/s12325-023-02560-8","title":"The Influence of Oral Cannabidiol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Untreated Hypertension: A Double-Blind, Placebo-Controlled, Cross-Over Pilot Study","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Okanagan University College; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"","keywords":"Cannabidiol; Medicine; Arterial stiffness; Blood pressure; Ambulatory blood pressure; Placebo; Heart rate; Cardiology; Crossover study; Ambulatory; Internal medicine; Anesthesia; Pathology","score_opus":0.033739390520634814,"score_gpt":0.34883872500381236,"score_spread":0.31509933448317756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379792157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99783,0.0007583064,0.00021258247,0.000068357695,0.00010883121,0.00040195728,0.00020406106,0.00002306442,0.0003927656],"genre_scores_gemma":[0.9947301,0.0012876765,0.0007716618,0.00023411194,0.00038643504,0.00061478466,0.00031118814,0.000021968119,0.0016419989],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9988663,0.0004862025,0.00009762076,0.00017403746,0.00018136494,0.00019447488],"domain_scores_gemma":[0.997692,0.00091163506,0.00026044113,0.00020280678,0.00015601859,0.0007770473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016545895,0.0013924146,0.0035778112,0.0005770758,0.0008315456,0.0007050689,0.0010812753,0.0019324367,0.0032886395],"category_scores_gemma":[0.002427706,0.0010490577,0.0012212821,0.0006089546,0.001870319,0.001245186,0.000616891,0.0026293122,0.0004698058],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9242553,0.040091198,0.0015040211,0.0003752147,0.0004867137,0.000070550595,0.00016819686,0.00015855911,0.017440975,0.000034990153,0.00017270686,0.015241531],"study_design_scores_gemma":[0.35891017,0.5954002,0.03685047,0.000030226114,0.0010801047,0.00007305104,0.00014359552,0.00079141575,0.005988516,0.0001026509,0.000552267,0.000077323515],"about_ca_topic_score_codex":0.0026443854,"about_ca_topic_score_gemma":0.003111995,"teacher_disagreement_score":0.0035778112,"about_ca_system_score_codex":0.00045434322,"about_ca_system_score_gemma":0.0011935169,"threshold_uncertainty_score":0.011001527},"labels":[],"label_agreement":null},{"id":"W4381113775","doi":"10.1007/s12325-023-02568-0","title":"Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review","year":2023,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Regeneron Pharmaceuticals; Sun Pharma; Sanofi Genzyme; Incyte; Eli Lilly and Company; Ortho Dermatologics; Purdue Pharma; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Purdue University","keywords":"Medicine; Adverse effect; Psoriasis; Clinical trial; Psoriatic arthritis; Internal medicine; Dermatology; Population; Intensive care medicine","score_opus":0.03196367031395327,"score_gpt":0.3203321296975279,"score_spread":0.28836845938357464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381113775","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038162217,0.9987124,0.00009092164,0.00020325174,0.00007743548,0.00005851389,0.00014322437,0.0000034592256,0.0003292576],"genre_scores_gemma":[0.0034587202,0.9956163,0.00017319513,0.00038783846,0.00010081296,0.0000708637,0.00011157073,0.0000016648692,0.000078977384],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982724,0.00041144833,0.00075850054,0.00015069594,0.0003592346,0.00004768637],"domain_scores_gemma":[0.99237293,0.0052625895,0.0015195775,0.000086547705,0.00068646064,0.0000718282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028851796,0.0009277252,0.002889044,0.003834991,0.00035084205,0.0017392318,0.0011533876,0.001314329,0.0031989203],"category_scores_gemma":[0.009188614,0.00043609072,0.0033844716,0.003856021,0.00042674554,0.0014776532,0.0006898245,0.0008644105,0.00043430104],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030875212,0.000034654604,0.00049320824,0.8452954,0.0027713655,0.00021131002,0.00017787046,0.00014609656,0.000525317,0.0006162943,0.0050965943,0.14432307],"study_design_scores_gemma":[0.00026204844,0.0005770833,0.004135207,0.7836364,0.033438623,0.0021963897,0.0003677175,0.00019642568,0.0006577664,0.0009998644,0.17347117,0.00006131749],"about_ca_topic_score_codex":0.0014691239,"about_ca_topic_score_gemma":0.0029263115,"teacher_disagreement_score":0.003834991,"about_ca_system_score_codex":0.0009564274,"about_ca_system_score_gemma":0.0036717483,"threshold_uncertainty_score":0.015258431},"labels":[],"label_agreement":null},{"id":"W4382182642","doi":"10.1007/s12325-023-02546-6","title":"Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn’s Disease","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"AbbVie","keywords":"Medicine; Ustekinumab; Crohn's disease; Internal medicine; Confidence interval; Maintenance therapy; Gastroenterology; Crohn disease; Clinical trial; Randomized controlled trial; Surgery; Disease; Chemotherapy; Adalimumab","score_opus":0.029267054082331632,"score_gpt":0.3186003664488895,"score_spread":0.28933331236655785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382182642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9463821,0.01810786,0.009919984,0.0011019997,0.0019431825,0.0048330934,0.007889344,0.00019350355,0.009628869],"genre_scores_gemma":[0.9872957,0.0009766101,0.004105002,0.0007089652,0.00024317678,0.0026999912,0.0020547442,0.00003050936,0.0018853281],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9776953,0.01744604,0.0013929895,0.0016366559,0.0010362838,0.0007927472],"domain_scores_gemma":[0.989268,0.006546894,0.0019615907,0.0011815919,0.000556809,0.0004849368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012022939,0.0019552752,0.0034073957,0.00066395896,0.00030390435,0.0012557631,0.0017439772,0.0018169009,0.012106566],"category_scores_gemma":[0.025445411,0.00069633883,0.010265777,0.0007010705,0.00073786336,0.0013935533,0.0018238202,0.0028092794,0.0009028251],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8460457,0.0019932818,0.01524548,0.0054545575,0.07104977,0.00011776115,0.0002525469,0.0046137,0.001203947,0.0020192116,0.0027815907,0.049222432],"study_design_scores_gemma":[0.44420195,0.20014256,0.10377356,0.0020987734,0.18616469,0.00055596314,0.0004173147,0.02868532,0.005150287,0.013928909,0.014538881,0.00034191355],"about_ca_topic_score_codex":0.0020801509,"about_ca_topic_score_gemma":0.0019907476,"teacher_disagreement_score":0.012106566,"about_ca_system_score_codex":0.0010704114,"about_ca_system_score_gemma":0.0011407483,"threshold_uncertainty_score":0.06358415},"labels":[],"label_agreement":null},{"id":"W4382501551","doi":"10.1007/s12325-023-02583-1","title":"DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"Manchester Biomedical Research Centre; McMaster University; Glenmark Pharmaceuticals; CSL Behring; Gilead Sciences; Sanofi; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Genentech; AstraZeneca","keywords":"Medicine; Fluticasone propionate; COPD; Lama; Indacaterol; Exacerbation; Bronchodilator; Pharmacotherapy; Internal medicine; Obstructive lung disease; Corticosteroid; Asthma","score_opus":0.03633041686003346,"score_gpt":0.35346605408801324,"score_spread":0.31713563722797977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382501551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76775646,0.0014763776,0.21659116,0.0021270667,0.00012819812,0.0002996057,0.001285878,0.0006743542,0.009660862],"genre_scores_gemma":[0.9844471,0.0003967238,0.012511567,0.0001248242,0.00002886096,0.00015184811,0.00034642222,0.000025177877,0.0019672986],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9996113,0.00018066283,0.00002413326,0.00007255568,0.000048441725,0.00006280729],"domain_scores_gemma":[0.99821043,0.0012682182,0.0002651534,0.00005193672,0.00013129687,0.00007306044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011908602,0.0010497046,0.0009754113,0.00069955713,0.00032781268,0.0013915084,0.0013900475,0.0013052716,0.0013512154],"category_scores_gemma":[0.0036534115,0.0006542229,0.0017436467,0.00048473218,0.00043793352,0.0006214032,0.0007280244,0.0010701892,0.00021960093],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000117443844,0.00004957898,0.0027264813,0.000037166843,0.000047358426,0.0000456345,0.0000391133,0.99201727,0.0005170564,0.00065606256,0.000092203576,0.0036545452],"study_design_scores_gemma":[0.000012721396,0.00008441484,0.00072016305,0.000007974606,0.0000358145,0.000020056248,0.0000112752505,0.9981517,0.00019487397,0.0005997585,0.00015144587,0.000009722497],"about_ca_topic_score_codex":0.018315326,"about_ca_topic_score_gemma":0.00940046,"teacher_disagreement_score":0.018315326,"about_ca_system_score_codex":0.0010609279,"about_ca_system_score_gemma":0.0012264192,"threshold_uncertainty_score":0.036417425},"labels":[],"label_agreement":null},{"id":"W4385331142","doi":"10.1007/s12325-023-02613-y","title":"Correction to: DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach","year":2023,"lang":"en","type":"erratum","venue":"Advances in Therapy","topic":"Inhalation and Respiratory Drug Delivery","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Medicine; Bronchodilator; COPD; Pharmacotherapy; Intensive care medicine; Disease; Rheumatology; Internal medicine; Asthma","score_opus":0.02996748469507819,"score_gpt":0.33206791315865947,"score_spread":0.30210042846358126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385331142","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007951446,0.00073258014,0.0010517924,0.03355686,0.9602845,0.000028736635,0.0017895651,0.00034231483,0.0021341718],"genre_scores_gemma":[0.013781266,0.010452068,0.011873842,0.08379188,0.59160113,0.00034682624,0.0050503532,0.0031798882,0.2799227],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9968905,0.0006424048,0.000593997,0.00043802374,0.0011618334,0.00027330313],"domain_scores_gemma":[0.97345155,0.007728382,0.0013421086,0.0015931855,0.014208876,0.0016759471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036954682,0.0024474673,0.0022085423,0.0027504198,0.0018174076,0.0043085204,0.0028266017,0.006461683,0.12389715],"category_scores_gemma":[0.062028892,0.0010178385,0.002158005,0.0018628724,0.0016947476,0.0021277182,0.0018185973,0.009985894,0.060832985],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004339912,0.000006172774,0.00005142731,0.000146492,0.00001153929,0.000114368384,0.000012700643,0.00008647605,0.000023905679,0.00053198106,0.9931431,0.0058285557],"study_design_scores_gemma":[0.00013575413,0.000030834413,0.0006076997,0.00059231103,0.000058141635,0.00058150035,0.00006877533,0.00087209255,0.00032778093,0.0027296527,0.99395,0.00004545533],"about_ca_topic_score_codex":0.016949281,"about_ca_topic_score_gemma":0.018904418,"teacher_disagreement_score":0.12389715,"about_ca_system_score_codex":0.0028267025,"about_ca_system_score_gemma":0.0057755243,"threshold_uncertainty_score":0.41447723},"labels":[],"label_agreement":null},{"id":"W4385340634","doi":"10.1007/s12325-023-02611-0","title":"Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Dalhousie University; University of British Columbia","funders":"","keywords":"Ustekinumab; Medicine; Persistence (discontinuity); Internal medicine; Hazard ratio; Proportional hazards model; Inflammatory bowel disease; Ulcerative colitis; Crohn's disease; Confidence interval; Population; Retrospective cohort study; Disease; Gastroenterology; Adalimumab","score_opus":0.014665309315881551,"score_gpt":0.28743616060410565,"score_spread":0.2727708512882241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385340634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9673104,0.017975418,0.0010173712,0.006649266,0.00021310568,0.000036731835,0.0013164461,0.000037937207,0.0054432666],"genre_scores_gemma":[0.9967595,0.0017441321,0.00033691723,0.0005366644,0.00013483079,0.000016505932,0.0003268391,0.00000619823,0.00013846223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973986,0.0012209868,0.00035315682,0.00025350793,0.00054237567,0.00023137675],"domain_scores_gemma":[0.99447143,0.0024333943,0.0018804944,0.00023442679,0.0004977053,0.0004826233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025992931,0.0001504526,0.0005963586,0.0003933933,0.0004921807,0.001881241,0.00026939335,0.0007778699,0.0019684762],"category_scores_gemma":[0.010712086,0.00009676894,0.00034128674,0.0010179752,0.00046837764,0.0010180236,0.0005462484,0.0011398906,0.0002924733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008518144,0.0007204275,0.7494388,0.0013389188,0.00068158633,0.0031503115,0.0012713094,0.0025920307,0.0032512774,0.00178248,0.009464736,0.21778998],"study_design_scores_gemma":[0.0005867969,0.0040936507,0.8895953,0.0013103997,0.0010238641,0.013044672,0.0051555466,0.008281116,0.0034131748,0.0061221095,0.06718659,0.00018675697],"about_ca_topic_score_codex":0.0013139641,"about_ca_topic_score_gemma":0.0019121425,"teacher_disagreement_score":0.0025992931,"about_ca_system_score_codex":0.0010181274,"about_ca_system_score_gemma":0.0006841844,"threshold_uncertainty_score":0.01374656},"labels":[],"label_agreement":null},{"id":"W4385396235","doi":"10.1007/s12325-023-02622-x","title":"The Economic Burden of Adults with Major Depressive Disorder in the United States (2019)","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Mental Health Treatment and Access","field":"Psychology","cited_by":194,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Sage Therapeutics; Biogen","keywords":"Major depressive disorder; Medicine; Presenteeism; Absenteeism; Economic cost; Indirect costs; Economic impact analysis; Psychological intervention; Psychiatry; Demography; Environmental health; Gerontology; Psychology; Business; Economics; Mood","score_opus":0.013943775197073006,"score_gpt":0.3560974645480499,"score_spread":0.3421536893509769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385396235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8248758,0.016376311,0.012984896,0.018521564,0.00081549183,0.00040241252,0.074923664,0.00025851725,0.050841305],"genre_scores_gemma":[0.9839109,0.004210826,0.0025817775,0.00086304796,0.00008332856,0.000075989556,0.0070413295,0.000009272239,0.0012235185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99943143,0.00026422564,0.000055091918,0.000046156696,0.00013748236,0.00006565516],"domain_scores_gemma":[0.99924904,0.00017135586,0.00025618635,0.000031124724,0.00020664715,0.00008556129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010583567,0.00034237292,0.00019875381,0.00060864846,0.00021100213,0.0009818466,0.0003427926,0.00040924686,0.00349293],"category_scores_gemma":[0.0032891738,0.0001656103,0.0008705341,0.0008600492,0.00027853932,0.00069302233,0.00073155115,0.00067532196,0.0003750226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006470492,0.00019854301,0.71895534,0.0011639091,0.0016312334,0.00071283424,0.0002906514,0.07627879,0.00071698666,0.020701064,0.05462258,0.12408103],"study_design_scores_gemma":[0.00024339012,0.00081498706,0.7782512,0.0027532554,0.0019473502,0.001975142,0.0018247262,0.09973208,0.0012989054,0.023414081,0.08759714,0.00014786974],"about_ca_topic_score_codex":0.040702894,"about_ca_topic_score_gemma":0.04722472,"teacher_disagreement_score":0.040702894,"about_ca_system_score_codex":0.0029612686,"about_ca_system_score_gemma":0.0015797783,"threshold_uncertainty_score":0.0809319},"labels":[],"label_agreement":null},{"id":"W4385564153","doi":"10.1007/s12325-023-02609-8","title":"Implementing an Evidence-Based COPD Hospital Discharge Protocol: A Narrative Review and Expert Recommendations","year":2023,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Emergency and Acute Care Studies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; AstraZeneca","keywords":"Medicine; COPD; Exacerbation; Health care; Intensive care medicine; Pulmonary rehabilitation; Protocol (science); Population; Physical therapy; Internal medicine; Alternative medicine; Environmental health; Pathology","score_opus":0.1258795260672343,"score_gpt":0.5087637387316973,"score_spread":0.38288421266446304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385564153","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013440661,0.8876449,0.008750577,0.06762236,0.005472612,0.020337813,0.002297347,0.00018498623,0.0063453326],"genre_scores_gemma":[0.015950548,0.8774489,0.040285673,0.028513277,0.0014791467,0.031169076,0.002164097,0.00006882328,0.00292058],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9330973,0.029684387,0.025767952,0.0020147269,0.008187241,0.0012484023],"domain_scores_gemma":[0.83351547,0.1036284,0.026238944,0.0030260098,0.03138377,0.0022074282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07857165,0.0024093187,0.005273341,0.011807512,0.0019135864,0.0069523756,0.006014253,0.0073479996,0.009391344],"category_scores_gemma":[0.25784022,0.001853639,0.00908617,0.009000163,0.002243915,0.009778329,0.005111515,0.006390349,0.002431845],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020770292,0.00008740013,0.0004838185,0.73766667,0.0014480855,0.00031651498,0.0017642083,0.0005141883,0.00024023475,0.0044563822,0.04085781,0.21195702],"study_design_scores_gemma":[0.00013275533,0.000034698376,0.00035041914,0.9441475,0.0020641661,0.00011281336,0.0003713809,0.00012007533,0.00010157004,0.0016491924,0.05087588,0.000039567803],"about_ca_topic_score_codex":0.012106543,"about_ca_topic_score_gemma":0.026073711,"teacher_disagreement_score":0.07857165,"about_ca_system_score_codex":0.015253569,"about_ca_system_score_gemma":0.061857957,"threshold_uncertainty_score":0.41553158},"labels":[],"label_agreement":null},{"id":"W4385779498","doi":"10.1007/s12325-023-02606-x","title":"Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Crizotinib; Brain metastasis; Anaplastic lymphoma kinase; Internal medicine; Oncology; ALK inhibitor; Lung cancer; Interim analysis; Tyrosine-kinase inhibitor; Progression-free survival; Metastasis; Clinical trial; Cancer; Overall survival","score_opus":0.02005702054535472,"score_gpt":0.364229775795692,"score_spread":0.34417275525033725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385779498","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011390363,0.184106,0.003543828,0.29264492,0.33331802,0.0007282288,0.0048322,0.0014818752,0.16795458],"genre_scores_gemma":[0.069137886,0.19880423,0.005125043,0.15909964,0.3273297,0.0004980043,0.0043613724,0.00060837367,0.23503584],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995185,0.00010228562,0.000040040468,0.00006028525,0.00019003318,0.00008885424],"domain_scores_gemma":[0.9982667,0.00042499055,0.00029448917,0.00007393145,0.00039374776,0.0005460779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011553927,0.00045773177,0.00067708903,0.00054256886,0.000850569,0.0027169746,0.00090614345,0.0026947202,0.026417695],"category_scores_gemma":[0.0033649572,0.00025206027,0.00084315997,0.00044426898,0.00060126715,0.0015157559,0.0008973697,0.005969571,0.006739156],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070574076,0.00009335175,0.00018183485,0.0003879685,0.00001955054,0.00019478658,0.000014168884,0.00015364293,0.0009241061,0.0017810072,0.8968122,0.098731644],"study_design_scores_gemma":[0.00039939318,0.00035054664,0.0013341666,0.00041803872,0.00003530124,0.0002934551,0.000017972085,0.00025683368,0.00038100302,0.0009982155,0.9954977,0.000017427252],"about_ca_topic_score_codex":0.0014942345,"about_ca_topic_score_gemma":0.0063261846,"teacher_disagreement_score":0.026417695,"about_ca_system_score_codex":0.0013673389,"about_ca_system_score_gemma":0.001462114,"threshold_uncertainty_score":0.088376045},"labels":[],"label_agreement":null},{"id":"W4386757238","doi":"10.1007/s12325-023-02634-7","title":"Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pfizer","keywords":"Medicine; Prostate cancer; Concomitant; Internal medicine; Adverse effect; Urology; Population; Cancer","score_opus":0.02484750801981962,"score_gpt":0.37897592618127074,"score_spread":0.35412841816145113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386757238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993228,0.0051614544,0.00027917515,0.00008523867,0.000038641654,0.00012655606,0.0007031909,0.000015945461,0.00036182738],"genre_scores_gemma":[0.99849474,0.00039398382,0.00015680236,0.0000774186,0.00004698121,0.000075805365,0.0006174442,0.000007234753,0.00012953213],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9975495,0.0012530729,0.00031296036,0.0003887581,0.00030430165,0.0001913977],"domain_scores_gemma":[0.9975266,0.0010701566,0.00059240975,0.00042699272,0.00012544233,0.0002583471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035668367,0.0006890433,0.0026311197,0.00055262586,0.00019115844,0.0007631181,0.0005371642,0.0005626793,0.0012133936],"category_scores_gemma":[0.0032068626,0.00023812066,0.0070665046,0.00056315766,0.0002821597,0.0003949158,0.0004706972,0.0007757055,0.00010337975],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52520424,0.00087436574,0.31390917,0.0019376604,0.11197583,0.00046755167,0.00030991746,0.002664442,0.0080325855,0.0001783792,0.0015979861,0.032847974],"study_design_scores_gemma":[0.043515638,0.03666784,0.825202,0.00017714329,0.08338695,0.0006925972,0.0003989466,0.0046315375,0.0021217132,0.00070789567,0.0023596017,0.00013816722],"about_ca_topic_score_codex":0.0007723703,"about_ca_topic_score_gemma":0.0019882862,"teacher_disagreement_score":0.0035668367,"about_ca_system_score_codex":0.0003720586,"about_ca_system_score_gemma":0.00043083893,"threshold_uncertainty_score":0.01886344},"labels":[],"label_agreement":null},{"id":"W4386878449","doi":"10.1007/s12325-023-02658-z","title":"Real-World Treatment Patterns Among Patients with Connective Tissue Disorder-Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; Rheumatology; Connective Tissue Disorder; Internal medicine; Pulmonary hypertension; Retrospective cohort study; Cardiology; Connective tissue; Connective tissue disease; Surgery; Pathology; Disease","score_opus":0.01531175510773769,"score_gpt":0.3036201549384517,"score_spread":0.288308399830714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386878449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99087113,0.0007778577,0.00020463472,0.00012905854,0.000009416106,0.000028573082,0.007448693,0.000008738099,0.0005218205],"genre_scores_gemma":[0.9952348,0.00024816985,0.00016530763,0.00007008076,0.000014579897,0.000030839044,0.0041645877,0.0000033631763,0.0000681749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998106,0.00047193404,0.00043946196,0.0004508105,0.00038203842,0.00014978486],"domain_scores_gemma":[0.99286413,0.0012711459,0.004479341,0.00050746865,0.0005084847,0.0003694614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001676208,0.0002062999,0.00046923765,0.0015558677,0.00039667464,0.00096114643,0.00051310187,0.0005092339,0.0010826916],"category_scores_gemma":[0.005047883,0.0003321328,0.0006740623,0.0028985913,0.00030263158,0.0007066709,0.00070240605,0.0007276117,0.00020215315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057458292,0.00002014277,0.99895716,0.000013721458,0.00007305556,0.000027674738,0.000036227295,0.000054076874,0.000030425526,0.000015590515,0.00019105278,0.0005235186],"study_design_scores_gemma":[0.000007778978,0.0000424646,0.9985757,0.000019247522,0.000050178973,0.00021634431,0.00015289348,0.0005375328,0.000035779653,0.000020799946,0.00033470252,0.00000663885],"about_ca_topic_score_codex":0.012252384,"about_ca_topic_score_gemma":0.009522373,"teacher_disagreement_score":0.012252384,"about_ca_system_score_codex":0.0006357839,"about_ca_system_score_gemma":0.0005827486,"threshold_uncertainty_score":0.024362147},"labels":[],"label_agreement":null},{"id":"W4387033069","doi":"10.1007/s12325-023-02661-4","title":"Symptom and Treatment Satisfaction in Members of the US and Canadian GBS/CIDP Foundations with a Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Peripheral Neuropathies and Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Toronto General Hospital","funders":"Grifols","keywords":"Medicine; Chronic inflammatory demyelinating polyneuropathy; Rheumatology; Polyneuropathy; Internal medicine; Physical therapy; Intensive care medicine; Immunology; Antibody","score_opus":0.009068447359378649,"score_gpt":0.2634096383506164,"score_spread":0.25434119099123775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387033069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949479,0.00029851662,0.000023746414,0.0004151497,0.000018993236,0.000020511945,0.00082682376,0.000002337319,0.0034460044],"genre_scores_gemma":[0.99872786,0.00012284277,0.000036468566,0.00014717199,0.0000066269185,0.000007951354,0.00045839764,0.0000014580722,0.0004910582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987338,0.00015014115,0.000080324615,0.00008260974,0.0004181117,0.0005349079],"domain_scores_gemma":[0.99745494,0.00022871935,0.0005976544,0.00004039682,0.0008185063,0.0008598143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093453645,0.00018031335,0.00045035957,0.00068496045,0.002096229,0.0013431516,0.00064391847,0.0005740003,0.0038507753],"category_scores_gemma":[0.005127318,0.00014269777,0.00076956465,0.0016645122,0.0008263639,0.00054680475,0.0009866651,0.0009007453,0.00026403688],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015095994,0.000082320475,0.9941666,0.000020564421,0.000051760664,0.00011387884,0.0013816976,0.00008262044,0.000058320093,0.000045925422,0.0009389224,0.0029063667],"study_design_scores_gemma":[0.0000070418587,0.000052961677,0.99328554,0.000018867038,0.000019555142,0.0001340514,0.0058029783,0.0001360644,0.000014490216,0.000018842458,0.0004996732,0.000009992762],"about_ca_topic_score_codex":0.7722331,"about_ca_topic_score_gemma":0.8453994,"teacher_disagreement_score":0.22776687,"about_ca_system_score_codex":0.006315992,"about_ca_system_score_gemma":0.006558375,"threshold_uncertainty_score":0.45821643},"labels":[],"label_agreement":null},{"id":"W4387033778","doi":"10.1007/s12325-023-02668-x","title":"Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Nintedanib; Medicine; Vital capacity; DLCO; Internal medicine; Placebo; Idiopathic pulmonary fibrosis; Interstitial lung disease; Pulmonary fibrosis; Body mass index; Diffusing capacity; Lung; Pathology; Lung function","score_opus":0.0033951741558211042,"score_gpt":0.2510020789738331,"score_spread":0.24760690481801198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387033778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859161,0.0113187,0.00021347513,0.00024387879,0.000115614785,0.00034601445,0.00035339748,0.000023065671,0.0014697047],"genre_scores_gemma":[0.99630785,0.0017123753,0.00031424523,0.0002928283,0.00010337517,0.0002924097,0.00060185057,0.000004527928,0.0003706536],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.999159,0.0004025266,0.000121292025,0.00015168112,0.000070204595,0.000095354764],"domain_scores_gemma":[0.99901867,0.00034876488,0.0002757308,0.00007216304,0.00006181244,0.00022289064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019034594,0.0007018132,0.0028693667,0.00023885009,0.00028414547,0.0006244117,0.00034387258,0.00055235863,0.002317845],"category_scores_gemma":[0.0015749,0.00022284151,0.0019419029,0.00023706569,0.00032976957,0.0005082362,0.00037579722,0.0010722285,0.00022637869],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89140975,0.0021149423,0.02627598,0.001838613,0.0059725167,0.00012337945,0.00012960215,0.00080487883,0.008083409,0.00012908358,0.00074569933,0.06237217],"study_design_scores_gemma":[0.5030118,0.24203618,0.23487654,0.0005509747,0.0082011,0.0006653323,0.00027788102,0.0015686515,0.003679672,0.00082037,0.0042249653,0.00008656306],"about_ca_topic_score_codex":0.00036478494,"about_ca_topic_score_gemma":0.0014318322,"teacher_disagreement_score":0.0028693667,"about_ca_system_score_codex":0.0004007929,"about_ca_system_score_gemma":0.0005377731,"threshold_uncertainty_score":0.010066569},"labels":[],"label_agreement":null},{"id":"W4387128991","doi":"10.1007/s12325-023-02666-z","title":"Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"","keywords":"Medicine; Rosuvastatin; Statin; Double blind; Ezetimibe; Randomized controlled trial; Internal medicine; Pill; Simvastatin; Single blind; Atorvastatin; Rheumatology; Pharmacology; Alternative medicine; Placebo","score_opus":0.0329011302102163,"score_gpt":0.36149323518587934,"score_spread":0.32859210497566305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387128991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971655,0.001079241,0.00016339798,0.00018366617,0.00009034638,0.0008027611,0.00019016147,0.00003566774,0.00028938093],"genre_scores_gemma":[0.9955844,0.00076760235,0.00080395676,0.0004722841,0.00015373157,0.0012420348,0.00038346695,0.0000061854585,0.00058640935],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99934524,0.00028845062,0.00006357096,0.00013658528,0.000072806106,0.000093350536],"domain_scores_gemma":[0.99908566,0.00016119739,0.00024616966,0.00008809796,0.00007149749,0.0003474013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020209334,0.0013266539,0.0036613664,0.00038041253,0.00045126094,0.0007244118,0.0008312205,0.0014929461,0.0034083235],"category_scores_gemma":[0.0013188381,0.0006448415,0.0020449639,0.0003968891,0.00093761913,0.00069706555,0.00036276676,0.0017162397,0.0005760212],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96518564,0.0115400255,0.002462687,0.00053866225,0.0012886855,0.00004909946,0.0000658745,0.00016224632,0.004309736,0.000041418705,0.00037005267,0.013985895],"study_design_scores_gemma":[0.89153653,0.10108797,0.005511859,0.0000151307195,0.0007621269,0.000037882055,0.00002184162,0.00033834967,0.0004436244,0.000036149137,0.00019118826,0.000017450615],"about_ca_topic_score_codex":0.0009426653,"about_ca_topic_score_gemma":0.002415043,"teacher_disagreement_score":0.0036613664,"about_ca_system_score_codex":0.00065922184,"about_ca_system_score_gemma":0.0015588773,"threshold_uncertainty_score":0.011401951},"labels":[],"label_agreement":null},{"id":"W4387129013","doi":"10.1007/s12325-023-02678-9","title":"Emotional Journey of Patients with Eosinophilic Esophagitis","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Eosinophilic Esophagitis","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Food Allergy Canada; American Partnership for Eosinophilic Disorders","keywords":"Eosinophilic esophagitis; Medicine; Dysphagia; Feeling; Quality of life (healthcare); Qualitative research; Enthusiasm; Disease; Physical therapy; Nursing; Internal medicine; Surgery; Psychology; Social psychology","score_opus":0.013065967431209698,"score_gpt":0.2879745948451665,"score_spread":0.27490862741395683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387129013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978246,0.004669839,0.0005775909,0.008328032,0.00022768095,0.00005162008,0.00012445844,0.000021869411,0.007753014],"genre_scores_gemma":[0.9953885,0.002043925,0.00026922685,0.0013163991,0.00002829105,0.000033384636,0.0000542354,0.00000614783,0.0008598917],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9978417,0.0015271672,0.00009666155,0.00007517678,0.00016683408,0.00029232638],"domain_scores_gemma":[0.997609,0.0009780647,0.0004393158,0.00006163505,0.00024221432,0.0006697453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021123216,0.00031600278,0.0004768846,0.00034221122,0.0031079252,0.002789771,0.0005290045,0.0010382046,0.0028120205],"category_scores_gemma":[0.0053452915,0.00022772326,0.000466948,0.00047549157,0.002621497,0.0020213383,0.0035170275,0.002333035,0.00046422056],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015554842,0.00011820552,0.035956964,0.00096146844,0.00006194917,0.0041628685,0.9276962,0.00013117692,0.0013807644,0.0018737643,0.0056637153,0.02183734],"study_design_scores_gemma":[0.0000129651435,0.00021949131,0.017369354,0.00043165064,0.000023911634,0.0045283367,0.95325017,0.00007589802,0.00018848052,0.0005690219,0.023291659,0.000039110782],"about_ca_topic_score_codex":0.0010775708,"about_ca_topic_score_gemma":0.001816523,"teacher_disagreement_score":0.0031079252,"about_ca_system_score_codex":0.0011284482,"about_ca_system_score_gemma":0.0014622123,"threshold_uncertainty_score":0.0111711025},"labels":[],"label_agreement":null},{"id":"W4387435562","doi":"10.1007/s12325-023-02638-3","title":"Summary of Research: Collaboration Between Healthcare Professionals and People with Multiple Sclerosis to Develop Communication Tools to Improve the Standard of Multiple Sclerosis Care","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Family Support in Illness","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Merck KGaA","keywords":"Medicine; Multiple sclerosis; Health professionals; Health care; Patient care; Nursing; Psychiatry","score_opus":0.12068137943232986,"score_gpt":0.41307197642408294,"score_spread":0.29239059699175307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387435562","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.069191866,0.6501736,0.00967315,0.1851154,0.023108998,0.01071778,0.004777192,0.00033130572,0.046910692],"genre_scores_gemma":[0.36901522,0.5008724,0.031316966,0.06691092,0.008376022,0.011523776,0.004274485,0.00018043503,0.007529791],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.9327913,0.042753298,0.009847372,0.002865981,0.009234479,0.0025074773],"domain_scores_gemma":[0.7826924,0.14757566,0.00923233,0.0041924934,0.046886858,0.009420267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.070173,0.0010966304,0.0019149274,0.004521204,0.003073603,0.009280952,0.0018839274,0.0039310115,0.007189022],"category_scores_gemma":[0.13760544,0.0007392886,0.0028235943,0.0051602107,0.0014094939,0.005995912,0.003260859,0.00390484,0.0019269832],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019154241,0.0019739508,0.017932633,0.17451678,0.0024460396,0.00045473818,0.01631317,0.00041145764,0.0011651348,0.007612654,0.07303824,0.70221984],"study_design_scores_gemma":[0.0017665087,0.018474335,0.069863655,0.44419986,0.014973312,0.0015390742,0.09206646,0.00095619436,0.0056385007,0.008768833,0.3413776,0.0003756463],"about_ca_topic_score_codex":0.009042121,"about_ca_topic_score_gemma":0.01317505,"teacher_disagreement_score":0.070173,"about_ca_system_score_codex":0.0069359313,"about_ca_system_score_gemma":0.03526274,"threshold_uncertainty_score":0.37111473},"labels":[],"label_agreement":null},{"id":"W4387439795","doi":"10.1007/s12325-023-02674-z","title":"Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Liver Disease and Transplantation","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Terlipressin; Medicine; Hepatorenal syndrome; Dialysis; Renal function; Midodrine; Internal medicine; Kidney disease; Acute kidney injury; Intensive care medicine; Cirrhosis; Surgery; Anesthesia; Blood pressure","score_opus":0.0104294428506266,"score_gpt":0.27646038003819773,"score_spread":0.26603093718757115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387439795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90294176,0.018457172,0.040394973,0.0061967545,0.00035919377,0.0034524228,0.013729444,0.00017417506,0.0142941605],"genre_scores_gemma":[0.9871651,0.0019528175,0.0062359013,0.00029087806,0.000043252738,0.00074865675,0.0023248254,0.000022419908,0.0012160548],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99734217,0.0019164796,0.00010813951,0.00015872832,0.00022399785,0.00025048963],"domain_scores_gemma":[0.9906301,0.0076756096,0.0006504766,0.0001487174,0.0005237314,0.00037141767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048292563,0.0012788555,0.002110768,0.001967519,0.00033379137,0.0017269736,0.0013376093,0.0012709438,0.0048490027],"category_scores_gemma":[0.015308122,0.0008546863,0.004901655,0.0019811266,0.00038301165,0.0013536053,0.0009781203,0.0018449102,0.0002609051],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053319046,0.0007288618,0.013014219,0.0013413935,0.0023309523,0.00050069246,0.00005873004,0.94619274,0.00033166734,0.0076811765,0.0026831191,0.019804655],"study_design_scores_gemma":[0.0013284269,0.0018330639,0.01024861,0.000449398,0.0028813637,0.00029854497,0.00021265514,0.9753424,0.00031280497,0.0043127523,0.0027099042,0.000070040274],"about_ca_topic_score_codex":0.024971662,"about_ca_topic_score_gemma":0.01193273,"teacher_disagreement_score":0.024971662,"about_ca_system_score_codex":0.007406715,"about_ca_system_score_gemma":0.0047520143,"threshold_uncertainty_score":0.053739727},"labels":[],"label_agreement":null},{"id":"W4387765093","doi":"10.1007/s12325-023-02697-6","title":"One-Year Consistent Safety, Utilization, and Efficacy Assessment of Remote Electrical Neuromodulation (REN) for Migraine Treatment","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Safran Electronics (Canada)","funders":"","keywords":"Medicine; Migraine; Adverse effect; Chronic Migraine; Neuromodulation; Clinical trial; Incidence (geometry); Anesthesia; Physical therapy; Internal medicine","score_opus":0.08284717459902385,"score_gpt":0.40588276592387607,"score_spread":0.3230355913248522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387765093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957273,0.0013282751,0.0005902783,0.00004583558,0.000015603073,0.00015416858,0.0006731117,0.000024661633,0.0014407417],"genre_scores_gemma":[0.9978898,0.00039762736,0.00041196388,0.00005102606,0.00005123828,0.00012643026,0.000715488,0.0000055244427,0.00035086327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970886,0.001103379,0.00055569544,0.0002455008,0.0008508869,0.0001559705],"domain_scores_gemma":[0.98860043,0.0027911144,0.006147439,0.0005381043,0.0014932936,0.00042967088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005020223,0.0003239398,0.0009370342,0.0010442308,0.00042104578,0.00047539864,0.0003545176,0.00033315583,0.00090042094],"category_scores_gemma":[0.010489235,0.00014644943,0.0009333231,0.00073428976,0.00022384794,0.0005967945,0.00043794076,0.00060641515,0.00025802362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008110602,0.0011010343,0.906136,0.0003085891,0.0006967845,0.00019593805,0.0003306267,0.00052767835,0.0029550612,0.000043614826,0.0003563869,0.07923768],"study_design_scores_gemma":[0.00011317696,0.0071046227,0.99050343,0.000021508788,0.0002493673,0.00034227793,0.00006703678,0.00036877053,0.00070465985,0.000020026573,0.0004894038,0.000015702302],"about_ca_topic_score_codex":0.0007025352,"about_ca_topic_score_gemma":0.0014203279,"teacher_disagreement_score":0.005020223,"about_ca_system_score_codex":0.00040092377,"about_ca_system_score_gemma":0.00031007823,"threshold_uncertainty_score":0.026549757},"labels":[],"label_agreement":null},{"id":"W4388014741","doi":"10.1007/s12325-023-02691-y","title":"Health Economic Assessments of Hyaluronic Acid Treatments for Knee Osteoarthritis: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"Ferring Pharmaceuticals","keywords":"Medicine; Osteoarthritis; Hyaluronic acid; Rheumatology; Physical therapy; Systematic review; Internal medicine; Alternative medicine; MEDLINE; Pathology","score_opus":0.05691427812644089,"score_gpt":0.43294863860138977,"score_spread":0.37603436047494887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388014741","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013199643,0.9974463,0.00014933993,0.00019606153,0.00010985927,0.00018551019,0.00037931008,0.000007197484,0.00020651467],"genre_scores_gemma":[0.038678095,0.95914674,0.00071176747,0.0005975186,0.00011697636,0.00033232634,0.0002860535,0.000006440827,0.00012419358],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.992046,0.003728478,0.0021760063,0.00043645935,0.0013472247,0.00026579987],"domain_scores_gemma":[0.9808959,0.014096128,0.003695969,0.00019470342,0.00089673564,0.00022056267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009238109,0.00157809,0.01088887,0.0057231006,0.00035534427,0.002529199,0.0015346835,0.0018757061,0.005858197],"category_scores_gemma":[0.034517568,0.0010163636,0.012157136,0.006263052,0.000713091,0.0016883999,0.0017094461,0.002044202,0.00022340316],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020264967,0.000047330574,0.0010178251,0.8675226,0.080214664,0.00008261868,0.00006725357,0.00030395988,0.00011692096,0.00031883855,0.0016371304,0.046644405],"study_design_scores_gemma":[0.005074422,0.0006377796,0.008221269,0.42179373,0.54688615,0.00030990678,0.00023796721,0.0004755914,0.0002116614,0.0010504578,0.01501575,0.00008537422],"about_ca_topic_score_codex":0.0068648346,"about_ca_topic_score_gemma":0.01998502,"teacher_disagreement_score":0.01088887,"about_ca_system_score_codex":0.0033511305,"about_ca_system_score_gemma":0.0048741847,"threshold_uncertainty_score":0.048856378},"labels":[],"label_agreement":null},{"id":"W4388538929","doi":"10.1007/s12325-023-02652-5","title":"Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors","year":2023,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Cardiorenal syndrome; Heart failure; Diabetes mellitus; Kidney disease; Intensive care medicine; Internal medicine; Renal function; Type 2 diabetes; Disease; Cardiology; Endocrinology","score_opus":0.060654851084780644,"score_gpt":0.3441065490192637,"score_spread":0.28345169793448305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388538929","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0074863033,0.97929,0.002287654,0.004317406,0.0006890634,0.000060423274,0.00031689103,0.00007678826,0.0054754126],"genre_scores_gemma":[0.06705254,0.92200917,0.0026963018,0.003461199,0.0011861478,0.0001602799,0.00055695354,0.000019633026,0.0028578148],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995315,0.00013829411,0.000092569455,0.00006302486,0.00010782957,0.00006676761],"domain_scores_gemma":[0.9995952,0.00020237602,0.000096111784,0.000011418503,0.0000724689,0.000022333354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000861123,0.0005339188,0.00096796395,0.00058815174,0.00019685159,0.0010950451,0.00072216644,0.0010111304,0.0038661633],"category_scores_gemma":[0.0013461643,0.00016286898,0.0012803954,0.00046591955,0.0003896503,0.000754786,0.00044071174,0.0014985293,0.0006363856],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024421054,0.00042388632,0.00483488,0.050971773,0.002235838,0.004037144,0.00049063604,0.0027632306,0.026681732,0.036394633,0.05050535,0.81821877],"study_design_scores_gemma":[0.0012248761,0.0026812435,0.01608849,0.013002529,0.0039983345,0.0111080315,0.00045228255,0.0036200134,0.020632725,0.029382747,0.8976278,0.00018090293],"about_ca_topic_score_codex":0.00042922012,"about_ca_topic_score_gemma":0.0011124929,"teacher_disagreement_score":0.0038661633,"about_ca_system_score_codex":0.00044936212,"about_ca_system_score_gemma":0.0005824935,"threshold_uncertainty_score":0.012933612},"labels":[],"label_agreement":null},{"id":"W4388598609","doi":"10.1007/s12325-023-02706-8","title":"Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal Clinical Research Institute","funders":"Novartis Pharma","keywords":"Medicine; Etanercept; Discontinuation; Biosimilar; Rheumatoid arthritis; Internal medicine; Psoriatic arthritis; Clinical endpoint; Pharmacology; Clinical trial","score_opus":0.023877749858004328,"score_gpt":0.3366253561703939,"score_spread":0.31274760631238957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388598609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942516,0.0015170373,0.00022621623,0.000088841705,0.000010807673,0.00019326614,0.0032915792,0.000011551488,0.00040917235],"genre_scores_gemma":[0.9945314,0.0004059986,0.00037237915,0.00010461565,0.000038020487,0.00019433722,0.0041432027,0.0000054352945,0.00020456141],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99286216,0.0039040642,0.0008655929,0.00085046084,0.0012185705,0.00029916456],"domain_scores_gemma":[0.976585,0.005697021,0.011767399,0.0016198923,0.0028175227,0.0015131051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010984574,0.00067750085,0.0015887393,0.0005136367,0.00037904258,0.0018563902,0.0006395784,0.0009450134,0.001995871],"category_scores_gemma":[0.010867033,0.0004003259,0.0022817792,0.0013890015,0.0008416264,0.0011399178,0.0010452654,0.00099648,0.00044685666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29900682,0.0033641222,0.6464209,0.0013131145,0.012375394,0.00018680649,0.0007561765,0.0023941442,0.002303915,0.00019377233,0.0017535079,0.02993138],"study_design_scores_gemma":[0.046327926,0.047025397,0.89226156,0.0003323748,0.0065906276,0.0006182686,0.00055360544,0.0018086577,0.0013146318,0.00013247537,0.0028969836,0.00013742769],"about_ca_topic_score_codex":0.0024870606,"about_ca_topic_score_gemma":0.0023453126,"teacher_disagreement_score":0.010984574,"about_ca_system_score_codex":0.0016438093,"about_ca_system_score_gemma":0.0011750909,"threshold_uncertainty_score":0.058092654},"labels":[],"label_agreement":null},{"id":"W4388796902","doi":"10.1007/s12325-023-02718-4","title":"Assessing the Fiscal Burden of Obesity in Canada by Applying a Public Economic Framework","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Obesity, Physical Activity, Diet","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novo Nordisk","keywords":"Per capita; Government revenue; Population; Revenue; Tax revenue; Obesity; Public health; Medicine; Government (linguistics); Consumption (sociology); Economics; Public economics; Environmental health; Finance","score_opus":0.021272389369096766,"score_gpt":0.32127567633950666,"score_spread":0.3000032869704099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388796902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85798484,0.005394694,0.018717801,0.009459972,0.00012387139,0.0005921348,0.031574875,0.0003686117,0.075783186],"genre_scores_gemma":[0.9811771,0.002033548,0.0081472,0.00019914331,0.000020450992,0.00010619104,0.0048117647,0.000028025182,0.003476606],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9989422,0.00026087966,0.00003525481,0.000084675354,0.00035073757,0.00032630828],"domain_scores_gemma":[0.99776506,0.0005030921,0.0002451078,0.000065199434,0.0011887521,0.00023283174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018527709,0.00068623753,0.00054741616,0.003733774,0.0019791939,0.0031229432,0.0013788877,0.0005416148,0.0032878672],"category_scores_gemma":[0.005007753,0.0003776275,0.0012075308,0.005011994,0.0008610611,0.0007453728,0.0013511428,0.0007759646,0.00016443268],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002138057,0.00017003069,0.21281043,0.00038324058,0.00047609763,0.00042889014,0.00050336716,0.7058181,0.00023766716,0.04103903,0.010047887,0.027871413],"study_design_scores_gemma":[0.00010576114,0.0001502667,0.15697093,0.00051536073,0.0004937112,0.0001400298,0.002550008,0.7991452,0.0002621918,0.01165676,0.027894808,0.000114912495],"about_ca_topic_score_codex":0.99240726,"about_ca_topic_score_gemma":0.99011713,"teacher_disagreement_score":0.082293965,"about_ca_system_score_codex":0.082293965,"about_ca_system_score_gemma":0.09590951,"threshold_uncertainty_score":0.59708726},"labels":[],"label_agreement":null},{"id":"W4388796981","doi":"10.1007/s12325-023-02721-9","title":"Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients’ Real-World Insights for Optimizing Outcomes","year":2023,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eagle Ridge Hospital","funders":"Bayer HealthCare","keywords":"Medicine; Prostate cancer; Quality of life (healthcare); Androgen deprivation therapy; Health care; Cognition; Cancer; Intensive care medicine; Internal medicine; Psychiatry; Nursing","score_opus":0.032301016615904836,"score_gpt":0.37516872691701947,"score_spread":0.3428677103011146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388796981","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46486533,0.04429148,0.0032752866,0.44947025,0.003391776,0.001010199,0.0026435012,0.00012388558,0.030928334],"genre_scores_gemma":[0.9065545,0.027719513,0.0055425963,0.0551276,0.0014575241,0.0007467941,0.0013395053,0.000038690458,0.0014733281],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9920853,0.0050620204,0.00057562994,0.0004206052,0.0007392105,0.0011172709],"domain_scores_gemma":[0.9892287,0.00393078,0.0015556688,0.0002308283,0.0023543634,0.0026996897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011000293,0.00032732828,0.0008296963,0.00080357306,0.00305531,0.003610115,0.0007749784,0.0017569638,0.0026805215],"category_scores_gemma":[0.024304803,0.00020143087,0.0010747301,0.0010222854,0.0009738086,0.002755267,0.005105526,0.0056546214,0.0004030099],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075988186,0.00087503006,0.25466275,0.004771412,0.0004940385,0.0015955486,0.050068308,0.0011255062,0.00090420793,0.0049709887,0.24305099,0.43672138],"study_design_scores_gemma":[0.0003920392,0.0024370896,0.34280157,0.014828783,0.00070114253,0.003303249,0.1878818,0.002626553,0.0010498385,0.01767827,0.42562258,0.0006771266],"about_ca_topic_score_codex":0.0051130843,"about_ca_topic_score_gemma":0.018701559,"teacher_disagreement_score":0.011000293,"about_ca_system_score_codex":0.0036308754,"about_ca_system_score_gemma":0.0074323784,"threshold_uncertainty_score":0.058175802},"labels":[],"label_agreement":null},{"id":"W4388845145","doi":"10.1007/s12325-023-02714-8","title":"Optimising Radioligand Therapy for Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumours: Expert Opinion from an Italian Multidisciplinary Group","year":2023,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Neuroendocrine tumors; Reimbursement; Psychosocial; Multidisciplinary approach; Protocol (science); Intensive care medicine; Internal medicine; Health care; Alternative medicine; Pathology","score_opus":0.054524717347923246,"score_gpt":0.4142345144384069,"score_spread":0.3597097970904837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388845145","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0069246297,0.4814344,0.002822861,0.4837448,0.0082205,0.00011972454,0.00015247687,0.000057976664,0.016522672],"genre_scores_gemma":[0.13395636,0.49385208,0.019849759,0.3181422,0.026326984,0.00047817663,0.00049830356,0.00006420701,0.0068319533],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970381,0.0017711668,0.00039809282,0.00017439834,0.00043574753,0.00018253883],"domain_scores_gemma":[0.99506134,0.0024952728,0.00066475436,0.000079175225,0.0014001599,0.0002992707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059412243,0.00038025627,0.0005806623,0.00051138754,0.00030795616,0.0016168285,0.0010908523,0.0035856308,0.0014146557],"category_scores_gemma":[0.012271206,0.00016369727,0.0009940095,0.0003892597,0.00060705503,0.001074317,0.0010529602,0.0023356949,0.0008040549],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000260939,0.00008012395,0.0048927767,0.0090005975,0.000316436,0.002759662,0.0013538713,0.0010485859,0.0017873863,0.0029363479,0.3871783,0.588385],"study_design_scores_gemma":[0.00021442896,0.0002432184,0.0067511396,0.018166695,0.0005568867,0.005405139,0.0019863995,0.00074433204,0.0006722023,0.0048799287,0.9603064,0.000073105446],"about_ca_topic_score_codex":0.001963908,"about_ca_topic_score_gemma":0.0037342561,"teacher_disagreement_score":0.0059412243,"about_ca_system_score_codex":0.0014293853,"about_ca_system_score_gemma":0.002626294,"threshold_uncertainty_score":0.03142059},"labels":[],"label_agreement":null},{"id":"W4388912340","doi":"10.1007/s12325-023-02724-6","title":"A Patient Charter for Chronic Urticaria","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Urticaria and Related Conditions","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; McGill University; University of British Columbia; Dalhousie University; Université Laval","funders":"","keywords":"Medicine; Angioedema; Charter; Quality of life (healthcare); Specialty; Health care; Physical therapy; Family medicine; Nursing; Dermatology","score_opus":0.013233137051226583,"score_gpt":0.31190821573193994,"score_spread":0.29867507868071336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388912340","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0291025,0.011168679,0.036020428,0.5162179,0.026372861,0.00892183,0.009624721,0.008942653,0.35362846],"genre_scores_gemma":[0.29635632,0.01811952,0.20305124,0.24856876,0.0207756,0.0096463235,0.020817293,0.0019095681,0.1807554],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99664116,0.0012212783,0.0004385283,0.00022623783,0.0010783979,0.00039437466],"domain_scores_gemma":[0.9749851,0.0049032685,0.0025189137,0.00095998956,0.009623435,0.0070093656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037134555,0.0005844251,0.00069180055,0.0013077136,0.0023793255,0.0017122894,0.0013000922,0.0024828613,0.050057247],"category_scores_gemma":[0.022947544,0.00027125728,0.0005216298,0.00093874417,0.0005442094,0.0024261673,0.0021524092,0.0051756357,0.009471481],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007745722,0.0001563293,0.0029278952,0.000089191155,0.0000053727363,0.00128719,0.00042726425,0.00019387838,0.00022122568,0.0029054577,0.9305902,0.06111857],"study_design_scores_gemma":[0.00017495452,0.0003240742,0.0068785795,0.0005168851,0.000011115903,0.0047785523,0.0008993026,0.0011367123,0.00030045773,0.0024665145,0.98241466,0.000098209406],"about_ca_topic_score_codex":0.0036610584,"about_ca_topic_score_gemma":0.008624427,"teacher_disagreement_score":0.050057247,"about_ca_system_score_codex":0.0024454796,"about_ca_system_score_gemma":0.007595234,"threshold_uncertainty_score":0.16745818},"labels":[],"label_agreement":null},{"id":"W4389307944","doi":"10.1007/s12325-023-02673-0","title":"The Impact of the COVID-19 Pandemic on Patients with Ulcerative Colitis: Results from a Global Ulcerative Colitis Narrative Patient Survey","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; McGill University Health Centre","funders":"Pfizer","keywords":"Medicine; Ulcerative colitis; Pandemic; Medical prescription; Family medicine; Disease; Coronavirus disease 2019 (COVID-19); Anxiety; Internal medicine; Psychiatry; Nursing; Infectious disease (medical specialty)","score_opus":0.015824180247196257,"score_gpt":0.3148297700543748,"score_spread":0.2990055898071785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389307944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963509,0.00033042135,0.00002910961,0.0005388466,0.000007807848,0.00004277852,0.0017938444,0.0000033947924,0.0009029285],"genre_scores_gemma":[0.9975326,0.00040413783,0.0000971096,0.00046027856,0.000015203119,0.000064711894,0.0012324015,0.0000025318966,0.00019102338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896526,0.00043389195,0.00017020637,0.00008974679,0.00017543722,0.00016547137],"domain_scores_gemma":[0.9956767,0.00095508085,0.0020105825,0.00010191464,0.00045734402,0.0007984627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016093075,0.00015836886,0.00029262865,0.0006764141,0.00041583335,0.000726119,0.00023439982,0.000592691,0.0013850413],"category_scores_gemma":[0.0057414533,0.0001862302,0.00051507883,0.0011817771,0.0002690394,0.0008282508,0.0010408157,0.00070493144,0.00026668908],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000095135605,0.00007439437,0.99432087,0.0000869323,0.000040384883,0.00008100841,0.0010132064,0.000040770465,0.000057991685,0.000012917746,0.0007804293,0.0033959032],"study_design_scores_gemma":[0.000010093202,0.00022279925,0.9960258,0.000037075846,0.00001783233,0.00012482717,0.0026731654,0.00006609648,0.00001673969,0.000008592752,0.0007895779,0.0000073950846],"about_ca_topic_score_codex":0.005910066,"about_ca_topic_score_gemma":0.009487214,"teacher_disagreement_score":0.005910066,"about_ca_system_score_codex":0.00050884887,"about_ca_system_score_gemma":0.0005029241,"threshold_uncertainty_score":0.011751354},"labels":[],"label_agreement":null},{"id":"W4389505117","doi":"10.1007/s12325-023-02745-1","title":"Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"CSL Behring","keywords":"Medicine; Confidence interval; Regimen; Internal medicine; Odds ratio; Body mass index; Surgery","score_opus":0.0883316305701726,"score_gpt":0.38474291144490447,"score_spread":0.2964112808747319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389505117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9725705,0.015189,0.0077613047,0.00024963322,0.00048912375,0.0009664992,0.0009788871,0.000107307875,0.0016876748],"genre_scores_gemma":[0.995407,0.0008382873,0.0024388933,0.00012225022,0.00007994757,0.00041153893,0.00029160362,0.000007240968,0.00040324742],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9896292,0.008266744,0.00047772753,0.0007660483,0.000601116,0.00025927427],"domain_scores_gemma":[0.993852,0.003922516,0.001395013,0.00047125554,0.00019127112,0.0001678742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010702721,0.0011310693,0.0024068546,0.00048267047,0.00015242423,0.0008204964,0.00076418236,0.00081219984,0.0036928635],"category_scores_gemma":[0.015166761,0.00033874472,0.004638148,0.0004377546,0.00044461258,0.0006804558,0.00070740667,0.0012867821,0.00019272412],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79479843,0.0015125712,0.028074898,0.004028249,0.08565813,0.0000790433,0.00016381698,0.0057577468,0.0022259208,0.0014129592,0.0010277062,0.075260505],"study_design_scores_gemma":[0.29714128,0.298287,0.17395662,0.0011072219,0.15560499,0.0006268363,0.00029639388,0.045138407,0.0115508605,0.008005795,0.0080361655,0.0002484363],"about_ca_topic_score_codex":0.0006959898,"about_ca_topic_score_gemma":0.0005428554,"teacher_disagreement_score":0.010702721,"about_ca_system_score_codex":0.0005600031,"about_ca_system_score_gemma":0.0005773016,"threshold_uncertainty_score":0.05660206},"labels":[],"label_agreement":null},{"id":"W4389946153","doi":"10.1007/s12325-023-02760-2","title":"Impact of Elevated Body Mass Index (BMI) on Hedonic Tone in Persons with Post-COVID-19 Condition: A Secondary Analysis","year":2023,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Long-Term Effects of COVID-19","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Brain and Cognition Discovery Foundation; University of Toronto","funders":"H. Lundbeck A/S","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Body mass index; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Rheumatology; Internal medicine; Index (typography); Cardiology; Pathology; Disease; Outbreak","score_opus":0.010795734771422812,"score_gpt":0.369300782142791,"score_spread":0.3585050473713682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389946153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948242,0.0007926396,0.00014889777,0.000060292186,0.000036306217,0.00016317343,0.0031278057,0.000006450908,0.00084031705],"genre_scores_gemma":[0.99494714,0.00033032606,0.0001685656,0.000071262875,0.000062134415,0.00026522076,0.0031453932,0.000004024527,0.0010059165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989506,0.00027267484,0.00014233982,0.00017110485,0.00021607886,0.00024712662],"domain_scores_gemma":[0.99799794,0.0006376513,0.0005707861,0.00012641067,0.00034953107,0.00031765463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011624581,0.00067916483,0.0014248664,0.0012184352,0.0008431146,0.0009958147,0.00066700135,0.00069643906,0.0064031905],"category_scores_gemma":[0.0026663686,0.00035978568,0.005900641,0.0012375684,0.00039482414,0.00068021065,0.0013587316,0.0016262045,0.0004816077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011850133,0.0016984805,0.96806705,0.00079051335,0.006631657,0.00016000241,0.00022382685,0.0002449423,0.00038844842,0.0001158684,0.00096582045,0.0088631045],"study_design_scores_gemma":[0.00031540362,0.0020999436,0.9944571,0.00006661922,0.0017988434,0.000091808884,0.00038449524,0.000252392,0.00008899958,0.00005533118,0.00036863555,0.000020418314],"about_ca_topic_score_codex":0.010420315,"about_ca_topic_score_gemma":0.01950222,"teacher_disagreement_score":0.010420315,"about_ca_system_score_codex":0.00095560175,"about_ca_system_score_gemma":0.0014566289,"threshold_uncertainty_score":0.021420777},"labels":[],"label_agreement":null},{"id":"W4390498067","doi":"10.1007/s12325-023-02732-6","title":"Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials","year":2024,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"AbbVie","keywords":"Medicine; Randomized controlled trial; Rheumatology; Systematic review; Immune system; Internal medicine; MEDLINE; Intensive care medicine; Immunology","score_opus":0.025493679472180158,"score_gpt":0.37101187627534854,"score_spread":0.34551819680316836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390498067","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018004059,0.99562186,0.00027837523,0.00020299584,0.00013946778,0.0008465988,0.0007208938,0.000016124624,0.00037327537],"genre_scores_gemma":[0.059491675,0.9331551,0.0018553807,0.0013087823,0.00023152329,0.0028248783,0.0008700234,0.000025288378,0.00023732244],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.96926403,0.012344962,0.012653006,0.0019254094,0.0033627935,0.0004497733],"domain_scores_gemma":[0.9009672,0.07447179,0.017455162,0.0012456803,0.005283965,0.00057626044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026887516,0.0021512972,0.015706046,0.010238614,0.0007380409,0.0037805568,0.0024519712,0.002328015,0.008006394],"category_scores_gemma":[0.09062365,0.0014081427,0.015094878,0.009054242,0.0015869251,0.0030085219,0.0020036774,0.0018616271,0.00046489545],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001019085,0.00001737655,0.0005022323,0.94799364,0.035555758,0.00004529683,0.00008493302,0.00007542438,0.000098332814,0.00011548918,0.00040082846,0.014091667],"study_design_scores_gemma":[0.0024656046,0.0006024272,0.003455607,0.6286297,0.35612002,0.00022789135,0.00018850031,0.000116068346,0.0002841358,0.00039679266,0.0074611185,0.000052060823],"about_ca_topic_score_codex":0.003914485,"about_ca_topic_score_gemma":0.009880522,"teacher_disagreement_score":0.026887516,"about_ca_system_score_codex":0.0044367,"about_ca_system_score_gemma":0.008282166,"threshold_uncertainty_score":0.14219648},"labels":[],"label_agreement":null},{"id":"W4390637832","doi":"10.1007/s12325-023-02719-3","title":"Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Bayer","keywords":"Aflibercept; Medicine; Macular degeneration; Dosing; Randomized controlled trial; Rheumatology; Ophthalmology; Bevacizumab; Internal medicine; Oncology; Chemotherapy","score_opus":0.013967966212247036,"score_gpt":0.31497919686516135,"score_spread":0.3010112306529143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390637832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785245,0.009235671,0.0010542384,0.0007478942,0.0005071903,0.0045449077,0.0019259837,0.00011965715,0.0033398478],"genre_scores_gemma":[0.98715115,0.0023438442,0.0016565133,0.00091517915,0.0006682281,0.0035946772,0.0013938629,0.000013934972,0.0022627348],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99815136,0.0011174963,0.00013094385,0.0002816721,0.00015090345,0.00016772862],"domain_scores_gemma":[0.99827254,0.0006908859,0.00042433492,0.00017787747,0.00009203851,0.00034238273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004701649,0.0012849083,0.002410513,0.00054669264,0.0004751773,0.0014619185,0.00091078336,0.0017910328,0.006095077],"category_scores_gemma":[0.0030239956,0.0005433977,0.0027128805,0.00038589083,0.00092295895,0.0013107636,0.00059807196,0.002771287,0.0005959933],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98689437,0.002400235,0.0005059581,0.00023593669,0.00086497504,0.000013546218,0.00002520703,0.0002005069,0.0011142672,0.00010343361,0.0003369567,0.007304679],"study_design_scores_gemma":[0.95117885,0.04468405,0.0019956327,0.000033027904,0.0008073203,0.000022315447,0.000010379576,0.00041582124,0.00019966243,0.00013098217,0.00050989556,0.000012092557],"about_ca_topic_score_codex":0.00058092445,"about_ca_topic_score_gemma":0.0015582831,"teacher_disagreement_score":0.006095077,"about_ca_system_score_codex":0.0005994184,"about_ca_system_score_gemma":0.00077744114,"threshold_uncertainty_score":0.024864972},"labels":[],"label_agreement":null},{"id":"W4390655880","doi":"10.1007/s12325-023-02765-x","title":"Comparative Safety of Pulsed Field Ablation and Cryoballoon Ablation Technologies for Pulmonary Vein Isolation in Patients with Paroxysmal Atrial Fibrillation: A Critical Literature Review and Indirect Treatment Comparison","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Biosense Webster","keywords":"Medicine; Adverse effect; Atrial fibrillation; Internal medicine; Confidence interval; Relative risk; Clinical trial; Meta-analysis; Ablation; Catheter ablation; Surgery","score_opus":0.02859878009776757,"score_gpt":0.3633925257742418,"score_spread":0.33479374567647424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390655880","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010708232,0.9872171,0.0003438799,0.00028419442,0.00013941256,0.00055135053,0.00034850065,0.00000644366,0.00040083478],"genre_scores_gemma":[0.26850164,0.7236538,0.0028569545,0.0012728801,0.0006238347,0.0019682983,0.000869094,0.000017885073,0.00023556041],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.97286046,0.013630515,0.008710913,0.0016761549,0.002855685,0.0002662643],"domain_scores_gemma":[0.8925527,0.08460972,0.016470116,0.0012514683,0.0046980237,0.00041811814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025972854,0.0015731285,0.009737884,0.008943325,0.00044776057,0.0030990147,0.0016468712,0.002214975,0.004045598],"category_scores_gemma":[0.0644802,0.00092170096,0.0142688565,0.0059648873,0.0011956254,0.0021188536,0.0012522193,0.0014348316,0.0002788619],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011107406,0.0001473957,0.006973361,0.6235601,0.29587197,0.00020866026,0.00028245925,0.0003649441,0.00058102363,0.00047560813,0.0005566747,0.059870377],"study_design_scores_gemma":[0.007252029,0.0046340055,0.018193223,0.114610665,0.84499717,0.00063884375,0.00036661056,0.00041121544,0.0006774183,0.0009401956,0.007178168,0.000100435005],"about_ca_topic_score_codex":0.0009703735,"about_ca_topic_score_gemma":0.0021909394,"teacher_disagreement_score":0.025972854,"about_ca_system_score_codex":0.0023986916,"about_ca_system_score_gemma":0.002911568,"threshold_uncertainty_score":0.13735926},"labels":[],"label_agreement":null},{"id":"W4390811971","doi":"10.1007/s12325-023-02730-8","title":"Real-World Management of Patients with Pulmonary Arterial Hypertension: Insights from EXPOSURE","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Actelion Pharmaceuticals","keywords":"Medicine; Rheumatology; Internal medicine; Pulmonary hypertension; Cardiology; Intensive care medicine","score_opus":0.015115327551187455,"score_gpt":0.282005116141619,"score_spread":0.26688978859043155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390811971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99561584,0.00093381933,0.0007595,0.0005786207,0.000007089642,0.000018904522,0.0008776366,0.0000058803626,0.0012026415],"genre_scores_gemma":[0.9981318,0.00042804072,0.00038300428,0.0001662567,0.000020673928,0.00001172548,0.0007726443,0.00000342113,0.000082473525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976152,0.0013857193,0.00016849009,0.0002715176,0.00032208688,0.0002369861],"domain_scores_gemma":[0.99529535,0.0015057855,0.0021114098,0.0004068419,0.00032123955,0.00035934345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025476252,0.0001107262,0.00035120014,0.00045287044,0.0002685868,0.0012593139,0.00035780706,0.0003306198,0.000632885],"category_scores_gemma":[0.00793528,0.00011479164,0.00045837386,0.0010032625,0.0004199038,0.00088857807,0.0007928771,0.00050519384,0.00007618737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002821772,0.000060877166,0.99227977,0.000031834672,0.00013783271,0.00009973476,0.000420166,0.00024479066,0.00012038124,0.00022536855,0.00021001912,0.005887172],"study_design_scores_gemma":[0.00001556243,0.00014404312,0.9968362,0.000025435722,0.000045375564,0.00022907283,0.0006990492,0.00063061365,0.000047136527,0.0003015649,0.001012995,0.000012961273],"about_ca_topic_score_codex":0.018081857,"about_ca_topic_score_gemma":0.02363378,"teacher_disagreement_score":0.018081857,"about_ca_system_score_codex":0.0008807221,"about_ca_system_score_gemma":0.0012422251,"threshold_uncertainty_score":0.035953164},"labels":[],"label_agreement":null},{"id":"W4391032221","doi":"10.1007/s12325-023-02773-x","title":"Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Seven Oaks General Hospital","funders":"Mitsubishi Tanabe Pharma Corporation; AstraZeneca","keywords":"Dapagliflozin; Medicine; Albuminuria; Kidney disease; Renal function; Internal medicine; Diabetes mellitus; Urology; Comorbidity; Population; Creatinine; Type 2 diabetes; Endocrinology","score_opus":0.01636351137419319,"score_gpt":0.30417992847754594,"score_spread":0.28781641710335276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391032221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99924207,0.0002889073,0.00009087292,0.00008241367,0.0000036107247,0.0000054466527,0.00016673189,0.0000015654946,0.00011842911],"genre_scores_gemma":[0.9994648,0.00012253909,0.00006880162,0.00003899173,0.00000660947,0.0000064874193,0.00025772388,0.0000017525648,0.0000323332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977258,0.0009080441,0.00027628487,0.0005391504,0.00025863192,0.00029202606],"domain_scores_gemma":[0.99490595,0.0009776296,0.0024185341,0.000368056,0.0005806248,0.00074920483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027471113,0.00022469876,0.0006024865,0.0007215896,0.00042945117,0.0011970287,0.0004287689,0.0003508543,0.0004909786],"category_scores_gemma":[0.00688801,0.0003054479,0.0013595324,0.0016663498,0.00048109636,0.0006156687,0.0009944893,0.00061983627,0.000068316855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029341457,0.000051349103,0.9973928,0.00001357104,0.00016310622,0.00003894553,0.00013880439,0.00012714627,0.0000802274,0.000033466888,0.00010484372,0.0015623614],"study_design_scores_gemma":[0.000017309372,0.00006507938,0.99837387,0.000004479579,0.00012975073,0.000043990174,0.0001490411,0.0010627287,0.000032124102,0.000017687553,0.00009655349,0.0000074001573],"about_ca_topic_score_codex":0.045853704,"about_ca_topic_score_gemma":0.026391633,"teacher_disagreement_score":0.045853704,"about_ca_system_score_codex":0.0013099499,"about_ca_system_score_gemma":0.0009875651,"threshold_uncertainty_score":0.09117359},"labels":[],"label_agreement":null},{"id":"W4391137655","doi":"10.1007/s12325-023-02770-0","title":"The Cost of Seasonal Influenza: A Systematic Literature Review on the Humanistic and Economic Burden of Influenza in Older (≥ 65 Years Old) Adults","year":2024,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; Influenza vaccine; Seasonal influenza; Quality of life (healthcare); Gerontology; Vaccination; Demography; Environmental health; Immunology; Internal medicine; Coronavirus disease 2019 (COVID-19); Disease; Infectious disease (medical specialty)","score_opus":0.05725106847658075,"score_gpt":0.42814892708900965,"score_spread":0.3708978586124289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391137655","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028687848,0.9951917,0.00008550303,0.00033517895,0.00008528722,0.00015909197,0.00092686573,0.0000043157597,0.00034329115],"genre_scores_gemma":[0.023257859,0.97519976,0.00037555132,0.00037074016,0.000072435025,0.00027144683,0.00037888595,0.0000032093335,0.0000700792],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99520797,0.0014658247,0.0019680616,0.00033924336,0.00084091147,0.00017800136],"domain_scores_gemma":[0.9743391,0.018935997,0.0044456045,0.0002318925,0.0018088998,0.00023839924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055752518,0.0012422084,0.005859661,0.012445456,0.00052478816,0.0024260485,0.0013681751,0.001571689,0.0037257457],"category_scores_gemma":[0.027404612,0.00079719396,0.0074784146,0.012274674,0.0005623373,0.0017674488,0.0012667056,0.00091278116,0.00019305242],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022106995,0.000019617273,0.0030267425,0.94591993,0.011797934,0.00016972568,0.00018343866,0.00016162905,0.000082228085,0.0002655555,0.0015513675,0.03660072],"study_design_scores_gemma":[0.00017429222,0.0002216117,0.014039147,0.89103264,0.07724719,0.0006287851,0.00045946386,0.00015371277,0.000110886125,0.00034964667,0.015539527,0.000043097625],"about_ca_topic_score_codex":0.01116022,"about_ca_topic_score_gemma":0.025387397,"teacher_disagreement_score":0.012445456,"about_ca_system_score_codex":0.0033964945,"about_ca_system_score_gemma":0.008766931,"threshold_uncertainty_score":0.029485106},"labels":[],"label_agreement":null},{"id":"W4391482304","doi":"10.1007/s12325-023-02763-z","title":"The Evolving Role of PD-(L)1 Inhibition in Optimizing Outcomes for High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): A Podcast","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Bladder cancer; Internal medicine; Oncology; Urology; Urothelial cancer; Cancer; Rheumatology","score_opus":0.010520303571385316,"score_gpt":0.31308453496181465,"score_spread":0.3025642313904293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391482304","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002908871,0.8562802,0.0019252793,0.1095818,0.021686971,0.00004837387,0.0005214174,0.00018194389,0.0068651186],"genre_scores_gemma":[0.03704821,0.83558506,0.005757297,0.07322326,0.04065339,0.00008357411,0.0006021096,0.000102890495,0.006944278],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987521,0.00030243394,0.00017552981,0.00023971635,0.00033735792,0.00019298357],"domain_scores_gemma":[0.99403125,0.0035779215,0.00058795145,0.000118481374,0.0009786,0.00070574536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006160216,0.00076142634,0.002047585,0.0008288433,0.0007372905,0.006005511,0.0016189974,0.0034403137,0.009198595],"category_scores_gemma":[0.0075572236,0.0003599236,0.0017774532,0.0007816953,0.001476478,0.0055112964,0.0019155771,0.010759578,0.0020100302],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013154413,0.00033330673,0.0020237209,0.0044660727,0.00024909657,0.00023520424,0.00014222944,0.0012456884,0.0013735484,0.020232534,0.24471536,0.7236678],"study_design_scores_gemma":[0.00081593636,0.0019209601,0.0044656014,0.006275897,0.0005657211,0.00064059,0.0006165848,0.0026103028,0.0007199683,0.030206878,0.95103055,0.00013100373],"about_ca_topic_score_codex":0.0021467726,"about_ca_topic_score_gemma":0.007993131,"teacher_disagreement_score":0.009198595,"about_ca_system_score_codex":0.0022019332,"about_ca_system_score_gemma":0.003354137,"threshold_uncertainty_score":0.032578707},"labels":[],"label_agreement":null},{"id":"W4391521245","doi":"10.1007/s12325-023-02776-8","title":"Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"National Institute of Environmental Health Sciences; Genentech; Teva Pharmaceutical Industries; Sanofi","keywords":"Medicine; Fluticasone propionate; Exacerbation; COPD; Internal medicine; Population; Budesonide; Formoterol; Corticosteroid","score_opus":0.012597062446416042,"score_gpt":0.28700559771391027,"score_spread":0.2744085352674942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391521245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99751943,0.00042919055,0.00004123814,0.00005941255,0.000016152953,0.000023005361,0.0015141426,0.0000021276896,0.00039525502],"genre_scores_gemma":[0.99732035,0.00015465192,0.000036167767,0.000059960683,0.000035148332,0.000032336215,0.002173302,0.0000020801483,0.00018592723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913365,0.00013460155,0.00012726705,0.00025940372,0.00012810787,0.00021690206],"domain_scores_gemma":[0.9980147,0.00022107337,0.0011720064,0.00010004597,0.00014505691,0.00034720698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007871141,0.00031227386,0.00055394927,0.000902816,0.00049175817,0.00086208637,0.00041178352,0.00080156326,0.0011565351],"category_scores_gemma":[0.0021906402,0.00034000108,0.0012821582,0.00094517,0.000372322,0.0009257517,0.00083321927,0.0012081583,0.0002072486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010924252,0.00015022543,0.996949,0.00003115159,0.00019163857,0.0001059303,0.00007467891,0.000108065346,0.00013022819,0.0000427413,0.00021699532,0.0009069439],"study_design_scores_gemma":[0.000057711575,0.0006319147,0.9981401,0.000020144114,0.00009095433,0.00021555566,0.00020409159,0.00024836132,0.000052479176,0.000050104594,0.00027554744,0.000013127053],"about_ca_topic_score_codex":0.006829034,"about_ca_topic_score_gemma":0.007169774,"teacher_disagreement_score":0.006829034,"about_ca_system_score_codex":0.0008530156,"about_ca_system_score_gemma":0.0005873389,"threshold_uncertainty_score":0.013578534},"labels":[],"label_agreement":null},{"id":"W4391721467","doi":"10.1007/s12325-023-02750-4","title":"Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; University of Toronto","funders":"","keywords":"Medicine; Semaglutide; Type 2 diabetes; Dipeptidyl peptidase-4 inhibitor; Dipeptidyl peptidase-4; Stroke (engine); Internal medicine; Alogliptin; Type 2 Diabetes Mellitus; Sitagliptin; Diabetes mellitus; Endocrinology; Liraglutide","score_opus":0.01236021062021096,"score_gpt":0.2968267479358921,"score_spread":0.2844665373156811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391721467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980495,0.00034893496,0.00010895829,0.000045040808,0.000010418813,0.000014907603,0.0011421079,0.0000035257096,0.00027666753],"genre_scores_gemma":[0.9980221,0.00018965914,0.00012036662,0.000044721215,0.000018829693,0.000023201505,0.001461908,0.0000013629676,0.000118076576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99917066,0.00025464708,0.00014202321,0.00025059754,0.000111680245,0.0000703918],"domain_scores_gemma":[0.9985902,0.00018151307,0.000902468,0.00011244518,0.00008517941,0.00012813689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000872871,0.00026696076,0.0004057474,0.0007157878,0.00035659937,0.0008564518,0.00033305294,0.00052035804,0.0014450043],"category_scores_gemma":[0.0026815238,0.0002815408,0.00077284785,0.0013221703,0.00024075141,0.00041882205,0.00040351233,0.00038201813,0.000233937],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060173386,0.0000547223,0.9980192,0.000016132744,0.00029266515,0.000044711876,0.000026418757,0.00009006416,0.000042606636,0.000018490215,0.00010255912,0.0006906068],"study_design_scores_gemma":[0.00011121954,0.00033831733,0.99776185,0.000014235435,0.00018950211,0.00035341317,0.00012934709,0.0006926677,0.000055150944,0.00008140147,0.00026396898,0.000009009689],"about_ca_topic_score_codex":0.0054662665,"about_ca_topic_score_gemma":0.004529589,"teacher_disagreement_score":0.0054662665,"about_ca_system_score_codex":0.00034335614,"about_ca_system_score_gemma":0.00027821737,"threshold_uncertainty_score":0.010868847},"labels":[],"label_agreement":null},{"id":"W4391781908","doi":"10.1007/s12325-024-02803-2","title":"Exploring Perceptions of Biologic Therapies: A Qualitative Study Among Canadians Living with Severe Asthma","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Broadcom (Canada); Eagle Ridge Hospital; Memorial University of Newfoundland; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Asthma; Thematic analysis; Context (archaeology); Qualitative research; Family medicine; Physical therapy; Internal medicine","score_opus":0.045204862448519074,"score_gpt":0.3524703112131509,"score_spread":0.30726544876463185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391781908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819775,0.0014074972,0.00046943896,0.008757295,0.00021262273,0.0002371978,0.000405912,0.000010921852,0.0065215593],"genre_scores_gemma":[0.9897579,0.0011254585,0.0004959856,0.005691294,0.0000435227,0.00017526491,0.00014543821,0.000022077824,0.0025431495],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99022794,0.0037721782,0.0003562317,0.0006691567,0.0012579564,0.0037164951],"domain_scores_gemma":[0.9733156,0.010273213,0.002257746,0.0003902901,0.0062995097,0.007463572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009893092,0.0008504904,0.0013406032,0.0020824177,0.039931282,0.00887224,0.0034843844,0.0038376315,0.005219046],"category_scores_gemma":[0.019774886,0.0010526092,0.0010047011,0.0039020162,0.012501125,0.0037788819,0.0068445625,0.009585946,0.0003701439],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038547674,0.000064161104,0.0064430907,0.00008239769,0.000008322031,0.00032609285,0.9902182,0.0000142452955,0.00021602932,0.00032862157,0.000941298,0.0013189466],"study_design_scores_gemma":[0.0000033365322,0.000017332455,0.002108854,0.00007585234,0.000004288697,0.00004568027,0.99457127,0.000013896783,0.000027399656,0.00004034443,0.0030769415,0.000014849884],"about_ca_topic_score_codex":0.88271254,"about_ca_topic_score_gemma":0.93721473,"teacher_disagreement_score":0.11728746,"about_ca_system_score_codex":0.055301607,"about_ca_system_score_gemma":0.08223064,"threshold_uncertainty_score":0.4012431},"labels":[],"label_agreement":null},{"id":"W4391953689","doi":"10.1007/s12325-023-02778-6","title":"Correction to: Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients’ Real-World Insights for Optimizing Outcomes","year":2024,"lang":"en","type":"erratum","venue":"Advances in Therapy","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eagle Ridge Hospital","funders":"","keywords":"Medicine; Prostate cancer; Cognitive impairment; Rheumatology; Cognition; Intensive care medicine; Internal medicine; Oncology; Cancer; Disease; Psychiatry","score_opus":0.009810852936459462,"score_gpt":0.3130978721432271,"score_spread":0.30328701920676765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391953689","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019405401,0.0011458832,0.0013794547,0.063919,0.9234949,0.00005509655,0.005028072,0.0006986371,0.0040850285],"genre_scores_gemma":[0.024123384,0.014397463,0.014813423,0.12538032,0.4810848,0.0006236428,0.0138433995,0.0065558995,0.3191778],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943562,0.0012354001,0.0010757742,0.000687251,0.0022491624,0.00039632968],"domain_scores_gemma":[0.94627887,0.01750528,0.0033707127,0.0031258306,0.02768883,0.002030476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063288943,0.0021391283,0.0015993927,0.0033983286,0.0021965099,0.0043213223,0.002756461,0.0047597177,0.14240494],"category_scores_gemma":[0.11511428,0.0009731455,0.0017659006,0.002909156,0.0019851632,0.0020922578,0.0019307524,0.009396171,0.061528742],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029758681,0.000003177748,0.000067585686,0.00012162929,0.00000776189,0.000083244384,0.000020617483,0.00002753567,0.000018659199,0.0004938812,0.9941999,0.004926332],"study_design_scores_gemma":[0.00008103178,0.000021126212,0.00061280763,0.0008348912,0.000046335535,0.0007350641,0.00009555685,0.00025269613,0.00034822916,0.0023184768,0.99460214,0.00005155426],"about_ca_topic_score_codex":0.0112299435,"about_ca_topic_score_gemma":0.014470023,"teacher_disagreement_score":0.14240494,"about_ca_system_score_codex":0.0030074867,"about_ca_system_score_gemma":0.0068357773,"threshold_uncertainty_score":0.47639197},"labels":[],"label_agreement":null},{"id":"W4392130094","doi":"10.1007/s12325-024-02797-x","title":"Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Cilag; Janssen Research and Development; Genentech; Chugai Pharmaceutical; EUSA Pharma; Servier; Incyte; bluebird bio; Regeneron Pharmaceuticals; Universidad de Salamanca; Adaptive Biotechnologies; Karyopharm Therapeutics; Legend Biotech; Celgene; Cerecor; Janssen Pharmaceuticals; Yale University; Sanofi; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Hazard ratio; Confidence interval; Relative risk; Refractory (planetary science); Proportional hazards model; Multiple myeloma; Gastroenterology; Surgery","score_opus":0.059782962332057994,"score_gpt":0.3848374014435362,"score_spread":0.3250544391114782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392130094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926791,0.0057361377,0.00020815809,0.00012839226,0.000043826436,0.00019610986,0.00030596062,0.000009245247,0.0006930673],"genre_scores_gemma":[0.9977059,0.0009939962,0.00020090153,0.00012481959,0.000058003832,0.00018181575,0.0004938504,0.0000025215788,0.00023820951],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9976109,0.0016202475,0.00019505464,0.00028632703,0.00016443287,0.00012299925],"domain_scores_gemma":[0.99738497,0.0009149903,0.00089777814,0.00026773746,0.00016993517,0.00036455202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005388006,0.0005536859,0.0013867458,0.00046221635,0.00024308008,0.0009646464,0.0006219969,0.0007693421,0.0017742545],"category_scores_gemma":[0.004151993,0.00022613123,0.0020945508,0.0005091424,0.0005060423,0.0006615102,0.0005717155,0.0007841061,0.00019469374],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9321881,0.002543623,0.019411603,0.00075993227,0.004077948,0.00004663596,0.00017598213,0.00067239546,0.0027384197,0.00018512251,0.00026162562,0.036938556],"study_design_scores_gemma":[0.26750493,0.51941264,0.18651488,0.0003425371,0.013154444,0.0003018486,0.0003577499,0.002780011,0.0029217529,0.0005258503,0.0060666064,0.000116646246],"about_ca_topic_score_codex":0.0006299783,"about_ca_topic_score_gemma":0.0010762301,"teacher_disagreement_score":0.005388006,"about_ca_system_score_codex":0.0009960192,"about_ca_system_score_gemma":0.0005363766,"threshold_uncertainty_score":0.028494835},"labels":[],"label_agreement":null},{"id":"W4392448305","doi":"10.1007/s12325-024-02794-0","title":"Patient and Clinician Perspectives: To Create a Better Future for Chronic Kidney Disease, We Need to Talk About Our Kidneys","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Seven Oaks General Hospital","funders":"AstraZeneca","keywords":"Medicine; Kidney disease; Intensive care medicine; Disease; Rheumatology; Clinical Practice; Nephrology; Disease management; MEDLINE; Health care; Physical therapy; Internal medicine","score_opus":0.00871123447423064,"score_gpt":0.32046771730716744,"score_spread":0.3117564828329368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392448305","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019671225,0.008550536,0.0015236951,0.9495903,0.01304179,0.000046462763,0.0002505585,0.00021821803,0.024811272],"genre_scores_gemma":[0.045969807,0.023409484,0.008043255,0.87835866,0.014520994,0.00016770266,0.0003551918,0.0003226221,0.02885228],"study_design_codex":"not_applicable","study_design_gemma":"qualitative","domain_scores_codex":[0.990974,0.0054625403,0.00035713677,0.0004891162,0.0016566443,0.0010605557],"domain_scores_gemma":[0.9769907,0.0073650894,0.0010536193,0.00036674706,0.006173716,0.008050059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008173382,0.0008725555,0.0009678819,0.0008725163,0.008021592,0.008170553,0.0014798075,0.012704243,0.048006263],"category_scores_gemma":[0.033419378,0.00047587606,0.001407144,0.0008221858,0.0034405047,0.010397166,0.0051568924,0.01959881,0.016382327],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004146358,0.000049639555,0.0010944052,0.00025236877,0.000018264613,0.0014407934,0.007158801,0.0000495197,0.00023345172,0.0020516273,0.9457516,0.041858125],"study_design_scores_gemma":[0.00005198506,0.00008293842,0.0011087507,0.0012038768,0.00003448395,0.0041531012,0.023909172,0.00012805697,0.00023164117,0.0058609718,0.96313554,0.00009945903],"about_ca_topic_score_codex":0.007014861,"about_ca_topic_score_gemma":0.017613884,"teacher_disagreement_score":0.048006263,"about_ca_system_score_codex":0.0041412064,"about_ca_system_score_gemma":0.006573868,"threshold_uncertainty_score":0.16059697},"labels":[],"label_agreement":null},{"id":"W4392614952","doi":"10.1007/s12325-024-02811-2","title":"Efficacy and Safety of Transitioning to Lemborexant from Z-drug, Suvorexant, and Ramelteon in Japanese Insomnia Patients: An Open-label, Multicenter Study","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Sleep and related disorders","field":"Psychology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mitsubishi Tanabe Pharma Corporation; Otsuka Pharmaceutical; Eisai; Shionogi; Meiji Seika Pharma; Boehringer Ingelheim Japan; Eisai Canada; Teijin Pharma; Takeda Pharmaceuticals U.S.A.","keywords":"Medicine; Insomnia; Drug; Psychiatry; Open label; Pharmacology; Adverse effect","score_opus":0.016436180121945188,"score_gpt":0.3523783801993804,"score_spread":0.3359422000774352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392614952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992632,0.00028490744,0.00008372086,0.000018542278,0.000006305011,0.00019309983,0.00006167664,0.0000044446115,0.00008403242],"genre_scores_gemma":[0.99853456,0.00029608177,0.00030697798,0.00011557987,0.000038908394,0.0003589053,0.00020615011,0.0000020674686,0.00014074342],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992899,0.00032326448,0.00010466355,0.00012079684,0.0000944293,0.00006681592],"domain_scores_gemma":[0.99825543,0.00026526398,0.0007061136,0.00015038585,0.00016471243,0.0004581122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022593064,0.0006286992,0.0011818716,0.00027948018,0.00044042905,0.00040264602,0.00036942636,0.00066441344,0.0010725872],"category_scores_gemma":[0.00151855,0.00033188338,0.0014808176,0.00031364543,0.0006117174,0.0005786025,0.0003640342,0.0007477643,0.0001775803],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60315424,0.0629241,0.2242554,0.0013047245,0.004591987,0.00021664165,0.001602718,0.00084536156,0.026917519,0.0000919916,0.00060941454,0.07348595],"study_design_scores_gemma":[0.12116883,0.54807913,0.32210416,0.000062790845,0.0027167534,0.000258341,0.00040891956,0.0017706683,0.0024670498,0.000058871497,0.000826981,0.000077520075],"about_ca_topic_score_codex":0.0009430134,"about_ca_topic_score_gemma":0.0011652735,"teacher_disagreement_score":0.0022593064,"about_ca_system_score_codex":0.00045686172,"about_ca_system_score_gemma":0.00076872535,"threshold_uncertainty_score":0.011948466},"labels":[],"label_agreement":null},{"id":"W4392744020","doi":"10.1007/s12325-024-02829-6","title":"Correction to: PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly","year":2024,"lang":"en","type":"erratum","venue":"Advances in Therapy","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Center for Advancing Translational Sciences","keywords":"Acromegaly; Medicine; Somatostatin; Somatostatin Analogue; Internal medicine; Medical physics; Rheumatology; Oncology; Octreotide; Growth hormone; Hormone","score_opus":0.03755480617398558,"score_gpt":0.3943675857701895,"score_spread":0.3568127795962039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392744020","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012656653,0.002625858,0.0006804101,0.16110182,0.82064927,0.00008266834,0.0049317684,0.00023843073,0.008424109],"genre_scores_gemma":[0.045690473,0.019432155,0.00582168,0.36778143,0.2992172,0.0007803709,0.011794042,0.0023162512,0.2471665],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99627566,0.00072538847,0.0006862563,0.00032765145,0.0016625064,0.0003226283],"domain_scores_gemma":[0.973937,0.008295264,0.002465869,0.0008118292,0.013129765,0.0013602034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030963172,0.0012149648,0.0008542284,0.0024067,0.0015481794,0.0022471715,0.0013150752,0.003143568,0.02751945],"category_scores_gemma":[0.05384831,0.00048041472,0.00079010194,0.0019516421,0.00095091294,0.0013468472,0.0010961023,0.0064093787,0.014669945],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000247382,0.00000737825,0.00043954366,0.00008483665,0.0000051952684,0.00015311499,0.00003774734,0.000014355901,0.000014420914,0.00014241094,0.9941963,0.004880013],"study_design_scores_gemma":[0.000057496636,0.000037272534,0.0041281753,0.00093172054,0.000039393257,0.0009265727,0.00037958153,0.00013183459,0.00022814934,0.00035327228,0.99274933,0.000037126123],"about_ca_topic_score_codex":0.01952231,"about_ca_topic_score_gemma":0.021549396,"teacher_disagreement_score":0.02751945,"about_ca_system_score_codex":0.0028035548,"about_ca_system_score_gemma":0.0041950466,"threshold_uncertainty_score":0.0920617},"labels":[],"label_agreement":null},{"id":"W4392923906","doi":"10.1007/s12325-024-02822-z","title":"Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada); Precision Nanosystems (Canada)","funders":"National Cancer Institute; Kite Pharma","keywords":"Mantle cell lymphoma; Medicine; Internal medicine; Hazard ratio; Population; Oncology; Progression-free survival; Confidence interval; Gastroenterology; Lymphoma; Chemotherapy","score_opus":0.01086648479791213,"score_gpt":0.2654537285972432,"score_spread":0.25458724379933106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392923906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99157363,0.0017696721,0.003557744,0.00012970697,0.00012952316,0.0004611482,0.001109067,0.000030130968,0.0012392646],"genre_scores_gemma":[0.9969771,0.00020240748,0.0013001636,0.00007872609,0.00002447656,0.00036900004,0.00058305723,0.0000070330525,0.00045819144],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99014574,0.0075615644,0.00046468855,0.00087766006,0.00047827352,0.00047201358],"domain_scores_gemma":[0.99186385,0.00483917,0.001841054,0.0008971058,0.00023123006,0.00032746597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010359295,0.0010123039,0.0014444621,0.0006336606,0.0002025533,0.0009272905,0.0013056527,0.000987885,0.005588852],"category_scores_gemma":[0.018031392,0.00047695963,0.006247825,0.000558021,0.00060631084,0.0007752403,0.001490813,0.001394099,0.0003753146],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6499955,0.0026000696,0.16716121,0.002736212,0.0792764,0.00034374854,0.00044667884,0.02336274,0.0028470359,0.0035265503,0.0017083681,0.0659954],"study_design_scores_gemma":[0.10998242,0.23484576,0.37855536,0.00091321266,0.13373613,0.0012815695,0.0008499006,0.10718767,0.008762679,0.013812126,0.009766587,0.0003066188],"about_ca_topic_score_codex":0.0011253817,"about_ca_topic_score_gemma":0.0010495756,"teacher_disagreement_score":0.010359295,"about_ca_system_score_codex":0.0009467197,"about_ca_system_score_gemma":0.0006894131,"threshold_uncertainty_score":0.054785907},"labels":[],"label_agreement":null},{"id":"W4393115557","doi":"10.1007/s12325-024-02826-9","title":"Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Tryptophan and brain disorders","field":"Neuroscience","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Brain and Cognition Discovery Foundation; University of Ottawa","funders":"","keywords":"Vortioxetine; Medicine; Placebo; Internal medicine; Clinical endpoint; Randomized controlled trial; Body mass index; Mood; Physical therapy; Major depressive disorder; Psychiatry; Pathology","score_opus":0.008732925826616594,"score_gpt":0.3325133837605865,"score_spread":0.32378045793396987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393115557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901447,0.0041519906,0.0004987549,0.00049889996,0.00066490064,0.0023249546,0.00062756566,0.000065878005,0.0010223885],"genre_scores_gemma":[0.98865604,0.0027070423,0.0013959167,0.000498044,0.0005449953,0.0033516088,0.0006552345,0.000016145275,0.002174933],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991899,0.00037219762,0.00007815344,0.00016357722,0.00006114271,0.00013506484],"domain_scores_gemma":[0.99912244,0.00028556198,0.00018982009,0.00007928492,0.000063186555,0.00025966714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016925709,0.0018406013,0.0052954233,0.00044588355,0.0006834125,0.0011686522,0.0010365424,0.00210602,0.0072792647],"category_scores_gemma":[0.0017417861,0.0009371565,0.0024730996,0.00044862597,0.0015071335,0.0012175934,0.0005490808,0.0035777637,0.000695368],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99209595,0.002636275,0.00028458532,0.00023699121,0.00079972873,0.000010641243,0.000011940481,0.00007562207,0.0006910443,0.000031896263,0.00009834125,0.0030269003],"study_design_scores_gemma":[0.96950656,0.027816482,0.0013639862,0.000021416929,0.0007207825,0.000008445341,0.000015937021,0.00020979656,0.00016080293,0.000045820398,0.00011919264,0.000010766448],"about_ca_topic_score_codex":0.002430286,"about_ca_topic_score_gemma":0.003987772,"teacher_disagreement_score":0.0072792647,"about_ca_system_score_codex":0.0007705413,"about_ca_system_score_gemma":0.0011158739,"threshold_uncertainty_score":0.024351597},"labels":[],"label_agreement":null},{"id":"W4393342156","doi":"10.1007/s12325-023-02766-w","title":"Modelling Treatment Sequences in Immunology: Optimizing Patient Outcomes","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Geomechanica (Canada)","funders":"","keywords":"Medicine; Psoriatic arthritis; Rheumatology; Rheumatoid arthritis; Ankylosing spondylitis; Internal medicine; Psoriasis; Infliximab; Disease; Reimbursement; Golimumab; Quality of life (healthcare); Physical therapy; Intensive care medicine; Adalimumab; Health care; Immunology","score_opus":0.027408015565223053,"score_gpt":0.32423304761687394,"score_spread":0.2968250320516509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393342156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7520467,0.003729016,0.2172458,0.0065685753,0.0002982578,0.0013560937,0.007212146,0.00034156267,0.011201925],"genre_scores_gemma":[0.9803049,0.0005725862,0.0155414045,0.00037858126,0.00003809947,0.00055222795,0.00094340096,0.000024133438,0.0016447509],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9954184,0.0035251908,0.00012328378,0.00046497228,0.00014093932,0.00032711643],"domain_scores_gemma":[0.9843225,0.0129119735,0.0015226338,0.00035589666,0.00039260855,0.0004944254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00811505,0.0013129245,0.0018259074,0.0012028877,0.0004392262,0.0017154735,0.0017090158,0.0022922198,0.006364183],"category_scores_gemma":[0.024034323,0.0008273539,0.0028832888,0.0011919367,0.0009998521,0.0012141365,0.00101896,0.0019026616,0.00038939333],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029077704,0.000071251656,0.004384364,0.00008235226,0.00014219197,0.000046832018,0.000044170294,0.9889297,0.000044307704,0.0024088786,0.00030900646,0.0032460932],"study_design_scores_gemma":[0.00033022006,0.0003507496,0.0025677995,0.00010504675,0.00028375146,0.000054116404,0.000078197416,0.98101383,0.00014500045,0.013985271,0.0010564311,0.000029709447],"about_ca_topic_score_codex":0.030854195,"about_ca_topic_score_gemma":0.015496166,"teacher_disagreement_score":0.030854195,"about_ca_system_score_codex":0.004118837,"about_ca_system_score_gemma":0.0041292827,"threshold_uncertainty_score":0.061349213},"labels":[],"label_agreement":null},{"id":"W4393950389","doi":"10.1007/s12325-024-02827-8","title":"Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"Fogarty International Center; Swedish Orphan Biovitrum; Apellis Pharmaceuticals","keywords":"Medicine; Paroxysmal nocturnal hemoglobinuria; Internal medicine; Adverse effect; Cutoff; Anemia; Population; Hemoglobin; Gastroenterology","score_opus":0.013220325758835647,"score_gpt":0.30904353567541964,"score_spread":0.295823209916584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393950389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993079,0.0011745137,0.00032284687,0.00019191136,0.000045483594,0.001607734,0.002178936,0.00006445125,0.0013351534],"genre_scores_gemma":[0.98769605,0.0012027011,0.0010851484,0.0006257665,0.00012305725,0.0039288113,0.0040991497,0.00001956314,0.0012197801],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991124,0.00041165558,0.00008891951,0.00014510154,0.00013516261,0.00010661044],"domain_scores_gemma":[0.9981615,0.00039584358,0.00054115726,0.0002297454,0.00021933,0.00045242984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030863392,0.00085932994,0.0021906183,0.00031129472,0.0004065574,0.0007015524,0.000522894,0.0010267831,0.0037447303],"category_scores_gemma":[0.0017812693,0.00036723126,0.0017012155,0.00040198962,0.0006297607,0.0007681842,0.00038673455,0.0018655175,0.0010626566],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9065158,0.020988867,0.012316502,0.0008270466,0.0016685296,0.00017185557,0.0002073836,0.0008237267,0.009784894,0.00012261551,0.0033031737,0.043269556],"study_design_scores_gemma":[0.6608033,0.27090308,0.0600519,0.00013213033,0.0010934405,0.00042125097,0.0000931378,0.0012827682,0.0018423982,0.00019523481,0.00313199,0.00004939172],"about_ca_topic_score_codex":0.00059010775,"about_ca_topic_score_gemma":0.0010734152,"teacher_disagreement_score":0.0037447303,"about_ca_system_score_codex":0.0006936091,"about_ca_system_score_gemma":0.0017490417,"threshold_uncertainty_score":0.016322315},"labels":[],"label_agreement":null},{"id":"W4394818893","doi":"10.1007/s12325-024-02832-x","title":"Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Bausch Health","keywords":"Rifaximin; Medicine; Irritable bowel syndrome; Internal medicine; Diarrhea; Retrospective cohort study; Gastroenterology; Antibiotics","score_opus":0.013078550320503753,"score_gpt":0.3009737151119435,"score_spread":0.28789516479143973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394818893","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95757204,0.007869469,0.018766154,0.0012190258,0.00013861313,0.00059850415,0.009730648,0.00009145688,0.0040140836],"genre_scores_gemma":[0.9856309,0.0005882835,0.010004731,0.00016202593,0.00014029306,0.00033110776,0.0029288102,0.000012875727,0.00020109185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.990123,0.0065644644,0.0010111722,0.00086581794,0.0011916202,0.00024395387],"domain_scores_gemma":[0.9745053,0.014034774,0.00901202,0.0010089206,0.0008421563,0.00059686304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015289365,0.00085361494,0.0013376201,0.0046851453,0.0003488581,0.0022413288,0.0012100985,0.0007110348,0.0021350689],"category_scores_gemma":[0.03162949,0.00028728542,0.002841361,0.003910707,0.0005930846,0.0017287469,0.0013981189,0.0012265783,0.0001803773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024364851,0.00048514435,0.9300912,0.00059526874,0.0052824467,0.000081235536,0.00020810144,0.011005302,0.00019841392,0.0015224969,0.0012794114,0.046814494],"study_design_scores_gemma":[0.0004492169,0.00332858,0.879491,0.00043682288,0.0023208805,0.0006819391,0.00065028196,0.10118021,0.00063501066,0.0059654396,0.004715495,0.00014513744],"about_ca_topic_score_codex":0.0023124292,"about_ca_topic_score_gemma":0.0025819784,"teacher_disagreement_score":0.015289365,"about_ca_system_score_codex":0.0016182963,"about_ca_system_score_gemma":0.0010278362,"threshold_uncertainty_score":0.080858886},"labels":[],"label_agreement":null},{"id":"W4395068084","doi":"10.1007/s12325-024-02825-w","title":"Stratified Patient Profiling for Vedolizumab Effectiveness in Crohn’s Disease: Identifying Optimal Subgroups for Enhanced Treatment Response in the EVOLVE Study","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"Takeda Pharmaceuticals International; Cedars-Sinai Medical Center","keywords":"Vedolizumab; Medicine; Internal medicine; Crohn's disease; Rheumatology; Profiling (computer programming); Disease","score_opus":0.01748624140895827,"score_gpt":0.34014957204818363,"score_spread":0.32266333063922537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395068084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99894565,0.00017439354,0.0004922476,0.000026600883,0.0000036490453,0.000018711902,0.00020635029,0.000004073503,0.00012831755],"genre_scores_gemma":[0.9990225,0.00003379257,0.0005011583,0.000020177175,0.000006522207,0.000014489841,0.00036198084,0.0000016883656,0.00003767882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978763,0.0012280942,0.00017331369,0.00030108256,0.00029290916,0.00012834616],"domain_scores_gemma":[0.9954379,0.002033694,0.0015447997,0.00050017395,0.00020482678,0.00027859336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042123827,0.00028874076,0.00087635405,0.0005971398,0.0002493454,0.00080792035,0.00028111407,0.00039718772,0.000570896],"category_scores_gemma":[0.0067283986,0.00014134408,0.0011954318,0.0005176989,0.00022269411,0.00036225477,0.0004386235,0.00038603897,0.00011486424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004540819,0.00007719584,0.9851039,0.000026612403,0.00054245855,0.000060987077,0.00010346092,0.0008431002,0.0011543095,0.000071522314,0.00014464105,0.0073309676],"study_design_scores_gemma":[0.00016499996,0.0014272884,0.9889775,0.00001806349,0.00045953857,0.00028137924,0.00012756448,0.0066527557,0.0010213634,0.0002247831,0.0006276091,0.000017122537],"about_ca_topic_score_codex":0.00057840446,"about_ca_topic_score_gemma":0.00090803235,"teacher_disagreement_score":0.0042123827,"about_ca_system_score_codex":0.00028078674,"about_ca_system_score_gemma":0.00031553674,"threshold_uncertainty_score":0.022277474},"labels":[],"label_agreement":null},{"id":"W4395068277","doi":"10.1007/s12325-024-02859-0","title":"Development and Application of an Attribute-Based Taxonomy on the Benefits of Oral Anticoagulant Switching in Atrial Fibrillation: A Delphi Study","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Petro-Canada; St. Paul's Hospital; Centre for Advancing Health Outcomes; Centre for Social Innovation; University of British Columbia Hospital; Vancouver General Hospital; Island Health; Royal Columbian Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Atrial fibrillation; Oral anticoagulant; Delphi; Delphi method; Internal medicine; Anticoagulant; Rheumatology; Cardiology; Warfarin; Artificial intelligence; Computer science","score_opus":0.09470546037646782,"score_gpt":0.36626309439185484,"score_spread":0.271557634015387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395068277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7730466,0.00081489614,0.15675417,0.0068583908,0.00026475705,0.036399107,0.002800232,0.00014607483,0.022915732],"genre_scores_gemma":[0.73218185,0.0007667401,0.23186173,0.0013113382,0.000045877834,0.031031063,0.0013229661,0.000060798367,0.0014176242],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.92731076,0.053865932,0.008353221,0.0014840494,0.0066776266,0.0023083598],"domain_scores_gemma":[0.79151535,0.15804337,0.0059114103,0.0060551893,0.036033973,0.0024407057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.16137016,0.0007989812,0.0012718254,0.005721527,0.0026393412,0.003932274,0.0017153412,0.0014677304,0.0041202377],"category_scores_gemma":[0.18073139,0.00067042944,0.0025958787,0.0037852975,0.0020735778,0.004023877,0.0075838165,0.002944565,0.00072132837],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026020785,0.0019087531,0.11829712,0.0103197275,0.001225358,0.0007118695,0.28578436,0.01172039,0.005963802,0.042647693,0.014032709,0.5047861],"study_design_scores_gemma":[0.0020856035,0.004864554,0.14774418,0.018590622,0.0024819588,0.0014689422,0.5272217,0.080048054,0.01053375,0.08361461,0.120487995,0.0008581421],"about_ca_topic_score_codex":0.0037151515,"about_ca_topic_score_gemma":0.00397347,"teacher_disagreement_score":0.16137016,"about_ca_system_score_codex":0.007041976,"about_ca_system_score_gemma":0.013946736,"threshold_uncertainty_score":0.85341716},"labels":[],"label_agreement":null},{"id":"W4395448014","doi":"10.1007/s12325-024-02855-4","title":"Implications of Cardiopulmonary Risk for the Management of COPD: A Narrative Review","year":2024,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Manchester Biomedical Research Centre; Genentech; National Institutes of Health; Sunovion; Glenmark Pharmaceuticals; AstraZeneca; CSL Behring; Sanofi; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Mylan; COPD Foundation; GlaxoSmithKline; Amgen","keywords":"Medicine; COPD; Intensive care medicine; Disease; Cause of death; Risk factor; Internal medicine","score_opus":0.0456409043811343,"score_gpt":0.43151400131990636,"score_spread":0.38587309693877203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395448014","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008174474,0.9982079,0.000091804366,0.00068369537,0.00024438245,0.0000139459735,0.000033094202,0.000003924642,0.0006394594],"genre_scores_gemma":[0.000656606,0.99839383,0.00017269641,0.00041015295,0.00013691944,0.000014623108,0.000027626049,0.0000011527607,0.00018638685],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99937695,0.00018100035,0.0001457165,0.00007390689,0.00018598858,0.00003643816],"domain_scores_gemma":[0.9978865,0.0014342188,0.0002954435,0.000033118897,0.00029290374,0.00005779168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013729812,0.0007603336,0.0013528431,0.0025430627,0.0004115563,0.0017524317,0.0009168228,0.001226573,0.0053102733],"category_scores_gemma":[0.005074733,0.000256918,0.0014186179,0.0023630857,0.00042124328,0.0015536724,0.0009657232,0.0014819129,0.0010130613],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000096162046,0.000046677324,0.0002655469,0.21079388,0.00046543992,0.00024470093,0.0003802121,0.00033351145,0.000520858,0.006211055,0.04280706,0.7378348],"study_design_scores_gemma":[0.000029676772,0.00010149838,0.0011870647,0.17642659,0.0015335806,0.0013527569,0.000300169,0.0001245267,0.00016291156,0.0035662837,0.81518465,0.000030283083],"about_ca_topic_score_codex":0.0018671004,"about_ca_topic_score_gemma":0.004393663,"teacher_disagreement_score":0.0053102733,"about_ca_system_score_codex":0.0009010114,"about_ca_system_score_gemma":0.003883246,"threshold_uncertainty_score":0.017764628},"labels":[],"label_agreement":null},{"id":"W4395456078","doi":"10.1007/s12325-024-02860-7","title":"The Use of Precision Epigenetic Methods for the Diagnosis and Care of Stable Coronary Heart Disease Reduces Healthcare Costs","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cytodiagnostics (Canada)","funders":"","keywords":"Medicine; Epigenetics; Coronary heart disease; Health care; Disease; Intensive care medicine; Precision medicine; Internal medicine; Cardiology; Pathology","score_opus":0.048423075050866904,"score_gpt":0.40716602636033367,"score_spread":0.35874295130946676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395456078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69277036,0.009509816,0.21407469,0.017635,0.00016688161,0.0017370443,0.0069531356,0.0006271656,0.05652594],"genre_scores_gemma":[0.9720978,0.002324483,0.023158424,0.00028715303,0.000041085157,0.00017628336,0.00047740914,0.000017554928,0.0014196784],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9978257,0.0012977864,0.000057278987,0.0001464239,0.00050453143,0.00016816329],"domain_scores_gemma":[0.9949892,0.0035958928,0.0007324725,0.00019265292,0.00031807597,0.00017171387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035680686,0.0005641647,0.00042607018,0.0007714909,0.00021311542,0.0012946695,0.0007195957,0.00064185367,0.008546852],"category_scores_gemma":[0.010752739,0.00026014005,0.0009928317,0.000696301,0.0004728785,0.00078803266,0.000745051,0.0006833083,0.0005529433],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018304136,0.000694383,0.09779916,0.0014015061,0.0008865976,0.00026991434,0.00018799824,0.42425966,0.0054148114,0.047775418,0.010666432,0.40881371],"study_design_scores_gemma":[0.0014529014,0.0045837215,0.14561409,0.0018526063,0.0017521842,0.0010418353,0.00048435197,0.69545275,0.009050219,0.07329628,0.06521513,0.00020391463],"about_ca_topic_score_codex":0.011287372,"about_ca_topic_score_gemma":0.00867246,"teacher_disagreement_score":0.011287372,"about_ca_system_score_codex":0.003383473,"about_ca_system_score_gemma":0.0051382435,"threshold_uncertainty_score":0.02859211},"labels":[],"label_agreement":null},{"id":"W4396552446","doi":"10.1007/s12325-024-02843-8","title":"Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Thyroid and Parathyroid Surgery","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; McMaster University","funders":"Novo Nordisk; Kowa Company; Alexion Pharmaceuticals; AstraZeneca; Chugai Pharmaceutical; Amgen","keywords":"Medicine; Hypoparathyroidism; Rheumatology; Internal medicine; Renal function; Urology","score_opus":0.017247183799326063,"score_gpt":0.2944128824721473,"score_spread":0.27716569867282126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396552446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913933,0.0050292267,0.00022385643,0.00035015852,0.0000718777,0.000644064,0.0011687182,0.00004316409,0.0010757135],"genre_scores_gemma":[0.9926016,0.002755976,0.0006153104,0.0006090191,0.00014970363,0.0007907021,0.0014340571,0.000010335915,0.0010333441],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991567,0.00044193288,0.00006237411,0.00010775347,0.000092971626,0.00013817266],"domain_scores_gemma":[0.9986413,0.00030138093,0.00043917628,0.00013522996,0.0001310775,0.0003518923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026685987,0.0007945684,0.0016494704,0.00019720908,0.00033254275,0.0009019155,0.00040499348,0.0011368181,0.0020070595],"category_scores_gemma":[0.001872912,0.0002851719,0.0022062506,0.00026461223,0.00043557328,0.000701756,0.00035877337,0.0014905022,0.00029648803],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92779034,0.009528391,0.007703881,0.0010439428,0.0026993412,0.000090796064,0.00013435961,0.00055254804,0.00552148,0.000098132856,0.0017760603,0.04306072],"study_design_scores_gemma":[0.7551263,0.18272923,0.0554849,0.00014566713,0.0026975728,0.0001897377,0.00008307679,0.00059131556,0.001052018,0.00022590088,0.0016394368,0.000034856377],"about_ca_topic_score_codex":0.00095422426,"about_ca_topic_score_gemma":0.0022386026,"teacher_disagreement_score":0.0026685987,"about_ca_system_score_codex":0.00049126416,"about_ca_system_score_gemma":0.0009175382,"threshold_uncertainty_score":0.014113069},"labels":[],"label_agreement":null},{"id":"W4396575375","doi":"10.1007/s12325-024-02865-2","title":"Observing the Clinical Course of Duchenne Muscular Dystrophy in Medicaid Real-World Healthcare Data","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Muscle Physiology and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Broadcom (Canada); Vancouver Coastal Health","funders":"Sarepta Therapeutics","keywords":"Medicine; Duchenne muscular dystrophy; Muscular dystrophy; Medicaid; Health care; Rheumatology; Physical therapy; Physical medicine and rehabilitation; Family medicine; Internal medicine","score_opus":0.05606112900153842,"score_gpt":0.42912104494120257,"score_spread":0.37305991593966414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396575375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9266566,0.00037125213,0.0008536316,0.0006564592,0.000011756646,0.0000643455,0.06987982,0.00003308014,0.0014731718],"genre_scores_gemma":[0.9548991,0.0002267955,0.0015366247,0.00016827848,0.000022757318,0.00012609691,0.042830274,0.0000057322786,0.00018425247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978123,0.00062035024,0.00042562414,0.00049464975,0.0004338632,0.0002132994],"domain_scores_gemma":[0.9895964,0.0024146372,0.006393181,0.00044263157,0.00082156324,0.00033154737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002241542,0.00018862364,0.00022456962,0.0017913713,0.00035618606,0.0005869919,0.00044623666,0.00033449568,0.0014035567],"category_scores_gemma":[0.009697851,0.00014555469,0.00038797897,0.0032762215,0.00022936276,0.00051714724,0.000858667,0.00037964742,0.00019520453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003989567,0.000012922494,0.99614906,0.00003147927,0.000059125272,0.00005873379,0.00007790273,0.0002643856,0.000088184905,0.00009562965,0.0013085735,0.0018141011],"study_design_scores_gemma":[0.000005340392,0.000022428721,0.99607444,0.000051955583,0.000024113344,0.00021871345,0.00026652898,0.0012969365,0.00011212864,0.000109397144,0.0018105268,0.0000075003823],"about_ca_topic_score_codex":0.03403663,"about_ca_topic_score_gemma":0.051026754,"teacher_disagreement_score":0.03403663,"about_ca_system_score_codex":0.001020303,"about_ca_system_score_gemma":0.0009399219,"threshold_uncertainty_score":0.06767702},"labels":[],"label_agreement":null},{"id":"W4396662793","doi":"10.1007/s12325-024-02867-0","title":"“You Take This Day by Day, Come What May”: A Qualitative Study of the Psychosocial Impacts of Living with Duchenne Muscular Dystrophy","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Muscle Physiology and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Broadcom (Canada); Vancouver Coastal Health","funders":"Sarepta Therapeutics","keywords":"Psychosocial; Duchenne muscular dystrophy; Medicine; Qualitative research; Muscular dystrophy; Quality of life (healthcare); Perspective (graphical); Health related quality of life; Disease; Gerontology; Social support; Physical therapy; Psychiatry; Internal medicine; Psychology; Nursing; Psychotherapist","score_opus":0.007325064491490143,"score_gpt":0.3192542250416676,"score_spread":0.3119291605501775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396662793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805596,0.0011784991,0.0034158416,0.0067944624,0.00018880672,0.0006235874,0.00045281515,0.00002837076,0.0067581506],"genre_scores_gemma":[0.98933053,0.0014161924,0.0017299736,0.0022127447,0.000047941827,0.0008862593,0.00013025502,0.000038046062,0.004208056],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.987357,0.010083293,0.00028644924,0.00044400772,0.00050568214,0.0013235878],"domain_scores_gemma":[0.977849,0.016867064,0.0011926779,0.00037493426,0.0014644426,0.0022517412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016560964,0.0009024875,0.0009694438,0.001570129,0.013688449,0.0038346997,0.0022443624,0.002271748,0.004888469],"category_scores_gemma":[0.019215249,0.00085982267,0.00056356005,0.0015259142,0.011998573,0.004602279,0.006176527,0.004111751,0.0005354632],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024079494,0.00003359922,0.0009522667,0.000098670665,0.0000025162963,0.0005719073,0.9956917,0.000022945105,0.00028010504,0.00045735092,0.00041554286,0.0014492277],"study_design_scores_gemma":[0.000002590407,0.000027849179,0.00043353759,0.00011175755,0.0000015564639,0.000118313255,0.9964079,0.00002325003,0.00007464158,0.00011368941,0.0026787405,0.0000060863686],"about_ca_topic_score_codex":0.01934907,"about_ca_topic_score_gemma":0.034948874,"teacher_disagreement_score":0.01934907,"about_ca_system_score_codex":0.0069454233,"about_ca_system_score_gemma":0.007233685,"threshold_uncertainty_score":0.08758378},"labels":[],"label_agreement":null},{"id":"W4399055997","doi":"10.1007/s12325-024-02875-0","title":"Epidemiology and Treatment Patterns of Patients with Vitiligo: A Real-World Analysis","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"melanin and skin pigmentation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ABB (Canada)","funders":"AbbVie","keywords":"Vitiligo; Medicine; Comorbidity; Population; Epidemiology; Depigmentation; Internal medicine; Incidence (geometry); Psoriasis; Alopecia areata; Dermatology","score_opus":0.012129846098345042,"score_gpt":0.3232031301508689,"score_spread":0.3110732840525238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399055997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979442,0.000517827,0.00008844143,0.00008167157,0.0000024137014,0.000015056416,0.0009889732,0.0000033062697,0.00035805054],"genre_scores_gemma":[0.99894553,0.00017568724,0.000070158814,0.000023877485,0.000005083499,0.0000113461365,0.0007382636,0.0000012039851,0.000028838573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99918574,0.0002633377,0.00013364627,0.0001707112,0.00014421654,0.00010237139],"domain_scores_gemma":[0.99809486,0.00032055442,0.0011982374,0.000091281094,0.00013909151,0.00015591095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073829695,0.00011370136,0.00031011252,0.0012142209,0.00023584015,0.00066726137,0.0003284402,0.00031537257,0.0012766223],"category_scores_gemma":[0.0022506905,0.00019481276,0.00040038812,0.0019046576,0.00020608697,0.0004802434,0.00045081897,0.0003156854,0.00013680877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024625755,0.000010294621,0.99925417,0.0000074767286,0.000026291571,0.000019436598,0.000021287766,0.000034808454,0.000024081284,0.000008265605,0.00004807476,0.0005210482],"study_design_scores_gemma":[0.000005306964,0.00003051463,0.9989795,0.000010117102,0.00001717054,0.00028158768,0.00019169274,0.00030592736,0.000021115009,0.000013405027,0.00014078598,0.000002803933],"about_ca_topic_score_codex":0.005070858,"about_ca_topic_score_gemma":0.004068443,"teacher_disagreement_score":0.005070858,"about_ca_system_score_codex":0.000448077,"about_ca_system_score_gemma":0.00034039983,"threshold_uncertainty_score":0.010082722},"labels":[],"label_agreement":null},{"id":"W4399326644","doi":"10.1007/s12325-024-02893-y","title":"Direct and Indirect Costs of Breast Cancer and Associated Implications: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AstraZeneca","keywords":"Medicine; Breast cancer; EconLit; Indirect costs; Health care; Health economics; MEDLINE; Disease burden; Epidemiology; Environmental health; Family medicine; Cancer; Public health; Demography; Economic growth; Population; Pathology; Accounting; Internal medicine; Business","score_opus":0.039705482735827566,"score_gpt":0.33405506546689123,"score_spread":0.29434958273106365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399326644","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001881867,0.9956957,0.0001416273,0.0003856701,0.0000871831,0.00031991352,0.0010337685,0.0000063567145,0.00044793697],"genre_scores_gemma":[0.030362355,0.9672117,0.0006639919,0.00042673235,0.000090661684,0.0006206625,0.00048104185,0.000006386842,0.00013651047],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9894422,0.0041158125,0.003386555,0.00052078435,0.0022253946,0.00030918545],"domain_scores_gemma":[0.9513267,0.038029265,0.0073987995,0.00042466,0.002529657,0.0002908839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008104671,0.00157897,0.0070764422,0.012588707,0.00061697303,0.0031691936,0.0016176554,0.0016778599,0.005527778],"category_scores_gemma":[0.05381649,0.0011253082,0.008417219,0.014725894,0.00083576614,0.002361528,0.0015030741,0.0013364721,0.00026248873],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002251332,0.00001190137,0.0016783719,0.9557319,0.015178011,0.00016257173,0.0001150559,0.00019123797,0.00004874371,0.00033838098,0.0015333451,0.024785357],"study_design_scores_gemma":[0.0003582187,0.00013817247,0.007830961,0.8779898,0.09822458,0.00068355346,0.00028114268,0.00018582026,0.00011530054,0.0007040861,0.013448515,0.000039851173],"about_ca_topic_score_codex":0.010581028,"about_ca_topic_score_gemma":0.029363796,"teacher_disagreement_score":0.012588707,"about_ca_system_score_codex":0.005440967,"about_ca_system_score_gemma":0.01104182,"threshold_uncertainty_score":0.042862117},"labels":[],"label_agreement":null},{"id":"W4399543904","doi":"10.1007/s12325-024-02902-0","title":"De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Biogen","keywords":"Medicine; Fingolimod; Multiple sclerosis; Ocrelizumab; Internal medicine; Expanded Disability Status Scale; Adverse effect; Clinical trial; Immunology; Rituximab","score_opus":0.044418579673088626,"score_gpt":0.33468176764115215,"score_spread":0.2902631879680635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399543904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990011,0.00028609153,0.00007591081,0.000033432738,0.0000061504848,0.000039700237,0.00025698595,0.0000030964238,0.00029764362],"genre_scores_gemma":[0.99903476,0.00009399356,0.00008797064,0.00008859426,0.0000125333,0.00006159107,0.0004581844,0.0000013898862,0.00016106456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989988,0.00025919516,0.00012162653,0.00020746552,0.00019858425,0.00021427624],"domain_scores_gemma":[0.9982951,0.00018938005,0.000890572,0.00009181983,0.00020504554,0.00032814813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019598624,0.00037353078,0.0006473097,0.00081484206,0.0007949633,0.0010179902,0.0004584416,0.0006994905,0.00083589676],"category_scores_gemma":[0.003687823,0.00031385303,0.0015835726,0.00064960564,0.00027758704,0.00081215997,0.00079443364,0.0009502206,0.00028992028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026457442,0.0005963869,0.9851053,0.0000739386,0.00043868923,0.00015001747,0.0005130499,0.00012683329,0.00045050328,0.00003642262,0.00020345308,0.009659667],"study_design_scores_gemma":[0.0001575902,0.0030154896,0.99477684,0.000038906113,0.0002940693,0.00023091584,0.00033284814,0.00038564176,0.00021607078,0.00007453162,0.00046058407,0.000016396598],"about_ca_topic_score_codex":0.0033240814,"about_ca_topic_score_gemma":0.0037831746,"teacher_disagreement_score":0.0033240814,"about_ca_system_score_codex":0.0005921834,"about_ca_system_score_gemma":0.00039543095,"threshold_uncertainty_score":0.0103648305},"labels":[],"label_agreement":null},{"id":"W4400419581","doi":"10.1007/s12325-024-02920-y","title":"Increased Risk of Severe Cardiovascular Events Following Exacerbations of Chronic Obstructive Pulmonary Disease: Results of the EXACOS-CV Study in Japan","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pulmonary disease; Internal medicine; Rheumatology; Cardiology; Disease; Intensive care medicine; Emergency medicine","score_opus":0.012654358702799186,"score_gpt":0.30352268772919216,"score_spread":0.290868329026393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400419581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99890125,0.00036786313,0.000027855252,0.00003134115,0.0000055168316,0.0000062345575,0.00041070872,0.0000016766312,0.0002476131],"genre_scores_gemma":[0.9989095,0.00016980534,0.000035093584,0.000027931055,0.000016916858,0.000007929225,0.0007251988,0.0000017808603,0.00010581428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99945575,0.0001399517,0.000064639455,0.00015069108,0.000093500035,0.00009541165],"domain_scores_gemma":[0.9986841,0.000098698765,0.0005113215,0.0001232199,0.00018617044,0.0003964775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010561952,0.0004127826,0.00059107086,0.0009294567,0.00048144843,0.00085999264,0.00040964322,0.000508579,0.00058242324],"category_scores_gemma":[0.0012982016,0.000407184,0.0008457067,0.0011962024,0.0002877295,0.00042040745,0.0007333296,0.00050893985,0.00012325252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001252517,0.000015312758,0.9992711,0.0000076070523,0.000076459604,0.000048942264,0.000051995827,0.00001318652,0.000074859556,0.0000045279544,0.00006440497,0.0002463281],"study_design_scores_gemma":[0.0000066591488,0.000021049469,0.9997584,0.000002727993,0.000029469293,0.000042828855,0.000059946004,0.00003380595,0.000005560066,0.0000026733874,0.00003510398,0.0000016374898],"about_ca_topic_score_codex":0.019062795,"about_ca_topic_score_gemma":0.024329606,"teacher_disagreement_score":0.019062795,"about_ca_system_score_codex":0.00043371314,"about_ca_system_score_gemma":0.0004960674,"threshold_uncertainty_score":0.037903666},"labels":[],"label_agreement":null},{"id":"W4400533986","doi":"10.1007/s12325-024-02928-4","title":"Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Anemia; Post-hoc analysis; Internal medicine; Gastroenterology; Subgroup analysis; Randomized controlled trial; Surgery; Meta-analysis; Bone marrow","score_opus":0.022127148808323633,"score_gpt":0.31237314423471757,"score_spread":0.29024599542639395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400533986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918699,0.0048278044,0.00037700284,0.00017375182,0.00009223763,0.0005573032,0.0012818297,0.000019450308,0.00080074917],"genre_scores_gemma":[0.99584395,0.0007566323,0.00039530697,0.00025787714,0.00014095331,0.000529499,0.0016362852,0.00000904757,0.00043057924],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99819165,0.0008986551,0.0002586752,0.00026008766,0.000197976,0.00019290362],"domain_scores_gemma":[0.99835205,0.00080049474,0.0003609949,0.00022060926,0.00008547601,0.0001804793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029806572,0.0010388305,0.0037723067,0.0006613592,0.00020957933,0.00093143363,0.0006948363,0.00082163047,0.0022056082],"category_scores_gemma":[0.0031210422,0.00032062214,0.008215767,0.0005804183,0.00032526927,0.0005147355,0.0005912599,0.0010477414,0.0001971508],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84179026,0.0015342679,0.060667645,0.0017847185,0.056916434,0.00039892204,0.00018715813,0.0021800855,0.006696207,0.00023334094,0.0017750325,0.025835924],"study_design_scores_gemma":[0.36935854,0.13441105,0.35474998,0.00047439008,0.1160043,0.001417388,0.000784959,0.009499327,0.0045948643,0.0020493905,0.006399797,0.0002560462],"about_ca_topic_score_codex":0.0006395278,"about_ca_topic_score_gemma":0.0021284686,"teacher_disagreement_score":0.0037723067,"about_ca_system_score_codex":0.0005174569,"about_ca_system_score_gemma":0.0007071677,"threshold_uncertainty_score":0.015763462},"labels":[],"label_agreement":null},{"id":"W4400594797","doi":"10.1007/s12325-024-02930-w","title":"Correction: Beyond Response: Aiming for Quality Remission in Depression","year":2024,"lang":"en","type":"erratum","venue":"Advances in Therapy","topic":"Health Policy Implementation Science","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Rheumatology; Depression (economics); Internal medicine; Quality (philosophy); Alternative medicine; Medical physics; Family medicine; Physical therapy; Pathology; Epistemology","score_opus":0.39784102213946215,"score_gpt":0.6976135019190107,"score_spread":0.2997724797795486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400594797","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026680385,0.0004208226,0.00018366291,0.13332327,0.8640408,0.000015235306,0.00044133316,0.00010269635,0.0014454937],"genre_scores_gemma":[0.004452026,0.0038410996,0.002202315,0.33761877,0.51364297,0.0003323976,0.00074004894,0.0007999094,0.13637051],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9859028,0.0030292778,0.002943273,0.0016588769,0.005245551,0.0012202291],"domain_scores_gemma":[0.91451865,0.03326202,0.003616125,0.004417496,0.039782595,0.004403028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01140201,0.003257849,0.0029912472,0.0038825653,0.0069859596,0.008699183,0.0061180214,0.023774307,0.06326672],"category_scores_gemma":[0.18165864,0.0018571182,0.002186911,0.0038736903,0.0066985306,0.0048066378,0.0040885825,0.03268121,0.04164721],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000067825713,0.0000018238982,0.000016278505,0.000039028364,0.0000037638142,0.000054858287,0.000019642854,0.000007731186,0.0000036034196,0.00047868284,0.99838614,0.0009816784],"study_design_scores_gemma":[0.00010482203,0.00001254884,0.00051440595,0.0008008747,0.00004871647,0.00031894472,0.0002350446,0.00022144208,0.00013730285,0.004284881,0.99325997,0.00006115054],"about_ca_topic_score_codex":0.06206687,"about_ca_topic_score_gemma":0.0713617,"teacher_disagreement_score":0.06326672,"about_ca_system_score_codex":0.010263365,"about_ca_system_score_gemma":0.019631954,"threshold_uncertainty_score":0.21164829},"labels":[],"label_agreement":null},{"id":"W4401182168","doi":"10.1007/s12325-024-02946-2","title":"Four-Strata Risk Assessment in Patients with Pulmonary Arterial Hypertension Treated with Selexipag in Real-World Settings (EXPOSURE Study)","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Rheumatology; Internal medicine; Cardiology; Pulmonary hypertension","score_opus":0.018058801456536967,"score_gpt":0.3114211555550988,"score_spread":0.2933623540985618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401182168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99913484,0.00008940943,0.00021071931,0.000036694186,0.0000034163315,0.000022998995,0.00028091337,0.0000060690713,0.00021492149],"genre_scores_gemma":[0.999047,0.00003658111,0.00027582722,0.000031846605,0.000010051319,0.00003018243,0.00042672016,0.0000025423387,0.00013932913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856263,0.0008511571,0.00009501182,0.00021811607,0.00011313468,0.00016002869],"domain_scores_gemma":[0.99813914,0.00037376367,0.00088604155,0.00026606253,0.00009019558,0.00024467483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018178187,0.00031922336,0.00042645438,0.0006041097,0.00034630726,0.0009309279,0.00035246837,0.0004201607,0.0016428743],"category_scores_gemma":[0.003812677,0.00023439626,0.0010247091,0.00067372096,0.0002589688,0.0006368874,0.0011726281,0.0007479382,0.0002298777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047619054,0.00022053953,0.98979294,0.00002714731,0.0003442173,0.00012032143,0.00026708277,0.00018592343,0.00029354374,0.00007214044,0.00023237172,0.003681816],"study_design_scores_gemma":[0.00040105387,0.0023924725,0.9940878,0.000014720757,0.00023654598,0.00041312855,0.00037482427,0.000957067,0.00024433443,0.00020858215,0.0006486762,0.000020751459],"about_ca_topic_score_codex":0.0015705283,"about_ca_topic_score_gemma":0.0016928609,"teacher_disagreement_score":0.0018178187,"about_ca_system_score_codex":0.00033072734,"about_ca_system_score_gemma":0.0004168498,"threshold_uncertainty_score":0.009613693},"labels":[],"label_agreement":null},{"id":"W4401404175","doi":"10.1007/s12325-024-02948-0","title":"A Real-World Comparison of Clinical Effectiveness in Patients with Rheumatoid Arthritis Treated with Upadacitinib, Tumor Necrosis Factor Inhibitors, and Other Advanced Therapies After Switching from an Initial Tumor Necrosis Factor Inhibitor","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AbbVie","keywords":"Medicine; Rheumatoid arthritis; Tumor necrosis factor alpha; Rheumatology; Tumor necrosis factor α; Necrosis; TNF inhibitor; Antirheumatic Agents; Internal medicine; Pharmacology; Arthritis; Oncology; Adalimumab","score_opus":0.01779634177568071,"score_gpt":0.34995272683928724,"score_spread":0.3321563850636065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401404175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998814,0.00062080845,0.00005045327,0.000032498217,0.000011437676,0.000017148745,0.00022412503,0.0000013467799,0.00022820706],"genre_scores_gemma":[0.99947697,0.000084621046,0.000043319404,0.000029312938,0.000012572326,0.000018554132,0.00029632077,5.137721e-7,0.000037757127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955735,0.0027113366,0.0004396439,0.0005793951,0.0004199018,0.0002762379],"domain_scores_gemma":[0.9909532,0.0036989113,0.0040688044,0.0003006421,0.00038595274,0.0005925103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004215796,0.00030683546,0.00068163674,0.00048739926,0.00026632904,0.0009231046,0.00039241774,0.0006386714,0.0010262066],"category_scores_gemma":[0.0074747065,0.00019189439,0.0012997227,0.0007200907,0.0004036785,0.00055967784,0.00038519915,0.0006415332,0.00014859528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06154284,0.0013361864,0.9152303,0.00032434636,0.005645728,0.00011853292,0.00021865004,0.001574929,0.00057018176,0.00008113207,0.00039812067,0.012959035],"study_design_scores_gemma":[0.0029194155,0.014937239,0.9772111,0.000060715647,0.0016055424,0.00023319278,0.00028510188,0.0017748477,0.00031654417,0.00008783269,0.0005288405,0.0000395275],"about_ca_topic_score_codex":0.0014629163,"about_ca_topic_score_gemma":0.001522286,"teacher_disagreement_score":0.004215796,"about_ca_system_score_codex":0.00069438096,"about_ca_system_score_gemma":0.00034724447,"threshold_uncertainty_score":0.022295475},"labels":[],"label_agreement":null},{"id":"W4401477608","doi":"10.1007/s12325-024-02912-y","title":"Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Medizinische Universität Wien; AbbVie","keywords":"Medicine; Vedolizumab; Tofacitinib; Ustekinumab; Ulcerative colitis; Internal medicine; Gastroenterology; Oncology; Adalimumab","score_opus":0.01835251176131486,"score_gpt":0.2988069700619812,"score_spread":0.28045445830066634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401477608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9068276,0.05020032,0.014096809,0.000809162,0.0008243426,0.007187058,0.011387428,0.00018572639,0.008481477],"genre_scores_gemma":[0.9838892,0.0031125138,0.0048351185,0.0003760455,0.00012204882,0.0037023542,0.0029299401,0.000024997064,0.0010075939],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9723766,0.0207468,0.002565581,0.0016516176,0.0020389426,0.00062042364],"domain_scores_gemma":[0.9794449,0.013546921,0.0041716215,0.0016620059,0.00075626426,0.00041818083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022776641,0.002116792,0.0047301464,0.0012078339,0.0003979171,0.0015985387,0.0015690252,0.0014464891,0.006745817],"category_scores_gemma":[0.02855698,0.00063408224,0.01322248,0.0015650963,0.0009748241,0.0011824657,0.0015823684,0.0019497363,0.0004349988],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6910873,0.0013069557,0.021495858,0.010174942,0.21112019,0.000094187126,0.00029640095,0.0059004896,0.001291709,0.0015233017,0.0010725532,0.054636102],"study_design_scores_gemma":[0.32894185,0.10161573,0.0931525,0.0018922482,0.43770355,0.00036883945,0.00028380408,0.012875548,0.005285551,0.00897638,0.008633701,0.0002702556],"about_ca_topic_score_codex":0.0018138101,"about_ca_topic_score_gemma":0.001500164,"teacher_disagreement_score":0.022776641,"about_ca_system_score_codex":0.001292783,"about_ca_system_score_gemma":0.0011610078,"threshold_uncertainty_score":0.12045586},"labels":[],"label_agreement":null},{"id":"W4401590460","doi":"10.1007/s12325-024-02942-6","title":"Real-World Treatment Persistence Among Advanced Therapy-Naïve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or Adalimumab","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Ustekinumab; Adalimumab; Internal medicine; Persistence (discontinuity); Hazard ratio; Ulcerative colitis; Psoriasis Area and Severity Index; Confidence interval; Gastroenterology; Psoriasis; Disease; Immunology","score_opus":0.020387610741738563,"score_gpt":0.30227606519998024,"score_spread":0.2818884544582417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401590460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988889,0.00019573412,0.000044344317,0.00007934785,0.000005169355,0.000005911267,0.0004943898,0.0000028399977,0.00028346182],"genre_scores_gemma":[0.9993649,0.00006754911,0.000033203887,0.000039727536,0.000009563193,0.000006781087,0.0004117423,0.0000011312077,0.000065431894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993406,0.00022302903,0.00007695221,0.00013675448,0.00007502308,0.00014763436],"domain_scores_gemma":[0.9978696,0.0004820554,0.0010911978,0.00010014559,0.00011582532,0.0003410795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005402005,0.00015752486,0.00035481245,0.0004228282,0.00047376036,0.0009488676,0.0002471365,0.00054162554,0.0012713337],"category_scores_gemma":[0.0026353037,0.000119964185,0.0004047208,0.0007314529,0.00026787558,0.0006869183,0.0005413533,0.0007294109,0.00020151136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046930028,0.000081805396,0.99646986,0.000019759427,0.00006377758,0.00011414388,0.00014264774,0.000063559055,0.00008103814,0.000024120454,0.00017547108,0.0022944694],"study_design_scores_gemma":[0.000022278304,0.00035850276,0.99721694,0.000017469922,0.000069593116,0.00046189837,0.0006734074,0.00047912233,0.000051455292,0.000062208026,0.0005731219,0.000013870787],"about_ca_topic_score_codex":0.0039556855,"about_ca_topic_score_gemma":0.0039941594,"teacher_disagreement_score":0.0039556855,"about_ca_system_score_codex":0.00046392286,"about_ca_system_score_gemma":0.0003218944,"threshold_uncertainty_score":0.00786531},"labels":[],"label_agreement":null},{"id":"W4401714924","doi":"10.1007/s12325-024-02963-1","title":"Real-World Long-Term Persistence and Surgical Procedure-Free Period Among Bio-naïve Patients with Crohn’s Disease and Fistula Initiated on Ustekinumab","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Ustekinumab; Crohn's disease; Fistula; Surgery; Persistence (discontinuity); Internal medicine; Crohn disease; Complication; Inflammatory bowel disease; Disease; Gastroenterology; Adalimumab","score_opus":0.008820874744162648,"score_gpt":0.25980678888953584,"score_spread":0.2509859141453732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401714924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989309,0.00026835862,0.00002984935,0.00004468146,0.0000068729555,0.0000034470024,0.00038226775,0.0000025931374,0.00033098453],"genre_scores_gemma":[0.99933004,0.000096303425,0.000017667235,0.000027023894,0.000011554179,0.000003765785,0.0004005304,8.137311e-7,0.000112308175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99966323,0.00006412883,0.000044954555,0.000078431236,0.000036791964,0.00011241914],"domain_scores_gemma":[0.9988158,0.0002010391,0.0005472893,0.00006244988,0.000074857715,0.0002986466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003060668,0.00018419193,0.00034834514,0.0005216057,0.00045715465,0.0008939127,0.00021778473,0.0005495879,0.0017485697],"category_scores_gemma":[0.0014917786,0.00013178513,0.0005050087,0.00072152086,0.00026839352,0.000817936,0.0004828704,0.0008111483,0.0002959292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004674746,0.00006945984,0.99720275,0.00001709504,0.00005365911,0.00018522961,0.00009065987,0.00004167084,0.0001569806,0.000019231344,0.000093365816,0.0016025145],"study_design_scores_gemma":[0.000012218407,0.00040465783,0.99760807,0.000011372245,0.00007216884,0.0007382577,0.00048961525,0.0001913,0.00005893031,0.00005016651,0.00035170894,0.000011537052],"about_ca_topic_score_codex":0.0018281621,"about_ca_topic_score_gemma":0.0018282144,"teacher_disagreement_score":0.0018281621,"about_ca_system_score_codex":0.0002922949,"about_ca_system_score_gemma":0.00025814274,"threshold_uncertainty_score":0.0058495402},"labels":[],"label_agreement":null},{"id":"W4402364275","doi":"10.1007/s12325-024-02974-y","title":"Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Eli Lilly and Company","keywords":"Medicine; Atopic dermatitis; Placebo; Rheumatology; Dermatology; Internal medicine; Randomized controlled trial; Physical therapy; Double blind; Alternative medicine; Pathology","score_opus":0.03107844180460009,"score_gpt":0.3778267599319135,"score_spread":0.34674831812731344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402364275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9579178,0.021088293,0.0019900426,0.0016840043,0.00082617084,0.01107809,0.0024251177,0.00029375553,0.0026966701],"genre_scores_gemma":[0.95402825,0.011958287,0.0069890837,0.0024512722,0.0009649153,0.018752854,0.0017794294,0.000053032956,0.0030229418],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99819857,0.0010671705,0.000168587,0.00024276899,0.00018528131,0.00013767875],"domain_scores_gemma":[0.9975067,0.0008832813,0.00074893975,0.00016792653,0.00029114,0.00040217498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005985108,0.001622444,0.0037239352,0.0005655605,0.0007118356,0.0015031205,0.0011491084,0.0031788372,0.00461254],"category_scores_gemma":[0.0037883702,0.000976689,0.0039161867,0.0006210512,0.0011435824,0.0016112354,0.0005706101,0.0034871073,0.0006401922],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95017666,0.012054034,0.0012531121,0.0026532635,0.0023889018,0.00005007981,0.00013154668,0.0002377643,0.0057454854,0.00012331709,0.0011882368,0.023997646],"study_design_scores_gemma":[0.94122833,0.054807324,0.0017835023,0.00008911165,0.0008006866,0.00003403195,0.000020918165,0.00016302655,0.00042045262,0.00008106028,0.0005570846,0.000014518664],"about_ca_topic_score_codex":0.00058262615,"about_ca_topic_score_gemma":0.0022642112,"teacher_disagreement_score":0.005985108,"about_ca_system_score_codex":0.000704006,"about_ca_system_score_gemma":0.0016711146,"threshold_uncertainty_score":0.03165269},"labels":[],"label_agreement":null},{"id":"W4402640848","doi":"10.1007/s12325-024-02961-3","title":"Summary of Research: Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seven Oaks General Hospital","funders":"AstraZeneca","keywords":"Medicine; Albuminuria; Dapagliflozin; Kidney disease; Internal medicine; Intensive care medicine; Disease; Urology; Endocrinology; Diabetes mellitus; Type 2 diabetes","score_opus":0.04193459373356344,"score_gpt":0.35978972029929357,"score_spread":0.3178551265657301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402640848","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01863824,0.9458265,0.00061005406,0.023270106,0.0025560884,0.00012705413,0.0030212298,0.00004452174,0.0059062275],"genre_scores_gemma":[0.11292938,0.8612356,0.002401376,0.010318694,0.00801795,0.00020335664,0.0035366209,0.000029643168,0.0013272887],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997299,0.00093792647,0.0007334867,0.00031166585,0.000538233,0.0001797243],"domain_scores_gemma":[0.98968655,0.003738986,0.002515222,0.00018089317,0.003326603,0.00055180374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006004774,0.00040075797,0.0011768674,0.002453686,0.00024963374,0.0023069563,0.0004296676,0.00072951237,0.0023462488],"category_scores_gemma":[0.010308135,0.00023859812,0.0021268032,0.003486506,0.00025561618,0.0009852889,0.00042680005,0.0010752293,0.000421472],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025496813,0.00038381267,0.07563442,0.039673295,0.006749308,0.00019021408,0.00036852833,0.00068648584,0.0010625937,0.0016266468,0.078629784,0.7924451],"study_design_scores_gemma":[0.0012485181,0.006471648,0.52295154,0.0662048,0.032921094,0.0013100046,0.0014700599,0.0013655549,0.0026380776,0.002021452,0.36115775,0.00023949894],"about_ca_topic_score_codex":0.010952406,"about_ca_topic_score_gemma":0.013746115,"teacher_disagreement_score":0.010952406,"about_ca_system_score_codex":0.0021320921,"about_ca_system_score_gemma":0.004137564,"threshold_uncertainty_score":0.0317567},"labels":[],"label_agreement":null},{"id":"W4403566765","doi":"10.1007/s12325-024-02985-9","title":"Differences Between Intravenous and Subcutaneous Modes of Administration in Oncology from the Patient, Healthcare Provider, and Healthcare System Perspectives: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Medicine; Health care; Rheumatology; Administration (probate law); Internal medicine; Intensive care medicine","score_opus":0.06060773984211042,"score_gpt":0.4284270474126201,"score_spread":0.3678193075705097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403566765","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00060413784,0.9990332,0.00005086863,0.000057380363,0.00003136,0.00003601389,0.00010884229,0.000001458546,0.000076798715],"genre_scores_gemma":[0.008719006,0.9904952,0.00029353725,0.00027824327,0.000038952523,0.000056246492,0.000069615766,0.000002279213,0.000046928075],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99661463,0.001052852,0.0012438279,0.0003881783,0.0005717137,0.00012890915],"domain_scores_gemma":[0.9862083,0.010982239,0.0020443976,0.00012851837,0.00051987683,0.00011675647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003992161,0.0009698716,0.0059860214,0.0034893483,0.0003519071,0.0020030178,0.0011732761,0.001528238,0.0037248943],"category_scores_gemma":[0.018941233,0.00062443636,0.008143806,0.0055926135,0.00063192094,0.0015339406,0.0009966518,0.0014709921,0.00023233921],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007145783,0.000045183675,0.0013894304,0.8908645,0.025650367,0.00009121567,0.00014294374,0.0001503317,0.00022075487,0.00025757344,0.0015365336,0.0789366],"study_design_scores_gemma":[0.0011354585,0.00054681726,0.012450936,0.6666734,0.28968418,0.0005108679,0.00047263512,0.00013307658,0.00029897093,0.00061436417,0.027388979,0.00009034483],"about_ca_topic_score_codex":0.00659142,"about_ca_topic_score_gemma":0.025810204,"teacher_disagreement_score":0.00659142,"about_ca_system_score_codex":0.0017853335,"about_ca_system_score_gemma":0.004311917,"threshold_uncertainty_score":0.0211128},"labels":[],"label_agreement":null},{"id":"W4403771038","doi":"10.1007/s12325-024-02999-3","title":"Fluticasone Furoate/Umeclidinium/Vilanterol Initiation Following a COPD Exacerbation: Benefits of Prompt Initiation on COPD Outcomes","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Medicine; Fluticasone propionate; COPD; Exacerbation; Copd exacerbation; Internal medicine; Fluticasone; Physical therapy; Rheumatology; Intensive care medicine; Corticosteroid; Acute exacerbation of chronic obstructive pulmonary disease","score_opus":0.033166634943709035,"score_gpt":0.3519477026347077,"score_spread":0.3187810676909987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403771038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932401,0.004979151,0.00024381059,0.00021336028,0.000047928912,0.000031260355,0.00029715002,0.000011033272,0.00093611394],"genre_scores_gemma":[0.99888664,0.00053568487,0.00017565345,0.000055266744,0.00005081506,0.000007963844,0.00018339686,0.0000019868467,0.00010260471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988746,0.00037142992,0.00013360707,0.00023867628,0.0001804376,0.00020132032],"domain_scores_gemma":[0.9957747,0.0016275985,0.0014506497,0.0003279255,0.00019555142,0.000623599],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022799487,0.00027571828,0.00074623054,0.00032434711,0.00021090498,0.00071859424,0.0002601929,0.0004964248,0.0011884171],"category_scores_gemma":[0.006790643,0.00013838572,0.0012689081,0.00042685436,0.0001607914,0.0006349936,0.000513823,0.0008734942,0.00010995392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09133952,0.0019095036,0.630561,0.0010528207,0.0015722344,0.00029113062,0.00018560418,0.0015300027,0.0025496858,0.00030187762,0.0009442736,0.26776236],"study_design_scores_gemma":[0.0015110231,0.009368279,0.9835127,0.000195302,0.0013884493,0.00038786582,0.00013220805,0.001465444,0.0007050125,0.00036371246,0.0009465467,0.000023455792],"about_ca_topic_score_codex":0.0012222182,"about_ca_topic_score_gemma":0.0021025615,"teacher_disagreement_score":0.0022799487,"about_ca_system_score_codex":0.00036169452,"about_ca_system_score_gemma":0.0006514318,"threshold_uncertainty_score":0.012057662},"labels":[],"label_agreement":null},{"id":"W4403876789","doi":"10.1007/s12325-024-02996-6","title":"Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hepatitis C virus research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Barrie Urology Group; Simon Fraser University","funders":"AbbVie","keywords":"Medicine; Internal medicine; Retrospective cohort study; Cirrhosis; Rheumatology; Hepatitis C; Crest; Hepatology; Gastroenterology; Surgery","score_opus":0.022229306867654595,"score_gpt":0.3242751436532075,"score_spread":0.30204583678555286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403876789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9630399,0.011313857,0.00062672613,0.00037161168,0.00014465848,0.00018563571,0.020383274,0.00004652765,0.003887833],"genre_scores_gemma":[0.97765803,0.0019626562,0.0007761966,0.00050971913,0.00023759091,0.00012976787,0.017970111,0.0000321036,0.00072380464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99607915,0.001633239,0.0006450749,0.0004086031,0.0009694291,0.0002644359],"domain_scores_gemma":[0.98118913,0.0069248416,0.0059973956,0.0023436067,0.0029400124,0.0006051326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053201173,0.00059262494,0.001768691,0.0007659066,0.00033890543,0.0015014831,0.00061599736,0.00056086975,0.002137068],"category_scores_gemma":[0.011594904,0.00044954292,0.0025224905,0.0020067615,0.00035021582,0.0008477887,0.0005560298,0.0009307546,0.00039440132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18467733,0.00059748907,0.71199787,0.0018386134,0.018109879,0.00046404093,0.0003462174,0.0017168156,0.0038524405,0.00024617612,0.0073471074,0.068806],"study_design_scores_gemma":[0.006495561,0.0028559475,0.9769209,0.00011120678,0.0083358055,0.00036509405,0.00011125398,0.00030131478,0.000481199,0.000077697725,0.0038856922,0.000058265763],"about_ca_topic_score_codex":0.005942275,"about_ca_topic_score_gemma":0.008529297,"teacher_disagreement_score":0.005942275,"about_ca_system_score_codex":0.00065161154,"about_ca_system_score_gemma":0.0009228477,"threshold_uncertainty_score":0.028135777},"labels":[],"label_agreement":null},{"id":"W4404184100","doi":"10.1007/s12325-024-03009-2","title":"Effect of Cariprazine on Anhedonia in Patients with Bipolar I Depression: Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Treatment of Major Depression","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"AbbVie","keywords":"Medicine; Post-hoc analysis; Anhedonia; Randomized controlled trial; Post hoc; Placebo; Internal medicine; Depression (economics); Physical therapy; Bipolar disorder; Psychiatry; Clinical psychology; Mood; Schizophrenia (object-oriented programming); Alternative medicine; Pathology","score_opus":0.01749421252127073,"score_gpt":0.39051661970359763,"score_spread":0.37302240718232693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404184100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9276999,0.045989174,0.0032405837,0.0010356599,0.0015681008,0.013107398,0.0037703486,0.0003889945,0.003199972],"genre_scores_gemma":[0.9752519,0.00908243,0.0028690035,0.0008460981,0.0005776112,0.008183028,0.0017307337,0.000061357314,0.0013978204],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9940467,0.0039202888,0.0007332614,0.00059209694,0.00032604442,0.0003816552],"domain_scores_gemma":[0.9928663,0.0036221358,0.0016827829,0.0005863306,0.0006478583,0.0005945272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009064258,0.0024024267,0.0075232354,0.000942884,0.00057983055,0.001991702,0.0010532581,0.0017619502,0.0039865673],"category_scores_gemma":[0.009749565,0.0008696363,0.008720036,0.00096115796,0.0010477738,0.0011251625,0.00065029727,0.0025469894,0.00046718883],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9652895,0.0013762898,0.00081757456,0.0020239046,0.01904592,0.000035923986,0.00004561526,0.00038939578,0.0019737354,0.000055670193,0.00050681253,0.0084396135],"study_design_scores_gemma":[0.9188805,0.049396314,0.006934036,0.00016018894,0.021851268,0.000048024063,0.0000518957,0.00079264655,0.00068167946,0.00016800087,0.0009847106,0.000050741182],"about_ca_topic_score_codex":0.001162174,"about_ca_topic_score_gemma":0.00388491,"teacher_disagreement_score":0.009064258,"about_ca_system_score_codex":0.0012243645,"about_ca_system_score_gemma":0.0015751821,"threshold_uncertainty_score":0.047936976},"labels":[],"label_agreement":null},{"id":"W4404252364","doi":"10.1007/s12325-024-03013-6","title":"Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021–2023","year":2024,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Ottawa Hospital","funders":"Novo Nordisk","keywords":"Reimbursement; Medicine; Drug approval; Health care; Oncology; Internal medicine; Intensive care medicine; Family medicine; Medical physics; Pharmacology; Drug","score_opus":0.364190534098096,"score_gpt":0.5518524548868433,"score_spread":0.18766192078874733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404252364","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027200475,0.9690101,0.0030559632,0.017497001,0.0012699413,0.0006153449,0.0012168234,0.000039025206,0.0045758258],"genre_scores_gemma":[0.08883397,0.8741686,0.0200869,0.011494854,0.0018184108,0.0017827805,0.0011555945,0.000097065145,0.0005618364],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.73897177,0.18091747,0.034681328,0.006652693,0.037284818,0.0014919305],"domain_scores_gemma":[0.27685916,0.6430885,0.040812127,0.0054255417,0.03250184,0.0013128271],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.20866823,0.0014241298,0.0045872945,0.018341903,0.0013528785,0.010401902,0.003220391,0.003797967,0.006497842],"category_scores_gemma":[0.475462,0.0013009167,0.0074585574,0.017781964,0.0032448329,0.0082692625,0.0037383477,0.00581887,0.0007401441],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089818647,0.00010151792,0.0032434268,0.3246912,0.0055528274,0.00013958314,0.0017617363,0.0022306496,0.00034495143,0.022393245,0.022538774,0.61610395],"study_design_scores_gemma":[0.0004998995,0.00063095306,0.0070906472,0.7551351,0.011124956,0.00036816575,0.0015164833,0.0014965475,0.0010242028,0.015037829,0.20587339,0.00020181862],"about_ca_topic_score_codex":0.0072778654,"about_ca_topic_score_gemma":0.013616007,"teacher_disagreement_score":0.20866823,"about_ca_system_score_codex":0.01397587,"about_ca_system_score_gemma":0.0396087,"threshold_uncertainty_score":0.97585297},"labels":[],"label_agreement":null},{"id":"W4404601188","doi":"10.1007/s12325-024-03047-w","title":"Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Biogen","keywords":"Medicine; Discontinuation; Dimethyl fumarate; Adverse effect; Incidence (geometry); Internal medicine; Multiple sclerosis; Observational study; Immunology","score_opus":0.02427547317549341,"score_gpt":0.37583402119553233,"score_spread":0.35155854802003894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404601188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97679204,0.018078951,0.00053223287,0.0005181146,0.000051691924,0.00017233007,0.0016992416,0.000033593686,0.0021216641],"genre_scores_gemma":[0.9949951,0.002598497,0.00048254253,0.0003991731,0.00009849947,0.000097158445,0.0011174814,0.000004820683,0.00020668766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969078,0.0017555851,0.00035675618,0.00031272238,0.0005516338,0.000115472256],"domain_scores_gemma":[0.9924258,0.0026354142,0.0033483268,0.00035542602,0.00081166404,0.00042340584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007263393,0.00033992538,0.0008958362,0.0002903623,0.0003369552,0.0006939784,0.00024202277,0.00062698725,0.0011146219],"category_scores_gemma":[0.008760804,0.00012132523,0.0014109153,0.00044008635,0.00040748512,0.00055263954,0.00032840137,0.00077445613,0.00019849435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2105148,0.0042680493,0.46638912,0.0032492946,0.0074155945,0.00045912134,0.00068645325,0.0029156585,0.011631903,0.0004592173,0.005038777,0.28697196],"study_design_scores_gemma":[0.03372585,0.18177755,0.745129,0.0006462066,0.005908745,0.0018910425,0.00033790013,0.0028892457,0.007554502,0.0006048327,0.019375797,0.00015938964],"about_ca_topic_score_codex":0.0004906602,"about_ca_topic_score_gemma":0.0008339638,"teacher_disagreement_score":0.007263393,"about_ca_system_score_codex":0.00047544605,"about_ca_system_score_gemma":0.00043989203,"threshold_uncertainty_score":0.03841293},"labels":[],"label_agreement":null},{"id":"W4404932315","doi":"10.1007/s12325-024-03042-1","title":"Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Saskatchewan Health Authority","funders":"Janssen Scientific Affairs","keywords":"Medicine; Secukinumab; Psoriatic arthritis; Discontinuation; Ixekizumab; Internal medicine; Cohort; Arthritis","score_opus":0.035536215093915684,"score_gpt":0.34500213515231065,"score_spread":0.30946592005839496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404932315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976127,0.0006947284,0.00015239973,0.000071127455,0.000020935038,0.000047020894,0.0008089849,0.0000037914874,0.0005883361],"genre_scores_gemma":[0.9969542,0.00023588282,0.000115271665,0.00011373038,0.00004629935,0.00006696348,0.0021962135,0.0000061415717,0.00026522658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99599695,0.0017919438,0.00057787995,0.00075739797,0.0004971115,0.00037875713],"domain_scores_gemma":[0.9758494,0.008530227,0.010942592,0.001796711,0.0014523211,0.0014288112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067076553,0.00037450148,0.000818047,0.0007396501,0.00034495033,0.0015462891,0.000650735,0.0008222869,0.0026144697],"category_scores_gemma":[0.021252476,0.00023261385,0.0018284859,0.000772083,0.0003747915,0.0012446382,0.0008190548,0.0010722633,0.00038147482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048057035,0.0011466411,0.9242462,0.0003188784,0.0030649004,0.00014541873,0.00045247478,0.00087924325,0.00053145876,0.00025559924,0.0008933508,0.020008793],"study_design_scores_gemma":[0.0016765072,0.0128303515,0.9749942,0.0001540923,0.0017282066,0.0005336057,0.0006361404,0.004019544,0.00034917373,0.0003695932,0.0026366648,0.000071947106],"about_ca_topic_score_codex":0.0012102033,"about_ca_topic_score_gemma":0.0010426875,"teacher_disagreement_score":0.0067076553,"about_ca_system_score_codex":0.0006281246,"about_ca_system_score_gemma":0.00046216458,"threshold_uncertainty_score":0.035473883},"labels":[],"label_agreement":null},{"id":"W4405079672","doi":"10.1007/s12325-024-03066-7","title":"Genetic Etiologies and Outcomes in Malignancy and Mortality in Activated Phosphoinositide 3-Kinase Delta Syndrome: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Etiology; Malignancy; Internal medicine; Rheumatology; Phosphoinositide 3-kinase; Oncology; Intensive care medicine; Bioinformatics; PI3K/AKT/mTOR pathway; Genetics; Signal transduction","score_opus":0.018689562186398008,"score_gpt":0.3274944721667329,"score_spread":0.3088049099803349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405079672","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035679908,0.99504095,0.0001261919,0.00021128912,0.00006957197,0.00015465615,0.00064982893,0.000007675426,0.00017181551],"genre_scores_gemma":[0.064775504,0.93252426,0.0006542478,0.00059106987,0.0001594765,0.00061833044,0.00056286313,0.000008276322,0.000105997846],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99343055,0.0020864818,0.002646697,0.000646648,0.0009277596,0.0002618354],"domain_scores_gemma":[0.9751697,0.016969647,0.0056939996,0.00033362705,0.0016038448,0.00022910269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008023334,0.001467161,0.009401298,0.010081908,0.0004783417,0.0023025046,0.0013990293,0.001536814,0.0028945506],"category_scores_gemma":[0.029633358,0.0008953515,0.012173581,0.011664945,0.000777029,0.0017321678,0.001271485,0.0008105573,0.00023449642],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003599896,0.000014149716,0.008596183,0.925992,0.0471646,0.0001818972,0.00016461151,0.00015310736,0.00014756847,0.00015497244,0.0009016414,0.016169248],"study_design_scores_gemma":[0.0004369768,0.00032275825,0.027177367,0.59030265,0.37102938,0.00082964846,0.00032122963,0.00018920818,0.00022700694,0.00043367982,0.008670355,0.000059811577],"about_ca_topic_score_codex":0.0050234324,"about_ca_topic_score_gemma":0.01139425,"teacher_disagreement_score":0.010081908,"about_ca_system_score_codex":0.0025391611,"about_ca_system_score_gemma":0.0061738756,"threshold_uncertainty_score":0.04243195},"labels":[],"label_agreement":null},{"id":"W4405079951","doi":"10.1007/s12325-024-03055-w","title":"Adherence and Persistence with Single-Inhaler Triple Therapy Among Patients with COPD Using Commercial and Medicare Advantage US Health Plan Claims Data","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Medicine; COPD; Inhaler; Medicare Advantage; Persistence (discontinuity); Health plan; Physical therapy; Rheumatology; Intensive care medicine; Internal medicine; Family medicine; Asthma; Health care","score_opus":0.057697442291397866,"score_gpt":0.3470230347695473,"score_spread":0.2893255924781495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405079951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780814,0.0008013201,0.00019389608,0.00024928656,0.00001144616,0.000026838223,0.019462163,0.000017528071,0.0011561739],"genre_scores_gemma":[0.9888102,0.00019951665,0.00021146276,0.000081149716,0.000023674023,0.000036677255,0.010466819,0.0000030480824,0.00016743467],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815327,0.00038725673,0.00039878592,0.00030199473,0.0006110378,0.00014776683],"domain_scores_gemma":[0.99367803,0.00082452194,0.0043670987,0.0003662297,0.00045484232,0.00030926077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00206994,0.00022806482,0.00036181384,0.001671145,0.0002891708,0.00078784645,0.00045605717,0.00037509928,0.001618572],"category_scores_gemma":[0.005470987,0.00016009013,0.00074488175,0.0030729393,0.00014729644,0.0005435414,0.0004976431,0.000416106,0.0002285069],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000081482816,0.000026062156,0.99741685,0.00002505802,0.0001328068,0.000013571613,0.000021946662,0.00009845177,0.00003558295,0.000022947912,0.00042157786,0.0017035236],"study_design_scores_gemma":[0.000010317207,0.00003198282,0.9987531,0.00002495104,0.00003880654,0.00006121876,0.00004549383,0.0005426879,0.000038000246,0.000026578464,0.00042364295,0.0000032402052],"about_ca_topic_score_codex":0.017549396,"about_ca_topic_score_gemma":0.018064953,"teacher_disagreement_score":0.017549396,"about_ca_system_score_codex":0.0004981138,"about_ca_system_score_gemma":0.00058337994,"threshold_uncertainty_score":0.034894466},"labels":[],"label_agreement":null},{"id":"W4405179396","doi":"10.1007/s12325-024-03051-0","title":"Baseline Characteristics of Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Medicine; Dupilumab; Asthma; Exhaled nitric oxide; Bronchodilator; Internal medicine; Eosinophil; Quality of life (healthcare); Clinical trial; Allergy; Immunology; Spirometry","score_opus":0.007122883553507687,"score_gpt":0.2871591282762942,"score_spread":0.2800362447227865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405179396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885245,0.0005230096,0.0001520388,0.00010847004,0.000014822922,0.0000711746,0.00902204,0.000014034127,0.0015699306],"genre_scores_gemma":[0.98645276,0.00034335075,0.00019899961,0.00020121846,0.000034054494,0.00016847711,0.01227639,0.000010133432,0.00031454992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999338,0.00017852744,0.000107618034,0.00018771173,0.00010961801,0.00007863358],"domain_scores_gemma":[0.9982804,0.00028536102,0.00082004577,0.00017435422,0.00017067985,0.00026915857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009501649,0.00025498623,0.0005615641,0.00070513843,0.0002988153,0.00053180155,0.00035215932,0.00040972774,0.0013894334],"category_scores_gemma":[0.0017292193,0.00021516308,0.00032865728,0.0012668396,0.00023049003,0.0007064483,0.0003736966,0.000548531,0.00052612793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005347025,0.00012882908,0.9955598,0.00003072767,0.000081725455,0.0001281017,0.00006312622,0.00010941468,0.00026243462,0.000034774417,0.0013120805,0.0017541805],"study_design_scores_gemma":[0.000092710696,0.0005584108,0.996135,0.000017979371,0.0000520573,0.00081164256,0.00023129108,0.00031861328,0.000078038676,0.000025810052,0.0016647466,0.000013687198],"about_ca_topic_score_codex":0.0017052703,"about_ca_topic_score_gemma":0.0019975528,"teacher_disagreement_score":0.0017052703,"about_ca_system_score_codex":0.00025629997,"about_ca_system_score_gemma":0.00031552534,"threshold_uncertainty_score":0.0050249696},"labels":[],"label_agreement":null},{"id":"W4405448205","doi":"10.1007/s12325-024-03043-0","title":"Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals","year":2024,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"COVID-19 and Mental Health","field":"Psychology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Technische Universität München; AstraZeneca United States","keywords":"Medicine; Pandemic; Population; Anxiety; Health care; Vaccination; Depression (economics); Economic impact analysis; Mental health; Disease; Intensive care medicine; Coronavirus disease 2019 (COVID-19); Psychiatry; Environmental health; Immunology; Internal medicine; Infectious disease (medical specialty)","score_opus":0.24668512617302282,"score_gpt":0.5680260971119089,"score_spread":0.32134097093888603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405448205","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016342492,0.9930656,0.00016452174,0.004000476,0.0011048233,0.000030569307,0.00016282582,0.000011447976,0.0012963982],"genre_scores_gemma":[0.0011048801,0.9950848,0.0002318518,0.0022619443,0.00061496656,0.000037039867,0.00014072827,0.0000038939597,0.00051988236],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990369,0.00027860934,0.00021820884,0.00011393047,0.0002747266,0.00007767553],"domain_scores_gemma":[0.9971144,0.0017011354,0.00041678935,0.0000343178,0.0006411021,0.000092219925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017979564,0.0007146455,0.0020930823,0.0018928797,0.00033723834,0.0020295726,0.0013298278,0.0024624472,0.010818688],"category_scores_gemma":[0.007162236,0.0003028319,0.0025181605,0.0014962499,0.00034834893,0.0016757239,0.00087533094,0.0017762885,0.0018494565],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021311146,0.00004958618,0.0004200572,0.17848231,0.00082852645,0.00048297178,0.00030616927,0.00037541828,0.0005204684,0.0031395892,0.13096485,0.684217],"study_design_scores_gemma":[0.00007409361,0.00014885952,0.0011850377,0.14786604,0.00185745,0.0012829587,0.0002621481,0.0001534017,0.00016929556,0.002004453,0.84495324,0.000042986256],"about_ca_topic_score_codex":0.002046049,"about_ca_topic_score_gemma":0.0038104753,"teacher_disagreement_score":0.010818688,"about_ca_system_score_codex":0.0009683966,"about_ca_system_score_gemma":0.003365277,"threshold_uncertainty_score":0.03619212},"labels":[],"label_agreement":null},{"id":"W4405701066","doi":"10.1007/s12325-024-03083-6","title":"Medicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact; Group for Research in Decision Analysis","funders":"","keywords":"Fluticasone propionate; Medicine; Asthma; Corticosteroid; Internal medicine; Population; Rate ratio; Fluticasone; Pediatrics","score_opus":0.006048360401840431,"score_gpt":0.27489551670097284,"score_spread":0.2688471562991324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405701066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954898,0.00034939288,0.00005481606,0.000095605734,0.00000984737,0.00002503602,0.0035359473,0.0000043421232,0.00043530136],"genre_scores_gemma":[0.9960296,0.00010814045,0.00006679033,0.00008603647,0.000019218192,0.000039063143,0.0034813483,0.0000015272674,0.00016819325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994042,0.00014084503,0.00010035413,0.00013681615,0.000107084285,0.000110779976],"domain_scores_gemma":[0.9986286,0.0001011966,0.0008654677,0.00005096906,0.00009039683,0.000263399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005844056,0.00033289328,0.00043672722,0.0009838102,0.0004545442,0.0009047204,0.00038247198,0.0006829795,0.0016301002],"category_scores_gemma":[0.0017668054,0.0002553911,0.0007187055,0.0013880837,0.0003268353,0.0008413322,0.0009076267,0.00073682825,0.00024962038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000317093,0.00010842326,0.997969,0.000019965124,0.00015201788,0.00005817826,0.000058591348,0.00013447156,0.00007447523,0.000042277617,0.00033367393,0.00073178863],"study_design_scores_gemma":[0.00003256122,0.00021082081,0.99844426,0.000018370894,0.000059076414,0.00019689866,0.00021682933,0.00044796814,0.000024290366,0.000031040247,0.00031152955,0.0000063377415],"about_ca_topic_score_codex":0.016395811,"about_ca_topic_score_gemma":0.012726116,"teacher_disagreement_score":0.016395811,"about_ca_system_score_codex":0.0006134462,"about_ca_system_score_gemma":0.00048740365,"threshold_uncertainty_score":0.03260076},"labels":[],"label_agreement":null},{"id":"W4405869080","doi":"10.1007/s12325-024-03088-1","title":"Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Medicine; Fluticasone propionate; COPD; Formoterol; Hazard ratio; Internal medicine; Formoterol Fumarate; Population; Physical therapy; Budesonide; Asthma; Confidence interval; Environmental health","score_opus":0.009763335949859092,"score_gpt":0.29664554877652494,"score_spread":0.2868822128266658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405869080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98606014,0.010457053,0.00020860441,0.0005559371,0.00011739416,0.00026271318,0.0009812621,0.000009616726,0.0013473395],"genre_scores_gemma":[0.99795026,0.0008342822,0.00019268726,0.000166864,0.00006269024,0.00013733898,0.00054994115,0.0000022335535,0.00010371281],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99319035,0.0042972253,0.00072984793,0.0006541195,0.00071615813,0.00041228093],"domain_scores_gemma":[0.99213797,0.0035300206,0.002672292,0.00033914496,0.0003121336,0.0010084428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069330977,0.000539834,0.0014106856,0.0006074434,0.0002516408,0.0012137248,0.00065148174,0.0010791904,0.0022995642],"category_scores_gemma":[0.015801994,0.00030150413,0.0040930333,0.00056777004,0.0006413586,0.0011695626,0.00080964057,0.0011527253,0.00015457769],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6590918,0.009191707,0.17817846,0.003950014,0.023477895,0.00015558791,0.00052517635,0.0059813852,0.0015894443,0.0013772269,0.0027445306,0.11373671],"study_design_scores_gemma":[0.17950547,0.27875766,0.48638695,0.002055959,0.02931093,0.0006316916,0.0010108756,0.011609946,0.0025590342,0.0019000992,0.006043803,0.00022761867],"about_ca_topic_score_codex":0.001855769,"about_ca_topic_score_gemma":0.0024101818,"teacher_disagreement_score":0.0069330977,"about_ca_system_score_codex":0.00178314,"about_ca_system_score_gemma":0.001271737,"threshold_uncertainty_score":0.036666155},"labels":[],"label_agreement":null},{"id":"W4405869081","doi":"10.1007/s12325-024-03091-6","title":"Simplified Approach to Managing Newly Diagnosed Patients with Mild-to-Moderate Hypertension in Routine Clinical Practice","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"Servier","keywords":"Medicine; Rheumatology; Clinical Practice; Internal medicine; Intensive care medicine; Cardiology; Physical therapy","score_opus":0.044435892856641866,"score_gpt":0.3547103765645311,"score_spread":0.31027448370788924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405869081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9582596,0.012863794,0.004671769,0.00599676,0.0002693612,0.0036093786,0.0043873675,0.00019604537,0.009745927],"genre_scores_gemma":[0.9721308,0.0052702622,0.015548445,0.0023791664,0.0004287871,0.0014069247,0.0019283564,0.000010579135,0.0008967425],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.994934,0.0024120633,0.00051443675,0.000629621,0.0013042282,0.00020568649],"domain_scores_gemma":[0.9916083,0.0016992104,0.0032152089,0.0006292735,0.0014875499,0.0013604077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042150253,0.0003238055,0.00084852654,0.00092947873,0.00080046186,0.0010668173,0.0009783761,0.000470535,0.0033611883],"category_scores_gemma":[0.014054942,0.00023550018,0.00067210966,0.0013155449,0.00043345318,0.00050733594,0.0011422869,0.0005635397,0.00041409698],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006226139,0.00281118,0.59230375,0.0028275126,0.0011596582,0.0002964526,0.0014054766,0.0009869167,0.0019388669,0.00040730956,0.012673924,0.37696278],"study_design_scores_gemma":[0.0020157876,0.005815035,0.9769458,0.0007411313,0.00052778947,0.00064204744,0.0006600962,0.0019634664,0.000277374,0.00047515568,0.009872519,0.00006375259],"about_ca_topic_score_codex":0.081110485,"about_ca_topic_score_gemma":0.18161117,"teacher_disagreement_score":0.081110485,"about_ca_system_score_codex":0.0026068303,"about_ca_system_score_gemma":0.006091387,"threshold_uncertainty_score":0.1612767},"labels":[],"label_agreement":null},{"id":"W4406081463","doi":"10.1007/s12325-024-03087-2","title":"Correction to: Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021–2023","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Ottawa Hospital","funders":"","keywords":"Medicine; Reimbursement; Health care; Intensive care medicine; Oncology; Internal medicine; Drug approval; Family medicine; Pharmacology; Drug","score_opus":0.27687616858635417,"score_gpt":0.5382367545615118,"score_spread":0.2613605859751576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406081463","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002804971,0.037192218,0.0022819506,0.1072388,0.8127868,0.0003658442,0.034032617,0.0008376397,0.004983651],"genre_scores_gemma":[0.03386157,0.1239008,0.025745483,0.23131035,0.41970304,0.004395449,0.027567329,0.0044247042,0.12909128],"study_design_codex":"not_applicable","study_design_gemma":"systematic_review","domain_scores_codex":[0.977121,0.008653583,0.0064524645,0.0014576055,0.005223626,0.0010917097],"domain_scores_gemma":[0.8579856,0.06455124,0.01625242,0.005961313,0.05298306,0.0022664114],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.021185802,0.0026693132,0.0046482394,0.007851215,0.0010679802,0.0052585024,0.004396177,0.0052549536,0.22418821],"category_scores_gemma":[0.2562568,0.0016321889,0.004839364,0.0100230435,0.0020382826,0.0036085697,0.0028877147,0.007838548,0.055049878],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021396455,0.000008034609,0.00014014017,0.0071338085,0.00022268854,0.00006310989,0.000041766227,0.0000710546,0.000028642584,0.00094054174,0.9727013,0.0184349],"study_design_scores_gemma":[0.0015638457,0.00007177948,0.003488541,0.021915372,0.0011666504,0.00050358125,0.00016089676,0.00047018324,0.0003033883,0.006412892,0.9637833,0.00015957371],"about_ca_topic_score_codex":0.0156009495,"about_ca_topic_score_gemma":0.022089705,"teacher_disagreement_score":0.9788142,"about_ca_system_score_codex":0.0042730602,"about_ca_system_score_gemma":0.011648344,"threshold_uncertainty_score":0.74998426},"labels":[],"label_agreement":null},{"id":"W4408003689","doi":"10.1007/s12325-025-03125-7","title":"Astaxanthin (AstaReal®) Improved Acute and Chronic Digital Eye Strain in Children: A Randomized Double-Blind Placebo-Controlled Trial","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Ocular Surface and Contact Lens","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"","keywords":"Medicine; Placebo; Randomized controlled trial; Rheumatology; Astaxanthin; Double blind; Internal medicine; Physical therapy; Pathology; Alternative medicine","score_opus":0.006855111473456546,"score_gpt":0.30166445913405454,"score_spread":0.294809347660598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408003689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96525276,0.019645061,0.0015079217,0.00079862645,0.001309031,0.0071226703,0.0018622408,0.00025258007,0.002249138],"genre_scores_gemma":[0.9664405,0.014996683,0.0027742903,0.0010292626,0.0010460145,0.008590428,0.0010347865,0.00004944457,0.0040385937],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999173,0.00032379496,0.00010441853,0.00017831897,0.00008077554,0.00013960237],"domain_scores_gemma":[0.9988714,0.00037898633,0.00030055104,0.00007859784,0.00008884627,0.0002816571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017459309,0.0021939927,0.0057626474,0.000751214,0.0006571042,0.0011431474,0.0010491477,0.0024693261,0.009782601],"category_scores_gemma":[0.0017868188,0.00097353174,0.0031429643,0.00071105483,0.0019845313,0.0011282224,0.00056463835,0.0029943474,0.00097646797],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98198366,0.004053196,0.0003023459,0.0020788175,0.0012967394,0.000043460128,0.000038260416,0.000089389636,0.0015786819,0.000078544894,0.00032932925,0.0081275785],"study_design_scores_gemma":[0.9738897,0.024185859,0.00078027416,0.000059515693,0.00055829313,0.000015408847,0.000016474776,0.00006945957,0.0001736737,0.00003077204,0.00021215016,0.000008343488],"about_ca_topic_score_codex":0.0018399636,"about_ca_topic_score_gemma":0.0027113676,"teacher_disagreement_score":0.009782601,"about_ca_system_score_codex":0.0007608972,"about_ca_system_score_gemma":0.0011781865,"threshold_uncertainty_score":0.03272611},"labels":[],"label_agreement":null},{"id":"W4408010209","doi":"10.1007/s12325-024-03078-3","title":"Patient and Health Care Professional Perspectives on the Burden and Daily Life Impact of Ulcerative Colitis and Crohn’s Disease: Results from the Japanese CONFIDE Study","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Mitsubishi Tanabe Pharma Corporation; Celltrion; Eli Lilly Japan; EA Pharma Co., Ltd.; Gilead Sciences; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Ulcerative colitis; Disease; Rheumatology; Crohn's disease; Internal medicine; Health care; Crohn disease; Inflammatory bowel disease; Burden of disease; Alternative medicine; Physical therapy; Family medicine; Pathology","score_opus":0.00803733676803766,"score_gpt":0.31974431467879477,"score_spread":0.31170697791075713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408010209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99896955,0.00022249676,0.000020142292,0.00013868496,0.0000060255725,0.000011294846,0.00012163713,7.861718e-7,0.0005093247],"genre_scores_gemma":[0.99945253,0.00015327542,0.000045333374,0.000077761746,0.000011178789,0.000020334135,0.00014870251,8.933224e-7,0.00008997494],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.997505,0.0014546514,0.00031021182,0.00014534275,0.00031594245,0.0002688018],"domain_scores_gemma":[0.98998016,0.0029687549,0.0038361244,0.00035784004,0.000992549,0.001864657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045135813,0.00023240568,0.00044898278,0.00088816794,0.0008844365,0.0011005428,0.00032366227,0.0005541143,0.0010042661],"category_scores_gemma":[0.01260113,0.00025813904,0.00095258054,0.000995274,0.0005152699,0.0010691273,0.0019590587,0.00084649224,0.00013047075],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023032229,0.00019259863,0.9833001,0.00009843788,0.0001925002,0.00012507343,0.0106487665,0.00004649225,0.00006904247,0.000034604185,0.00042054174,0.004641481],"study_design_scores_gemma":[0.000020676402,0.00019793722,0.98532736,0.000033179094,0.000067063454,0.00014849461,0.013384949,0.00010612118,0.000029140163,0.000024939478,0.0006433181,0.00001688647],"about_ca_topic_score_codex":0.005523772,"about_ca_topic_score_gemma":0.006357878,"teacher_disagreement_score":0.005523772,"about_ca_system_score_codex":0.0005340831,"about_ca_system_score_gemma":0.00047580057,"threshold_uncertainty_score":0.023870349},"labels":[],"label_agreement":null},{"id":"W4408081825","doi":"10.1007/s12325-025-03132-8","title":"Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Astellas Pharma US; Pfizer","keywords":"Medicine; Enzalutamide; Prostate cancer; Abiraterone; Internal medicine; Oncology; Docetaxel; Chemotherapy; Cancer; Abiraterone acetate; Urology; Androgen deprivation therapy; Androgen receptor","score_opus":0.03130694606278112,"score_gpt":0.3684111111346669,"score_spread":0.3371041650718858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408081825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95365566,0.04299236,0.000493924,0.00032977542,0.00007543733,0.000058087124,0.0017980787,0.000015790703,0.00058076996],"genre_scores_gemma":[0.9930346,0.004869079,0.00039876878,0.0001906965,0.000086558255,0.000039074555,0.0011944174,0.000006765603,0.00018023112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841344,0.00086469104,0.0001682171,0.00029179064,0.00017339557,0.000088517634],"domain_scores_gemma":[0.9985226,0.0004541329,0.00064555614,0.00018936847,0.00006084271,0.0001275693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037225217,0.0005274676,0.0011596632,0.0006108618,0.00014593004,0.00086956745,0.0004603557,0.00042852346,0.00069171126],"category_scores_gemma":[0.0031675205,0.00031624147,0.0036026274,0.00097110687,0.00020433695,0.00036354832,0.0004625185,0.00052127964,0.00010780627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14007238,0.0010700641,0.6457568,0.00382152,0.111492,0.0005046384,0.00027171793,0.006214328,0.002669733,0.0008691242,0.0031040055,0.08415374],"study_design_scores_gemma":[0.014180146,0.007313364,0.8802618,0.00058766885,0.08307218,0.0005727696,0.00014874552,0.0054980135,0.0012013823,0.00070989016,0.006355109,0.000098923665],"about_ca_topic_score_codex":0.0029078808,"about_ca_topic_score_gemma":0.0047373087,"teacher_disagreement_score":0.0037225217,"about_ca_system_score_codex":0.00074133987,"about_ca_system_score_gemma":0.00054561015,"threshold_uncertainty_score":0.019686818},"labels":[],"label_agreement":null},{"id":"W4408206616","doi":"10.1007/s12325-025-03138-2","title":"A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Ustekinumab; Medicine; Psoriasis Area and Severity Index; Biosimilar; Randomized controlled trial; Internal medicine; Clinical endpoint; Adverse effect; Psoriasis; Dermatology; Infliximab; Disease","score_opus":0.021678752856792344,"score_gpt":0.3021284946839793,"score_spread":0.28044974182718696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408206616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98360574,0.0022404026,0.000931379,0.00046437964,0.0006274849,0.009618637,0.0007948115,0.000082867395,0.0016342594],"genre_scores_gemma":[0.97782975,0.0010961836,0.0020384714,0.000835562,0.0005680683,0.013765982,0.0008190941,0.000015767182,0.003031163],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99870753,0.0007125867,0.000108226326,0.00023997875,0.000099308,0.00013239431],"domain_scores_gemma":[0.998181,0.0005500927,0.000497909,0.00018833848,0.00013329471,0.00044950919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002901113,0.0016570819,0.0033541082,0.00050387176,0.0006256239,0.00085650355,0.0010373741,0.002315116,0.00999719],"category_scores_gemma":[0.002780732,0.00090801547,0.0017704851,0.0004596951,0.0016401261,0.0011832064,0.00063245476,0.0019281087,0.0017171917],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99076813,0.004549425,0.00017159781,0.00014927184,0.00016231208,0.000012840731,0.000021575355,0.000074994074,0.0010055735,0.00003668311,0.00013792796,0.0029097719],"study_design_scores_gemma":[0.9529848,0.046069484,0.00043243723,0.000009844361,0.00006641127,0.000013342532,0.000005519516,0.00009743399,0.000120206874,0.00004675072,0.00014809902,0.000005605201],"about_ca_topic_score_codex":0.0006451633,"about_ca_topic_score_gemma":0.0010976071,"teacher_disagreement_score":0.00999719,"about_ca_system_score_codex":0.0008532932,"about_ca_system_score_gemma":0.0015143399,"threshold_uncertainty_score":0.033443928},"labels":[],"label_agreement":null},{"id":"W4408730910","doi":"10.1007/s12325-025-03158-y","title":"Pharmacokinetic Comparability and Safety Between Original and Citrate-Free Mirikizumab Formulations for Subcutaneous Injections: Results from Three Clinical Trials","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Eli Lilly and Company","keywords":"Medicine; Comparability; Pharmacokinetics; Clinical trial; Rheumatology; Pharmacology; Intensive care medicine; Internal medicine; Medical physics","score_opus":0.12910321262455474,"score_gpt":0.47651952724574037,"score_spread":0.3474163146211856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408730910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95953447,0.028741453,0.004341515,0.0005192276,0.0002157532,0.0036785358,0.00092402694,0.00012043121,0.0019246],"genre_scores_gemma":[0.98649025,0.006765347,0.0030522349,0.00059342914,0.00018245335,0.0016391823,0.0008058315,0.000048160193,0.000423145],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9948382,0.002762319,0.00076038175,0.00065612735,0.0008032473,0.00017968823],"domain_scores_gemma":[0.9921233,0.0031501732,0.00264858,0.0007296781,0.000847934,0.00050040276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010483247,0.0009086182,0.0025713365,0.00046037565,0.00038619095,0.0015546557,0.0009969291,0.0017848051,0.0018512601],"category_scores_gemma":[0.012516486,0.00060062995,0.002361519,0.00072259153,0.0011046786,0.0013113586,0.000346845,0.0025546688,0.00040427007],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69435185,0.015414463,0.0075890766,0.0066545913,0.009577185,0.00020898931,0.0009389406,0.0018086545,0.08798826,0.0005776343,0.0020793853,0.17281096],"study_design_scores_gemma":[0.3573636,0.55134,0.041558567,0.00056255545,0.013061138,0.0008288717,0.00021172379,0.0032952507,0.021908624,0.0008824097,0.008801585,0.00018572953],"about_ca_topic_score_codex":0.00038209098,"about_ca_topic_score_gemma":0.0005848938,"teacher_disagreement_score":0.010483247,"about_ca_system_score_codex":0.00078162114,"about_ca_system_score_gemma":0.0010282887,"threshold_uncertainty_score":0.05544138},"labels":[],"label_agreement":null},{"id":"W4409209212","doi":"10.1007/s12325-025-03145-3","title":"Assessment of Access Barriers to Rifaximin Among Patients with Hepatic Encephalopathy Using Adjudicated Claims Data","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Liver Disease and Transplantation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Bausch Health","keywords":"Rifaximin; Medicine; Hepatic encephalopathy; Internal medicine; Rheumatology; Encephalopathy; Intensive care medicine; Cirrhosis","score_opus":0.02347803123815045,"score_gpt":0.3655692152713887,"score_spread":0.34209118403323824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409209212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992927,0.00037476953,0.00044635517,0.00024831944,0.000009527321,0.00006343784,0.0051246546,0.000012038265,0.00079388294],"genre_scores_gemma":[0.9962469,0.00010110141,0.0003304735,0.00005588981,0.00001365809,0.000074078554,0.0030751803,0.000002384328,0.00010033175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950905,0.0015445654,0.001289337,0.0005731075,0.0010965663,0.00040594744],"domain_scores_gemma":[0.9741536,0.0054475325,0.016199568,0.0013532632,0.0019249503,0.0009210942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004990642,0.00031099987,0.00040895146,0.0021014921,0.00044560822,0.0013778617,0.00073547504,0.00048481906,0.0015686061],"category_scores_gemma":[0.01810137,0.00026650328,0.0008638733,0.002873528,0.0003059014,0.0009848413,0.0016599202,0.0006642928,0.0003358763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010613964,0.000037248858,0.99747604,0.00004345328,0.0000755564,0.000022042566,0.00011474276,0.00010409377,0.000047238904,0.000049486873,0.00021292476,0.0017110169],"study_design_scores_gemma":[0.000022831071,0.00012913371,0.9965834,0.00008200852,0.00004406041,0.00011644939,0.00042480289,0.0015690309,0.00012840072,0.00009312825,0.00079665624,0.000010007828],"about_ca_topic_score_codex":0.010500074,"about_ca_topic_score_gemma":0.009081364,"teacher_disagreement_score":0.010500074,"about_ca_system_score_codex":0.00079578266,"about_ca_system_score_gemma":0.0013083346,"threshold_uncertainty_score":0.026393354},"labels":[],"label_agreement":null},{"id":"W4409772562","doi":"10.1007/s12325-025-03144-4","title":"Pembrolizumab with Carboplatin and Paclitaxel Versus Alternative Systemic Treatments Recommended for the First-Line Treatment of Recurrent/Metastatic Head and Neck Cancer: An Indirect Treatment Comparison","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Medicine; Pembrolizumab; Carboplatin; Head and neck cancer; Paclitaxel; Internal medicine; Oncology; First line treatment; Cancer; Chemotherapy; Cisplatin; Immunotherapy","score_opus":0.13731959727465098,"score_gpt":0.46446788718191817,"score_spread":0.3271482899072672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409772562","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023161029,0.996931,0.00004618652,0.000096507785,0.00008153024,0.00003164137,0.00008843249,0.0000014049126,0.00040717312],"genre_scores_gemma":[0.023104576,0.97582203,0.00029215543,0.00027819528,0.000099821904,0.00005753682,0.000114215654,0.0000015970961,0.00022991959],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9989618,0.0005404044,0.00019663377,0.00010742353,0.00016252988,0.000031244355],"domain_scores_gemma":[0.998278,0.0012529385,0.00031333952,0.000023887962,0.00009583458,0.000036046364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022287238,0.0006667096,0.003119722,0.0012558241,0.00013442463,0.0008134751,0.0007673333,0.00065267127,0.0055296053],"category_scores_gemma":[0.0031893859,0.00024311901,0.0031834776,0.0016244813,0.00029548036,0.0006961202,0.00043135794,0.0012967223,0.00022632362],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01688336,0.0003090304,0.0013200954,0.35844526,0.046450783,0.00011152129,0.00011277099,0.00058492017,0.0010251547,0.0015052051,0.0037366392,0.5695153],"study_design_scores_gemma":[0.03992252,0.01612136,0.042576455,0.22632931,0.480902,0.0017716297,0.000825717,0.0011165054,0.0020713822,0.003222738,0.18498017,0.00016034329],"about_ca_topic_score_codex":0.0021095392,"about_ca_topic_score_gemma":0.007185854,"teacher_disagreement_score":0.0055296053,"about_ca_system_score_codex":0.0010295714,"about_ca_system_score_gemma":0.0009873045,"threshold_uncertainty_score":0.01849842},"labels":[],"label_agreement":null},{"id":"W4409951695","doi":"10.1007/s12325-025-03198-4","title":"The Limitations of Artificial Intelligence in Head and Neck Oncology","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Artificial Intelligence in Healthcare and Education","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Rheumatology; Head and neck; Internal medicine; Radiation oncology; Oncology; Medical physics; Head and neck cancer; Radiation therapy; Surgery","score_opus":0.3660024584419,"score_gpt":0.5541710030371777,"score_spread":0.1881685445952777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409951695","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000072723415,0.9953053,0.00020865703,0.0028464806,0.00022327724,0.0000029566484,0.000010195151,0.000004718735,0.0013257724],"genre_scores_gemma":[0.0015845294,0.9961959,0.0003495427,0.0012470891,0.00030843593,0.000007889034,0.000012693139,0.0000024727003,0.0002915563],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980236,0.00081663,0.00023669723,0.00019150914,0.0006490922,0.00008246954],"domain_scores_gemma":[0.9916402,0.006668441,0.00038441975,0.00017021658,0.0010007868,0.00013585741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004135152,0.00053742825,0.0011895094,0.0025391418,0.00054444827,0.0027882408,0.0011383096,0.0023043763,0.0033414934],"category_scores_gemma":[0.0069365622,0.0003117949,0.000938492,0.002853116,0.001873109,0.0036559294,0.0013826124,0.0035785595,0.0011557648],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033665856,0.00003371547,0.00021317409,0.026303895,0.000121419274,0.00013976272,0.0002924278,0.0005486681,0.00035457543,0.032669935,0.030860601,0.90842813],"study_design_scores_gemma":[0.000008147493,0.00005099098,0.00072897336,0.022280626,0.00012435432,0.0007247601,0.00028085028,0.00022974814,0.00023306366,0.022894513,0.9524137,0.000030248464],"about_ca_topic_score_codex":0.002724362,"about_ca_topic_score_gemma":0.004328766,"teacher_disagreement_score":0.004135152,"about_ca_system_score_codex":0.0017560701,"about_ca_system_score_gemma":0.004340325,"threshold_uncertainty_score":0.021869004},"labels":[],"label_agreement":null},{"id":"W4410136066","doi":"10.1007/s12325-025-03183-x","title":"One-Year Efficacy of Guselkumab Versus Advanced Therapies for the Treatment of Moderately to Severely Active Crohn’s Disease: A Network Meta-Analysis","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Johnson and Johnson","keywords":"Medicine; Crohn's disease; Internal medicine; Rheumatology; Disease; Meta-analysis; Oncology","score_opus":0.07057943722818513,"score_gpt":0.3817224484559923,"score_spread":0.3111430112278072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410136066","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07569048,0.9100431,0.00852405,0.0009338728,0.00095733313,0.0005871052,0.0018738651,0.00020144487,0.0011887487],"genre_scores_gemma":[0.875962,0.11137007,0.007493313,0.0009645759,0.00044090048,0.0010006562,0.0019433852,0.000115337214,0.00070982456],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9773301,0.016768258,0.0022447032,0.0020958853,0.0012107361,0.00035030348],"domain_scores_gemma":[0.9660366,0.02810195,0.002726847,0.0014947455,0.0011085997,0.00053115265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03223689,0.0033804113,0.016522372,0.005671188,0.0005244301,0.0034484416,0.0024300318,0.0025021513,0.00269542],"category_scores_gemma":[0.040454276,0.0015377898,0.05803013,0.0044590924,0.0005882162,0.0023039258,0.00216809,0.002964349,0.00026842192],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006072059,0.000026464246,0.0038340576,0.014028574,0.97065485,0.00006151772,0.000027384263,0.0019844628,0.00014461965,0.000102919876,0.00015586984,0.0029071984],"study_design_scores_gemma":[0.0010275776,0.0002793857,0.002493902,0.0008773798,0.9927285,0.00004358814,0.000018501512,0.0016993883,0.0000746148,0.00030409658,0.00043434382,0.000018781742],"about_ca_topic_score_codex":0.00580995,"about_ca_topic_score_gemma":0.0071518407,"teacher_disagreement_score":0.03223689,"about_ca_system_score_codex":0.0020533458,"about_ca_system_score_gemma":0.001429663,"threshold_uncertainty_score":0.17048699},"labels":[],"label_agreement":null},{"id":"W4410586462","doi":"10.1007/s12325-025-03232-5","title":"Real-World Insights on Satisfaction and Experience with Acthar Gel via SelfJect (RISE™): A Cross-Sectional Patient Survey","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Cross-sectional study; Medicine; Rheumatology; Patient satisfaction; Family medicine; Internal medicine; Nursing; Pathology","score_opus":0.016034298690402283,"score_gpt":0.3461847020189336,"score_spread":0.3301504033285313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410586462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981377,0.00007850297,0.00009286609,0.00021165401,0.0000041312665,0.0000467889,0.0008691567,0.0000055701325,0.00055356714],"genre_scores_gemma":[0.9981172,0.00016186181,0.0003030276,0.0003229563,0.0000106892085,0.00011329211,0.0006719743,0.0000030010076,0.0002959834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844307,0.00070804154,0.00022661011,0.00015376628,0.00025806465,0.0002104399],"domain_scores_gemma":[0.9942509,0.0013599643,0.002474303,0.00016952143,0.00083539065,0.00090993533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023860207,0.0001692009,0.00038022638,0.00070139696,0.0004458181,0.00081583613,0.00024815768,0.0006191142,0.0028819756],"category_scores_gemma":[0.0058972375,0.00022654471,0.0005375486,0.0006041074,0.00029962006,0.0008649856,0.00066567847,0.00080937636,0.00066327973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012261931,0.0002522455,0.98987573,0.0000836104,0.000051278894,0.00011129809,0.002421464,0.000070255766,0.00023474514,0.00002767999,0.0010434501,0.005705597],"study_design_scores_gemma":[0.000024254376,0.0011417778,0.98836446,0.000055638982,0.00003556425,0.00067708635,0.0070126373,0.0004869667,0.00017246767,0.000025965026,0.0019723822,0.00003085359],"about_ca_topic_score_codex":0.0020136272,"about_ca_topic_score_gemma":0.0024298423,"teacher_disagreement_score":0.0028819756,"about_ca_system_score_codex":0.00041536705,"about_ca_system_score_gemma":0.00037998977,"threshold_uncertainty_score":0.012618601},"labels":[],"label_agreement":null},{"id":"W4410586982","doi":"10.1007/s12325-025-03195-7","title":"Driving Best Practices Throughout the Treatment Journey for Patients with NSCLC with Actionable Alterations: A Podcast Discussion","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"EMD Serono","keywords":"Medicine; Rheumatology; Internal medicine; Oncology; Family medicine; General surgery; Intensive care medicine","score_opus":0.020835090550126657,"score_gpt":0.40953198234919574,"score_spread":0.3886968917990691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410586982","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006314379,0.113523506,0.0019651938,0.7793632,0.09880143,0.0000753613,0.00040222376,0.0002552588,0.004982399],"genre_scores_gemma":[0.011654233,0.26233563,0.008002574,0.556823,0.14377362,0.0003063144,0.0010290572,0.0003137455,0.015761813],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947876,0.0018629731,0.00067862356,0.0007250776,0.0012143819,0.0007313752],"domain_scores_gemma":[0.96273595,0.020209257,0.0024524278,0.00093836547,0.007336341,0.0063275644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012141146,0.0009616466,0.0020317584,0.001389751,0.002419492,0.008925263,0.0039937915,0.0146952905,0.022471284],"category_scores_gemma":[0.032800086,0.0006549949,0.0022047153,0.0015686061,0.003383579,0.013506426,0.0050437558,0.032333903,0.00680484],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011913225,0.00013206585,0.0002748562,0.0023342164,0.0000597113,0.00017453653,0.00028988102,0.00039302246,0.00017889806,0.010691521,0.84544325,0.13990885],"study_design_scores_gemma":[0.00009417465,0.00018212447,0.0005097058,0.0055746986,0.000061553095,0.00029221995,0.000976394,0.00026626146,0.00011093058,0.015831836,0.97604316,0.000056795423],"about_ca_topic_score_codex":0.0034835401,"about_ca_topic_score_gemma":0.007235185,"teacher_disagreement_score":0.022471284,"about_ca_system_score_codex":0.0047394605,"about_ca_system_score_gemma":0.010851401,"threshold_uncertainty_score":0.075173914},"labels":[],"label_agreement":null},{"id":"W4410872297","doi":"10.1007/s12325-025-03239-y","title":"Economic Burden and Provider Referral Patterns Among Patients with Unresectable Stage III EGFR-Mutated NSCLC Receiving Chemoradiotherapy in the United States","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Medicine; Referral; Stage (stratigraphy); Chemoradiotherapy; Internal medicine; Rheumatology; Oncology; Family medicine; Overall survival","score_opus":0.007839728466091026,"score_gpt":0.31028360856865783,"score_spread":0.3024438801025668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410872297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97312385,0.0007599546,0.00011176054,0.00052981137,0.00001771595,0.00003544239,0.024412047,0.000009864117,0.0009994633],"genre_scores_gemma":[0.9823646,0.000481652,0.00018940627,0.00035449723,0.000034849283,0.000079846846,0.016219646,0.000008181714,0.0002672417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985947,0.0003531965,0.00031754433,0.00026256396,0.0002519124,0.00022001714],"domain_scores_gemma":[0.99417263,0.00070268265,0.0040211356,0.00019824308,0.0004899713,0.00041536812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010810544,0.00023815106,0.00038246324,0.0015050969,0.00046282166,0.0008974767,0.00061312877,0.00045023576,0.001865995],"category_scores_gemma":[0.004889984,0.00028308982,0.0007369551,0.0034348837,0.0002515578,0.0007425868,0.0010296602,0.0008292636,0.00032793832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009837446,0.000031235908,0.9960341,0.000029808352,0.000062734114,0.00005176579,0.00005186383,0.00014243776,0.000029401992,0.000046043206,0.002174672,0.0012476366],"study_design_scores_gemma":[0.000021251233,0.00003974405,0.9972445,0.000061726154,0.0000415416,0.00022141423,0.00032857395,0.00080325286,0.000046299447,0.00005013173,0.0011328529,0.00000873499],"about_ca_topic_score_codex":0.049999222,"about_ca_topic_score_gemma":0.060830884,"teacher_disagreement_score":0.049999222,"about_ca_system_score_codex":0.0018308442,"about_ca_system_score_gemma":0.0010991896,"threshold_uncertainty_score":0.099416435},"labels":[],"label_agreement":null},{"id":"W4411223753","doi":"10.1007/s12325-025-03226-3","title":"Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"Sanofi Genzyme; Grifols; BioCryst; Regeneron Pharmaceuticals; Moderna; Takeda Pharmaceuticals U.S.A.; BioMarin Pharmaceutical; AstraZeneca; CSL Behring; Amgen; Sanofi; GlaxoSmithKline","keywords":"Medicine; Tolerability; Hereditary angioedema; Angioedema; Rheumatology; Internal medicine; Adverse effect; Intensive care medicine; Physical therapy; Dermatology","score_opus":0.009382766756255299,"score_gpt":0.33892470648832074,"score_spread":0.3295419397320654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411223753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99724954,0.0007804199,0.00012915362,0.00006745204,0.000011530443,0.00047628244,0.00061263196,0.000019861716,0.000652976],"genre_scores_gemma":[0.99695337,0.0003944222,0.00038450252,0.0001739626,0.000047515347,0.0005194329,0.0009976327,0.000005047335,0.0005239592],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9989151,0.0006125483,0.00006663111,0.00012600039,0.00015577294,0.00012388923],"domain_scores_gemma":[0.99785954,0.0003996837,0.000861304,0.00019254706,0.0001969405,0.00048985844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034209366,0.0007100506,0.00076770014,0.00021674877,0.00035151414,0.0010178777,0.0004930637,0.00062271615,0.0023894657],"category_scores_gemma":[0.001958789,0.0003317113,0.00095843244,0.00024070965,0.0007020045,0.0007598407,0.00040556316,0.001617586,0.0005503212],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7191158,0.05765835,0.14109348,0.0008070771,0.0035770787,0.00025327117,0.00049276947,0.0012484386,0.010760438,0.00013158571,0.0032101031,0.06165164],"study_design_scores_gemma":[0.27828395,0.4637192,0.24767534,0.0000995395,0.0018190831,0.0007187577,0.00022941807,0.0011658258,0.0030846254,0.00016916293,0.002966219,0.00006888984],"about_ca_topic_score_codex":0.0007662497,"about_ca_topic_score_gemma":0.0016251511,"teacher_disagreement_score":0.0034209366,"about_ca_system_score_codex":0.00065555016,"about_ca_system_score_gemma":0.00083726825,"threshold_uncertainty_score":0.018091857},"labels":[],"label_agreement":null},{"id":"W4412063527","doi":"10.1007/s12325-025-03295-4","title":"Comparative Effectiveness of FF/UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up From Dual Therapy","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact; Group for Research in Decision Analysis; GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; COPD; Internal medicine; Dual (grammatical number); Rheumatology; Physical therapy","score_opus":0.012974904815215123,"score_gpt":0.32779301825035484,"score_spread":0.3148181134351397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412063527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926587,0.005530509,0.0001604307,0.00012970447,0.00005174346,0.00012357144,0.00046207462,0.0000040522077,0.00087918463],"genre_scores_gemma":[0.997521,0.0010402903,0.0004061159,0.00014280106,0.00006235804,0.000112815505,0.00059136446,0.000002880452,0.0001205068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99546236,0.002427796,0.00057170005,0.0005759714,0.0006495663,0.0003125189],"domain_scores_gemma":[0.9954574,0.0017883822,0.0016074096,0.0002555362,0.00025664992,0.0006346945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040217256,0.00038554883,0.0013656333,0.0007122505,0.00022969695,0.0010389383,0.00050527207,0.0006974154,0.0012045697],"category_scores_gemma":[0.008353479,0.00024850454,0.002751096,0.00059326837,0.00030827193,0.0008444694,0.0006661044,0.0010350671,0.00016218847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31300032,0.005932775,0.49692625,0.003402161,0.015643584,0.0002275149,0.0006315093,0.0022887255,0.0028807835,0.00075917394,0.0011963682,0.15711084],"study_design_scores_gemma":[0.021688018,0.131192,0.82512736,0.0010234475,0.010387617,0.0006336049,0.00093458424,0.0032547181,0.0021119802,0.0005626243,0.0029619772,0.00012207808],"about_ca_topic_score_codex":0.00092772435,"about_ca_topic_score_gemma":0.0016786893,"teacher_disagreement_score":0.0040217256,"about_ca_system_score_codex":0.0008046883,"about_ca_system_score_gemma":0.0005496748,"threshold_uncertainty_score":0.021269143},"labels":[],"label_agreement":null},{"id":"W4412187101","doi":"10.1007/s12325-025-03296-3","title":"Broad Impact of Bowel Urgency in Ulcerative Colitis and Crohn’s Disease: US, European, and Japanese Patient and Healthcare Professional Perspectives from the Communicating Needs and Features of IBD Experiences (CONFIDE) Survey","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Eli Lilly and Company","keywords":"Medicine; Ulcerative colitis; Inflammatory bowel disease; Crohn's disease; Health care; Disease; Internal medicine; Rheumatology; Family medicine; Health professionals; Crohn disease; Gastroenterology","score_opus":0.008744103949303722,"score_gpt":0.3129416128593667,"score_spread":0.30419750891006303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412187101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99891424,0.00013588923,0.000029635326,0.00013371065,0.000003414805,0.000008910707,0.00029336935,0.0000016075695,0.00047920857],"genre_scores_gemma":[0.9991264,0.00015619374,0.00011406941,0.000094829935,0.000006261056,0.000018290239,0.00037819907,0.0000011653585,0.00010456532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984763,0.0007133484,0.0002822248,0.00010144078,0.00022948848,0.00019718273],"domain_scores_gemma":[0.99614185,0.0006998877,0.0018930264,0.0001163311,0.00034522277,0.00080378156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022830127,0.00016928157,0.00033163224,0.00084660196,0.0005358574,0.0006703815,0.000227258,0.00039752788,0.00085376785],"category_scores_gemma":[0.004613359,0.00014824458,0.00054720906,0.0011660318,0.00036232313,0.00073644187,0.0015286003,0.00046585008,0.00009547689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008808745,0.0000557232,0.9894169,0.000058671783,0.00007229889,0.000111608235,0.0049229115,0.000049318092,0.00017189886,0.0000232532,0.00046193379,0.0045674182],"study_design_scores_gemma":[0.000005872569,0.00009109333,0.9912846,0.000023284456,0.000021284914,0.00017098497,0.007615711,0.000080899794,0.000046675334,0.000014334621,0.00063597824,0.000009202811],"about_ca_topic_score_codex":0.0058558397,"about_ca_topic_score_gemma":0.010220718,"teacher_disagreement_score":0.0058558397,"about_ca_system_score_codex":0.00036255328,"about_ca_system_score_gemma":0.00036636702,"threshold_uncertainty_score":0.012073815},"labels":[],"label_agreement":null},{"id":"W4412462061","doi":"10.1007/s12325-025-03274-9","title":"Efficacy and Safety of TV-46000 and Second-Generation Long-Acting Injectable Antipsychotics for Schizophrenia: A Systematic Literature Review and Network Meta-Analysis of Randomized Controlled Trials","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; McGill University Health Centre; EVERSANA (Canada); Global Affairs Canada","funders":"","keywords":"Medicine; Meta-analysis; Randomized controlled trial; Schizophrenia (object-oriented programming); MEDLINE; Systematic review; Internal medicine; Psychiatry","score_opus":0.08478789504659646,"score_gpt":0.422756095169057,"score_spread":0.33796820012246054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412462061","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042898017,0.9939568,0.00040746815,0.00021114912,0.00009802139,0.00024902567,0.0005155569,0.00001761758,0.00025443346],"genre_scores_gemma":[0.16906503,0.82457,0.0023670993,0.0012370559,0.00027595815,0.0010050338,0.0011802235,0.000034067136,0.0002653623],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.985521,0.0063902996,0.0047163693,0.0015111492,0.001532701,0.00032850035],"domain_scores_gemma":[0.9695756,0.021408409,0.005872758,0.0007657858,0.0020763262,0.00030110683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017337555,0.0023944585,0.0156033,0.0075870003,0.0005538223,0.0031481348,0.0019480407,0.0021167295,0.003448866],"category_scores_gemma":[0.03993992,0.0013977062,0.035697192,0.0074044014,0.00081677,0.0017934599,0.001563933,0.0019881565,0.00031937953],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002170257,0.000036146183,0.0035637636,0.37751198,0.5993584,0.00008446883,0.00007292642,0.0004526099,0.00020104219,0.00014559858,0.0005389113,0.015863935],"study_design_scores_gemma":[0.0008479969,0.00022309028,0.0038697151,0.029288717,0.9636647,0.00008012491,0.00003978484,0.00020389126,0.00011325111,0.00022027914,0.0014228212,0.000025565243],"about_ca_topic_score_codex":0.008028094,"about_ca_topic_score_gemma":0.017405732,"teacher_disagreement_score":0.017337555,"about_ca_system_score_codex":0.0029095074,"about_ca_system_score_gemma":0.004089157,"threshold_uncertainty_score":0.0916909},"labels":[],"label_agreement":null},{"id":"W4412493533","doi":"10.1007/s12325-025-03258-9","title":"Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022–2023","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Novartis Pharma; Samsung; LEO Pharma; Swedish Orphan Biovitrum; Chugai Pharmaceutical; Celltrion; UCB Pharma; Regeneron Pharmaceuticals; Baxalta; Biogen; Celgene; Cilag; Mylan; Gilead Sciences; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ixekizumab; Medicine; Secukinumab; Psoriatic arthritis; Psoriasis; Dermatology; Ustekinumab; Quality of life (healthcare); Internal medicine; Physical therapy; Adalimumab; Rheumatoid arthritis","score_opus":0.042011582688675476,"score_gpt":0.3994908874577577,"score_spread":0.3574793047690822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412493533","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001027627,0.99721366,0.000148786,0.00032261747,0.0001259596,0.00027397324,0.0005688677,0.0000074297495,0.00031108924],"genre_scores_gemma":[0.01862971,0.9782542,0.0007998013,0.00089221477,0.00015735015,0.0006139306,0.0005253235,0.0000091731345,0.00011826132],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9859958,0.0049470654,0.005815361,0.0008898486,0.0020195085,0.00033245917],"domain_scores_gemma":[0.94373465,0.04083403,0.010442857,0.0006946468,0.00388342,0.0004103937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012898155,0.0017224099,0.008471758,0.013862187,0.0006476624,0.0033656878,0.001868978,0.0020783541,0.00658906],"category_scores_gemma":[0.0545318,0.0010936565,0.01034606,0.011217741,0.0010339549,0.002284146,0.0017997955,0.0014419202,0.00054855633],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002226389,0.0000149031375,0.00066526263,0.96345365,0.0135420235,0.00006583454,0.00009046579,0.000073611605,0.0001239736,0.00012369228,0.0008454451,0.020778405],"study_design_scores_gemma":[0.00036235483,0.00022499014,0.0030666522,0.8716553,0.11161299,0.00027970504,0.00017929637,0.000075394186,0.00016146379,0.00023473361,0.01211477,0.000032308562],"about_ca_topic_score_codex":0.0064362604,"about_ca_topic_score_gemma":0.017100818,"teacher_disagreement_score":0.013862187,"about_ca_system_score_codex":0.0036142766,"about_ca_system_score_gemma":0.011910369,"threshold_uncertainty_score":0.06821281},"labels":[],"label_agreement":null},{"id":"W4412552202","doi":"10.1007/s12325-025-03305-5","title":"Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Eli Lilly and Company","keywords":"Medicine; Ixekizumab; Rheumatology; Axial spondyloarthritis; Quality of life (healthcare); Duration (music); Internal medicine; Signs and symptoms; Physical therapy; Arthritis; Psoriatic arthritis; Sacroiliitis; Secukinumab","score_opus":0.007269823551129115,"score_gpt":0.2827602829955768,"score_spread":0.2754904594444477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412552202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962807,0.003013144,0.00007326962,0.00006394921,0.00001917046,0.000036787966,0.000095166346,0.0000048293887,0.00041302753],"genre_scores_gemma":[0.99861395,0.0006876111,0.00015587457,0.00011679043,0.000037417565,0.000035842906,0.00016290117,0.0000011477159,0.00018850502],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995165,0.00023429404,0.000076883654,0.00005726868,0.000058109872,0.000056918143],"domain_scores_gemma":[0.999173,0.00023378928,0.000336632,0.000052969142,0.00005047728,0.00015311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012657264,0.00026151625,0.0009825868,0.00016496821,0.00016618118,0.00032275973,0.00016993203,0.00021526137,0.0008543192],"category_scores_gemma":[0.0012728095,0.00015937565,0.0008107743,0.00019388528,0.00021277169,0.0003335108,0.00018692813,0.00042955598,0.00009729467],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43106622,0.008745232,0.3183994,0.0017062066,0.004968589,0.0004603071,0.00039279592,0.0021083825,0.045267638,0.00012019274,0.00139917,0.18536593],"study_design_scores_gemma":[0.044481732,0.20870012,0.7382919,0.00011643419,0.0018107722,0.0007929149,0.0001867945,0.0013888414,0.0024772342,0.000114407325,0.001604335,0.000034467474],"about_ca_topic_score_codex":0.00041003918,"about_ca_topic_score_gemma":0.0010751878,"teacher_disagreement_score":0.0012657264,"about_ca_system_score_codex":0.00018382893,"about_ca_system_score_gemma":0.0003271951,"threshold_uncertainty_score":0.00669384},"labels":[],"label_agreement":null},{"id":"W4412695394","doi":"10.1007/s12325-025-03310-8","title":"Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Swedish Orphan Biovitrum; Apellis Pharmaceuticals","keywords":"Paroxysmal nocturnal hemoglobinuria; Medicine; Rheumatology; Internal medicine; Nocturnal; Hemoglobinuria; Pediatrics; Anemia","score_opus":0.0051057788509720516,"score_gpt":0.267746939681555,"score_spread":0.2626411608305829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412695394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960263,0.0023703254,0.00014022997,0.00013232099,0.000013937289,0.0000735329,0.00030363887,0.000015943302,0.00092385686],"genre_scores_gemma":[0.9983987,0.00047398877,0.0001848107,0.00015957025,0.000028312787,0.00005228723,0.00048674975,0.0000018125635,0.00021378839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999602,0.00011248916,0.000047950627,0.00007941358,0.00008397382,0.0000742186],"domain_scores_gemma":[0.9989483,0.00020093773,0.00045269926,0.00006621346,0.0001307619,0.00020113809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014612066,0.00017598538,0.00069621735,0.00015215875,0.00029577292,0.00037449223,0.00013785232,0.0003251285,0.00084482675],"category_scores_gemma":[0.0015118336,0.000093965085,0.0007413267,0.00023938951,0.00012180271,0.0003616878,0.00019947656,0.00052804913,0.00013191991],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07614717,0.002378835,0.60147566,0.0005159858,0.0015867965,0.00045673831,0.0004855736,0.0013236539,0.011572422,0.000115107425,0.0026085663,0.3013336],"study_design_scores_gemma":[0.004190349,0.047982186,0.9397143,0.00009289956,0.00102298,0.00092324056,0.000106037274,0.0009208115,0.001962715,0.000095849144,0.0029690727,0.000019467068],"about_ca_topic_score_codex":0.00080921437,"about_ca_topic_score_gemma":0.0016122482,"teacher_disagreement_score":0.0014612066,"about_ca_system_score_codex":0.0004467787,"about_ca_system_score_gemma":0.00049057975,"threshold_uncertainty_score":0.0077276826},"labels":[],"label_agreement":null},{"id":"W4412717873","doi":"10.1007/s12325-025-03309-1","title":"Key Learnings from Clinical Research and Real-World Evidence on Asfotase Alfa Effectiveness in Hypophosphatasia: 10 Years Post-Approval","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Alkaline Phosphatase Research Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Hypophosphatasia; Rheumatology; Key (lock); Internal medicine; Intensive care medicine; Medical physics; Family medicine; Alkaline phosphatase","score_opus":0.20057118062795315,"score_gpt":0.5627583183409461,"score_spread":0.362187137712993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412717873","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009089221,0.9603988,0.00074058626,0.021392392,0.006963739,0.00041727143,0.0009022532,0.000057139696,0.00821883],"genre_scores_gemma":[0.014468906,0.9506695,0.0026885688,0.023471601,0.004254043,0.0006520841,0.00095875585,0.00008396271,0.0027524906],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.98538405,0.005398459,0.003915934,0.0009814958,0.0036986412,0.0006214125],"domain_scores_gemma":[0.9219284,0.044606972,0.009795437,0.0019892666,0.019440167,0.0022397537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.029286586,0.00090868794,0.0037529848,0.00272298,0.00055736717,0.0064671836,0.0021216644,0.0043091625,0.017653385],"category_scores_gemma":[0.08837154,0.00054794183,0.0044876495,0.003133845,0.0013594495,0.0063664746,0.0023661656,0.005535682,0.0038744872],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020758873,0.00011147937,0.0006953103,0.21394104,0.002316944,0.00042764476,0.0004986619,0.00039462943,0.0009960553,0.0098224105,0.09892606,0.6697939],"study_design_scores_gemma":[0.0008827311,0.0006368934,0.0017597293,0.2388733,0.0038884736,0.0005489615,0.00027439374,0.00015010122,0.0008436674,0.0050715893,0.74699837,0.00007185606],"about_ca_topic_score_codex":0.0014216981,"about_ca_topic_score_gemma":0.0024617244,"teacher_disagreement_score":0.029286586,"about_ca_system_score_codex":0.0028972975,"about_ca_system_score_gemma":0.009130343,"threshold_uncertainty_score":0.1548841},"labels":[],"label_agreement":null},{"id":"W4413792153","doi":"10.1007/s12325-025-03328-y","title":"Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Charité – Universitätsmedizin Berlin; AbbVie","keywords":"Medicine; Psoriatic arthritis; Rheumatoid arthritis; Inflammatory bowel disease; Dermatology; Atopic dermatitis; Rheumatology; Psoriasis; Ankylosing spondylitis; Internal medicine; Disease","score_opus":0.0049820408310046966,"score_gpt":0.26221983043281205,"score_spread":0.2572377896018074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413792153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94449854,0.04049767,0.0011069318,0.000095481555,0.000016558788,0.00020729058,0.012272913,0.000033949353,0.0012706228],"genre_scores_gemma":[0.9893265,0.0046178726,0.00029721353,0.000096879485,0.000031805343,0.00016608437,0.00527799,0.000010276436,0.00017534965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99469334,0.0010717544,0.001721342,0.0010603893,0.0012507513,0.00020240077],"domain_scores_gemma":[0.98405415,0.0054371133,0.008700465,0.00060865126,0.0009036739,0.00029609122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006281345,0.00041321188,0.0015767869,0.0030184572,0.00026537498,0.0010614364,0.00040903877,0.00038530305,0.0013804907],"category_scores_gemma":[0.007636111,0.0003113713,0.0034476896,0.0036945676,0.0002882954,0.0007851529,0.0007313971,0.00047741152,0.00019335064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052757934,0.00008246167,0.95793533,0.0021716456,0.01523293,0.00023060766,0.00014707774,0.00088522566,0.0006942453,0.000050096354,0.0005599789,0.016734518],"study_design_scores_gemma":[0.00040243912,0.0014463048,0.98268306,0.0004751452,0.009669023,0.0015443319,0.00021306322,0.000574295,0.0005100886,0.00009094747,0.0023521709,0.00003907374],"about_ca_topic_score_codex":0.0008751741,"about_ca_topic_score_gemma":0.0012843845,"teacher_disagreement_score":0.006281345,"about_ca_system_score_codex":0.00043714434,"about_ca_system_score_gemma":0.00044304255,"threshold_uncertainty_score":0.033219337},"labels":[],"label_agreement":null},{"id":"W4414132918","doi":"10.1007/s12325-025-03345-x","title":"Healthcare Costs Associated with Adverse Events in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Claims-Based Study","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Adverse effect; Health care; Rheumatology; Patient safety; MEDLINE; Adverse drug event; Healthcare system","score_opus":0.014235280551496279,"score_gpt":0.3298150909744432,"score_spread":0.31557981042294697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414132918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99664885,0.00053484476,0.00012273985,0.000099724384,0.0000066393736,0.00003675382,0.0022073945,0.000003043576,0.00034008088],"genre_scores_gemma":[0.9972843,0.00040095893,0.00018357176,0.000059695773,0.000025600799,0.00003751811,0.001956653,0.0000019825663,0.00004978649],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980861,0.00054953917,0.0003673169,0.0002498924,0.0005718817,0.0001753233],"domain_scores_gemma":[0.9930629,0.0011574818,0.004804536,0.00021725637,0.0004241739,0.00033366834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016116942,0.00033953428,0.00043865023,0.0018726153,0.00039265517,0.0008761642,0.00068219693,0.0004936294,0.0014104458],"category_scores_gemma":[0.00719101,0.00034751988,0.0013551384,0.0029813403,0.00027598682,0.0007664086,0.000984884,0.00083089224,0.00015107564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010806002,0.000047028632,0.9982318,0.00003318608,0.00014901435,0.000052287713,0.000035580146,0.0001213519,0.000020872054,0.00004386507,0.00015504412,0.0010019225],"study_design_scores_gemma":[0.000024475548,0.000097564414,0.99832016,0.000040736188,0.000100361314,0.00026974978,0.0001353209,0.0007404782,0.000031263502,0.000035190315,0.00019994496,0.0000047464982],"about_ca_topic_score_codex":0.011536928,"about_ca_topic_score_gemma":0.00967961,"teacher_disagreement_score":0.011536928,"about_ca_system_score_codex":0.0014336803,"about_ca_system_score_gemma":0.0008122192,"threshold_uncertainty_score":0.022939563},"labels":[],"label_agreement":null},{"id":"W4414167020","doi":"10.1007/s12325-025-03359-5","title":"A Narrative Review of the Immunomodulatory Effects of Acthar® Gel Beyond Its Steroidogenic Properties","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Immune Response and Inflammation","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Immune system; Narrative review; Rheumatoid arthritis; Adverse effect; Receptor; Melanocortin; Rheumatology; Adrenocorticotropic hormone","score_opus":0.005476303432366392,"score_gpt":0.25526784872908204,"score_spread":0.24979154529671566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414167020","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018307552,0.9974903,0.00011077162,0.00047460594,0.00037745468,0.000019233019,0.000088679604,0.0000069860425,0.001248897],"genre_scores_gemma":[0.000898317,0.9970119,0.00025889435,0.0005380283,0.00041678865,0.000026566611,0.000106813684,0.0000025019658,0.000740049],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99970144,0.00006303053,0.00008425958,0.00004271298,0.000089602036,0.0000188989],"domain_scores_gemma":[0.99929416,0.0004071965,0.00013647402,0.000010372869,0.00012180505,0.000029995119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052870205,0.0007377484,0.0010965718,0.0027967324,0.0002663849,0.0012254245,0.00053930946,0.00084751524,0.008078263],"category_scores_gemma":[0.0017270246,0.00023594475,0.0008788142,0.001810455,0.00022494506,0.0011738541,0.00050880987,0.0010048939,0.001673729],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001811716,0.000059395305,0.00026966317,0.14748143,0.00026965595,0.00067934085,0.00028491046,0.00029490775,0.0021899545,0.0035567563,0.08162495,0.76310784],"study_design_scores_gemma":[0.000023651419,0.00015049212,0.0008774002,0.032122448,0.00040755825,0.002264503,0.00011721043,0.0000686981,0.00035022083,0.0008924948,0.9627026,0.000022830603],"about_ca_topic_score_codex":0.0008996183,"about_ca_topic_score_gemma":0.0017473542,"teacher_disagreement_score":0.008078263,"about_ca_system_score_codex":0.00048583985,"about_ca_system_score_gemma":0.0014913668,"threshold_uncertainty_score":0.027024508},"labels":[],"label_agreement":null},{"id":"W4414416604","doi":"10.1007/s12325-025-03373-7","title":"The IMPACT Survey: The Economic Impact of Caring for an Individual with Osteogenesis Imperfecta","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Connective tissue disorders research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Mereo BioPharma","keywords":"Economic impact analysis; Osteogenesis imperfecta; Rheumatology; Productivity; Social impact; Health care; Impact assessment; Health economics","score_opus":0.02189328852987421,"score_gpt":0.393577280307019,"score_spread":0.3716839917771448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414416604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7881023,0.0018882523,0.0019375343,0.0025501365,0.00026074462,0.0046828547,0.17083398,0.00020465221,0.029539581],"genre_scores_gemma":[0.81939125,0.004311927,0.008435844,0.0018030112,0.00023973525,0.008364419,0.14846864,0.000074246615,0.008910937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979838,0.000662861,0.00054761214,0.00010459996,0.0004974286,0.00020364806],"domain_scores_gemma":[0.9930962,0.0014409975,0.0024636586,0.00023475943,0.0018702159,0.0008941555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032416976,0.00043783267,0.00059841207,0.002137244,0.00055145455,0.000679329,0.00059635035,0.0003744601,0.003748174],"category_scores_gemma":[0.0096323425,0.00036525435,0.00074947753,0.002538269,0.00030276232,0.0010915508,0.0018963163,0.001191297,0.0008654172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065706443,0.0008819161,0.82176596,0.0009595768,0.0004321163,0.00023374813,0.0010346543,0.00094615924,0.00028909015,0.0008940909,0.09324953,0.07865613],"study_design_scores_gemma":[0.0001085153,0.00054063386,0.9596676,0.0002921551,0.000068400266,0.00025784687,0.00093826326,0.00051854696,0.00017936986,0.00029616724,0.037087634,0.00004479455],"about_ca_topic_score_codex":0.010960559,"about_ca_topic_score_gemma":0.018950162,"teacher_disagreement_score":0.010960559,"about_ca_system_score_codex":0.0013924344,"about_ca_system_score_gemma":0.001509816,"threshold_uncertainty_score":0.021793485},"labels":[],"label_agreement":null},{"id":"W4414418254","doi":"10.1007/s12325-025-03363-9","title":"IL-17C as a Driver of Inflammation in Psoriasis","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bausch Health","keywords":"Psoriasis; Autocrine signalling; Inflammation; Rheumatology; Psoriatic arthritis; Mechanism of action; Ustekinumab; Cytokine","score_opus":0.019473864995041102,"score_gpt":0.3204962230484371,"score_spread":0.301022358053396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414418254","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006357828,0.9990114,0.00007783965,0.00022661524,0.00024138532,0.00000209828,0.000012725323,0.000004356844,0.00036002204],"genre_scores_gemma":[0.00050771976,0.99834967,0.00011183949,0.00020762433,0.0003947201,0.0000033894758,0.0000233395,0.0000010027243,0.0004007808],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982977,0.000028531196,0.000020872276,0.000028366188,0.000069716996,0.000022670993],"domain_scores_gemma":[0.99975353,0.00010388446,0.000036415717,0.0000073634096,0.00006772854,0.000031046085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006117279,0.00075242127,0.0013204771,0.0011755695,0.00016359492,0.001109975,0.00060455926,0.0009168364,0.0028089336],"category_scores_gemma":[0.00064245675,0.00024563423,0.00036929734,0.0012433088,0.00037633962,0.0009629902,0.0006807788,0.0022334324,0.0018235311],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015884457,0.00006113512,0.00021103419,0.008385243,0.00007431956,0.00013460062,0.00002456108,0.0002817708,0.0017948317,0.0027255903,0.031438004,0.9547101],"study_design_scores_gemma":[0.0000652453,0.0001420743,0.0012005215,0.003758708,0.00019269164,0.0009912306,0.00005968352,0.00017821132,0.00063344085,0.0032232315,0.98953164,0.00002324235],"about_ca_topic_score_codex":0.00081070396,"about_ca_topic_score_gemma":0.001499415,"teacher_disagreement_score":0.0028089336,"about_ca_system_score_codex":0.0004781122,"about_ca_system_score_gemma":0.001034586,"threshold_uncertainty_score":0.009396791},"labels":[],"label_agreement":null},{"id":"W4414519113","doi":"10.1007/s12325-025-03351-z","title":"Meta-analysis to Investigate the Correlation Between Event-Free Survival and Overall Survival in Patients with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Overall survival; Head and neck squamous-cell carcinoma; Correlation; Head and neck; Neoadjuvant therapy; Rheumatology; Adjuvant; Radiation therapy; Head and neck cancer","score_opus":0.030650267883544483,"score_gpt":0.30389759177776005,"score_spread":0.2732473238942156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414519113","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019623267,0.97446287,0.001946377,0.00048549636,0.0004573877,0.0003172731,0.0017869914,0.000092914204,0.0008275077],"genre_scores_gemma":[0.7000905,0.2851102,0.004698179,0.0028209528,0.00069507305,0.0013444505,0.0035765765,0.00013847587,0.0015255513],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9876588,0.00789105,0.0021299995,0.001238847,0.000756376,0.0003249161],"domain_scores_gemma":[0.9748464,0.020586113,0.0021921108,0.0010529042,0.0010357474,0.00028671074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016197339,0.002654756,0.014446692,0.0042444277,0.0005307662,0.0030920838,0.001879911,0.0021961534,0.0041019097],"category_scores_gemma":[0.035821326,0.0010282672,0.04738154,0.005726317,0.000517061,0.001821601,0.0013629476,0.0027425888,0.00051532045],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030868251,0.000020079782,0.0048040026,0.052202456,0.93452066,0.00009515401,0.00002683581,0.00066380075,0.00015040189,0.00011328077,0.0004605584,0.0038557854],"study_design_scores_gemma":[0.00076974515,0.0001713344,0.0034583246,0.002618665,0.991305,0.00005814013,0.000016348615,0.00034470187,0.00007037748,0.00029284463,0.00087904464,0.000015518908],"about_ca_topic_score_codex":0.0063245515,"about_ca_topic_score_gemma":0.011081076,"teacher_disagreement_score":0.016197339,"about_ca_system_score_codex":0.0018014611,"about_ca_system_score_gemma":0.0019321498,"threshold_uncertainty_score":0.085660756},"labels":[],"label_agreement":null},{"id":"W4414542678","doi":"10.1007/s12325-025-03372-8","title":"The IMPACT Survey: The Humanistic Impact of Caring for an Individual with Osteogenesis Imperfecta","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Connective tissue disorders research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Mereo BioPharma","keywords":"Osteogenesis imperfecta; Rheumatology; Quality of life (healthcare); MEDLINE; Health care; Empathy; Alternative medicine","score_opus":0.02815782071704819,"score_gpt":0.4085189092588146,"score_spread":0.3803610885417664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414542678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93565434,0.0013019262,0.0014167659,0.0022514584,0.00016645482,0.0025049876,0.03590315,0.00011765473,0.020683326],"genre_scores_gemma":[0.9545381,0.0025873135,0.0054643285,0.0011178473,0.00012356997,0.003268301,0.02857708,0.000032050466,0.0042914487],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9979359,0.00071555143,0.00050805876,0.000083972765,0.00053163455,0.00022487198],"domain_scores_gemma":[0.99347526,0.0013602453,0.0022688275,0.00022424676,0.0016734765,0.0009980642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034707023,0.0002874054,0.00041803904,0.0017007929,0.0005717003,0.00053729326,0.00040438276,0.00027931557,0.002492985],"category_scores_gemma":[0.009072459,0.00024909736,0.0006476964,0.0017411537,0.00040154305,0.000803219,0.001774876,0.00089080795,0.00040747016],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002810653,0.00041216955,0.8846628,0.00054954895,0.00020024097,0.00021002813,0.0020220354,0.00051994756,0.0003356589,0.0004929936,0.03368621,0.07662727],"study_design_scores_gemma":[0.00005030198,0.00041753025,0.9696638,0.00021424051,0.000040035186,0.000285813,0.0019935586,0.0003007812,0.00018788368,0.00022923423,0.026580049,0.000036855],"about_ca_topic_score_codex":0.008998728,"about_ca_topic_score_gemma":0.017384842,"teacher_disagreement_score":0.008998728,"about_ca_system_score_codex":0.0012741613,"about_ca_system_score_gemma":0.001434167,"threshold_uncertainty_score":0.018355072},"labels":[],"label_agreement":null},{"id":"W4414571303","doi":"10.1007/s12325-025-03378-2","title":"Peak Nasal Inspiratory Flow and the Association with Nasal Obstruction in Patients with Severe CRSwNP from the SINUS-24/-52 Studies","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Sinusitis and nasal conditions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation; Université de Montréal","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Rheumatology; Nose; Rhinomanometry; Pathophysiology; Breathing","score_opus":0.007289450487137565,"score_gpt":0.26146575807545963,"score_spread":0.25417630758832205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414571303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959734,0.0020707455,0.0001273183,0.000048641294,0.000019942823,0.000024448655,0.00034527454,0.0000042900438,0.0013858903],"genre_scores_gemma":[0.9978828,0.0008975386,0.00018145404,0.00003892069,0.00004970158,0.000018610172,0.0006520719,0.0000016514094,0.0002771259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996606,0.00008918535,0.0000673591,0.000059199512,0.000074546144,0.00004913226],"domain_scores_gemma":[0.99915767,0.0002580027,0.00028089999,0.000054186134,0.00010955654,0.0001396692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007796457,0.00032832063,0.00049475505,0.0009433298,0.0003625002,0.0005450049,0.00026581786,0.00040461513,0.0020105317],"category_scores_gemma":[0.0013400778,0.00015245489,0.0010381389,0.00073565834,0.00024833568,0.00041881064,0.00034796278,0.00048813949,0.00022771825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097164436,0.00015633799,0.9899594,0.000112394555,0.00030004742,0.00026105615,0.00009677132,0.000049710197,0.0015468579,0.000035192035,0.0000961634,0.0064143734],"study_design_scores_gemma":[0.000017459803,0.0007654469,0.9976083,0.00001699456,0.0001255225,0.00055577385,0.00022261802,0.00007672831,0.0002387534,0.000017168046,0.00034848746,0.0000066961516],"about_ca_topic_score_codex":0.0013230678,"about_ca_topic_score_gemma":0.001541551,"teacher_disagreement_score":0.0020105317,"about_ca_system_score_codex":0.00023371517,"about_ca_system_score_gemma":0.00029420754,"threshold_uncertainty_score":0.0067258477},"labels":[],"label_agreement":null},{"id":"W4414948117","doi":"10.1007/s12325-025-03377-3","title":"Real-World Health Care Resource Utilization and Costs Among Patients with Activated Phosphoinositide 3-Kinase Delta (PI3Kδ) Syndrome in the United States","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Health care; Managed care; Delta; Rheumatology; MEDLINE; Patient care; Public health","score_opus":0.0062765451594935,"score_gpt":0.2638679887652232,"score_spread":0.2575914436057297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414948117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99867564,0.0003188291,0.000058208683,0.0001052938,0.0000031508364,0.0000033206802,0.00071103015,0.0000022042898,0.00012239761],"genre_scores_gemma":[0.999212,0.00013994653,0.000057837555,0.000039285278,0.0000051737843,0.0000052309288,0.00051816955,6.203507e-7,0.00002169804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989611,0.0004496428,0.00019785899,0.00014338987,0.00014350357,0.00010453396],"domain_scores_gemma":[0.9982078,0.0003911806,0.001052079,0.000057207824,0.00010565096,0.00018613598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006733089,0.0002570616,0.00032209055,0.0009866942,0.00023498769,0.000865517,0.0002851148,0.00049072615,0.00052344875],"category_scores_gemma":[0.0026853776,0.0002259433,0.0006292285,0.0017172177,0.00030486984,0.00066896813,0.00057561457,0.00048344798,0.000064778986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005897334,0.000019300769,0.99846125,0.000009242408,0.00011379762,0.00007639931,0.000036014288,0.00032512017,0.000042253596,0.000035099656,0.00010378729,0.0007187038],"study_design_scores_gemma":[0.000008906685,0.00006229054,0.9971418,0.000013728523,0.000049534257,0.00030803971,0.0003265002,0.0018547255,0.000033169286,0.00005514816,0.00013833541,0.000007669898],"about_ca_topic_score_codex":0.0232767,"about_ca_topic_score_gemma":0.021966333,"teacher_disagreement_score":0.0232767,"about_ca_system_score_codex":0.0010418945,"about_ca_system_score_gemma":0.00039427972,"threshold_uncertainty_score":0.04628241},"labels":[],"label_agreement":null},{"id":"W4415063955","doi":"10.1007/s12325-025-03382-6","title":"Therapeutic Advances in Hereditary Angioedema: A Focus on Present and Future Options","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Calgary","funders":"","keywords":"Hereditary angioedema; Narrative review; Personalized medicine; Quality of life (healthcare); Genome editing; Autonomy; Precision medicine; Bradykinin","score_opus":0.024453131652032663,"score_gpt":0.36171896063001835,"score_spread":0.3372658289779857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415063955","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008419229,0.99866486,0.000082183644,0.0004219486,0.00021593181,0.0000030024767,0.000010065889,0.000004644118,0.0005132813],"genre_scores_gemma":[0.00056601706,0.99840146,0.00016560493,0.00032266675,0.00021239974,0.0000045121947,0.00001848178,0.0000012482908,0.00030750106],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997739,0.00005274822,0.00003836157,0.000033692508,0.000076054275,0.000025202078],"domain_scores_gemma":[0.9994673,0.0003364944,0.000058487625,0.000011144795,0.00009564342,0.000030913423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068361306,0.0005833524,0.0008765849,0.0017170127,0.00024347787,0.00094994676,0.000573813,0.00091564306,0.0041385996],"category_scores_gemma":[0.0011034713,0.00015947688,0.00058687356,0.0013027095,0.0003657401,0.0013034838,0.00057712116,0.0017472751,0.001046813],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000092894385,0.00007553672,0.00014387297,0.029230302,0.000113551185,0.00032292362,0.00012752153,0.00039420914,0.0016167506,0.0062913154,0.039107483,0.92248356],"study_design_scores_gemma":[0.00002109776,0.00011926699,0.00048555006,0.009108154,0.00017379495,0.0014871688,0.000093462084,0.00011536493,0.00031754552,0.0025780324,0.98548317,0.000017386166],"about_ca_topic_score_codex":0.00067577785,"about_ca_topic_score_gemma":0.0015459447,"teacher_disagreement_score":0.0041385996,"about_ca_system_score_codex":0.00051406375,"about_ca_system_score_gemma":0.001105256,"threshold_uncertainty_score":0.013844967},"labels":[],"label_agreement":null},{"id":"W4415323057","doi":"10.1007/s12325-025-03388-0","title":"Fetal Surgery for Congenital Heart Diseases: A Systematic Review and Single-Arm Meta-analysis","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Congenital Heart Disease Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cardiac surgery; Heart disease; Rheumatology; MEDLINE; Multicenter study; Fetus; Orthopedic surgery","score_opus":0.09142833783795772,"score_gpt":0.4022150068843841,"score_spread":0.3107866690464264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415323057","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034167296,0.9941256,0.0008555218,0.00019477883,0.00015272277,0.0005990254,0.00043058852,0.000028821343,0.00019613902],"genre_scores_gemma":[0.12978147,0.8577998,0.0053813183,0.0010124904,0.00034027765,0.0041018007,0.0010612448,0.00004307434,0.00047856293],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9873122,0.0065977857,0.0032050607,0.0011448379,0.001338206,0.00040182934],"domain_scores_gemma":[0.98191017,0.013228287,0.0025812327,0.00061039533,0.0014370958,0.00023285214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019398782,0.003415076,0.024749646,0.0075412183,0.00079821213,0.00377776,0.0024713872,0.0027064378,0.0047014616],"category_scores_gemma":[0.037713587,0.0016287939,0.051443,0.007075293,0.00076477794,0.0024073378,0.0018926626,0.0025304626,0.0003438403],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018195574,0.00003699062,0.0018697693,0.3565468,0.6280675,0.00011334955,0.000080848586,0.00050729327,0.00015450317,0.00015667918,0.0006055418,0.01004118],"study_design_scores_gemma":[0.000608136,0.00018440651,0.0019562144,0.025954563,0.9693894,0.00006837098,0.00003575992,0.00021620953,0.00007674733,0.00022252543,0.0012631329,0.00002447552],"about_ca_topic_score_codex":0.007358853,"about_ca_topic_score_gemma":0.016740778,"teacher_disagreement_score":0.024749646,"about_ca_system_score_codex":0.0035245789,"about_ca_system_score_gemma":0.0044989544,"threshold_uncertainty_score":0.10259175},"labels":[],"label_agreement":null},{"id":"W4415500029","doi":"10.1007/s12325-025-03392-4","title":"Visualizing Improvements in Airway Dysfunction After Inhaled Therapy in Patients With Uncontrolled Asthma: A Narrative Review","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Asthma; Airway; Spirometry; Narrative review; Bronchodilator; Clinical trial; Magnetic resonance imaging; Fluticasone","score_opus":0.004408364618635577,"score_gpt":0.2930193637082804,"score_spread":0.2886109990896448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415500029","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012228133,0.9993781,0.00004459927,0.00015107823,0.0000865396,0.000014898634,0.000039359616,0.0000028014804,0.00016028695],"genre_scores_gemma":[0.0011673158,0.9982436,0.00014441015,0.0002001805,0.00012370964,0.000024431507,0.000037149824,0.0000011666085,0.00005815687],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99922466,0.00016682727,0.00029734083,0.00012043652,0.00016117003,0.000029590194],"domain_scores_gemma":[0.9962842,0.0026527662,0.0006415532,0.00003606141,0.00033383095,0.000051638148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014410019,0.0009591248,0.0025983083,0.0040621455,0.0002531851,0.0017705086,0.0010931795,0.001366622,0.0029542558],"category_scores_gemma":[0.0046284697,0.00043498137,0.0018953822,0.003458567,0.00047872693,0.0016130697,0.00074045063,0.00096374744,0.00047820105],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029622222,0.00006572532,0.00057228014,0.49351594,0.0011422153,0.00029750867,0.00024133963,0.00020418651,0.0006529583,0.0012665589,0.013203599,0.48854142],"study_design_scores_gemma":[0.00016976794,0.0005598556,0.0063774064,0.46336022,0.011763649,0.0040343194,0.0006144725,0.00029715194,0.0006974502,0.0014722846,0.51054645,0.000106948944],"about_ca_topic_score_codex":0.0014237671,"about_ca_topic_score_gemma":0.0020855255,"teacher_disagreement_score":0.0040621455,"about_ca_system_score_codex":0.0005699478,"about_ca_system_score_gemma":0.0018446539,"threshold_uncertainty_score":0.009882927},"labels":[],"label_agreement":null},{"id":"W4416502533","doi":"10.1007/s12325-025-03411-4","title":"Clinical Complications, Mortality, and Healthcare Resource Utilization of Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in Ontario, Canada: A Retrospective Cohort Study","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; Government of Ontario; Institute for Clinical Evaluative Sciences; Vertex Pharmaceuticals","keywords":"Retrospective cohort study; Disease; Health care; Cohort study; Resource use; Rheumatology; MEDLINE","score_opus":0.02118208301244729,"score_gpt":0.33648017140864156,"score_spread":0.3152980883961943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416502533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99591786,0.00033250643,0.000056501918,0.0000922654,0.000004565785,0.000055048393,0.0028489514,0.0000052925657,0.0006869971],"genre_scores_gemma":[0.9975383,0.00029218898,0.00010385583,0.00006791851,0.0000061590636,0.000027909558,0.0017147298,0.0000025115178,0.00024639862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990095,0.00006274863,0.00010475599,0.00019300645,0.00034489972,0.00028507638],"domain_scores_gemma":[0.99779046,0.00008366814,0.0007833497,0.00011898355,0.00078976207,0.00043376707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061260804,0.0003938836,0.0005736858,0.0014514979,0.0023216002,0.0011597836,0.0010561952,0.0004256514,0.0010748227],"category_scores_gemma":[0.0016870406,0.0005105737,0.00075013563,0.0039919103,0.00066729065,0.00046090983,0.0009022067,0.00054973847,0.00017598353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020635132,0.000010567243,0.9992085,0.000008618541,0.000025723783,0.000051560364,0.00014277989,0.000015574285,0.000037768088,0.000009043436,0.00015769452,0.00031147353],"study_design_scores_gemma":[0.0000054209313,0.00001994296,0.9991405,0.000013105793,0.00002194257,0.00009676901,0.00036642395,0.000089831556,0.000013699563,0.0000052661258,0.000222257,0.000004840827],"about_ca_topic_score_codex":0.96014464,"about_ca_topic_score_gemma":0.9683487,"teacher_disagreement_score":0.03985536,"about_ca_system_score_codex":0.014664998,"about_ca_system_score_gemma":0.015244275,"threshold_uncertainty_score":0.10640252},"labels":[],"label_agreement":null},{"id":"W4416775922","doi":"10.1007/s12325-025-03409-y","title":"Comparative Efficacy of Talquetamab vs. Real-World Physician’s Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Johnson and Johnson; Universidad de Salamanca; Regeneron Pharmaceuticals; Genentech; Celgene; Adaptive Biotechnologies; Karyopharm Therapeutics; Gilead Sciences; Sanofi; Pfizer; Amgen","keywords":"Identifier; Rheumatology; MEDLINE; Comparative effectiveness research; Identification (biology)","score_opus":0.058499155964655956,"score_gpt":0.41023446096345717,"score_spread":0.35173530499880123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416775922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436826,0.003491093,0.00028491256,0.0001256752,0.000038114442,0.0001649918,0.0006853351,0.000015487287,0.0008260753],"genre_scores_gemma":[0.9981194,0.00041684989,0.00023362275,0.00012777394,0.00004571946,0.00011200483,0.00067131827,0.0000072001985,0.0002661349],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9942636,0.0043780254,0.00022237959,0.0005064873,0.00034652802,0.00028300332],"domain_scores_gemma":[0.991435,0.0039916453,0.0029445826,0.0007682637,0.00029690942,0.00056361564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008282213,0.00072216784,0.001749802,0.0005505573,0.00016971002,0.0009656689,0.000988791,0.00075050385,0.0025923105],"category_scores_gemma":[0.007802906,0.00029389103,0.003631838,0.0005699405,0.0006108339,0.0007696123,0.000674607,0.0014278146,0.00024113599],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8904118,0.0030810565,0.03357225,0.00081140856,0.016118176,0.000036058766,0.000189066,0.0025920365,0.0020744987,0.00023014104,0.0006190619,0.050264478],"study_design_scores_gemma":[0.1959071,0.39694327,0.34450278,0.0003156808,0.039308913,0.0003116576,0.00032808524,0.008704514,0.006026949,0.000827032,0.0066723945,0.00015158235],"about_ca_topic_score_codex":0.0014730899,"about_ca_topic_score_gemma":0.0024080754,"teacher_disagreement_score":0.008282213,"about_ca_system_score_codex":0.0013524507,"about_ca_system_score_gemma":0.00063980033,"threshold_uncertainty_score":0.04380107},"labels":[],"label_agreement":null},{"id":"W4416939994","doi":"10.1007/s12325-025-03440-z","title":"Efficacy of Lebrikizumab on Pruritus: A Narrative Review","year":2025,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Narrative review; Quality of life (healthcare); Atopic dermatitis; Disease; Clinical trial; Rheumatology; Alternative medicine; Clinical efficacy","score_opus":0.027435745872139178,"score_gpt":0.4247709164721386,"score_spread":0.39733517059999945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416939994","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011405316,0.9993986,0.000025528478,0.0000848239,0.000053831038,0.0000066162465,0.00002789808,0.00000262626,0.00028601845],"genre_scores_gemma":[0.00088264677,0.99875975,0.00005925123,0.00012337032,0.0000502862,0.000008372637,0.000032735432,7.896996e-7,0.00008283537],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99968934,0.000059262165,0.000091415335,0.000051030842,0.00008732093,0.000021623135],"domain_scores_gemma":[0.99913114,0.00056959124,0.00015028715,0.000013152825,0.00011140606,0.000024411267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007637321,0.00073626643,0.0017740619,0.0024244979,0.00025781928,0.0011256095,0.0008134177,0.0008117673,0.0042139366],"category_scores_gemma":[0.0020452216,0.0002482102,0.0012886965,0.0025461426,0.00026531907,0.00089151703,0.000555575,0.0007974147,0.0006372486],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002012801,0.000051603405,0.0003037129,0.26901615,0.00071351277,0.00018281338,0.00014133097,0.00028677023,0.0007467163,0.0014737331,0.019524407,0.70735794],"study_design_scores_gemma":[0.00013748468,0.00034481272,0.003383455,0.19520576,0.0058415136,0.002812243,0.00026848537,0.00023032849,0.00062706077,0.0018205374,0.78927565,0.000052561638],"about_ca_topic_score_codex":0.001274532,"about_ca_topic_score_gemma":0.0023094753,"teacher_disagreement_score":0.0042139366,"about_ca_system_score_codex":0.0005351793,"about_ca_system_score_gemma":0.0015967991,"threshold_uncertainty_score":0.014096975},"labels":[],"label_agreement":null},{"id":"W4416940022","doi":"10.1007/s12325-025-03424-z","title":"Clinical Characteristics and Patient Burden of Cluster Headache in Brazil: A Real-World Study","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Brock University","funders":"Eli Lilly Canada","keywords":"Cluster (spacecraft); Psychological intervention; Rheumatology; Cluster headache; Socioeconomic status; Disease; Burden of disease","score_opus":0.02685882319281423,"score_gpt":0.41750712691110603,"score_spread":0.3906483037182918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416940022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997431,0.0007965844,0.00005620354,0.00012611678,0.000006008013,0.00002198208,0.00079244917,0.0000027880046,0.00076688564],"genre_scores_gemma":[0.9991333,0.00036853473,0.000045327066,0.00003156647,0.000009243533,0.00001071457,0.00035806376,0.0000014626871,0.00004174722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99924976,0.0002436231,0.00010481216,0.00013443976,0.0001310151,0.00013631213],"domain_scores_gemma":[0.9980318,0.00041030545,0.00090263796,0.000120496086,0.00023241316,0.0003023986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063887564,0.0002653798,0.00056115957,0.0012042295,0.00052477786,0.00077486323,0.00041313592,0.00053977384,0.0011191043],"category_scores_gemma":[0.00335291,0.0002793736,0.00066658127,0.0020109487,0.0006298453,0.0005141368,0.00070990954,0.00042798585,0.0001208894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053686592,0.00003974223,0.9980932,0.000034550885,0.00007110683,0.00009308672,0.00034796112,0.00002046301,0.00012436722,0.000041407202,0.00010507576,0.00097545015],"study_design_scores_gemma":[0.000005443215,0.000053985514,0.99843425,0.000017645201,0.00003609012,0.00023423796,0.00093246455,0.00005666597,0.000012357861,0.000023507795,0.00018736589,0.0000060489024],"about_ca_topic_score_codex":0.037195936,"about_ca_topic_score_gemma":0.037488602,"teacher_disagreement_score":0.037195936,"about_ca_system_score_codex":0.001063485,"about_ca_system_score_gemma":0.0009385621,"threshold_uncertainty_score":0.073958814},"labels":[],"label_agreement":null},{"id":"W4417148083","doi":"10.1007/s12325-025-03435-w","title":"Therapeutic and Preventive Role of Integrated Moderate-to-Vigorous Recreational Activity Programs in Type 2 Diabetes Care: A Systematic Review and Meta-Analysis","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Physical Activity and Health","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Biotech (Canada)","funders":"","keywords":"Type 2 diabetes; Recreation; Rheumatology; Diabetes mellitus; MEDLINE; Physical activity","score_opus":0.04341038760262197,"score_gpt":0.3634356148806266,"score_spread":0.32002522727800464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417148083","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015109338,0.9830935,0.0004966943,0.00013545279,0.00020667835,0.00028317582,0.00035672254,0.000029508581,0.0002889031],"genre_scores_gemma":[0.41730043,0.57629204,0.0031370437,0.0012229742,0.0003479644,0.00065549393,0.00058748986,0.00003582512,0.00042076176],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99496776,0.0018919768,0.0015753623,0.0007108886,0.00060566154,0.00024844208],"domain_scores_gemma":[0.9932893,0.0043112086,0.0014702454,0.00032734976,0.00044017602,0.00016180497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007716843,0.0022469962,0.014965329,0.002863374,0.0005727286,0.0025756154,0.0019297225,0.0023469643,0.0033555962],"category_scores_gemma":[0.016155852,0.0014699034,0.031004356,0.0038385468,0.00077877473,0.0015915139,0.0016886187,0.0023168912,0.00024903347],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009914627,0.00016229071,0.0049813646,0.2018392,0.7655669,0.0000823732,0.00011843168,0.00040802057,0.00032645353,0.000092382856,0.00035872034,0.01614931],"study_design_scores_gemma":[0.0023451059,0.0004010221,0.004506856,0.008571328,0.98313326,0.00003115204,0.000045051434,0.000121653036,0.00006635231,0.000075216136,0.0006823199,0.000020711223],"about_ca_topic_score_codex":0.008634001,"about_ca_topic_score_gemma":0.021128727,"teacher_disagreement_score":0.014965329,"about_ca_system_score_codex":0.0017440825,"about_ca_system_score_gemma":0.0023050627,"threshold_uncertainty_score":0.04081106},"labels":[],"label_agreement":null},{"id":"W7117101903","doi":"10.1007/s12325-025-03442-x","title":"Evaluating Asthma Clinical Remission with Inhaled Therapy: Post Hoc Analyses of CAPTAIN","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Asthma; Post-hoc analysis; Rheumatology; Post hoc; MEDLINE","score_opus":0.08155075590346315,"score_gpt":0.5017766244504785,"score_spread":0.4202258685470154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117101903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95239884,0.0047513605,0.014924323,0.0009632563,0.002094488,0.007999713,0.008857151,0.0007408123,0.007270139],"genre_scores_gemma":[0.94603246,0.0008640374,0.017723333,0.0017436201,0.0011271279,0.016657919,0.006254747,0.0006775043,0.008919336],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.95907634,0.03076147,0.001252134,0.003713807,0.0028654756,0.0023308375],"domain_scores_gemma":[0.9218644,0.063195914,0.0048932396,0.0059567955,0.0025134461,0.0015761991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04183141,0.004023028,0.008427123,0.0013243253,0.00054880034,0.002008615,0.0029375232,0.0024964274,0.009006961],"category_scores_gemma":[0.04106224,0.0008692362,0.013514535,0.0011639633,0.0012828954,0.0026452986,0.0019447902,0.0052918056,0.0010445615],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9106253,0.0040737856,0.011482676,0.0022764457,0.0391727,0.00025215538,0.00024850972,0.0041756253,0.0045169047,0.000749148,0.005836199,0.016590677],"study_design_scores_gemma":[0.15832305,0.5548792,0.12428673,0.00036502245,0.0673585,0.0004681473,0.00050015666,0.05234546,0.017942639,0.0027883307,0.020388536,0.00035429298],"about_ca_topic_score_codex":0.0011762258,"about_ca_topic_score_gemma":0.0012022858,"teacher_disagreement_score":0.04183141,"about_ca_system_score_codex":0.0011343316,"about_ca_system_score_gemma":0.0021545866,"threshold_uncertainty_score":0.22122836},"labels":[],"label_agreement":null},{"id":"W7117129385","doi":"10.1007/s12325-025-03444-9","title":"Correction to: Peak Nasal Inspiratory Flow and the Association with Nasal Obstruction in Patients with Severe CRSwNP from the SINUS-24/-52 Studies","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Sinusitis and nasal conditions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation; Université de Montréal","funders":"","keywords":"Rheumatology; Peak flow meter; Breathing; Airway obstruction; Bronchial obstruction","score_opus":0.006677489225963944,"score_gpt":0.263541801161339,"score_spread":0.25686431193537507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117129385","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019088356,0.003991881,0.00059941376,0.032608844,0.9506082,0.00009212897,0.006060993,0.00020895802,0.0039206413],"genre_scores_gemma":[0.08693756,0.023625867,0.0087406365,0.054763686,0.56146175,0.0007050105,0.018391738,0.0013495606,0.2440242],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99858165,0.0001924482,0.00036042492,0.00022357023,0.00046674846,0.00017513586],"domain_scores_gemma":[0.9896716,0.0019478123,0.00091134076,0.0006462617,0.0058298805,0.0009930357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017419312,0.0012901803,0.0011006969,0.0019425674,0.0007102631,0.001438597,0.0017687829,0.001983557,0.06280025],"category_scores_gemma":[0.021144267,0.0004514518,0.0011765127,0.0015411429,0.00058656937,0.00083485,0.0007746373,0.0031526708,0.015162988],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021754841,0.000017391585,0.0017384532,0.0007623737,0.00005553145,0.0005111662,0.000039336934,0.000048121023,0.00018020268,0.0003752873,0.9801031,0.015951483],"study_design_scores_gemma":[0.00026632656,0.00011738855,0.024036843,0.0011801728,0.00017042624,0.0027119934,0.0002481987,0.00040605423,0.0007027841,0.0006360009,0.96944964,0.00007413531],"about_ca_topic_score_codex":0.010873472,"about_ca_topic_score_gemma":0.011591832,"teacher_disagreement_score":0.06280025,"about_ca_system_score_codex":0.0011021869,"about_ca_system_score_gemma":0.0026084995,"threshold_uncertainty_score":0.21008778},"labels":[],"label_agreement":null},{"id":"W7117517214","doi":"10.1007/s12325-025-03471-6","title":"The Balancing Act of Paid Work and Caregiving in Duchenne Muscular Dystrophy (DMD): Results from a Cross-sectional Survey","year":2025,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Muscle Physiology and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Broadcom (Canada)","funders":"Sarepta Therapeutics; Parent Project Muscular Dystrophy","keywords":"Duchenne muscular dystrophy; Work (physics); Paid work; Muscular dystrophy; Rheumatology; Work hours; MEDLINE","score_opus":0.007792480871328333,"score_gpt":0.28594667277196484,"score_spread":0.2781541919006365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117517214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991899,0.00015170926,0.000037545055,0.000056318117,0.0000030444037,0.000010153559,0.00032686366,0.0000014054609,0.00022295606],"genre_scores_gemma":[0.9992417,0.00016581656,0.000071774986,0.00005631835,0.000004664663,0.000016395812,0.00033177625,7.29605e-7,0.00011073725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904734,0.0003971516,0.00016204477,0.00009196441,0.00020798451,0.00009346147],"domain_scores_gemma":[0.99694616,0.00066625746,0.0015670138,0.00010815741,0.00035238682,0.00036007972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001705755,0.00017971295,0.00019960938,0.0006120104,0.00032651017,0.00053798326,0.00025792723,0.0004056362,0.00068427663],"category_scores_gemma":[0.0038644795,0.00024873804,0.00032181706,0.0008492323,0.00023998505,0.00045933877,0.00058734784,0.00042777354,0.00017146507],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010977685,0.000021624044,0.99904233,0.000007877899,0.000013014622,0.000023513612,0.00017985588,0.000012227166,0.00003144549,0.0000022897652,0.000060169015,0.0005947026],"study_design_scores_gemma":[9.5064956e-7,0.000036048437,0.99937564,0.000006508678,0.0000041481107,0.000073416806,0.00038416183,0.000029721716,0.000010881226,0.0000017706591,0.00007542919,0.0000013048452],"about_ca_topic_score_codex":0.0074897273,"about_ca_topic_score_gemma":0.010865819,"teacher_disagreement_score":0.0074897273,"about_ca_system_score_codex":0.00032127663,"about_ca_system_score_gemma":0.0002989122,"threshold_uncertainty_score":0.01489228},"labels":[],"label_agreement":null}]}